



TFOS DEWS III Management and Therapy Report

Lyndon Jones , Jennifer P. Craig , Maria Markoulli , Paul Karpecki ,
Esen K. Akpek , Sayan Basu , Etty Bitton , Wei Chen ,
Deepinder K. Dhaliwal , Murat Dogru , José Alvaro P. Gomes ,
Miranda Koehler , Jodhbir S. Mehta , Victor L Perez ,
Fiona Stapleton , David A. Sullivan , Joseph Tauber , Louis Tong ,
Sònia Travé-Huarte , James S. Wolffsohn , Monica Alves ,
Christophe Baudouin , Laura Downie , Giuseppe Giannaccare ,
Jutta Horwath-Winter , Zuguo Liu , Shizuka Koh ,
Messmer Elisabeth , Ernesto Otero , Edoardo Villani ,
Stephanie Watson , Kyung Chul Yoon

PII: S0002-9394(25)00274-0
DOI: <https://doi.org/10.1016/j.ajo.2025.05.039>
Reference: AJOPHT 13397

To appear in: *American Journal of Ophthalmology*

Received date: May 23, 2025
Accepted date: May 26, 2025

Please cite this article as: Lyndon Jones , Jennifer P. Craig , Maria Markoulli , Paul Karpecki ,
Esen K. Akpek , Sayan Basu , Etty Bitton , Wei Chen , Deepinder K. Dhaliwal , Murat Dogru ,
José Alvaro P. Gomes , Miranda Koehler , Jodhbir S. Mehta , Victor L Perez , Fiona Stapleton ,
David A. Sullivan , Joseph Tauber , Louis Tong , Sònia Travé-Huarte , James S. Wolffsohn ,
Monica Alves , Christophe Baudouin , Laura Downie , Giuseppe Giannaccare ,
Jutta Horwath-Winter , Zuguo Liu , Shizuka Koh , Messmer Elisabeth , Ernesto Otero ,
Edoardo Villani , Stephanie Watson , Kyung Chul Yoon , TFOS DEWS III Management and Therapy
Report, *American Journal of Ophthalmology* (2025), doi: <https://doi.org/10.1016/j.ajo.2025.05.039>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: TFOS DEWS III Management and Therapy Report

Author: Lyndon Jones
Affiliation: Centre for Ocular Research & Education (CORE), School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada
Email: lwjones@uwaterloo.ca

Author: Jennifer P. Craig (corresponding author)
Affiliation: Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
Email: jp.craig@auckland.ac.nz

Author: Maria Markoulli
Affiliation: School of Optometry and Vision Science, UNSW Sydney, NSW, Australia
Email: m.markoulli@unsw.edu.au

Author: Paul Karpecki
Affiliation: Kentucky Eye Institute, University of Pikeville School of Optometry, Lexington, KY, USA
Email: karpecki@karpecki.com

Author: Esen K. Akpek
Affiliation: The Foster Center for Ocular Immunology, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA
Email: esakpek@jhmi.edu

Author: Sayan Basu
Affiliation: Shantilal Shanghvi Cornea Institute, Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India
Email: sayanbasu@lvpei.org

Author: Etty Bitton
Affiliation: School of Optometry, Université de Montréal, Montreal, QC, Canada
Email: etty.bitton@umontreal.ca

Author: Wei Chen
Affiliation: Eye Hospital of Wenzhou Medical University, National Eye Clinic Research Center, Peoples Republic of China
Email: chenwei@mail.eye.ac.cn

Author: Deepinder K. Dhaliwal
Affiliation: Department of Ophthalmology, University of Pittsburgh School of Medicine, UPMC Vision Institute, Pittsburgh, Pennsylvania, USA
Email: dhaliwaldk@upmc.edu

Author: Murat Dogru
Affiliation: Dept of Ophthalmology Ichikawa, Chiba, Japan
Email: muratodooru2005@yahoo.co.jp

Author: José Alvaro P. Gomes
Affiliation: Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo/Paulista School of Medicine, Sao Paulo, SP, Brazil
Email: jagomes13@gmail.com

Author: Miranda Koehler
Affiliation: Kentucky Eye Institute, University of Pikeville School of Optometry, Lexington, KY, USA
Email: mirandakoehlerod@gmail.com

Author: Jodhbir S. Mehta
Affiliation: Corneal and External Eye Disease, Singapore National Eye Center, Singapore
Email: jodmehta@gmail.com

Author: Victor L Perez
Affiliation: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA
Email: vperez4@med.miami.edu

Author: Fiona Stapleton
Affiliation: School of Optometry and Vision Science, UNSW Sydney, NSW, Australia
Email: f.stapleton@unsw.edu.au

Author: David A. Sullivan
Affiliation: Tear Film & Ocular Surface Society, Boston, MA, USA
Email: david@tearfilm.org

Author: Joseph Tauber
Affiliation: Tauber Eye Centre, Kansas City, MO, USA
Email: jt@taubereye.com

Author: Louis Tong
 Affiliation: Corneal and External Eye Disease, Singapore National Eye Center, Singapore;
 Ocular Surface Research Group, Singapore Eye Research Institute, Singapore
 Email: Louis.tong.h.t@singhealth.com.sg

Author: Sònia Travé-Huarte
 Affiliation: Optometry and Vision Science, College of Health and Life Sciences, Aston University, Birmingham, UK
 Email: s.trave-huarte@aston.ac.uk

Author: James S. Wolffsohn
 Affiliation: Optometry and Vision Science, College of Health and Life Sciences, Aston University, Birmingham, UK
 Email: J.S.W.Wolffsohn@aston.ac.uk

Author: + TFOS Collaborator Group *

Corresponding author: Jennifer Craig, Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand jp.craig@auckland.ac.nz

* TFOS Collaborator Group and Review Panel for this Report comprised

Monica Alves (Brazil)	monicalves@me.com
Christophe Baudouin (France)	cbaudouin@15-20.fr
Laura Downie (Australia)	ldownie@unimelb.edu.au
Giuseppe Giannaccare (Italy)	giuseppe.giannaccare@unicz.it
Jutta Horwath-Winter (Austria)	jutta.horwath@medunigraz.at
Zuguo Liu (China)	zuguoliu@xmu.edu.cn
Shizuka Koh (Japan)	cizciz@gmail.com
Elisabeth Messmer (Germany)	Elisabeth.Messmer@med.uni-muenchen.de
Ernesto Otero (Colombia)	otero.ernesto@gmail.com
Edoardo Villani (Italy)	edoardo.villani@unimi.it
Stephanie Watson (Australia)	stephanie.watson@sydney.edu.au
Kyung Chul Yoon (South Korea)	kcyoon@jnu.ac.kr

Table of Contents

1	KEYWORDS.....	8
2	ABBREVIATIONS	8
3	ABSTRACT	10
4	REPORT AIMS.....	11
5	LIFESTYLE ADVICE	11
6	TEAR INSUFFICIENCY	13
6.1	Tear replenishment	13
6.1.1	Tear supplements and stabilisers	13
6.1.1.1	Guar-based supplements	16
6.1.1.2	Hyaluronic acid-containing supplements.....	16
6.1.1.3	Xanthan gum	18
6.1.1.4	Polymer combinations	19
6.1.1.5	Lipid-containing supplements.....	20
6.1.1.6	Perfluorohexyloctane ophthalmic solution.....	24
6.1.1.7	Trehalose-containing supplements	26
6.1.1.8	Ectoine-containing supplements	27
6.1.1.9	Antioxidant-containing supplements.....	27
6.1.1.10	Vitamin-containing supplements (A; B12; C; D).....	28
6.1.1.11	Challenges in using tear supplements	30
6.2	Tear conservation devices	33
6.2.1	Contact lenses.....	33
6.2.2	Moisture retaining spectacles.....	35
6.2.3	Punctal plugging.....	36
6.2.4	Newer plug designs and other technologies	37
6.3	Tear restoration or stimulation	38
6.3.1	Restoration or stimulation of lipid	38
6.3.1.1	Meibomian Gland Dysfunction: At-home treatments.....	38
6.3.1.1.1	Warm compresses	38
6.3.1.1.2	Essential fatty acids	43
6.3.1.1.3	Topical pharmacological treatments	43

6.3.1.1.3.1	Topical azithromycin	44
6.3.1.1.3.2	Topical selenium sulfide	44
6.3.1.2	Meibomian Gland Dysfunction: In-office treatments	45
6.3.1.2.1	Device-driven technologies: Inner eyelid heating and massaging	45
6.3.1.2.2	Device-driven technologies: External eyelid heating	46
6.3.1.2.3	Device-driven technologies: Various	50
6.3.1.2.3.1	Intense pulsed light (IPL)	50
6.3.1.2.3.2	Low-level light therapy (LLLT: Red light)	54
6.3.1.2.3.3	Plasma treatment	57
6.3.1.2.3.4	Quantum Molecular Resonance Electrotherapy	57
6.3.1.2.3.5	Radiofrequency	58
6.3.1.2.3.6	Thermo-mechanical skin treatment	59
6.3.1.3	Lid margin treatments	59
6.3.1.3.1	Intraductal meibomian gland probing	59
6.3.1.3.2	Lid margin debridement	62
6.3.2	Restoration or stimulation of aqueous	63
6.3.2.1	Topical secretagogues	63
6.3.2.1.1	Diquafosol tetrasodium	63
6.3.2.2	Oral secretagogues	67
6.3.3	Restoration or stimulation of mucin	68
6.3.3.1	Diquafosol tetrasodium	68
6.3.3.2	Rebamipide	68
6.3.4	Neuromodulation / neurostimulation	72
6.3.4.1	Device-driven neuromodulation	72
6.3.4.1.1	Nasal electrochemical stimulation	72
6.3.4.1.2	Transcutaneous electrical stimulation	73
6.3.4.2	Pharmacological neuromodulation	74
6.3.4.2.1	Acotremone	74
6.3.4.2.2	Cryosim-3	75
6.3.4.2.3	Varenicline	76
7	TREATMENTS FOR EYELID ABNORMALITIES	80
7.1	Blink and lid closure anomalies	81
7.1.1	Inadequate lid seal / lagophthalmos	81
7.1.2	Partial blinking	83
7.2	Methods to reduce eyelid microbial load	84

7.2.1	Anti- <i>Demodex</i> therapies.....	85
7.2.1.1	Ivermectin	86
7.2.1.2	Lotilaner ophthalmic solution	87
7.2.1.3	Okra (<i>Abelmoschus esculentus</i>)	88
7.2.1.4	Tea tree oil.....	89
7.2.2	Blepharoexfoliation.....	90
7.2.3	Hypochlorous acid.....	91
7.2.4	Lid hygiene products	92
7.2.5	Low-level light therapy (LLLT: Blue light)	98
7.2.6	Manuka honey.....	99
7.2.7	Topical antibiotics.....	100
8	ANTI-INFLAMMATORY PHARMACOLOGICAL THERAPIES.....	101
8.1	Corticosteroids	101
8.1.1	Loteprednol etabonate 0.25%	102
8.1.2	Medicated tear supplements	104
8.2	T-cell immunomodulatory topical drugs	105
8.2.1	Cyclosporine A	105
8.2.2	Lifitegrast.....	110
8.2.3	Tacrolimus.....	112
8.3	Pharmacological compounds under development	113
8.3.1	Carbonized nanogels	113
8.3.2	Fenofibrate.....	113
8.3.3	Ferulic acid.....	114
8.3.4	Lacritin.....	114
8.3.5	Naringenin	114
8.3.6	Repository corticotropin injection	115
8.3.7	Reproxalap	115
8.3.8	Topical porphyrin	116
8.3.9	Visomitin	116
9	ORAL ANTIMICROBIAL AGENTS	117
9.1	Tetracycline and analogues	117
9.2	Macrolide antibiotics	119

10	OCULAR SURFACE PROMOTORS/REGENERATORS	121
10.1	Biologics.....	121
10.1.1	Blood-based treatments	121
10.1.2	Autologous serum tears	124
10.1.3	Allogeneic serum tears	125
10.1.4	Platelet derived preparations	126
10.1.5	Platelet Rich Plasma (PRP)	127
10.1.6	Plasma Rich in Growth Factors (PRGF)	129
10.1.7	Autologous serum versus PRP or PRGF	130
10.1.8	Umbilical cord serum (UCS) eye drops	131
10.1.9	Whole blood autologous tears	132
10.2	Lubricin.....	133
10.3	Amniotic membrane and amniotic membrane extract drops	133
10.4	Cenegermin 0.002%.....	135
10.5	RGN-259 0.1%	136
10.6	Silk-derived protein (SDP-4).....	136
10.7	Topical insulin.....	137
11	TREATMENTS FOR ANATOMICAL SURFACE ABNORMALITIES	138
11.1	Ocular surface anatomical irregularities.....	138
11.1.1	Conjunctivochalasis	138
11.1.2	Lid Parallel Conjunctival Folds.....	140
11.1.3	Pingueculum	140
11.1.4	Pterygium.....	140
12	NUTRITIONAL MODIFICATIONS AND ALTERNATIVE THERAPIES .	141
12.1	Macronutrients.....	141
12.2	Micronutrients.....	145
12.3	Natural products and interventions.....	147
12.3.1	Acupuncture.....	147

12.3.2	Herbs and spices	147
12.3.3	Hydration.....	149
12.3.4	Lactoferrin	149
12.3.5	Manuka honey	150
12.3.6	Nutritional supplements	150
13	PREVENTION AND TREATMENT OF SURGICAL IATROGENIC DRY EYE DISEASE	151
13.1	Dry eye disease and cataract surgery	151
13.2	Dry eye disease and refractive surgery	152
14	SURGICAL MANAGEMENT	154
14.1	Permanent punctal occlusion	154
14.2	Tarsorrhaphy.....	156
14.3	Surgical management of lid abnormalities	156
14.3.1	Botulinum toxin injection	156
14.3.2	Dermatochalasis	157
14.3.3	Entropion and ectropion.....	158
14.3.4	Lagophthalmos	159
14.4	Surgical management of anatomical surface abnormalities	159
14.4.1	Conjunctivochalasis	159
14.4.2	Pterygium and pinguecula	160
14.5	Salivary gland transplantation	161
14.6	Reinnervation of the lacrimal gland	162
15	PRESCRIBING ALGORITHM.....	163
16	SUMMARY AND CONCLUSIONS	164
17	ACKNOWLEDGEMENTS.....	165
18	LIST OF TABLES	165
19	REFERENCES.....	166

1 Keywords

Artificial tears; dry eye disease; lifestyle advice; management; therapy; treatment; medication; pharmacological

2 Abbreviations

CMC	Carboxymethylcellulose
CsA	Cyclosporine
DED	Dry eye disease
DEWS	Dry eye workshops
FDA	Food and Drug Administration
HP-guar	Hydroxypropyl guar
HA	Hyaluronic acid
IL	Interleukin
IPL	Intense pulsed light
LASIK	Laser-assisted in situ keratomileusis
LLT	Lipid layer thickness
LLLT	Low-level light therapy
MGD	Meibomian gland dysfunction
MMP	Matrix metalloproteinase
NGF	Nerve growth factor
NIBUT	Non-invasive breakup time
NF-kB	Nuclear factor kappa-light-chain-enhancer of activated B cells
OSDI	Ocular Surface Disease Index
PEG	Polyethylene glycol
PRGF	Plasma rich in growth factors
PRP	Platelet-rich plasma
PUFA	Polyunsaturated fatty acids
RCT	Randomized controlled trial
rhPRG4	Recombinant human proteoglycan 4
ROS	Reactive oxygen species
SANDE	Symptom Assessment iN Dry Eye (questionnaire)

SDP-4	Silk-derived protein
SPEED	Standard Patient Evaluation of Eye Dryness (questionnaire)
TBUT	Tear breakup time
TFOS	Tear Film & Ocular Surface Society
TMH	Tear meniscus height
TRPM8	Transient Receptor Potential cation channel subfamily M member 8
TTO	Tea tree oil
UCS	Umbilical cord serum

3 Abstract

This report provides an evidence-based review of current strategies to manage dry eye disease (DED). First-line management focuses on methods to replenish, conserve and stimulate the tear film, with an emphasis on ocular supplements, which remain the cornerstone of DED treatment. Meibomian gland dysfunction, a primary contributor to DED, is typically treated with warm compresses and a wide variety of in-office treatments, including device-driven technologies to warm the eyelids, intense pulsed light therapy, low-level light therapy and other new and emerging technologies. Lid hygiene treatments include lid wipes, anti-*Demodex* therapies, blepharoexfoliation and topical antibiotics.

DED caused by certain etiological drivers can benefit from anti-inflammatory therapies, including corticosteroids, T-cell immunomodulatory topical drugs and a wide variety of pharmacological agents, in addition to biologic tear substitutes such as autologous serum and platelet-rich plasma. Emerging therapies, such as neuromodulation via nasal neurostimulation and novel pharmacological treatments offer potential future options. Advanced options, including amniotic membrane grafts and complex surgical methods, provide options for severe or refractory cases. Lifestyle modifications, including optimized blinking, dietary supplementation and environmental adjustments, play a crucial role in long-term management. Patient education and adherence to treatment regimens remain essential for sustained symptom relief.

The TFOS DEWS III prescribing algorithm provides an evidence-based framework to offer guidance to clinicians in selecting relevant interventions based on disease etiology that aim to provide targeted management of the subtype of DED that an individual is experiencing.

Keywords: Artificial tears; dry eye disease; lifestyle advice; management; therapy; treatment; medication; pharmacological

4 Report aims

The aim of this report was to provide a contemporary overview of the available evidence on the management of patients with dry eye disease (DED). The subsequent aim was to provide an evidence-based algorithm to assist clinicians with when to use these therapies. The presenting signs and symptoms and diagnostic testing, informed by the Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III subclassifications were considered in developing the algorithm ¹. The report was focused on evidence published since the previous TFOS DEWS II Management & Therapy Report ².

A number of treatments listed overlap with other broad areas of management due to overlapping mechanisms of action (for example, some treatments may be anti-inflammatory or antimicrobial and also treat lid and lid abnormalities). The final aim was to outline whether there is evidence to support use of the listed management options to treat one or more of the updated subclassifications described in the TFOS DEWS III Diagnostic Methodology Report ¹.

5 Lifestyle advice

Lifestyle factors play a critical role in both the development and management of DED, influencing not only ocular health but also overall happiness and quality of life ^{3,4}. Modern behaviors, including poor sleep ⁵⁻¹⁰, use of cosmetics ¹¹, choice of elective ocular and peri-ocular procedures ¹² and systemic medications ^{9,12} can exacerbate or create dry eye symptoms, leading to discomfort, visual disturbances, and reduced daily functioning.

Excessive digital device use is one of the most significant lifestyle contributors to DED ^{9,13,14}. Reduced blink rates and incomplete blinking while staring at screens can lead to tear film instability, increased evaporation, and ocular surface damage ¹⁴. This chronic discomfort often leads to frustration, fatigue, and decreased productivity, negatively impacting mental well-being. Diet also plays a role in DED severity. Diets rich in omega-3 fatty acids, found in fish and

flaxseeds, can improve tear quality and reduce inflammation. Conversely, diets high in processed foods and low in essential nutrients can contribute to systemic inflammation, worsening ocular surface disease^{9,15-18}.

The cumulative burden of dry eye symptoms can extend beyond physical discomfort, affecting mood, social engagement, and overall quality of life^{3,19}. Patients with chronic DED frequently report higher levels of anxiety and depression²⁰⁻²⁴, likely due to persistent irritation and visual impairment interfering with daily activities^{5,25}.

Environmental conditions can affect the ocular surface and may lead to DED. These have been described comprehensively in the TFOS Lifestyle report on the topic²⁶, and include climate factors (sunlight, temperature, humidity, windspeed and vapors), pollutants and allergens. The conditions can affect the ocular surface directly, causing immediate sensation, or indirectly such as through ultraviolet radiation causing pterygia, the physical presence of which affects lid-globe congruity and leads to disruption of the tear film (see Section 11.1.4).

Specific lifestyle considerations to discuss include:

- Avoidance of factors that precipitate symptoms of DED: while this may not always be possible, it can be recommended for specific factors that are known to exacerbate DED, such as prolonged reading or avoidance of draughty environments²⁶.
- Control of the local environment: Humidifiers, including simple USB-driven desktop devices that enhance the humidity of the local air, improve tear-film stability and subjective comfort^{27,28}. Humidifiers built into eyewear also have a similar effect²⁹.
- Physical protection: side panels offer protection of the eyes from windspeed and vapors, but this has only been investigated in conjunction with increasing humidity around the eyes³⁰. Moisture retaining spectacles (see Section 6.2.2) protect the eye from evaporation³¹ and pollutants, and

increase the humidity of the air adjacent to the face of the wearer, and are effective in improving the ocular surface³² and tear film, and in reducing DED symptoms³³. Ultraviolet light protection of the ocular surface in the form of soft contact lenses for a period of at least five years, did not visibly improve the ocular surface, although the tear film was not assessed³¹.

By recognizing the profound connection between lifestyle, dry eye symptoms, and quality of life, clinicians can guide patients toward sustainable changes that foster long-term relief and improved happiness. A recent publication³⁴ demonstrated that laughter can have therapeutic effects on DED, with improvements in symptoms and signs outperforming those of topical 0.1% hyaluronic acid (HA). Addressing lifestyle factors through conscious modifications, such as screen breaks, improved nutrition, and sleep hygiene, can significantly alleviate symptoms, enhancing both ocular health and overall well-being. These lifestyle modifications should be considered for all subjects, regardless of the type of DED and the management options proposed to deal with their presenting signs and symptoms.

6 Tear insufficiency

6.1 Tear replenishment

6.1.1 Tear supplements and stabilisers

Tear supplements are agents that enhance and/or stabilise the tear film in cases of DED and remain a cornerstone of DED management for addressing tear insufficiency or dysfunction that can arise regardless of the underlying etiology³⁵.

While these products are available in some countries as non-prescription, 'over-the-counter' drops, more recently, this group of supplements have been joined by agents that may only be available on prescription due to their regulatory approval. The goal of these therapies is to restore homeostasis of the tear film and ocular surface microenvironment, in many cases by stabilising the precocular tear film. This should minimize perpetuation of the cycle of tear film instability,

hyperosmolarity, inflammation and epithelial damage described as the 'vicious circle of DED' ³⁶⁻³⁸.

These products have been designed to mimic the tear film components, but lack the biologically active components found in the natural tear film ³⁹. While it is possible to list the "active" ingredients that may be included in tear supplements and stabilisers, their efficacy may not be solely related to an individual ingredient, and what is considered "active" can be restricted by the regulatory body of a region. For example, in the US, non-prescription tear supplements must have only active ingredients from a short list in the Food and Drug Administration (FDA) monograph, despite possibly having important excipients. Some formulations, for example, may contain two active demulcents but also "inactive polymers", all of which play distinct but important roles of lubrication, retention, and hydration. Thus, it is the overall formulation and composition and the way in which the components interact that impact their performance. Coupled with this is consideration of the presence or absence of preservatives and the delivery system.

As previously described ^{2,40-44}, the composition of tear supplements is complex and may include:

- Viscosity-enhancing agents that can be aqueous-based formulations targeting aqueous deficient DED, such as carbomer 940, carboxymethylcellulose (CMC), dextran, hydroxypropyl guar (HP-guar), hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone and polyethylene glycol (PEG).
- Lipomimetic formulations targeting evaporative DED, which reduce the surface tension of the tear film and permit a more even distribution of tears over the ocular surface ³⁹. Lipids incorporated (see Section 6.1.1.5) include phospholipids, triglycerides, saturated and unsaturated fatty acids, mineral oil, castor oil, coconut oil and lecithin ^{40-43,45,46}. Phospholipids can be neutral (zwitterionic), negatively (anionic) or positively (cationic) charged.

- A tear stabiliser (perfluorohexyloctane), which is a prescription drug in the US and a medical device in other regions ⁴⁷⁻⁵⁰.
- Hyaluronic acid (HA), an increasingly common constituent of tear supplements. As a naturally occurring glycosaminoglycan, it is found throughout the body, including within synovial fluid, the vitreous and aqueous humor. The high molecular weight formulation of HA has been reported in an animal model to be more effective than its lower molecular counterpart in treating DED ⁵¹, and to protect against corneal cell apoptosis and inflammation in vitro ⁵². Further information is provided in Section 6.1.1.2.
- Preservatives, including benzalkonium chloride and ethylene diamine-tetraacetic acid, are used to protect against bacterial contamination of the drops. Preservatives such as benzalkonium chloride can result in toxic and pro-inflammatory effects, exacerbating dry eye signs and symptoms ^{53,54}. There has therefore been a move towards using preservative-free unit-dose formulations, less damaging preservatives such as stabilized oxychloro complex (Purite®) ^{55,56} or sodium perborate (GenAqua®; Alcon, Ft Worth, TX, USA; Dequest®) ⁵⁷, or the use of multi-dose, preservative-free bottles that are specifically designed to prevent contamination with microorganisms ⁵⁸. Another preservative with a long history of use in tear supplements is polyquaternium-1 (Polyquad®; Alcon, Ft Worth, TX, USA) ⁵⁷. This is a bactericidal quaternary ammonium compound used in tear supplements at a typical concentration of 0.001%. At this concentration it has been shown to have no adverse effects on the cytokinetic movement, morphology, or mitotic activity of cultured human corneal epithelial cells after a 24-hour exposure period ⁵⁹.
- Hypo-osmotic agents designed to counteract the hypertonicity of the tear film in DED ⁶⁰.
- Osmoprotectants, that aim to optimize cellular health to enable the ocular surface to withstand the impacts of tear hyperosmolarity and inflammation ⁶¹⁻⁶³. Examples include L-carnitine, erythritol, trehalose (see Section 6.1.1.7), betaine, sorbitol and glycerin ⁴³.

- Excipients:
 - buffers: (e.g. bicarbonate, phosphate, citrate, borate) to maintain the normal pH (7.4) of the tear film ^{2,53,58}
 - salts to regulate tonicity.

The following section reviews various tear supplement formulations, with a primary focus on new knowledge since the publication of the equivalent report for TFOS DEWS II ².

6.1.1.1 Guar-based supplements

Hydroxypropyl guar (HP-guar) is a high molecular weight polymer with chemistry along the polymer backbone to generate a high viscosity gel when placed in the eye. The hydroxypropyl groups block the intermolecular hydrogen bonding so that the solubility of guar is increased and can bind preferentially to hydrophobic regions via the hydroxypropyl groups to damaged areas of the glycocalyx surface ⁶⁴. Borate is a buffer in Systane® (Alcon; Ft Worth, TX, USA) formulations and the borate ions bind with cis-diols of the HP-guar to form covalent bonds and crosslink the polymers to form viscoelastic gels ⁶⁵. The HP-guar viscosity-enhancing polymer in combination with demulcents forms a hydrated scaffold on the ocular surface to protect and resist desorption for long term protection ⁶⁶. The in-situ crosslinking generated with HP-guar and borate is unique in that it works with the ocular pH of the tear film ⁶⁶. The generated gel is facilitated by the physiological pH of the ocular surface tear film to help retain the demulcents on the ocular surface ⁶⁷. Clinical studies have demonstrated that the HP-guar based supplement, in combination with PEG and/or propylene glycol, significantly enhances tear film stability and provides prolonged lubrication ⁶⁸. It has also been shown to reduce tear osmolarity, corneal staining, and improve overall ocular surface health ⁶⁹. Additionally, this combination improves goblet cell density and promotes epithelial repair by creating a protective layer that prevents further damage to the ocular surface, supporting the renewal of surface epithelial cells ⁷⁰.

6.1.1.2 Hyaluronic acid-containing supplements

Hyaluronic acid is a naturally occurring, anionic non-sulfated glycosaminoglycan found throughout the body's extracellular matrix, including as a major component of synovial fluid. The molecular weight of HA can be very large, often reaching several million Daltons. Its primary function is to contribute to cell proliferation and migration, and it is used in a variety of tear supplements to increase viscosity and provide enhanced lubrication. Hyaluronic acid exhibits non-Newtonian shear-thinning properties, where viscosity varies with shear rate ^{71,72}. These shear-thinning properties are also dependent upon molecular weight ⁷³. A study demonstrated that high molecular weight HA provided longer tear breakup time (TBUT) and lower lissamine green staining scores than either low molecular weight HA or diquafosol drops in a mouse model of DED ⁵¹.

A review of published literature on the safety and efficacy of tear supplements containing HA for DED management identified 53 eligible clinical trials, including eight placebo-controlled studies ⁷⁴. Studies used HA concentrations ranging from 0.1% to 0.4% over periods of four weeks to three months and, overall, demonstrated effectiveness in improving both signs and symptoms of DED without any serious side effects. Major knowledge gaps identified were the ideal drop frequency, and the optimal formulation and concentration of HA.

A literature review of 21 randomized trials compared HA to 17 other single ingredient DED treatments ⁷⁵. Most ocular surface and tear film measures showed no significant difference between treatment groups, suggesting either equivalence of treatments, or that the studies were underpowered, the drop frequency was not optimised (between one and eight drops were prescribed daily) or the concentration of HA used may have been too low to be therapeutically relevant.

A systematic review with meta-analysis of 18 studies comparing HA to non-HA-based tear supplements showed superiority of HA-containing tear supplements in improving ocular staining, as well as patient-reported symptoms ⁷⁶. Tear production measured by the Schirmer test and tear film stability measured by TBUT did not significantly differ between the treatments.

Efficacy and safety of tear supplements combining CMC with HA, to CMC alone, applied twice daily for 90 days were assessed in a large multicenter study ⁷⁷. Both participant-reported symptoms and clinician-measured ocular surface and tear film parameters improved significantly relative to baseline, albeit with minimal difference in outcomes between groups.

Hyaluronic acid can be modified in various ways, such as its molecular weight, viscosity, and hydrophobicity, to alter its properties. Cross-linking certain sections of the molecule may increase its resistance to degradation and enhance bioavailability ⁷⁸.

6.1.1.3 Xanthan gum

Xanthan gum is a highly viscous polysaccharide molecule extracted from *Xanthomonas campestris* ⁷⁹. Its behavior has been likened to tears, including features such as decreasing viscosity with increasing shear rate, and similarities in temperature, biopolymer and salt concentrations, as well as pH ⁷⁹. These behaviors have enabled xanthan gum to be used as a vehicle in ophthalmic drugs to improve residence times on the ocular surface ⁸⁰. In DED, the effects of xanthan gum have been compared to CMC ⁷⁹ and PEG/propylene glycol ⁸¹. Xanthan gum has been evaluated *in vitro* and in rabbits in combination with other constituents with regard to its antioxidant and osmoprotective effects ⁸².

In a study that evaluated a 0.2% concentration of xanthan gum in 15 participants with DED, xanthan gum was found to significantly improve goblet cell parameters, conjunctival cytological features and corneal staining when used

four times a day for one month, compared to CMC, although a reduction in the Schirmer I test was also reported ⁷⁹. A Phase III, multicenter randomized controlled trial (RCT) involved 148 participants with DED who used 0.09% xanthan gum with 0.1% chondroitin sulfate, xanthan gum four times a day for 60 days compared to PEG/propylene glycol ⁸¹. Efficacy was found to be similar between the two treatments, with both improving clinical signs such as Schirmer test score, TBUT and ocular comfort ⁸¹.

A prospective, multicentre clinical investigation was undertaken on a preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025% instilled three times a day in 30 participants with DED ⁸³. The study formulation was associated with a significant reduction in redness after one month of treatment compared to baseline. In addition, the solution significantly increased TBUT and promoted a significant reduction in corneal and conjunctival staining. It also reduced DED symptoms and exhibited a very good safety profile.

6.1.1.4 Polymer combinations

Multi-polymer formulations, including polymers with anti-inflammatory properties, such as xanthan gum and guar gum, have been reported to contribute to reducing inflammation and promoting epithelial healing ^{84,85}.

One commonly used combination includes HP-guar and HA. A systemic review evaluating preclinical and clinical effects of this combination of polymers summarised their hydration, lubrication and moisture retention capabilities ⁸⁶. In an in-vivo corneal injury model, HP-guar+HA significantly accelerated corneal re-epithelialization, outperforming other HA-based eye drops ⁸⁷.

Clinical trials highlighted that this combination of dual-polymer lubricating drops reduced the clinical signs & symptoms of DED, improved TBUT and exhibited improved retention time on the ocular surface ^{88,89}. In a retrospective study of post-cataract surgery patients, the dual-polymer formulation was associated with

reduced dry eye symptoms and corneal damage, especially when administered pre-operatively ⁹⁰. In healthy individuals, HP-guar+HA drops significantly enhanced tear film quality, increasing both TBUT and tear meniscus height (TMH) ⁹¹. Additionally, in digital device users, the dual polymer composition significantly improved eye comfort and quality of life ⁹².

Clinical studies have demonstrated that tear supplements containing polymer combinations outperform single-polymer formulations in terms of DED symptom relief, tear film stability and patient satisfaction ^{77,93,94}. For example, an RCT comparing HA+CMC combination drops to a product containing CMC alone showed significantly greater improvement in Ocular Surface Disease Index (OSDI) scores and TBUT in the combination group ⁷⁷. Another study reported that tear supplements with PEG and propylene glycol, used three times a day for 90 days, significantly improved goblet cell density and corneal and conjunctival staining relative to baseline levels ⁷⁰.

6.1.1.5 Lipid-containing supplements

Lipid-containing tear supplements, formulated as emulsions, are increasing in availability and popularity ^{40-43,45,46,95,96}. When comparing lipid-containing and non-lipid-containing formulations, lipid-containing tear supplements have been reported to be more effective at improving lipid layer appearance in both the short-term ^{46,97} and longer-term ⁹⁸⁻¹⁰⁰. Additionally, lipomimetic tear supplements have been associated with greater subjective symptom relief and higher patient satisfaction among contact lens wearers, as well as improved clinical signs such as lid wiper epitheliopathy and corneal staining ⁴⁵. In head-to-head comparisons of lipid-containing tear supplements, a Phase IV, multicenter, randomized, double-masked study of 231 adults with evaporative DED compared two lipid-containing tear supplements when used four times a day for 35 days ¹⁰¹. The drops were found to perform similarly in terms of TBUT and both were well-tolerated ¹⁰¹. Large, multicentre clinical trials have demonstrated that a HP-guar phospholipid nanoemulsion resulted in significant improvements in TBUT and

reduced dry eye symptoms for up to eight hours in various sub-types of DED, significantly improving tear film stability, lipid layer thickness (LLT), and ocular comfort (aqueous deficient, evaporative & mixed) ¹⁰²⁻¹⁰⁴.

Preclinical studies showed superior hydration, retention and faster recovery, enhancing lubrication and tear film stability ¹⁰⁵. Clinical trials demonstrated significant improvements in tear film BUT, reducing dry eye symptoms that included burning, grittiness, and stinging ¹⁰⁴. A phospholipid nanoemulsion with HP-guar effectively targets key aspects of DED, offering both immediate and sustained symptom relief, improved ocular surface health, and enhanced tear film quality ¹⁰².

Table 1 provides data on peer-reviewed publications on various commercially available lipid-containing drops and the lipids that they contain.

Table 1: Examples of studies examining lipid containing supplements

Lipid component	Brand name (Manufacturer)	Published studies
Castor oil	Optive Plus (Allergan, Irvine, CA, USA)	Kaercher et al. 2014 ¹⁰⁶ Karcenty et al. 2021 ¹⁰⁷
	Refresh Endura (Allergan, Irvine, CA, USA)	Di Pascuale et al. 2004 ¹⁰⁸ Fogagnolo et al. 2016 ¹⁰⁹
	Refresh Optive Advanced (Allergan, Irvine, CA, USA)	Jenkins et al. 2020 ¹⁰¹
Medium chain triglycerides	Liposic (Bausch + Lomb, Rochester, NY, USA)	Wang et al. 2010 ¹¹⁰ Chung et al. 2016 ¹¹¹ Kim et al. 2017 ¹¹²
	Artelac Lipid (Bausch + Lomb, Rochester, NY, USA)	Mihaltz et al. 2018 ¹¹³ Lim et al. 2020 ¹¹⁴
Mineral oil	Cationorm (Santen, Japan)	Robert et al. 2016 ¹¹⁵ Lim et al. 2020 ¹¹⁴ Fogagnolo et al. 2020 ¹¹⁶ Makri et al. 2021 ¹¹⁷
	Retaine (marketed as Cationorm outside of the USA)	Ousler et al. 2015 ¹¹⁸
	Soothe (Bausch + Lomb, Rochester, NY, USA)	Fogagnolo et al. 2016 ¹⁰⁹
	Soothe XP (Bausch + Lomb, Rochester, NY, USA)	Korb et al. 2005 ¹¹⁹
Mineral oil + phospholipids	Systane Balance (Alcon, Fort Worth, TX, USA)	Aguilar et al. 2014 ¹²⁰ Guthrie et al. 2015 ⁴⁵ Gokul et al. 2018 ¹²¹ Jenkins et al. 2020 ¹⁰¹

	Systane Complete (Alcon, Fort Worth, TX, USA)	Silverstein et al., 2020 ¹⁰² Yeu et al., 2020 ¹⁰³ Muntz et al. 2020 ⁴⁶ Pucker et al. 2021 ¹²² Craig et al. 2021 ⁹⁸ Antman et al. 2024 ¹²³
Omega-3 fatty acid (flaxseed oil)	Refresh Optive Mega-3 (Allergan, Irvine, CA, USA)	Deinema et al. 2017 ¹²⁴ Fogt et al. 2019 ¹²⁵ Downie et al. 2020 ¹²⁶
Liposomal spray	Tears Again (Optima, Hallbergmoos, Germany)	Turnbull et al. 2018 ¹²⁷
Phospholipids	Emustil (SIFI, San Antonio, Italy)	McCann et al. 2012 ¹²⁸
	Tears Again (Optima Medical, Switzerland)	Craig et al. 2010 ¹²⁹ Rohit et al. 2017 ¹³⁰ Essa et al. 2018 ⁹⁹ Pult et al. 2021 ¹³¹

6.1.1.6 Perfluorohexyloctane ophthalmic solution

Perfluorohexyloctane ophthalmic solution (Miebo®, Bausch + Lomb, Bridgewater, NJ, USA) is a single ingredient, water-free, preservative-free formulation. The active ingredient, perfluorohexyloctane, has amphiphilic properties and is comprised of a lipophobic fluorocarbon segment and a lipophilic hydrocarbon segment⁴⁸. This formulation received marketing approval in the US in 2023 and has been available for several years in Europe, Australia and New Zealand (EvoTears® /NovaTears®), including variations with and without added omega-3^{132,133}. While the majority of tear supplements in this category are available without a prescription, this tear stabiliser is available only by prescription in some countries, due to the required regulatory approval pathway of the non-monograph active ingredient.

There are several proposed mechanisms of action for perfluorohexyloctane in the treatment of signs and symptoms of DED. The first is inhibition of tear evaporation through the formation of a monolayer at the interface of the tear film with the environment^{48,134,135}. In support of this, *in vitro*, perfluorohexyloctane ophthalmic solution has been shown to outperform tear supplements and meibum extracted from a single healthy volunteer in terms of reducing the evaporation of saline⁴⁷, but this not been confirmed *in vivo* using devices that clinically determine rates of evaporation. *In vivo*, preclinical data has demonstrated that topical application of perfluorohexyloctane for seven days in healthy rabbits improved the lipid level grade as early as five minutes after a single instillation and following repeated doses from five to seven days, although there was no significant effect on the tear film evaporation rate, or on tear film volume or osmolarity in this healthy animal model¹³⁶. When compared to a cationic nano-emulsion in patients with DED, the emulsion increased LLT and higher order aberrations immediately after application, while perfluorohexyloctane led to an increase in LLT over 12 weeks, with no change in higher order aberrations¹³⁷. Improvements in both the lipid layer grade and tear film thickness were also observed in a four-week study in patients with DED and

meibomian gland dysfunction (MGD) ¹³⁸. Topical perfluorohexyloctane reduces the corneal surface temperature and increases the activity of corneal Transient Receptor Potential cation channel subfamily M member 8 (TRPM8) cold thermoreceptors. This response could lead to heightened reflex lacrimation and blinking, alleviation of the dry eye, and a decrease in discomfort and pain ¹³⁹.

Efficacy and safety of perfluorohexyloctane were demonstrated in multiple clinical studies in participants with DED ¹⁴⁰⁻¹⁴⁴. In a Phase II study, treatment with perfluorohexyloctane instilled either two or four times a day resulted in significant improvements over control (isotonic saline) in total corneal fluorescein staining and eye dryness, although four times daily dosing resulted in greater efficacy ¹⁴⁰. Two Phase III studies confirmed that perfluorohexyloctane dosed four times a day resulted in significant improvements over control (hypotonic saline) in both DED signs and symptoms as early as Day 15 (the first evaluation time point) and at Day 57, which was the primary endpoint ^{141,142}. Across the studies, the most common adverse event with perfluorohexyloctane was blurred vision (2.1% of participants), which was mild and transient ¹⁴⁵. Similar results have been reported in a Phase III study conducted in Chinese participants ¹⁴⁴. In randomized clinical trials in patients treated with perfluorohexyloctane, the most common event (reported in 2.5% of cases) was blurred vision ⁵⁰. Perfluorohexyloctane used topically was found to be non-toxic and non-bio-accumulative based on a rigorous program of non-clinical studies ¹⁴⁶.

A Phase III, multicenter, single-arm, open-label study in participants with evaporative DED treated with perfluorohexyloctane ophthalmic solution (n = 208) four times a day for 52 weeks found the treatment to be safe, well-tolerated and efficacious in improving the signs and symptoms of DED ¹⁴³. Participants who were switched from saline (n=111) to perfluorohexyloctane experienced an improvement in DED signs and symptoms after four weeks, which was the first evaluation time point ¹⁴³. Efficacy of perfluorohexyloctane ophthalmic solution in reducing dry eye symptoms was observed in a multicenter, single-arm study at

five minutes and 60 minutes following a single instillation and also at day three, seven and 14 with four times daily dosing ⁴⁹.

A systematic review published in 2023 reviewed six RCTs and reported a greater improvement in most variables recorded (OSDI, LLT, corneal staining, adverse events) in participants using perfluorohexyloctane ophthalmic solution compared to control drops ¹³³. However, TBUT was longer in the control group ¹³³. A recent meta-analysis concluded that perfluorohexyloctane is an effective and safe alternative for the treatment of evaporative DED secondary to MGD and can significantly reduce corneal staining and eye dryness symptoms ⁵⁰.

6.1.1.7 Trehalose-containing supplements

Trehalose is a natural disaccharide consisting of two glucose molecules, and is reported to stabilize proteins and membranes, prevent denaturation and inhibit oxidative damage ¹⁴⁷⁻¹⁴⁹. *In vitro*, trehalose has been shown to enhance autophagic flux when combined with HA-based eye drops ¹⁵⁰, which contributes to osmoprotective effects, and the maintenance of epithelial cell homeostasis in DED ¹⁵⁰. This is important because autophagy degrades and recycles cellular components, allowing the cellular environment to adapt to a desiccated environment. In a desiccating model of DED, a combination of 3% trehalose and 0.15% HA in a preservative-free formulation (Thealoz® Duo; Laboratoires Thea, Clermont-Ferrand, France) showed goblet cell recovery and reduced inflammatory markers compared to a combination of 0.001% hydrocortisone and 0.2% HA ¹⁵¹.

In humans, trehalose-containing tear supplements have been reported to have an excellent safety profile ¹⁵². The use of trehalose-containing tear supplements in DED has been described in a systematic review that included 10 RCTs ¹⁵³. When compared to controls, trehalose-containing tear supplements showed an improvement in terms of ocular comfort and markers of homeostasis (TBUT and corneal staining) and no adverse events were reported in any of the studies

analyzed ¹⁵³. Since publication of this systematic review, other studies have compared trehalose as a component of tear supplements relative to other formulations, most commonly in combination with HA. There is reported efficacy of this formulation in patients with DED ¹⁵⁴, in peri-menopausal and post-menopausal women ¹⁵⁵, and in patients post-cataract surgery ¹⁵⁶.

6.1.1.8 Ectoine-containing supplements

Ectoine is a bacteria-derived extremolyte with the ability to protect proteins and biological membranes from damage caused by extreme environmental conditions and is considered a natural osmoprotectant ¹⁵⁷. A prospective study on 18 participants with DED using a preservative-free ectoine-containing eye spray used three times daily for approximately 2 weeks demonstrated a reduction in DED symptoms and increase in non-invasive TBUT ¹⁵⁸. A study investigated the impact of a topical ectoine-based drop on a desiccation mouse model compared to a vehicle control ¹⁵⁹. The ectoine treatment protected mice from corneal damage in a concentration-dependent manner, and ectoine at 1.0 and 2.0% significantly restored corneal regularity and reduced corneal staining. Expression of various pro-inflammatory cytokines and chemokines was significantly elevated in the corneas and conjunctivas of desiccation-exposed mice, whereas 1.0 and 2.0% ectoine suppressed these inflammatory mediators to near normal levels ¹⁵⁹. In a similar mouse model, topical 2% ectoine was shown to significantly reduce corneal damage, and enhance goblet cell density and mucin production compared with vehicle through restoring imbalanced interleukin (IL)-13/Interferon-gamma signaling in a murine dry eye model ¹⁶⁰.

6.1.1.9 Antioxidant-containing supplements

Oral nutritional supplements containing antioxidants are often advocated for improved ocular health, particularly age-related macular degeneration ¹⁶¹. The use of antioxidants as constituents in tear supplements has been studied in relation to cataracts ¹⁶¹, but less is known regarding their use to manage patients with DED.

Antioxidants are mainly associated either with lipophilic membranes or lipoproteins such as vitamin E and ubiquinol, or aqueous components such as ascorbate, glutathione and thioredoxin ¹⁶².

A study on alpha-lipoic acid, a naturally occurring antioxidant that can interact with both lipid and aqueous phases, in patients with diabetes and DED showed that a topical combination of alpha-lipoic acid and hydroxypropyl methylcellulose resulted in a greater improvement in corneal staining than with hydroxypropyl methylcellulose alone ¹⁶², while both groups displayed an improvement in TBUT ¹⁶².

The application of selenium to cells can increase selenoprotein expression, counteracting the effect of reactive oxygen species (ROS) by increasing the presence of antioxidant enzymes ¹⁶³.

6.1.1.10 Vitamin-containing supplements (A; B12; C; D)

In DED, vitamins are typically studied as oral supplements rather than as components of topically applied tear supplements. See Section 12.2 for further details.

Vitamin A is perhaps the most well-studied vitamin in regard to DED, particularly as an oral supplement ¹⁶. It has also been studied as a topical supplement. One RCT compared the efficacy of topical vitamin A (retinyl palmitate 0.05%) four times a day versus cyclosporine A (CsA) 0.05% twice a day, versus control in 150 participants with DED ¹⁶⁴ alongside tear supplements. Both treatment groups improved in symptoms and signs, including TBUT, corneal staining, goblet cell density and impression cytology gradings ¹⁶⁴. However, as recently reviewed ¹¹, one of the vitamin A metabolites, isotretinoin (13-cis retinoic acid) is detrimental to meibomian gland health ^{165,166}. This Vitamin A metabolite inhibits the proliferation and promotes the death of human meibomian gland epithelial cells

^{165,166}. These effects may be the reason, at least in part, for the 13-cis retinoic acid–related induction of MGD ^{166,167}.

Vitamin B12 is reported to have antioxidant and anti-inflammatory properties, and as such has been evaluated in 30 participants using a topical formulation with 0.3% HA in post-menopausal female participants with DED ¹⁶⁸. The HA 0.3% and vitamin B12 eye drops decreased dry eye symptoms and improved tear film stability and tear volume compared to baseline. A larger randomized comparative clinical trial is needed to establish if the combination has greater efficacy than HA alone. Similar symptom and sign results were found with a formulation of 0.15% HA, 0.5% PEG 8000 and vitamin B12 in participants with moderate or severe DED ¹⁶⁹.

Ascorbic acid is the pure form of vitamin C and an antioxidative agent known to maintain free radical balance by scavenging ROS ¹⁷⁰. One study reported on the use of an eyedrop incorporating ascorbic acid and mesenchymal stem cell-derived exosomes, showing a decrease in ocular surface inflammation and reduced ocular surface damage *in vitro* and *in vivo* ¹⁷¹.

A systematic review and meta-analysis showed that serum levels of vitamin D were significantly lower in participants with DED, and correlated with OSDI scores, but no other DED parameter ¹⁷². Very few studies have investigated the direct incorporation of vitamin D into topical lubricants. A small cohort of eight participants with obstructive MGD were treated with a topical eyelid application of an analog of vitamin D3 ¹⁷³. The clinical scores for plugging of the meibomian gland orifices, lid margin vascularity, TBUT, meibum grade, and meibomian gland area were significantly improved in the participants with MGD after the eight-week treatment period, compared with pretreatment values. Oral supplementation with vitamin D resulted in significant improvements in the production, stability and quality of tears by reducing ocular surface damage and inflammatory markers in the tears ^{172,174-176}.

In conclusion, there is emerging evidence that antioxidants and vitamins may have a role in the management of patients with DED. However, prior to their widespread adoption in DED management, high quality evidence is needed on their safety and efficacy when used alone and in combination with other compounds.

6.1.1.11 Challenges in using tear supplements

Patients often face a trial-and-error approach to product selection, leading to significant costs and frustration ¹⁷⁷. A Cochrane systematic review of 43 RCTs looking at head-to-head comparisons of non-prescription tear supplements in 3497 people with DED ¹⁷⁸, indicated that while tear supplements may be effective in providing symptomatic relief, the relative lack of published head-to-head studies resulted in uncertainty as to which tear supplements were most effective. Moreover, there was limited agreement between studies in terms of the diagnostic criteria used, the study design and the measurements taken ¹⁷⁸. The review, however, found that 0.2% polyacrylic acid-based tear supplements were more effective at treating DED symptoms than 1.4% polyvinyl alcohol-based tear supplements ¹⁷⁸; it was not possible to draw conclusions on other tear supplements due to conflicting findings across studies.

In a more recent systematic review, combination formulations were found to be more effective than products containing a single active ingredient ⁹⁴. The combination of CMC with HA was more effective than either in isolation, while HA and the lower molecular weight, sodium hyaluronate, appear to benefit from the addition of trehalose, and CMC is enhanced by the addition of glycerine. A PEG-based lubricant was found to be more effective than CMC+carmellose sodium and hydroxypropyl methylcellulose-based products ⁹⁴.

A recent parallel-group study ¹⁷⁹ consisting of 20 participants per arm with moderate DED compared five differing lubricants every 15 minutes for one-hour

post-insertion, with one eye acting as the control (no drops). These five commercially available lubricants were based on products containing 0.5% and 1% CMC, 0.1% HA+trehalose, 0.4% PEG 400+0.3% propylene glycol and 0.1% HA+0.4% PEG 400+0.3% propylene glycol. Over the course of the test period, there was no difference between products or between eyes (test vs control) for TMH or ocular redness at any time point. There was a significant increase in non-invasive breakup time (NIBUT) between eyes and at all time points over the hour, with no product demonstrating superiority. These results demonstrate that short-term increases in tear stability can be achieved promptly with varying lubricant formulations¹⁷⁹.

The dosage and duration of treatment required to observe an effect have also been debated. A systematic review of 64 RCTs found “good” evidence that symptoms of DED can improve within one month of four times daily use of lubricants⁹⁴. In comparison, dry eye signs can take around four months to improve⁹⁸. This is highly relevant to the clinical advice given to patients. Patients failing to see an improvement in symptoms following use of the lubricants for at least one month, should consider a different artificial tear product or an alternative management strategy. Approximately one quarter of patients may not benefit from a particular artificial tear⁹⁸. This also has implications for study design, whereby shorter studies, less than four months in duration, are unlikely to demonstrate a clinical improvement in ocular surface and tear film parameters.

There are some practical considerations with respect to tear supplements. Different bottle types, each with their unique material strength and dispensing mechanism, may be challenging for patients with limited dexterity and pinch strength. An examination of the average force required to dispense a product was undertaken on 60 different bottles (57 lubricants and three dry eye medications)¹⁸⁰. The average force varied depending on the bottle type, with multidose preservative free bottles requiring more force than all other bottle types. This suggests that hand and pinch strength should be considered when

choosing products for DED management, as the squeezability of a lubricant drop bottle may influence compliance with its administration. Storage of lubricants is a consideration, as some patients store their lubricants in the fridge to provide a “cool and refreshing feeling” upon administration. However, the complex formulation of many products could be adversely affected by refrigeration and factors such as viscosity may be impacted, resulting in adverse effects on comfort and vision upon application. Indeed, studies have shown that there are no demonstrable comfort benefits through adopting such a refrigeration approach^{181,182}.

In conclusion, careful consideration of the literature suggests that while there is a great number of tear supplements, most of which are readily available over-the-counter, there is little agreement as to whether one formulation works better than another in treating different subtypes of DED. However, the evidence would suggest that patients with lipid deficiency benefit most from lipid-containing supplements⁹⁸. One month’s compliant use of the lubricant four times daily is likely to determine if a particular artificial tear supplement will be effective for symptom relief. To observe an effect on signs, an artificial tear supplement would be expected to require more extended use, for around four months⁹⁸.

Research continues to explore novel polymer combinations and advanced delivery systems to further enhance the efficacy of tear supplements. Innovations such as nanotechnology-based carriers and biodegradable microspheres are being investigated to provide sustained release of lubricants and therapeutic agents, potentially offering even greater benefits for patients experiencing the effects of chronic and severe DED⁹⁶. Future studies need to be more consistent in study design, including the selection of core outcome measures and there is a need for evidence-based, well run clinical studies comparing products over an adequate follow-up period, in well-defined groups of patients with DED.

6.2 Tear conservation devices

6.2.1 Contact lenses

Contact lenses can be a risk factor for DED due to their impact on the ocular surface¹⁸³, and therefore DED management may involve modifying the contact lens material, design, frequency of replacement or care system to mitigate this effect^{184,185}. In contrast, they can also protect the ocular surface from the stress forces of the eyelids moving over a poorly lubricated cornea and reduce corneal desiccation, leading to improved corneal healing and a reduction in pain, possibly by shielding the nociceptors¹⁸⁶.

Hydrophilic bandage lens materials worn on an extended wear basis for one week decrease dry eye signs and symptoms in participants with MGD following cataract extraction and intraocular lens implantation^{187,188}. Six weeks use of a bandage silicone hydrogel lens (replaced after three weeks of continuous wear) outperformed autologous serum in the management of participants with Sjögren disease over a three-month period¹⁸⁹. Soft contact lenses can also be used to hold an amniotic membrane over the ocular surface (see Section 10.3)¹⁹⁰. Soft contact lenses can also be used for improving drug delivery to the ocular surface^{191,192}, but this has not yet been developed into a commercial product for the management of DED.

Microbial keratitis is a risk factor when bandage contact lenses are worn overnight¹⁹³⁻¹⁹⁵, and in wearers with severe DED this risk is exacerbated^{186,196}. In such cases, topical non-preserved antibiotics are often added to the regime to reduce the risk of serious infection¹⁸⁶.

Scleral contact lenses have been used to treat patients with DED¹⁹⁷, providing the therapeutic benefit of enhancing both visual function and improving the health of the ocular surface. One retrospective study of 134 participants wearing scleral

lenses showed an improvement in OSDI scores in all but two participants from lens fit to follow-up, regardless of duration over which the lens had been worn ¹⁹⁸. Constructed from rigid, highly gas-permeable polymers, these lenses vault over the cornea and rest on the sclera ^{186,199,200}. This design creates a fluid reservoir between the posterior surface of the lens and the anterior surface of the corneal epithelium. This void can be filled with tear supplements or saline, creating a fluid reservoir, hence acting as a liquid bandage to not only provide ongoing moisture, but to also prevent evaporation at the ocular surface. They have been reported to be efficacious and well-tolerated in participants with severe DED ²⁰¹. In a retrospective report of scleral lenses when used in conjunction with plasma rich in growth factors (PRGF) eye drops in participants with a range of ocular surface diseases, the combination was found to be safe and effective in decreasing patient symptoms ²⁰². The rigid nature of the lens also offers protection against the microtrauma induced by the movement of the lid over the cornea. Additionally, the lens reduces evaporation of the tear film and the resulting increase in tear volume provides significant benefits. Improvement in visual acuity occurs due to the correction of the irregular astigmatism that is often present in these patients ¹⁸⁶.

Several studies have reported an improvement in visual acuity in patients with DED due to various underlying conditions such as Stevens-Johnson syndrome, Sjögren disease, and ocular graft versus host disease ²⁰³⁻²⁰⁶. Scleral contact lens use also improves ocular staining scores for both the cornea and conjunctiva, along with reduction in tear osmolarity levels ^{203,205,207}. Symptomatic improvement, reflected by improved OSDI scores, has also been accompanied by enhanced quality of life scores ^{203,205}. The fluid reservoir of the scleral contact lenses has been used as a modality for drug delivery. A study reported improvement in corneal neovascularization and visual acuity with concurrent instillation of bevacizumab to the reservoir ²⁰⁸ and another loaded the reservoir with CsA in nine participants with DED ²⁰⁹.

To fully realize the benefits of scleral contact lenses, it is essential to ensure optimal fitting parameters^{200,210}. This is even more important in patients with DED, who also have compromised ocular surfaces. Proper edge alignment with good central and limbal vault while avoiding mid haptic vessel compression can help improve comfort with scleral contact lens use. A common challenge associated with scleral contact lens use is midday fogging, which occurs due to accumulation of debris within the tear reservoir^{186,200,211,212}. Poor wettability of the lens can also be an issue, which can increase discomfort and hamper visual function. Nevertheless, scleral contact lens use is generally not linked to significant complications and effectively improve the symptoms and signs of DED^{200,205,207,213,214}. However, to date there is sparse evidence in the form of robust studies to advocate the use of scleral lenses for the management of patients with DED, despite its relatively common use in clinical practice.

6.2.2 Moisture retaining spectacles

Moisture retaining spectacles enclose the space surrounding the eyes, thereby limiting periocular airflow, increasing periocular humidity and reducing the rate of tear film evaporation^{32,33,215}. Sponge inserts can further increase chamber humidity in the periocular environment. For these to be effective, the frames need to be adjusted to the shape of the patient's face, to minimize leaks.

In a study evaluating the short-term effects of moisture retaining spectacles on participants with DED (n = 30), ocular comfort, TMH, NIBUT, and LLT continuously increased over time, reaching maximum levels at 60 minutes before gradually decreasing. However, these values remained higher than the baseline compared to a group who received sterile saline drops³³. In another study of 14 participants with DED, when exposed to a controlled wind exposure environment for 10 minutes, those wearing the moisture retaining spectacles had greater ocular comfort than those wearing conventional spectacles and those not wearing spectacles at all³¹. Tear evaporation rate and blink rate were also less,

and ocular surface measures (TBUT and fluorescein staining) after exposure were not different from baseline ³¹.

6.2.3 Punctal plugging

Punctal occlusion is recognized as an interventional treatment for moderate-to-severe aqueous deficient DED ², with the aim of increasing ocular surface fluid retention by partially or totally blocking the tear drainage system. A Cochrane systematic review that included 18 RCTs of collagen or silicone punctal plugs did not find conclusive improvements in symptoms or signs of DED ²¹⁶. One trial found that the frequency of artificial tear application was lower in eyes with punctal plugs than those without. Variations in the type of punctal plug used, in the DED subtype and severity of recruited participants, and a lack of standardized trial methodology limited the evidence surrounding efficacy and safety ²¹⁶. The review also found that punctal plugs can be associated with adverse reactions such as epiphora and plug displacement and, more rarely, with inflammatory and infectious conditions such as canaliculitis, pyogenic granuloma and dacryocystitis ²¹⁶.

In a prospective, longitudinal, single-center study, nonabsorbable punctal plugs were inserted bilaterally into the lower punctum of 30 patients with moderate DED. Three weeks after punctal occlusion, tear proteins including glutathione synthase and IL-1 were upregulated, while cholinergic receptor (neuronal) alpha-7 and lymphocyte cytosolic protein-1 were down-regulated ²¹⁷.

An RCT that enrolled 50 participants with DED to receive either an intracanalicular injection of hydroxybutyl chitosan solution (Qisheng Biologic Agent Limited Company, Shanghai, China) or VisiPlug® treatment (Lacrimedics Inc, Dupont, WA, US) found both methods comparably alleviated symptoms and signs of DED relative to baseline after 12 weeks of treatment ²¹⁸.

One study examined the microbiologic outcomes of removing silicone punctal plugs from dry-eye participants due to discomfort, mostly secondary to protrusion of the plug, with or without granulation ²¹⁹. Bacterial culture was positive in 42.2% of cases, with *Klebsiella* being the most frequently identified organism (18.5%). Susceptibility to vancomycin was demonstrated to be 100%, to third-generation cephalosporins was 88.5%, and to levofloxacin was 81.0% among the quinolones tested ²¹⁹. These findings, along with local knowledge of antimicrobial resistance patterns for ocular isolates, may help guide the selection of antibiotics for treating complications associated with silicone punctal plugs ^{220,221}.

6.2.4 Newer plug designs and other technologies

A single-site, prospective, open-label study evaluated an intracanalicular plug made of cross-linked HA. Sixty-three participants with DED for whom tear supplements were not effective were included. The study found improvements in corneal staining, Schirmer test scores, TBUT and TMH relative to baseline, three months after fitting ⁷⁸.

A prospective, multicenter, double-masked RCT was conducted with 157 participants to compare a novel crosslinked HA canalicular filler (LACRIFILL® Canalicular Gel; Nordic Pharma, Hoofddorp, The Netherlands) with a commercially available hydrogel canalicular plug ²²². The filler or plugs were inserted bilaterally in the inferior canaliculi. The filler was found to be non-inferior to plugs for the mean Schirmer test score change from baseline and for the proportion of participants achieving a clinically important improvement in OSDI. The study concluded that the crosslinked HA filler is a safe, well-tolerated, and effective method to treat DED by canalicular occlusion. Clinically and statistically significant improvements in signs and symptoms of DED were sustained through six months ²²².

Other innovative technologies have been proposed to improve the efficacy of punctal plugs in treating DED. Drug-loaded hydrogel or organogel punctal plugs

using highly biocompatible HA derivatives or immunomodulators such as CsA have been tested *in vitro* and *in vivo*^{223,224}. Whilst 3D printing has been used to create personalized punctal plugs with built-in drug delivery systems tailored to individual punctal morphology, no clinical studies have been published to date²²⁵.

6.3 Tear restoration or stimulation

Tear deficiency due to reduced volume or altered composition can lead to DED. A lack of individual tear film constituents can be addressed through various approaches (Sections 6.3.1, 6.3.2 and 6.3.3), that restore or stimulate the production of the individual missing tear film elements. As discussed in Section 6.3.4, an emerging category of “neuromodulation” is based on increasing activity of the trigeminal nerve to stimulate tear production that includes several tear components.

6.3.1 Restoration or stimulation of lipid

The 2011 TFOS workshop on MGD demonstrated the significant impact that MGD has as an etiological driver of DED^{167,226-229} prompting considerable research in optimising its management to enhance lipid delivery to the ocular surface.

6.3.1.1 Meibomian Gland Dysfunction: At-home treatments

6.3.1.1.1 Warm compresses

Warm compresses are employed in the treatment of MGD, with the objective of melting thickened meibum within the glands, facilitating gland expression via subsequent manual massage. The aim of warm compresses is to enhance tear film LLT and encourage improved gland function.

There has been a surge in options available for patient-applied (‘at-home’) therapies, whereby the patient warms their eyelids with non-prescription over-

the-counter warm compresses, ranging from heated, moist towels, to commercially available products through to more technological electronic devices²³⁰⁻²⁴³. At-home therapies are readily accessible to consumers through online platforms and small manufacturers. However, not all available options have accompanying evidence regarding their safety and efficacy, or even a standardized approach to application^{234,236,241}.

Secretions from obstructed meibomian glands have higher melting points than those from normal glands²⁴⁴. Therefore, it is recommended to use heating temperatures between 40°C and 41.5°C and to ensure the heat is retained long enough to be effective²⁴⁵. The temperatures reached should not be so high as to risk burning the skin or other adverse effects on the eyelids and ocular surface²³⁶.

Warm compresses can be classified into those that apply dry or wet heat, subdivided into those that are chemically heated, microwave heated or electronically powered, and it is recognized that they may not have equivalent efficacy^{234,239}. One study compared dry heat and moist heat warm compresses and reported that, during the moist heat treatment, the eyelids may become wet, leading to a potentially counterproductive effect due to evaporative cooling²⁴⁶.

Based on the limited available evidence, it is suggested that an appropriate heated device is used at least once a day for 10 minutes²³⁹ or twice a day for five minutes²⁴⁷, followed by gentle expression of the glands to help express the meibum. Towels heated to 45°C every two minutes have been found to be comparable in their delivery of heat to commercially available devices²⁴¹, but this is a time-intensive process, risking potential challenges with patient compliance over time.

Following the application of warm compresses, lid massage is required to express the meibum and help unblock the meibomian glands^{241,248-250}. While massage of the lids and the globe chronically has been associated with corneal deformation and keratoconus, a prospective study reviewing corneal topography

following 30 minutes of eyelid warming and massage found no significant differences during the observation period ²⁵¹.

The efficacy of several new products have been reported, with varying degrees of certainty with regards to supporting evidence ^{230,232,233,235,238,252-255}. Increasingly, the clinician plays a valuable role in guiding patients about the evidence supporting these products and to recommend suitable treatments tailored to their specific diagnosis.

One study investigated the impact of a warm compress containing menthol as a potential treatment for DED by examining its effects on the tear film in 20 healthy participants and 35 participants with DED ²⁵⁶. Repeated application of menthol-containing warm compresses significantly increased tear meniscus volume and TBUT in both groups. The authors suggested that the repeated use of the warm compress containing menthol stimulated TRPM8 channels and could be a potential novel treatment for DED ²⁵⁶.

Previous reviews of clinical studies using warm compresses for the management of MGD have been published ^{230,234,236,241}. Table 2 highlights a variety of studies using different warm compress approaches and their significant findings.

A number of topics require further investigation and clarification, including:

- The general lack of studies on many commercially available warming masks;
- Lack of evidence as to how long a compress or mask should be applied;
- Lack of standardization as to the appropriate type and length of eyelid massage following mask use;
- Lack of evidence on the effect on corneal topography that extended time may have when wearing a 'heavier' mask, as some patients may fall asleep with their mask on their eyes.

Table 2: Example of studies using warm compresses to treat MGD

Study	Type of participants	Treatment	Product comparison	Sample size	Duration	Randomized	Outcomes showing improvement	No significant differences from comparator
Leeungurasati en et al, 2020 ²³⁸	Healthy	Wheat hot pack	Pottery hot pack	30 crossover	10 mins use and after 10 mins	Yes	-	Surface lid temperature Tissue blood flow
Travé-Huarte and Wolffsohn, 2021 ²⁴³	DED (TFOS DEWS II criteria)	Water propelled, heating eye massager	No treatment	15	2 weeks	Yes	Symptoms	Osmolarity NIBUT TMH LLT corneal and conjunctival staining heart rate sleep pattern
Garcia-Marques et al, 2022 ²³⁵	DED (TFOS DEWS II criteria)	MGDRx Eyebag in 18-31 year olds	MGDRx Eyebag in 61-90 year olds	30 younger ; 30 older	2 weeks	No	NIBUT LLT	Symptoms Meibomian gland loss Meibum quality Gland obstruction

								Telangiectasia
Arazi et al, 2024 ²⁵⁴	Meibomian gland disease	Spectacle mounted infrared warming device	None	10	2 weeks	No	-	Symptoms TBUT Schirmer
Wang et al, 2024 ²⁵⁷	Mixed form DED	Disposable self- heating mask	Hot cotton towel	134	12 weeks	Yes, non- masked	Symptoms TBUT Corneal staining	Schirmer

LLT: lipid layer thickness; NIKBUT: non-invasive Keratograph breakup time; OSDI: Ocular Surface Disease Index; TBUT: tear breakup time; TMH: tear meniscus height

6.3.1.1.2 Essential fatty acids

Polyunsaturated fatty acids (PUFA) such as omega-3s can play a role in improving the signs and symptoms of DED in patients with MGD ²⁵⁸⁻²⁶³, although some studies have been unable to demonstrate any positive benefits of oral omega-3 intake on MGD parameters ^{264,265}.

A prospective, randomized, double-masked, RCT enrolled 50 subjects with mild to moderate DED who exhibited signs of MGD ²⁶². Patients were divided into two groups: 24 patients in the omega-3 group and 26 patients in the placebo group. The omega-3 group received 600 mg of eicosapentaenoic acid and 1640 mg of docosahexaenoic acid, while the placebo group received 3000 mg of olive oil. The TBUT, corneal staining and OSDI scores improved significantly after four and eight weeks in both groups. After eight weeks, TBUT and MGD score in the omega-3 group was significantly improved to a greater degree than the placebo group ²⁶².

A multicenter, randomized, investigator-masked study investigated the effectiveness of a re-esterified triglyceride form of omega-3 in 107 subjects with MGD, post cataract surgery ²⁶³. Patients were randomly assigned to the omega-3 group or a control group. After 12 weeks, TBUT, corneal staining, Standard Patient Evaluation of Eye Dryness (SPEED) and OSDI scores were significantly improved in the omega-3 group compared with the control group. In addition, meibomian gland quality and expressibility were significantly improved in subjects with more severe MGD in the omega-3 group only ²⁶³.

6.3.1.1.3 Topical pharmacological treatments

The TFOS Meibomian Gland Disease Workshop concluded that the core mechanisms of gland obstruction were ductal hyperkeratinization and increased meibum viscosity, with consequent orifice plugging, ductal obstruction and dilation, and ultimately gland atrophy observed clinically as dropout ¹⁶⁷.

6.3.1.1.3.1 *Topical azithromycin*

Application of topical azithromycin is also an option for the management of MGD, as it offers comparable results to oral antibiotics, such as doxycycline, without the systemic side effects (gastrointestinal disturbance being the most common) ²⁶⁶⁻²⁶⁸. Further RCTs with large populations and different demographics are needed to assess the long-term effects of topical antibiotics such as azithromycin as a management option for MGD.

6.3.1.1.3.2 *Topical selenium sulfide*

Topical preparations of selenium sulfide are an effective treatment for hyperkeratotic conditions, tinea versicolor, seborrheic keratitis and other dermatologic conditions ^{269,270}. Selenium sulfide is thought to break down protein aggregates and may slow future deposition of keratin ²⁷¹. Selenium products have poor ability to cross epithelial boundaries. They must be applied topically at the site of intended action, where a redox reaction causes breakage of disulfide bonds and consequent protein disaggregation ²⁷²⁻²⁷⁴. AZR-MD-001 (Azura Ophthalmics, Tel Aviv, Israel) containing selenium sulfide, was developed as a semi-solid ointment for ophthalmic use. A Phase II study of 245 participants with MGD treated with ointment to the eyelid margin twice weekly demonstrated efficacy after three months in improving both patient symptoms (by OSDI, visual analog scale and SPEED questionnaires) and clinical signs ²⁷¹. The number of meibomian glands yielding liquid secretion, meibum quality and TBUT improved after three months of treatment relative to vehicle, and this was sustained after six months of treatment ²⁷⁵. Separate studies in 67 participants with MGD and contact lens discomfort reported improvements in the number of glands yielding liquid secretion, meibum quality, TBUT and contact lens wearing time ^{276,277}. These studies indicated that AZR-MD-001 is safe, well-tolerated and effective for the treatment of evaporative DED secondary to MGD with only two bed-time applications per week.

6.3.1.2 Meibomian Gland Dysfunction: In-office treatments

6.3.1.2.1 Device-driven technologies: Inner eyelid heating and massaging

The LipiFlow® Thermal Pulsation System (Johnson & Johnson Surgical Vision, Inc. Irvine, CA, USA) is an in-office vectored thermo-mechanical therapy that delivers localized heat and pressure to the meibomian glands, facilitating the flow of the meibum to contribute to the tear film lipid layer at the ocular surface in a single application². This procedure requires topical anaesthesia prior to its use. It has been shown that a single procedure can increase meibomian gland secretions and reduce DED symptoms and that the effect can be sustained for at least six months^{278,279}. In a study of 20 participants with evaporative DED secondary to MGD, a single 12-minute thermal pulsation procedure was shown to result in significant improvement in meibomian gland secretions and SPEED scores for up to three years²⁸⁰.

A publication reviewed 11 articles on the value of LipiFlow in treating DED²⁸¹. While LipiFlow has shown benefits relative to warm compress treatment, the three studies without direct industry support concluded that LipiFlow treatment was not significantly more effective than warm compress and eyelid hygiene regimens, when these latter regimens are undertaken appropriately²⁸¹. A systematic review evaluating the outcomes reported from 13 trials with a total of 1155 randomized participants²⁸² found no evidence of a difference in meibomian gland expression, meibum quality, or TBUT when comparing LipiFlow with warm compresses. Another five trials found thermostatic devices (TearCare; iLux; MiBoFlo) achieved a mean of 4.59 points better on OSDI than LipiFlow at four weeks, although the evidence was of low certainty²⁸². When comparing LipiFlow plus an eyelid hygiene with eyelid hygiene alone, there was no evidence of a difference in signs or symptoms at any evaluated time point²⁸².

Systane iLux® (TearFilm Innovations, Inc., Alcon, Fort Worth, TX, USA) is an eyelid thermal pulsation system consisting of a single-use patient interface device and a handheld, battery-powered instrument ^{283,284}. Its purpose is to maintain an eyelid temperature of 38-42°C to melt meibum, while simultaneously compressing and expressing the meibomian glands ^{283,284}. This treatment also requires topical anaesthesia prior to device application. No adverse events related to device use were reported in two clinical studies ^{283,284}.

When iLux was compared with LipiFlow treatment, both treatments improved the signs and symptoms of MGD, including meibomian gland score, TBUT, and OSDI scores after four weeks of treatment, with no statistically significant difference between them ²⁸³. Another randomized trial demonstrated that iLux improved clinical parameters, such as meibomian gland score, NIBUT and patient symptoms (by Impact of Dry Eye in Everyday Life - Symptom Bother scale), after 12 months following a single treatment ²⁸⁵.

A review of various in-office thermal treatments suggested that iLux could be a better treatment option for patients who prefer a single treatment over 6-12 months or are not compliant with time-intensive, at-home regimens ²⁸⁴. However, while such in-office treatments provide rapid relief of symptoms that may last up to one year, there is a considerably higher cost than the at-home treatments ²⁸⁴. A new generation device, iLux²® is available, which has replaced the magnifier with a screen for meibomian gland imaging, hence it can be used both as a diagnostic tool and a therapeutic treatment option.

6.3.1.2.2 Device-driven technologies: External eyelid heating

The TearCare® System (Sight Sciences, Inc. Menlo Park, CA, USA) consists of four electrothermal devices (SmartLids®) that are adhesively affixed to the upper and lower eyelids ^{284,286-288}. These devices deliver regulated thermal energy across the eyelids at temperatures ranging from 41°C to 45°C for 15 minutes at a

single visit ²⁸⁸. Meibomian gland expression is then manually performed after lid heating by the eyecare practitioner ^{284,286-288}. Application of this treatment itself does not require anesthesia and because the adhesives are placed on the outer lid, the person can blink normally and go about their daily activities (ie. reading, watching tv, etc) when being treated.

TearCare treatment demonstrated a significant improvement in TBUT (of nearly 12 secs by two weeks), corneal and conjunctival staining, and meibomian gland score compared to a daily warm compress regimen (n=12 in each group), that was maintained over six months ²⁸⁷. No adverse events were reported. The study group underwent re-treatment at month seven, and the participants experienced additional benefits in both objective and subjective parameters ²⁸⁷.

A multicenter RCT was undertaken whereby participants with DED due to MGD received either a single TearCare treatment (n = 67) or a single LipiFlow treatment (n = 68) at baseline and were followed up for one month post-treatment ²⁸⁹. Both groups demonstrated significant improvements in TBUT, meibomian gland secretion score and symptoms, with no significant differences for any result between the treatments. The results demonstrated that a single TearCare treatment significantly alleviates the signs and symptoms of DED in participants with MGD and was equivalent in its safety and effectiveness profile to a single LipiFlow treatment ²⁸⁹. In a follow-up multicenter RCT, participants with MGD received either a single TearCare treatment (n = 115) or a single LipiFlow treatment (n = 120) and were followed for one month post-treatment ²⁹⁰. In participants with more severe MGD, TearCare performed significantly better than LipiFlow in improving quality of vision and overall DED symptom frequency, as determined by OSDI and Symptom Assessment in Dry Eye (SANDE) questionnaires ²⁹⁰.

In another study, TearCare-treated participants showed more significant improvements in TBUT and meibomian gland scores over a six-month period

than those treated with twice daily CsA (Restasis®; AbbVie; North Chicago, IL, USA) drops ²⁹¹. Symptoms improved similarly in both groups, and conjunctival and corneal staining, meibomian gland score and Schirmer test scores were also similar ²⁹¹.

MiBoFlo Thermoflo® (MiBo Medical, Dallas, TX, USA) is a thermostatic device that consists of a silver-plated handheld probe that delivers thermoelectric heat to the outer eyelid, maintaining a temperature of 42°C for 10 minutes ²⁹². This procedure does not require anaesthesia. A retrospective case series involving 102 participants with MGD demonstrated that 6 months following three MiBoFlo treatments, with a two week interval between each, there was a 36% improvement in SPEED and a 35% improvement in OSDI questionnaire scores compared to baseline ²⁹³. Objective parameters, such as corneal and conjunctival staining, TBUT, osmolarity and the number of glands secreting any liquid also improved significantly, and no device-related adverse events were reported ²⁹³.

In a prospective clinical trial involving 54 participants with MGD, MiBoFlo and LipiFlow similarly improved OSDI and meibomian gland secretions relative to baseline, but had no effect on non-invasive TBUT, corneal fluorescein staining or meibomian gland loss ²⁹². In a non-randomized case series, participants were either treated with MiBoFlo and manual expression or automated expression using LipiFlow ²⁹⁴. Both treatments showed improved OSDI and SPEED questionnaire scores and corneal staining, lissamine green conjunctival staining and TBUT at the six-month follow-up visit. Manual therapy with MiBoFlo resulted in greater subjective and objective improvement scores than automated therapy with the LipiFlow device.

Latent heat using a goggle, marketed under the name Blephasteam® (Laboratoires Thea, Clermont-Ferrand, France), has been described previously in the TFOS DEWS II Management report ² and others ^{295,296}.

In a prospective study, 73 participants used the device twice a day for 21 days²⁹⁷. Participants found the device comfortable and were able to carry out certain activities (ie. watching TV, reading and using a computer) during the treatment session, with no adverse events reported. Symptoms, using a visual analog scale, decreased significantly. Schirmer score, osmolarity and TBUT showed no significant changes during the study period.

A three-month RCT examined participants with MGD who were randomized into three treatment groups (warm towel, EyeGeine® self-heating eye mask and Blephasteam)²⁹⁸. Participants using the Blephasteam device reported a significant improvement in symptoms compared to those using a warm towel, with the EyeGeine mask not significantly different to the warm towel. No significant changes were observed for Schirmer score, TBUT or number of occluded meibomian glands.

Treatment effectiveness according to MGD severity was evaluated using three treatment options (Blephasteam, a liposomal spray and a microwaveable eye-mask¹²⁷. NIBUT and lipid layer grade improved after 10 minutes, independent of treatment type. The improvement in NIBUT was significant for the pronounced MGD group, with the mild and control groups failing to reach significance. More research is needed to evaluate efficacy across gland dropout severity groups with a variety of eyelid warming devices.

A prospective, case-controlled study compared hot compresses, Blephasteam and a sauna for 10 minutes at approximately 85° C, on the temperature of the eyelid using infrared thermography²⁵³. The study revealed that Blephasteam significantly increased the mean eyelid temperature from baseline and was more effective than hot compresses.

An open-label, randomized study evaluated a microwaveable eye mask (TheraPearl, Bausch + Lomb, Rochester, NY) and Blephasteam in a Norwegian

population with mild to moderate MGD ²⁹⁹. Both treatments improved TBUT and OSDI but did not differ from each other after six months of daily use. Of note is that a decrease in compliance was observed using a daily diary for both treatments over the study period, which remains an issue with the management of patients with DED.

A review of the literature in 2021 resulted in 18 articles on warm, moist air eyelid warming devices ³⁰⁰. For a single application, seven studies using Blephasteam and four studies using a steam-based research prototype found an increase in eyelid temperature, and improvements in LLT and TBUT.

Overall, the latent heat Blephasteam device appears to be a well-tolerated, safe device for elevating eyelid temperature to therapeutic levels and improving signs and symptoms in patients with MGD. However, there remains a paucity of RCTs comparing this latent heat device with other eyelid warming devices across the dry eye severity spectrum and evidence of moist versus dry heat benefits are still lacking.

6.3.1.2.3 Device-driven technologies: Various

6.3.1.2.3.1 Intense pulsed light (IPL)

The TFOS DEWS II Management & Therapy Report suggested that intense pulsed light (IPL) was a safe and effective way to treat MGD and DED ². It has been used in dermatology for many years to improve a variety of skin complaints and the exact mechanism of action in managing DED remains largely unknown. Potential mechanisms include thrombosis of abnormal blood vessels below the skin surrounding the eyes, heating the meibomian glands, activation of fibroblasts, decreasing bacterial load on the eyelids, regulation of anti-inflammatory agents and changes in the levels of ROS ³⁰¹⁻³⁰⁴.

IPL, which involves the application of a series of non-coherent polychromatic light to the periorbital region, produces selective photothermolysis of the irradiated tissue, leading to ablation and reduction of telangiectatic blood vessels around the eyelid margin ³⁰⁵.

Since 2017, an increasing number of clinical trials have been conducted to assess the efficacy and safety of IPL. These trials have mostly been aimed at treatment of moderate to advanced MGD. IPL treatments have demonstrated reduced symptoms and signs of DED ³⁰⁶⁻³⁰⁹, improved optical quality ³⁰⁸, supporting an improved tear film lipid layer ^{309,310} and reduced dependence on the application of tear supplements ³¹⁰.

A randomized trial involving 132 participants demonstrated that IPL was more effective for treating DED secondary to MGD than daily use of a traditional warm compress and eyelid gland massage ³¹¹. An RCT of 45 participants assigned them to receive either the combination of IPL and meibomian gland expression or meibomian gland expression alone ³¹². The results demonstrated that the combination therapy showed a benefit in lid margin abnormalities, LLT, TBUT and NIBUT, meibomian gland score and ocular surface fluorescein staining score at 24 and 32 weeks, as well as significant improvement in the SPEED score at 32 weeks ³¹². Another clinical trial evaluated three sessions of IPL combined with meibomian gland expression compared to a sham, showing an improvement in meibomian gland yielding secretion score and TBUT at one, three and six months, but no difference at nine months ³¹³. Studies have suggested that IPL is more effective in patients with less severe meibomian gland atrophy ³⁰⁶, if there is a lower baseline TBUT ³¹⁴, and in younger patients ³¹⁵.

Several systematic reviews have appraised the body of evidence for IPL in the management of DED. One included RCTs studying the effectiveness or safety of IPL for treating MGD ³¹⁶. Three RCTs included data from 114 adults (228 eyes), with follow-up periods ranging from 45 days to nine months. The authors

concluded that their review found a scarcity of RCT evidence relating to the effectiveness and safety of IPL as a treatment for MGD. In addition, due to a lack of comprehensive reporting of adverse events, the safety profile of IPL in this patient population was also unclear ³¹⁶. A systematic review provided data from 11 RCTs published between 2015 and 2021 on 759 participants ³¹⁷. The authors reported that IPL had a positive effect on tear stability (evaluated by TBUT and NIBUT) compared with baseline. However, the effect on DED symptoms (OSDI and SPEED) were less clear. Lei and colleagues included 1842 participants from 11 RCTs up to January 2022 ³¹⁸. Their results reported that IPL therapy was associated with significantly reduced OSDI and SPEED scores and that both TBUT and NIBUT significantly increased, but corneal fluorescein staining was unaffected ³¹⁸. The most recent systematic review published to date reported on studies up to March 2022, and included 13 studies on 931 participants ³¹⁹. The results demonstrated that TBUT and OSDI scores improved significantly post intervention, but that corneal fluorescein staining and SPEED scores showed no statistically significant difference from baseline. They concluded that current evidence indicates IPL as a possible adjunctive treatment in individuals with DED, but that further studies through more extensive trials are needed to validate this finding and elucidate its mechanism of action ³¹⁹.

IPL treatment typically targets the skin below the lower eyelids and both temporal areas, excluding the upper eyelid ³²⁰. In a prospective trial, 30 participants had standard IPL treatment, with half randomly assigned to receive additional IPL treatment on the upper eyelid ³²⁰. While dry eye symptoms improved in both groups, participants who received additional upper eyelid treatment showed a greater improvement and patient satisfaction remained high ³²⁰.

In IPL treatment, the penetration depth and selective chromophore targeting can be adjusted using specific filters and fluences. In a study involving 40 participants ³²¹, IPL treatment was randomly administered using more power in one eye (560 nm and 16 mJ/cm² versus 590 nm and 14 mJ/cm²). There was no significant

difference in therapeutic efficacy and patient satisfaction, but less discomfort was reported by the group treated with the shorter wavelength and higher energy filter. Another prospective, randomized paired eye trial found a cut-off (590nm filter) and a notch (acne) filter both similarly improved ocular surface parameters, meibomian gland function, and subjective symptoms ³²². A comparison of an IPL device using three treatments of 'optimal pulse technology' (with no pulse spike) compared to four treatments of 'intense regulated pulsed light (regulated train pulses) found that while both devices improved signs and symptoms for three months, the former performed better in enhancing the meibomian gland function in the lower eyelids and in improving some tear film metrics ³²³. However, it should be noted that this study lacked a control group, and the follow-up period was relatively short.

Studies have analyzed changes in cytokine levels following IPL treatment. One RCT involving 13 participants ³²⁴ found those treated with IPL combined with meibomian gland expression exhibited greater reductions in IL-6, IL-6R, IL-1b, IL-13, and CCL11/Eotaxin than those using warm compresses combined with meibomian gland expression. Both groups showed a significant decrease in all tear cytokine levels compared to baseline.

In addition to patients with MGD, studies have demonstrated that patients with blepharokeratoconjunctivitis ³²⁵, Sjögren disease ³²⁶, glaucoma-related DED ³²⁷, refractive surgery-induced DED ³²⁸, graft-versus-host disease ³²⁹ and neuropathic pain ^{330,331} can all benefit from IPL treatment.

In addition to treatment with IPL alone, various studies have reported positive responses from combination treatments for patients with DED. These include the use of IPL in combination with 0.05% CsA ³³², diquafosol ³³³, doxycycline ³³⁴, blood extract eyedrops ³³⁰, thermal pulsation ^{335,336}, heated eye masks ^{337,338}, and microblepharoexfoliation ³³⁹.

Several companies now manufacture IPL instruments, and it is important to consult the user manual and individual company for any precautions inherent to each specific instrument. IPL is generally contraindicated in pregnant or breastfeeding women, those wearing a pacemaker or cardiac defibrillator, patients with diabetes, epilepsy or hemophilia, recent or planned radiation or chemotherapy, patients with a dark skin color (Fitzpatrick scale Type VI), previous history of sunlight allergy, recent exposure to tanning procedures (creams, tanning beds) and those using photosensitizing treatments such as doxycycline and tetracycline ³⁴⁰. IPL should be avoided in young children and those with anterior uveitis or glaucomatocyclitic crises ³⁴¹. Caution should be taken with those with active skin infections or inflammation (eczema), tattoos, permanent eye makeup, cold sores, open lacerations or abrasions in the treatment zone. Cosmetics/creams should be removed prior to the procedure and moles/nevi in the treatment zone should be covered. Instrument-specific eye covers/shields/goggles should be used during the procedure for the patient and appropriate UV-filtering protective eyewear for the examiner. A sign or other identifier should be displayed outside the room to signal when the instrument is being used to avoid unintended light exposures for others as the light intensity is very bright. A report has shown preliminary positive outcomes of using IPL directly on the eyelids, under carefully controlled conditions, without a protective eye shield ³⁴². However, this remains to be investigated with other IPL instruments or protocols. This list of precautions is not exhaustive, and the literature is lacking a well-defined list of contraindications and precautions for IPL.

In conclusion, most studies investigating the use of IPL to treat patients with MGD-related DED have demonstrated improved symptoms and signs, although the degree of efficacy and its duration varied greatly depending on concomitant treatment, and the number of treatment sessions. In addition, there can be differences between instruments and the algorithms used. There is still a need for independent, large, randomized, controlled long-term studies to define the

most efficacious treatment regime and to predict which patients may benefit the most.

6.3.1.2.3.2 *Low-level light therapy (LLLT: Red light)*

Low-level light therapy (LLLT) is the application of low-power, high-fluence monochromatic or quasi-monochromatic light from light-emitting diodes through a wide array of wavelengths (e.g., red, yellow, blue). LLLT is believed to work via the process of photobiomodulation ³⁴³, which is a non-thermal biological process activated by specific wavelengths of light via photoacceptor molecules, to induce a cascade of physiological events.

In this process, the primary photoacceptor implicated is cytochrome c oxidase, an enzyme in the mitochondrial respiratory chain. When photons are absorbed by this enzyme, it undergoes redox changes, leading to enhanced mitochondrial activity. This results in increased production of adenosine triphosphate, the cell's primary energy currency ^{344,345}. Additionally, photobiomodulation induces the photodissociation of nitric oxide from cytochrome c oxidase, improving mitochondrial respiration by relieving inhibition caused by nitric oxide ^{346,347}. This process also generates ROS at controlled levels, which act as secondary messengers to activate signaling pathways ³⁴⁸. Together, these mechanisms are believed to contribute to LLLT's therapeutic benefits, including accelerated tissue healing, pain relief, and anti-inflammatory effects. By carefully controlling parameters such as wavelength, intensity, and energy dose, photobiomodulation can precisely modulate cellular responses without causing harm to the tissue

^{343,346,348,349}

This type of photobiomodulation had its beginnings in dermatology and is now also demonstrating efficacy in lid diseases that contribute to DED and other inflammatory conditions of the ocular surface and periocular area. The limited studies that have investigated the efficacy of LLLT as a stand-alone treatment have used varying devices, light parameters and clinical protocols, although the

majority within the ophthalmology literature have employed the eye-light® (Espansione Group, Bologna, Italy) device ³⁵⁰⁻³⁵⁴. One review suggested that, at the time, there was a lack of clear evidence demonstrating that LLLT alone is beneficial in the management of MGD ³⁵⁵.

A randomized clinical trial of LLLT twice a week for three weeks compared to a sham (n=20 in each group) showed better results with respect to fluorescein and lissamine green ocular surface staining, Schirmer test, and upper lid meibomian gland drop out scores, but not TBUT, lid swelling, lid telangiectasia, meibomian gland secretion, and expressibility scores ³⁵⁰. Thirty participants with mild-to-moderate DED underwent three applications of LLLT for 15 mins with the eye-light® device at each visit over three weeks ³⁵⁴. Treatment with LLLT resulted in significant differences in NIBUT, TMH, tear film LLT, OSDI score, Schirmer test score, meibum quality score and eyelid temperature.

A significant difference between LLLT and IPL is that LLLT can be applied directly to the eyelids, unlike IPL. Also, LLLT is unaffected by skin colour and can therefore be applied safely to all skin types. A randomized clinical trial comparing LLLT and IPL (n=20 in each group) found both treatments to be effective in alleviating ocular discomfort symptoms and safe, although LLLT resulted in a more significant improvement in symptoms and an increase in tear volume ³⁵¹.

Several studies have combined the effect of IPL with LLLT using the eye-light® device in participants with MGD ³⁵⁶⁻³⁶⁰. In a multicenter retrospective chart review, researchers evaluated the effects of combined IPL and LLLT therapy delivered with the eye-light® device on 460 eyes of participants who were unresponsive to other medical management for MGD ³⁶⁰. Combined treatment was applied in intense short pulses on the area of the face near the eye. This was followed by longer exposure to low-level red light on the cheek and over the closed lids. Two to four treatments were applied one to two weeks apart. Following the combined treatment, mean OSDI scores were significantly lower. In

addition, a one-step or greater reduction in MGD grading was found in 70% of eyes, and 28% of eyes had a two-step or greater reduction and TBUT also improved. Prior to treatment, TBUT was ≤ 6 seconds in 86.7% of eyes, versus 33.9% of eyes after treatment ³⁶⁰.

More research is needed to fully understand the long-term efficacy of LLLT and optimal treatment protocols, and it is often considered most effective when combined with other treatments for DED. More work is needed to determine the relative contributions to the benefits of LLLT from photobiomodulation and from other possible mechanisms, such as the heat generated by the light-emitting diode array in the treatment device ³⁵⁵.

6.3.1.2.3.3 *Plasma treatment*

Plasma treatment for evaporative DED secondary to MGD involves plasma application directly onto both the upper and lower eyelids ³⁶¹. This technology produces mobile ions from atmospheric gas, to transform the superficial layers of the target tissue from a solid form to a gaseous state at low temperatures ³⁶². To date, little evidence is available on its efficacy for the management of DED. A single cohort study with 20 participants with MGD and no control group reported an improvement in symptoms relative to baseline (although no statistics were presented), but no sustained benefit in tear film stability or volume ³⁶¹.

6.3.1.2.3.4 *Quantum Molecular Resonance Electrotherapy*

Quantum molecular resonance is a technique in which a low intensity high frequency electric current is administered to a specific biological tissue. In vitro studies have shown that electrical stimulation ('electrotherapy') can increase cell migration and proliferation ³⁶³. There are several studies of its use in participants with DED ³⁶⁴⁻³⁶⁹.

A case series in participants with mixed DED using the standard protocol of a 20-minute session per week for four weeks showed improvements in OSDI, NIBUT, corneal staining and meibomian gland parameters, in addition to a reduction in

matrix metalloproteinase-9 (MMP-9) levels³⁶⁷. In addition, it has also been found to be effective in the management of DED participants exhibiting MGD³⁶⁴. More recently it has been shown to be effective in treating patients with recalcitrant DED³⁶⁵. However, the follow-up for this study was limited at only two weeks post treatment. A double-blind RCT in an academic medical center for two years was conducted in which 40 participants (20 per arm) received treatment or placebo with the quantum molecular resonance device, once per week for four weeks³⁶⁹. The mean OSDI score significantly improved in the intervention group, whereas the control group showed no significant change. MGD scores and corneal staining significantly improved in the intervention group only. No significant difference was seen in TBUT, visual acuity, and Schirmer scores between the test and control groups.

More research is needed to understand the true value of this technique, with randomized trials conducted over extended periods of time.

6.3.1.2.3.5 *Radiofrequency*

Radiofrequency is an electromagnetic wave that uses an oscillatory field to charge particles within the target tissue, generating heat through friction between vibrating tissue particles³⁷⁰. A pilot study involving 10 participants with MGD compared LipiFlow with ThermoLid® radiofrequency (Pellevé wrinkle reduction system, Ellman International, UK)³⁷⁰. After three months of treatment, they had similar efficacy in improving meibomian gland expression, wax plugging score, SPEED, and OSDI scores. The Marx line score decreased after three months in the radiofrequency group, but neither group showed improvements in NIBUT, corneal staining, tear osmolarity, or Schirmer score. Additionally, a cohort study of 31 participants that combined radiofrequency with IPL and meibomian gland expression demonstrated significant improvements in the signs and symptoms of MGD, but there was no control group³⁷¹.

Currently, there is no strong evidence that supports the use of radiofrequency for the treatment of DED and more studies, especially RCTs with larger groups and for longer follow-up periods, are needed to better understand how this technology works and how it fits into the management of DED.

6.3.1.2.3.6 Thermo-mechanical skin treatment

Thermo-mechanical fractional skin treatment (Tixel, Novoxel, Israel) is a novel therapy approved by the FDA in 2021 for cosmetic use in the field of dermatology³⁷². Periorbital treatment involves the application of a 400°C titanium-tipped handpiece comprising a matrix of 24 pyramid-shaped protrusions, that transiently contacts the skin for between five and 18 milliseconds, over an area of 0.3cm². Device application has been reported to reduce the appearance of periorbital rhytides (wrinkles), and signs of acne rosacea, hemangiomas and scarring, in addition to having the potential to facilitate transdermal drug delivery³⁷². Its application as a non-ablative treatment in evaporative DED has been explored in studies with positive outcomes in terms of safety and efficacy although, to date, only in open-label studies^{373,374}. A manufacturer-sponsored prospective, investigator-masked study of the Tixel thermo-mechanical treatment described comparable clinical outcomes to thermal pulsation therapy³⁷⁵.

Of note, a recent industry-supported study reported statistically and clinically significant changes in spectacle refraction, with the most marked changes observed in participants with more severe DED³⁷⁶. On this basis, the authors caution users if the treatment is to be applied prior to biometric assessment for refractive surgery³⁷⁶.

6.3.1.3 Lid margin treatments

6.3.1.3.1 Intraductal meibomian gland probing

Intraductal meibomian gland probing involves the introduction of a stainless-steel, non-sharp probe (76 µm in diameter and lengths of 1, 2, 4 or 6 mm) into

the obstructed meibomian gland to forcefully remove or dislodge the obstructed material and promote meibum secretion ³⁷⁷. As the probe enters the orifice towards the central duct of the meibomian gland, an audible 'pop' may be heard when resistance is encountered. Since the TFOS DEWS II Management and Therapy Report ², more studies using this procedure for the treatment of MGD have been reported, including three RCTs, as well as retrospective and/or non-randomized studies.

A prospective study with 58 eyes from 30 MGD participants had intraductal meibomian probing undertaken using a modified technique, receiving one to four probing procedures during the study ³⁷⁸. All participants were prescribed additional treatments, which included topical antibiotics, corticosteroids, tear supplements, warm compresses and eyelid massage. At three months post treatment, significant improvements in TBUT, conjunctival hyperemia, lid margin vascularization and OSDI scores were observed. However, it is difficult to differentiate the impact of the probing from the additional treatments.

A retrospective chart review of 108 consecutive participants with obstructive MGD, representing 11,776 glands, noted that 84% showed mechanical resistance ³⁷⁹. However, the clinical relevance of this resistance and its relation to gland expressibility has yet to be fully elucidated.

A retrospective review of video recordings of meibography-guided intraductal probing using a 1 mm probe from 38 lower lids have addressed some of the concerns surrounding the invasive nature of this technique and its potential for damage to the delicate structure of the meibomian glands ³⁸⁰. Recordings revealed that 99.9% of the glands (996/997) were successfully probed and 91.8% revealed the location of the probe. A different study used *in vivo* confocal microscopy to retrospectively study the duct microanatomy of meibomian glands, post probing ³⁸¹. Thirty-six glands from the upper lids of MGD participants (n=16) revealed an increase in basement membrane, duct wall (layers and thickness)

and lumen area compared to MGD controls (n= 4) who did not receive probing. The authors propose that the procedure stimulates an epithelial regenerative process, although further research is needed to understand the mechanism of action and which factors direct this process.

A review of the literature in 2020 resulted in 14 studies that were identified, with most (10/14) lacking a control group³⁸². The intraductal probing procedure was found to be “safe”, with no major post-operative complications. However, bleeding (dot hemorrhages) of the eyelid and gland orifices were frequent, but self-limiting. Tear breakup time was the most common reported objective measure and showed improvement in most studies, except in the only randomized sham-control trial³⁸³, which found no difference. Some studies had adjunctive therapies (antibiotics, steroids, IPL) potentially confounding the results for TBUT. Corneal staining was also reported (5/14 studies) as an outcome measure, but similarly to TBUT, adjunctive treatments were reported, making for unclear interpretation. The inventor of the procedure disagreed with the conclusions of this review and wrote a rebuttal letter on some of the conclusions reached³⁸⁴.

Three RCTs have been published on intraductal gland probing in recent years. Intraductal probing in addition to conventional treatments (tear supplements, warm compresses, eyelid massage, lid hygiene, topical antibiotics, omega-3 supplements and oral azithromycin) showed better outcomes (OSDI score, Schirmer test, TBUT and Oxford grading) than conventional treatments alone over 90 days, except for meibum expressibility³⁸⁵. A study with 90 eyes from 45 obstructive MGD participants separated into three groups; an IPL group (three treatments at three week intervals); a group who received a single intraductal probing; and a group who received probing followed by IPL³⁸⁶. All groups showed improvement, however the probing-IPL group had better outcomes (SPEED score, TBUT, corneal staining, meibum grade) than either of the other two groups at relieving signs and symptoms. The only double masked RCT that

did not include an additive treatment revealed that intraductal probing had significant improvement for symptoms, but failed to show improvement in clinical signs over placebo ³⁸³.

In conclusion, intraductal meibomian gland probing appears, on the basis of relatively short-term outcomes, to be a procedure with self-limiting adverse events. Prospective RCTs are needed to obtain a better understanding of its mechanism of action in improving symptoms, signs, meibomian gland ductal integrity and meibum expressibility without concurrent treatments. Meibography-guided intraductal probing may provide an added value in the management of obstructive MGD, with larger scale studies and long-term evaluation of gland structural integrity.

6.3.1.3.2 Lid margin debridement

Meibomian gland blockage is primarily caused by the buildup of keratinized material around the eyelid margin and duct openings ^{167,227}. This buildup can obstruct the gland, preventing the release of meibum into the tear film. Debridement of the eyelid margin physically removes accumulated debris and keratinized cells from the surface of the lid margin, thereby encouraging improved outflow of meibum from the glands and into the tear film ³⁸⁷. Two, one-month RCTs reported improvements in symptoms and meibomian gland secretion with debridement relative to control, untreated participants ^{387,388}.

A novel, multi-modal thermal device (MGrx, OcuSci®, Inc, CA, USA) has been developed to facilitate thermal lid debridement, thermal lid massage, and thermal gland expression. A study was undertaken that included 37 adult participants with MGD and DED in an open-label treatment with the MGrx ³⁸⁹. A statistically significant improvement in SPEED score, TBUT, and meibomian gland score for both eyes was noted after the treatment. No adverse reactions were noted in this small cohort. A subsequent RCT found a similar improvement in symptoms from conventional and MGrx treatment, but clinical signs were not improved ³⁹⁰.

A retrospective case series study reported that combining lid margin debridement with microblepharoexfoliation (BlephEx®; RySurg, Fort Worth, FL, USA) and meibomian gland expression resulted in improvements in clinical outcomes, subjective symptoms, meibomian gland function, and ocular surface MMP-9 levels ³⁹¹. However, there remains a lack of prospective studies with sham treatments and double masking.

6.3.2 Restoration or stimulation of aqueous

6.3.2.1 Topical secretagogues

6.3.2.1.1 Diquafosol tetrasodium

3% Diquafosol ophthalmic solution has a novel mechanism of action involving the stimulation of both aqueous and mucin secretion ³⁹². It is a P2Y2 purinergic receptor agonist that activates P2Y2 receptors on the ocular surface. Diquafosol stimulates both fluid secretion from the conjunctival epithelial cells and mucin secretion from the conjunctival goblet cells directly on the ocular surface, by an interaction with the P2Y2 receptors ^{392,393}.

Multiple, long-term studies have been undertaken on this class of topical medication (Table 3). A meta-analysis of 14 RCTs indicated that, relative to participants treated with other topical drops, such as tear supplements or HA-based products, application of 3% diquafosol drops was associated with significantly better improvement at four weeks in terms of TBUT, Schirmer score, corneal fluorescein staining score and Rose Bengal conjunctival staining ³⁹⁴. No discernible difference was apparent in terms of OSDI symptom score ³⁹⁴.

In a group of participants (n = 47) with MGD, one drop of tear supplements or one drop of diquafosol was applied randomly to the eyes of each patient ³⁹⁵. Diquafosol significantly increased LLT and NIBUT for at least 90 mins, whereas

tear supplements had no such effect. These results suggest that diquafosol may be a potential treatment not only for aqueous-deficient DED but also for evaporative DED associated with MGD.

Journal Pre-proof

Table 3: Prospective interventional studies examining the efficacy and safety of Diquafosol

Study	Type of participants	Treatment	Product comparator	Sample size	Duration	Randomized	Outcomes showing improvement	No significant differences from comparator
Miyake and Yokoi, 2017 ³⁹⁶	4 weeks post-cataract surgery	Diquas 3%	Artificial tears	433	1 month	Yes	TBUT Total symptom score	Corneal staining Conjunctival staining
Shimazaki et al, 2017 ³⁹⁷	Computer users DED	Diquas 3%	Rebamipide	67	2 months	Yes	Satisfaction score	DEQS TBUT NIBUT Corneal staining
Cui et al, 2018 ³⁹⁸	DED post-cataract surgery	Diquas 3%	0.15% HA	94	3 months	No	OSDI TBUT Goblet cell density	ST
Kaido et al, 2018 ³⁹⁹	Short TBUT DED	Diquas 3%	Artificial tears	27	5 weeks	No	Corneal sensitivity TBUT	TMH
Jun et al, 2019 ⁴⁰⁰	DED post-cataract surgery	Diquas 3% preservative free	a) Diquas 3% preserved b) 0.15% HA	117	3 months	No	TBUT MGD grade meibum quality	OSDI Corneal staining

Fukuoka & Arita, 2019 ³⁹⁵	DED with MGD	Diquas 3%	Artificial tears	47	90 mins	Yes	NIBUT LLT	
Ji et al., 2019 ⁴⁰¹	DED	Diquas 3%	CsA 0.05%	18	1 month	No	Tear proteome	OSDI TBUT ST Corneal staining Conjunctival staining
Kim et al, 2021 ⁴⁰²	DED post-cataract surgery	Diquas 3%	0.15% HA	56	15 weeks	Yes	LLT TBUT	OSDI ST
Eom & Kim, 2021 ⁴⁰³	DED	Diquas 3%	CsA 0.1% or combination	279	3 months	No	TBUT	SANDE DEQS Corneal staining Conjunctival staining
Yamazaki et al, 2022 ⁴⁰⁴	Post-Femto cataract surgery	Diquas 3%	Saline	20	2 weeks	Yes	TBUT	TMH DEQS ST Corneal staining
Jung et al, 2023 ⁴⁰⁵	DED	Diquas 3%	CsA 0.1% CsA 0.05%	80	3 months	No	Tear proteome	SANDE TBUT Conjunctival staining
Wang et al, 2023 ⁴⁰⁶	Femtosecond LASIK	Diquas 3% + 0.15% HA	0.15% HA	40	1 month	No	OSDI TBUT LLG Bulbar redness	NIBUT SRI

							Limbal redness	
Kaido & Arita, 2024 ⁴⁰⁷	DED	High viscosity Diquas 3%	Convention al Diquas 3%	66	1 month	No	Questionnaire Corneal staining TBUT	
Arita et al, 2024 ⁴⁰⁸	DED	High viscosity Diquas 3%	Convention al Diquas 3%	341	3 months	No	SPEED TBUT TMH Corneal staining ST	

CsA: cyclosporine; DED: dry eye disease; DEQS: Dry Eye-Related Quality-of-Life Score; Femto: femtosecond laser; HA: hyaluronic acid; LASIK: laser in-situ keratomileusis; LLG: lipid layer grade; LLT: lipid layer thickness; MGD: meibomian gland dysfunction; MMP-9: matrix metalloproteinase-9; NIBUT: non-invasive breakup time; OSDI: Ocular Surface Disease Index; SANDE: Symptom Assessment in Dry Eye questionnaire; SMILE: small incision lenticule extraction; SPEED: Standard Patient Evaluation of Eye Dryness; SRI: surface regularity index; ST: Schirmer test; TBUT: tear breakup time; TFLL: tear film lipid layer; TMH: tear meniscus height

6.3.2.2 Oral secretagogues

An early body of literature described the use of oral pilocarpine and cevimeline for the treatment of DED, specifically in patients with Sjögren-related DED ².

Pilocarpine and cevimeline are both cholinergic agonists, which act as an acetylcholine-mimicking neurotransmitter and as a targeting-selector for muscarinic receptors M1 to M3.

Since the TFOS DEWS II Management and Therapy report ², most of the studies on oral secretagogues have involved participants with Sjögren disease, due to the medication targeting the salivary glands. A placebo-controlled crossover study involving 5mg of pilocarpine, taken orally four times a day, reported improvements in OSDI score, along with increased NIBUT and fluorescein TBUT and Schirmer scores, and improved ocular surface staining and tear ferning test grades in patients with DED. However, there was a high percentage of drug-induced side effects ⁴⁰⁹.

Oral administration of secretagogues results in simultaneous stimulation of muscarinic receptors on other exocrine glands and can result in increased sweating, salivation, frequency of urination, flushing, paraesthesia and myalgia ⁴⁰⁹⁻⁴¹². Other side effects not reported in published clinical trials but reported on national formularies (such as National Institute for Health and Care Research; NIHR) include diaphoresis, nausea, bradycardia, bronchospasm and diarrhoea, headaches and vision disorders.

6.3.3 Restoration or stimulation of mucin

A number of pharmacological agents seek to act by increasing tear mucins.

6.3.3.1 Diquafosol tetrasodium

As described previously (see Section 6.3.2.1.1), Diquafosol is reported to stimulate mucin production on the ocular surface ^{392,393}.

6.3.3.2 Rebamipide

Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid; OPC-12759), a mucosal protective agent, has been used to treat gastritis and stomach ulcers via oral administration. Rebamipide has also been shown to stimulate COX2 and production of prostaglandins, scavenges oxygen radicals, suppress proinflammatory cytokines and functions as an anti-inflammatory drug in both acute and chronic mucosal inflammation⁴¹³. Although this drug has been found to increase the number of goblet cells in the conjunctiva, the exact mechanism at the molecular level and the nature of the cellular receptor remain unknown⁴¹⁴.

Several clinical trials on the use of rebamipide have been reported (Table 4). In studies, 1% and 2% rebamipide DED groups had greater improvements than placebo in TBUT, corneal staining score and Schirmer scores, but not in OSDI score⁴¹⁵. In a randomized, controlled, double-masked study, participants with digital eye strain treated with 2% rebamipide showed significantly reduced corneal staining and nasal bulbar conjunctival redness scores compared to those treated with topical 0.1% HA drops for four weeks, although improvements in OSDI, the 5-item Dry Eye Questionnaire, TBUT and conjunctival staining scores were similar across the two groups⁴¹⁶. A systematic review of the use of rebamipide in the management patients with DED included seven papers⁴¹⁷. It was noted that the majority of the studies were company sponsored. Rebamipide outperformed the control group for total corneal fluorescein staining, Schirmer test without anesthesia, TBUT and dry eye-related quality of life score. A more recent systematic review and meta-analysis produced similar findings⁴¹⁸.

Table 4: List of comparative trials for rebamipide

Study	Type of participants	Treatment	Product comparison	Sample size	Duration	Randomized	Outcomes showing improvement	No significant differences from comparator
Kinoshita et al, 2013 ⁴¹⁹	DED	Rebamipide 2% 4-6 times a day	0.1% HA 4-6 times a day	188	4 weeks	Yes	Conjunctival staining Some symptoms	Corneal staining Schirmer's test TBUT Some symptoms
Igarashi et al, 2015 ⁴²⁰	DED after corneal refractive surgery	Rebamipide 2% qid	Artificial tears qid	60	4 weeks	Yes – no direct comparison	Schirmer score, TBUT Corneal staining Ocular scatter index Some symptoms	Some symptoms
Kobashi et al, 2017 ⁴²¹	DED after penetrating keratoplasty	Rebamipide	Diquafosol	40	4 weeks	Yes	-	TBUT Corneal staining Symptoms
Shimazaki et al, 2017 ³⁹⁷	DED in computer users	Rebamipide 2% qid	Diquafosol 3% 6 times a day	79	8 weeks	Yes	-	Symptoms TBUT
Eom et al, 2023 ⁴¹⁵	DED	Rebamipide 1%	Placebo (vehicle)	220	12 weeks	Yes	Symptoms Corneal staining (wrt 2%)	TBUT Schirmer

		2% qid	qid					Corneal staining (wrt 1%)
Jain et al, 2023 ⁴²²	DED	Rebamipide 2% qid	0.5% CMC- based lubricant qid	80	12 weeks	Yes	** Only category analysis was conducted	TBUT Schirmer Corneal and conjunctival staining
Lee & Han, 2024 ⁴¹⁶	DED in computer users	Rebamipide 2% qid	0.1% HA qid	56	4 weeks	Yes	Corneal staining	Symptoms TBUT Conjunctival staining

CMC: carboxymethylcellulose; DED: dry eye disease; HA: Hyaluronic acid; OSDI: Ocular Surface Disease Index; qid: four times a day; TBUT: tear breakup time; tid: three times a day

6.3.4 Neuromodulation / neurostimulation

Stimulation of tear film production is driven by environmental stimuli detected by sensory afferent nerves of the cornea and conjunctiva, as well as parasympathetic nerves found in the nasal cavity. Once activated, these sensory nerves relay this environmental information via action potentials through the trigeminal nerve, triggering an efferent parasympathetic response that orchestrates increased activity of the secretory glands of the lacrimal functional unit (lacrimal glands, meibomian glands and goblet cells) ^{36,423-426}.

Neuromodulation as a treatment for DED is based on stimulating these sensory nerves to activate trigeminal nerve signaling, which leads to an increase in basal tear production that is not solely related to an increase in the aqueous component of the tears ^{423,425-430}. Such modulation can be accomplished through mechanical, electrical pressure/vibration or pharmacological means.

6.3.4.1 Device-driven neuromodulation

6.3.4.1.1 Nasal electrochemical stimulation

Neurostimulation through the nasal cavities has been achieved by transcutaneous electrical stimulation of the mucosa and anterior ethmoidal branch of the trigeminal nerve, which triggers nasolacrimal reflex tear production.

The FDA-approved a device for intranasal stimulation (TrueTear® Intranasal Tear Neurostimulator), but the product was discontinued in 2020 ⁴²⁵. However, examination of the results from various studies examining the impact of this concept provides useful information on this potential method to manage DED. Two intranasal tips were inserted into each nasal cavity and, by means of a low-level electrical current, the tips vibrated while in contact with the intranasal tissue. An RCT comparing intranasal vs extranasal stimulation (control), found that three minutes after one intranasal stimulation session, aqueous production (measured via TMH and tear meniscus area) and conjunctival mucin-producing goblet cell density (via impression cytology) were increased compared to baseline, for both

DED and non-DED participants ⁴³¹. In a study with very similar methodology, following a three minute-treatment delivery, dryness and ocular discomfort scores were significantly reduced five minutes post-treatment ⁴³². Another RCT compared active and sham intranasal stimulation applied between four to eight times a day, for durations of between 30 seconds and three minutes in participants with DED ⁴³³. Reviewed at days 0, seven, 14, 30 and 90, acute tear production (Schirmer test score) was significantly higher in the active stimulus group than sham, across all time points. The acute response to stimulation for the active group was highest at the early timepoints, around triple that of sham, but then declined to around twice the sham response by day 14 and remained consistent throughout the remainder of the study. At day 90, mean corneal and conjunctival staining scores showed some decrease from baseline, similarly in both active and sham groups, whilst the reported pain score was significantly decreased only in the active treatment group ⁴³³. Nosebleeds, an electrical stinging sensation, nasal discomfort, headache, eyelid irritation, rhinorrhea (runny nose) and sensitive teeth were some of the events noted with the use of this device, most of them being transient in nature ⁴³²⁻⁴³⁴. Improved Schirmer scores with intranasal stimulation versus external stimulation have also been noted following a three-minute treatment in participants with Sjögren disease, ⁴³⁵.

External therapy aims to stimulate the external branch of the anterior ethmoidal nerve. A multicenter, open-label, single-arm clinical trial of external nasal stimulation for 30 seconds, on each side of the nose, at least twice a day using a new, novel device (iTear® 100) on 101 participants found OSDI scores decreased from day 14 to 30. Schirmer scores increased from day 14 and remained elevated until the end of the study on day 180. There were no serious adverse events reported ⁴³⁶.

6.3.4.1.2 Transcutaneous electrical stimulation

High and low transcutaneous electrical nerve stimulation is a non-pharmacological therapy aimed at activating peripheral nerve pathways directly,

to block, change or correct pain perception. This therapy delivers alternating current via cutaneous electrodes placed proximal to the terminal cutaneous trigeminal nerve branches on the forehead and temple. The afferent electrical input arrives to the central nervous system, activating descending inhibitory systems to reduce hyperalgesia and releasing endogenous opioids^{427,437}. Electrical stimulation is considered of potential benefit in modulating pain sensation in difficult-to-treat patients, such as those who exhibit “pain-without-stain”, neuropathic patients, photophobia and other chronic pain conditions that may be associated with ocular hyperalgesia⁴³⁸⁻⁴⁴⁰.

An RCT in 45 participants comparing HA-containing tear supplements with or without transcutaneous electrical nerve stimulation found greater improvements in symptomatology, TBUT, Schirmer scores and corneal staining after four weeks of treatment with the stimulated group; no serious adverse events were recorded⁴⁴¹. In another study of 27 participants, reduced OSDI scores and increased Schirmer scores were maintained after 12 months, and the improvements in TBUT and ocular staining score were still evident six months later⁴⁴².

6.3.4.2 Pharmacological neuromodulation

6.3.4.2.1 Acoltremon

Acoltremon (Alcon, Ft Worth, TX, USA) is a potent and highly selective TRPM8 agonist, and acoltremon ophthalmic solution 0.003% (formerly AR-15512) is under clinical evaluation for the treatment of the signs and symptoms of DED.

Members of the superfamily of transient receptor potential (TRP) channels are cation-permeable, plasma membrane ion channels that respond to a wide range of stimuli⁴⁴³. Expressed on corneal thermosensory neurons innervating the cornea and upper eyelids, TRPM8 ion channels are stimulated by small reductions in temperature and hyperosmolarity, such as occurs during evaporative cooling and corneal drying^{423,443-445}. Stimulation of TRPM8, in turn,

activates the cold thermosensory neurons, leading to increased signalling through the trigeminal nerve and stimulation of basal tear production ^{445,446}.

There has been one comparative clinical trial conducted with acoltremon ⁴⁴⁷. In this RCT of 0.0014% and 0.003% AR-15512 compared to its vehicle, evidence of both symptom and sign efficacy was observed as follows: improved ocular discomfort score (at day 84) and also an improved global SANDE score (days 14, 28 and 84), increased tear production (unanesthetized Schirmer score and TMH, at days one and 14), reduced conjunctival redness (day 84) and improved ocular surface staining scores (days 14 and 84) with the 0.003% dosage. Mild adverse events were reported (instillation burning/stinging). There were no significant differences between active and vehicle groups for the co-primary endpoints, which were changes from baseline in ocular discomfort (ODS-VAS) and anesthetized Schirmer score at Day 28 ⁴⁴⁷.

6.3.4.2.2 Cryosim-3

Cryosim-3 (C3, 1-diisopropylphosphorylnonane) is a water soluble selective TRPM8 agonist. Topically applied to the upper eyelid surface, it may reduce discomfort by activating the TRPM8 receptor, which then elicits the sensation of cooling. In a randomized double-masked study comparing C3 (dissolved in 2mg/mL of distilled water) to vehicle, the intensity of symptoms decreased from five to 16 minutes after application, tear secretion increased at 20, 40 and 60 minutes and TBUT increased after 30 and 40 minutes with C3 compared to vehicle. An improvement in symptoms at two weeks after application was also reported ⁴⁴⁸. A pilot study, where the participants were treated with C3 four times/day for one month, found similar results, with increased Schirmer scores and decreased ocular pain assessment survey scores at the end of the treatment period ⁴⁴⁹. It is not currently in any active clinical trials as per publicly available information.

6.3.4.2.3 Varenicline

Varenicline (OC-01) is delivered in the form of an intranasal spray, with a therapeutic mechanism that targets nicotinic acetylcholine-receptors within the nasal cavity. Trigeminal nociceptors on the nasal mucosa and ocular surface form the start of the afferent arm that controls the production of tears. Nicotinic acetylcholine receptors on nasal nerve endings trigger an automatic reflex arc that causes endogenous tears to be secreted when triggered by pharmacologic nasal neural stimulation ⁴²⁶. The nasal spray (Tyrvaya®; Oyster Point Pharma, NJ, USA) is FDA-approved to treat the signs and symptoms of DED. When the intranasal spray stimulates the receptor, it activates the trigeminal nerve pathway eliciting a lacrimation response.

In an effort to examine the effect of varenicline on conjunctival goblet cells, a phase 2, single-center, vehicle-controlled study examined 18 subjects with DED ⁴⁵⁰. Subjects were randomized 2:1 to receive a 50µl dose of OC-01 0.06 mg or vehicle via a nasal spray in each nostril. OC-01 treatment decreased mean goblet cell area and perimeter, whereas the vehicle had no effect. This study demonstrated that a single administration of OC-01 in patients with DED reduced conjunctival goblet cell area and perimeter, suggesting goblet cell degranulation and associated release of lubricating mucin ⁴⁵⁰.

A randomized trial evaluating varenicline efficacy at different concentrations compared with a buffered saline found a dosage of 0.03 mg, administered twice a day resulted in a significant reduction in an eye dryness score by day 28 ⁴⁵¹. A second study from the same authors reported an effective increase in Schirmer score over a 12-week period, when using 0.03mg of varenicline ⁴⁵¹. Similar results have been found by other authors when using a 0.06mg concentration ^{452,453}.

In Phase III clinical trials, varenicline OC-01 improved mean Schirmer scores and symptoms to a comparable or higher degree than lifitegrast, as reported in an

indirect comparison⁴⁵⁴. Varenicline was reported to be well tolerated and had an overall patient study completion rate of >93%⁴⁵⁵. However, almost all participants receiving OC-01 sneezed at least once during treatment (93.8% for OC-01 0.03 mg, 95.9% for OC-01 0.06 mg, and 28.3% for vehicle). Most sneezing (84.5% for OC-01 0.03 mg and 81.3% for OC-01 0.06 mg) occurred within the first minute after administration⁴⁵⁶.

A systematic review and meta-analysis of the efficacy and safety of varenicline nasal spray for the management of DED versus placebo included three RCTs (n=1063 participants)⁴⁵⁷. There was a significant increase in mean Schirmer test result from baseline on day 28 and no significant difference between varenicline and placebo in the frequency of ocular adverse events. However, varenicline did have a significant effect on developing nasal cavity-related adverse events (cough and throat irritation). A more recent systematic review included eight studies⁴⁵⁸. Varenicline nasal spray achieved greater improvement than vehicle for eye dryness score, Schirmer test and total corneal fluorescein staining.

Table 5 details key contemporary clinical trials on varenicline.

Table 5: Comparative clinical trials of varenicline

Study	Type of participants	Treatment	Product comparison	Sample size	Duration	Randomized	Outcomes showing improvement	No significant differences from comparator
Dieckmann et al, 2022 ⁴⁵⁰	DED	OC-01 0.06mg Once	Vehicle nasal spray	18	Single spray	No	Decreased conjunctival goblet cell area and perimeter	Meibomian gland area
Quiroz-Mercado et al, 2022 ⁴⁵²	DED	OC-01 0.03 mg 0.06 mg bid	Vehicle nasal spray bid	123	12 weeks	Yes	Schirmer	-
Torkildsen et al, 2022 ⁴⁵⁹	DED	OC-02 Simpinieline 0.11 mg, 0.55 mg, or 1.1 mg	Vehicle nasal spray	165	Single dose, 5 min post-use	Yes	Symptoms (0.55 & 1.1mg) Schirmer	-
Wirta et al, 2022 ⁴⁵¹	DED	Varenicline OC-01 0.006mg, 0.03mg, 0.06mg bid	Vehicle nasal spray bid	182	4 weeks	Yes	Symptoms (0.03mg) Schirmer test (0.03 and 0.06mg groups.	-
Wirta et al, 2022 ⁴⁵⁶	DED	Varenicline OC-01 0.03mg	Vehicle nasal spray	758	4 weeks	Yes	Symptoms Schirmer	-

		0.06mg bid	bid					
Tian et al, 2024 ⁴⁶⁰	DED	OC-01 0.6 mg/mL bid	Vehicle nasal spray bid	340	4 weeks	Yes	Symptoms Schirmer	Corneal fluorescein staining

bid: twice a day

7 Treatments for eyelid abnormalities

The eyelids are a critical part of the lacrimal functional unit and appropriate identification, and correction of lid margin abnormalities is an essential part of DED treatment. Since publication of the TFOS DEWS II Management & Therapy Report in 2017 ², many studies have been published investigating newer treatment strategies for managing lid margin pathology.

These treatments can be grouped into the following broad categories:

1. **At-home treatments** include the use of warm compresses, relatively simple devices ^{232,235-237,239,241,242,256} and various eyelid wipes ^{231,461,462}. It should be remembered that warm compresses need to be followed up by lid massage for maximum efficacy.
2. **In-office procedures** include IPL ²³⁰, vectored thermal pulsation ²⁸², low-level light therapy ³⁵¹, microblepharoexfoliation ⁴⁶³, thermo-mechanical treatment ^{373,374}, portable 445nm laser ⁴⁶⁴, various manual methods of heat-delivery to the lids and meibomian glands ^{240,285,289}, intraductal probing ^{382,465} and manual meibomian gland expression ⁴⁶⁶.
3. **Pharmacological agents** such as lotilaner ^{467,468} and ivermectin-metronidazole gel ⁴⁶⁹. These products target parasitic blepharitis and may improve patient symptoms and tear film and ocular surface parameters. Other pharmacological strategies for MGD management undergoing regulatory clinical trials include selenium sulfide ²⁷¹ and azithromycin ⁴⁷⁰.

Evidence surrounding use of these therapies in the clinical setting are described according to disease presentation, below.

7.1 Blink and lid closure anomalies

Methods to optimise blinking, both frequency and completeness, are some of the simplest forms of management to recommend for managing DED, but perhaps one of the more difficult to execute. Web-based platforms and software programs exist to monitor blink rates when using digital devices and remind patients to blink appropriately ⁴⁷¹.

7.1.1 Inadequate lid seal / lagophthalmos

Lagophthalmos refers to the inability to fully close the eyelids, while nocturnal lagophthalmos specifically describes this condition occurring only during sleep, meaning the eyes can close normally when awake but not while sleeping ⁴⁷². Inability to close the eyes is a major cause of non-responsive DED ⁴⁷³. A Japanese survey evaluated the prevalence of nocturnal lagophthalmos and sleep quality in 2000 participants ⁶. Participants were divided into two groups according to the presence or absence of DED symptoms. Sleep duration in those with DED was significantly shorter and sleep efficacy was worse compared with the non-DED group. Participants who self-reported nocturnal lagophthalmos were more prevalent in the DED group and the study concluded that nocturnal lagophthalmos was associated with worsened DED symptoms and poor sleep quality ⁶.

Conditions such as floppy eyelid syndrome, surgical cosmetic procedures and chemodenevation injections, lid deformities, Bell's palsy, age-related lid laxity, dermatochalasis, senile ectropion, trauma, Grave's disease and anatomical abnormalities can all lead to incomplete lid seal or lid closure ^{472,474}. Lid closure is a fundamental requirement to protect the eye from desiccation at night, especially since tear production is reduced during sleep ⁴⁷⁵. Night-time application of ointment for incomplete eye closure is frequently recommended ⁴⁷⁶, but the benefits have not been formally evaluated.

Despite anecdotal reports, there are no studies on the impact of taping the eyelids at night to seal them closed. Patients' tolerability of such treatment may be expected to be limited due to risk of eyelid tissue reactions, the frequent need to navigate to the bathroom at night for older individuals and risk of lash loss upon tape removal. New lid seal products, which are hypoallergenic, latex-free, oxygen-permeable and don't stick to lashes have recently become available.

Sleep masks can help to an extent, in so far as they limit environmental conditions from exacerbating desiccative stress by limiting air movement ⁴⁷⁷. Moisture goggles may be more useful than sleep masks in this regard since they provide a humid environment while limiting air movement, even when the eyes are not anatomically sealed shut (see Section 6.2.2).

Several studies have investigated the use of bandage soft contact lenses and, in particular, scleral lenses to manage chronic exposure ^{199,478-484}. As pointed out by Jacobs and colleagues ¹⁹⁹, of the many papers reporting on the management of exposure, few mention contact lenses as an option, suggesting that they are a potentially overlooked management strategy.

Thyroid eye disease can also result in exposure due to exophthalmos and lid retraction ^{13,476,485-487}. A study of conservative management (lubrication with tear supplements, cool compresses, sleeping with the head elevated in bed, taping of the eyelids while sleeping and avoidance of smoking) concluded that mild cases had reduced symptoms and increased satisfaction at follow-up, while moderate cases also required additional topical steroids and severe cases required surgical intervention, but supporting data were not provided ⁴⁸⁶. A study comparing participants before and six months after steroid pulse therapy followed by orbital radiotherapy showed improvements in proptosis, Clinical Activity Scores, and MGD, but not in other DED parameters ⁴⁸⁸.

A novel therapy involving an anti-IGF1R antibody (teprotumumab; Tepezza®; Amgen Therapeutics, Thousand Oaks, CA, USA) has shown promise for managing thyroid eye disease. This systemic treatment improves diplopia, proptosis, tear insufficiency and visual function ^{489,490}. However, side effects include hyperglycemia, diarrhea, hearing loss, and dryness of the skin and mucosa ⁴⁹¹. Given the high frequency of DED in thyroid eye disease and the benefits of reducing orbital inflammation, further studies are needed to balance the positive and negative impacts of anti-IGF therapy on DED and ocular surface health.

In thyroid eye disease participants with extreme exposure due to thyroid eye disease and its associated upper lid retraction, lateral tarsconjunctival flap, blepharotomy or Botox injections may reduce ocular surface damage, although the procedures were not compared ⁴⁹².

For severe lagophthalmos, such as that seen in facial paralysis through trauma or disease, surgical options include temporary or permanent tarsorrhaphy, upper eyelid weight placement in cases of lid retraction, and lateral canthoplasty, with or without a middle lamellar spacer for lower eyelid retraction, although comparative studies are lacking ⁴⁹³⁻⁴⁹⁵. A novel method involves lipofilling of the upper eyelid with autologous fat, which avoids the risk of migration associated with loading the lid with weights. Upper eyelid lipofilling on 75 participants with unilateral facial palsy demonstrated immediate improvement in corneal discomfort and favourable aesthetic and functional results ⁴⁹⁶.

7.1.2 Partial blinking

Incomplete blinking and eyelid misalignment are prevalent regardless of eyelid morphology ⁴⁹⁷ and are associated with a 2.2 times increased risk of DED ⁴⁹⁸. Individuals with incomplete blinking have higher OSDI scores, more significant meibomian gland dropout, more MGD signs, poorer tear film LLT and a shorter NIBUT ⁴⁹⁸. In this study, blink frequency did not correlate with any ocular surface

parameters⁴⁹⁸. Along with tear film distribution, the muscle of Riolan contracts during complete blinking, exerting pressure on the meibomian glands and is believed to facilitate expression of meibum from the glands onto the ocular surface¹⁶⁷. It is hypothesised that reduced meibum release from incomplete blinking has longer term impacts, including meibomian gland blockage and drop out, that perpetuates decreased lipid distribution at the ocular surface⁴⁹⁸. Studies have shown that intentional and repeated forceful blinks can enhance tear film LLT⁴⁹⁹, and NIBUT, as well as improve dry eye symptomology and blink completeness⁵⁰⁰.

Providing information on blink exercises and how to blink fully can reduce symptoms in patients with DED^{500,501}. Additionally, techniques that promote more frequent blinking, such as animations for computer users, have been found to reduce dry eye symptoms^{502,503}.

7.2 Methods to reduce eyelid microbial load

Anterior blepharitis is a chronic eyelid inflammation located at the base of the eyelashes, its follicles (marginal blepharitis) and/or eyelid skin (blepharodermatitis) which is often characterised by redness, exanthema, sores, eschar, and swelling^{35,504,505}.

While the exact etiology is unknown, it is likely multifactorial, including chronic low-grade overcolonisation of the ocular surface with bacteria, infestations with parasites and inflammatory skin conditions such as seborrhea. Blepharitis can be categorized in several different ways.⁵⁰⁴⁻⁵⁰⁶ Categorization can be based on the length of disease process (acute or chronic) or the causative agent, with anterior blepharitis being staphylococcal (bacterial), seborrheic or due to the presence of *Demodex* mites^{504,505,507-510}. Treatment for anterior blepharitis depends on the underlying cause, but treatments typically attempt to reduce the microbial load of the eyelids.

While it is entirely possible to have microbial bioburden on the eyelid margin and remain asymptomatic ⁵¹¹, therapeutic benefits have been shown from lowering the eyelid margin bioburden, and several treatments for anterior blepharitis focus on this mechanism of action.

7.2.1 Anti-*Demodex* therapies

There appears to be a clear association between *Demodex* mite infestation and anterior blepharitis ^{36,512,513}. *Demodex* mites are also found on the eyelids of normal, healthy individuals, and *Demodex* infestation increases during aging and is higher in patients with DED, MGD, glaucoma and contact lens wear ^{510,512,514-518}.

As noted previously ⁵¹⁹, much remains to be described with respect to *Demodex* studies to allow for study comparisons, including standard nomenclature (cylindrical dandruff vs collarettes), the technique for mite retrieval from the lids (epilation vs lash rotation/manipulation), in addition to the technique used to identify the mites (in vivo vs ex vivo).

In symptomatic patients, *Demodex* infestation can be assumed to be the primary driver of the symptoms when patients present with cylindrical dandruff/collarettes on their eyelashes ⁵¹⁸, which are considered the pathognomonic sign of *Demodex* infestation ^{515,518-520}. Since the life cycle of mites is about 14 to 23 days ^{513,521}, treatment may need to be administered over several weeks to target the mites at all life-stages. Several treatment options exist, from over the counter at-home remedies to prescription drops, creams and systemic medications.

A consensus on best practice for diagnosis and treatment for demodicosis has been published ⁵²², where an expert panel of eye care practitioners recommended at-home use of tea tree oil (TTO)-containing lid wipes as first line treatment. There was consensus on four to six weeks duration of treatment, on a twice daily basis, with a suggested patient recall of between two and six weeks

after treatment commencement to reassess and change to a second line of treatment if needed ⁵²².

Care should be taken when treating for ocular *Demodex*, as the aim of the *Demodex* therapy should not necessarily be to completely eradicate the mites, but rather to decrease its numbers to restore the ecology of the lid margin to a commensal state of balance ⁵⁰⁹. This concept appears reasonable, as *Demodex* has been suggested to play a role in mediating bacterial activity, as defence against other mite species ⁵⁰⁹. A Delphi panel agreed that complete eradication of mites was not necessary ⁵¹⁸. With respect to what constitutes successful treatment of a patient with *Demodex* blepharitis, it has been suggested that no remaining itching of the lids, minimal to no lid erythema, reduced symptoms and decrease in collarettes would be reasonable outcomes to assess success ⁵¹⁸.

While several studies have shown a link between the presence of *Demodex* mites and the presence of MGD and symptoms and signs of DED ⁵²³⁻⁵²⁸, to date there is no peer-reviewed evidence for *Demodex* directly causing DED or MGD. This concept requires further evidence to directly link the pathogenesis of MGD with the presence of mites.

7.2.1.1 Ivermectin

First derived from *Streptomyces avermitilis* in the 1970s, ivermectin is a broad-spectrum antiparasitic ⁵²⁹. In its initial form, as an oral medication, ivermectin was shown to be safe, even at high doses ⁵³⁰, while reducing *Demodex* mite load and improving tear film stability ^{2,531,532}. Topical ivermectin has been proposed as a more efficient treatment that can be directly applied to the site of infestation ⁵³³. It has been shown to be efficacious, but also quite uncomfortable for some participants ⁵³³⁻⁵³⁶.

Compared with eyelid hygiene using a TTO cleaning product alone (n=51), participants treated with topical ivermectin 1% cream applied to the upper and

lower eyelashes once weekly, and subsequently removed with an eyelid cleanser 15 minutes later, had significantly improved symptoms, ocular surface staining, eyelash debris, redness/swelling and telangiectasia⁵³⁴.

In another study, 75 participants with ocular demodicosis applied topical ivermectin 1% cream to the lid margins of both eyes every night for three months⁵³⁶. Participants exhibited a significant reduction in all three ocular demodicosis characteristics, including the absolute numbers and proportion of lashes with cylindrical dandruff/collarettes, with visible *Demodex* tails and with follicle pouting. In addition, corneal fluorescein staining severity score improved significantly from baseline. Side effects were reported in two participants and included skin irritation and stinging upon application.

In a six year retrospective study reporting on 2157 participants (4314 eyes) with a diagnosis of *Demodex* blepharitis that were treated with topical ivermectin 1% once a day for two months⁵³⁵, there were significantly less cylindrical dandruff/collarettes and conjunctival redness, as well as improved symptoms (OSDI score) post-treatment. All participants were followed for six months, and 312 participants (14.4%) underwent a second course of treatment following reoccurrence of cylindrical dandruff/collarettes. Fourteen participants (0.6%) reported ocular discomfort and irritation. Finally, ivermectin has also been combined with metronidazole for the treatment of *Demodex*, with a meta-analysis reporting that the combination reduces mite counts⁵³⁷

7.2.1.2 Lotilaner ophthalmic solution

Lotilaner ophthalmic solution 0.25% (XDEMVEY®; Tarsus, Irvine, CA, USA) is the only FDA-approved treatment for the eradication of ocular *Demodex* mites. Lotilaner is a gamma-aminobutyric acid-gated chloride channel inhibitor selective for mites. Inhibition of these chloride channels causes paralysis in the target organism, leading to death⁵³⁸. Further, the lipophilic nature of the drop may promote its uptake in the oily sebum of the eyelash follicles where the mites

reside⁵³⁸⁻⁵⁴⁰. Dosing is twice a day for six weeks to account for the life cycle of the mites.

Efficacy (based on reduction in cylindrical dandruff/collarettes) and safety for lotilaner ophthalmic solution 0.25% was evaluated in 883 participants involved in two Phase III clinical trials (SATURN-1 and SATURN-2)^{468,540}. In SATURN-1, at day 43, the proportion of patients achieving ≤ 2 collarettes was significantly higher in lotilaner-treated patients compared to vehicle (44% vs. 7.4%)⁵⁴⁰. The proportion of patients with ≤ 10 collarettes was 81.3% in the test group versus 23% in the control group. Similarly, in SATURN-2 the proportion of patients achieving ≤ 2 collarettes at day 43 was significantly higher in the lotilaner-treated group compared to the vehicle control group (56% vs. 12.5%)⁴⁶⁸. The proportion of eyes with ≤ 10 collarettes was 89.1% in the treated group versus 33.0% in the control group. Additionally, 96.4% of lotilaner-treated eyes had at least a one grade improvement in collarettes after six weeks of treatment. Demonstrating long term efficacy, a significantly higher proportion of patients treated with lotilaner ophthalmic solution 0.25%, had ≤ 2 collarettes and ≤ 10 collarettes throughout a one year extension study compared to those who received vehicle control⁵⁴¹.

Mite eradication was evaluated at Day 43 in the Phase 3 clinical trials. In the SATURN-1 study, complete mite eradication (0 mites / lash) was achieved in 67.9% of study patients vs. 17.6% of control patients⁵⁴⁰. In the SATURN-2 study, complete mite eradication was seen in 51.8% in the study group vs. 14.6% in the control group⁴⁶⁸. The most common adverse effect was instillation site stinging and burning, reported in 10% of participants, with <2% experiencing chalazion/hordeolum and punctate keratitis at the one year follow-up^{468,540,541}.

The clinical relevance of reducing collarettes in asymptomatic participants remains to be addressed.

7.2.1.3 Okra (*Abelmoschus esculentus*)

Okra (*abelmoschus esculentus*) is rich in polysaccharides and other compounds with antibacterial and anti-inflammatory properties⁵⁴². Due to the irritating nature of some TTO-impregnated lid wipes^{543,544}, coupled with the findings that TTO-derivatives can be toxic to the epithelium of both meibomian glands and corneal tissue^{545,546}, an alternative option is desirable for the management of *Demodex* blepharitis. A randomized study compared the anti-demodectic activity of an okra versus a TTO-based lid wipe for three months⁵⁴⁷. In both groups, the *Demodex* mite count reduced at 1 and 3 months, however the okra-based lid wipe outperformed the TTO-wipe for corneal staining at both time points. The okra-based lid wipe was well tolerated with no adverse events reported, making this a potential option for patients with ocular sensitivities, such as the pediatric and geriatric population. More research is warranted to evaluate the anti-demodectic activity of okra-based lid hygiene products over a longer time frame.

7.2.1.4 Tea tree oil

Tea tree oil or terpinen-4-ol is derived from the leaves of the Australian native plant *Melaleuca alternifolia*² and has traditionally been the most widely used topical antimicrobial treatment for *Demodex* blepharitis^{509,518}. This essential oil is available in many forms, including impregnated wipes, foaming cleansers, and liquids and has been shown to exhibit antibacterial, antifungal and anti-inflammatory properties⁵⁴⁸.

Studies have demonstrated that TTO reduces ocular *Demodex* load and effectively improves both the signs and symptoms of blepharitis at concentrations ranging from 2.5% to 50%^{463,513,524,547,549-557}. Although TTO more effectively eradicates mites than other at-home treatment mainstays such as baby shampoo^{555,556}, safety and tolerability are concerns with higher concentrations of TTO or with long-term use^{11,12,544}. A lower dose concentration of 2.5% terpinen-4-ol eye wipes were well tolerated in two reports^{557,558}.

While research has shown that high-concentration TTO products (>50%) are more effective for mite eradication than lower concentrations that result in variable mite eradication⁵⁵⁹, >50% concentration is deemed unsafe for home use⁵¹³. An *in vitro* study demonstrated that terpinen-4-ol is toxic to human meibomian gland epithelial cells at concentrations even 10- to 100-fold lower than those used to kill *Demodex* mites⁵⁴⁵. To that end, next-generation formulations are in development, with one formulation which encapsulates 5% terpinen-4-ol (T4O) in a nano-lipidic particle emulsion demonstrating a 100% kill rate within 137 minutes of exposure in an *in vitro* study⁵⁶⁰.

7.2.2 Blepharoexfoliation

Motorised rotational electric toothbrush-like mechanical devices are available to aid with cleaning the lid margins and base of the eyelashes (a process termed microblepharoexfoliation or blepharoexfoliation). A single application with a foam cleanser reduced eyelid bacterial load and improved comfort and ocular surface signs in symptomatic contact lens wearers^{561,562}.

A one-month study of a prototype unpowered lid hygiene brush suggested improvement over simple cleansing with water, more so if it was used in conjunction with an ocular shampoo⁵⁶³.

The benefits of microblepharoexfoliation have been explored in combination with TTO-based products for managing *Demodex* blepharitis. An RCT comparing terpinen-4-ol-containing lid wipes or a non-terpinen-4-ol sham twice daily for one month following microblepharoexfoliation reported reduced *Demodex* infestation levels, but there was no statistically meaningful improvements in other dry eye and blepharitis metrics observed between the groups⁵⁶⁴. An RCT comparing a nightly wash with TTO and a commercial lid scrub with or without prior microblepharoexfoliation found a similar reduction in *Demodex* folliculorum, with all three approaches after two and four weeks of treatment⁵⁵⁰. A longer RCT comparing the use of eyelid scrubs with 2% TTO shampoo twice a day for eight weeks with or without prior microblepharoexfoliation demonstrated additional

benefit of pre-treatment with microblepharoexfoliation in the reduction of symptoms and *Demodex* count⁴⁶³. Treatment effects may therefore take longer than one month to become apparent. Furthermore, a clear relationship between reduced *Demodex* counts and improved symptoms and signs of DED has not yet been established. In considering such chronic use of TTO-containing products, study outcomes recommend caution due to a potential for adverse ocular surface and adnexal effects¹¹.

A Delphi panel of 12 clinicians did not reach consensus on the necessity for mechanical intervention, such as microblepharoexfoliation for *Demodex* blepharitis. This type of intervention was still used by n=10 (83%) of the panel, but it was hoped that in future, with more effective therapeutic agents, that mechanical intervention might be negated⁵⁶⁵.

7.2.3 Hypochlorous acid

Hypochlorous acid has broad antimicrobial activity⁵⁶⁶ and is a powerful antibacterial agent⁵⁶⁷. At a concentration of 0.01%, it is as effective as 5% povidone iodine in reducing the bacterial load of the lid margins by over 90%, without altering the diversity of bacterial species on the skin of the lower lid^{568,569}. At a concentration of 0.01%, *in vitro*, it could eliminate or diminish bacteria in biofilms, but was not found to disrupt biofilm structures and the susceptibility of tested staphylococcal blepharitis isolates varied by species⁵⁷⁰. Hypochlorous acid demonstrates a good ocular safety profile at a concentration of 0.01%^{543,571} and may offer the highest degree of patient comfort among several eyelid cleansers⁵⁴³.

Hypochlorous acid is commercially available mainly as a spray in concentrations ranging from 0.0085 to 0.2%. Further studies are warranted to determine if concentration is correlated to effectiveness for blepharitis management. Patient education is important as hypochlorous acid becomes unstable when exposed to light, air or extreme temperatures⁵⁷².

Hypochlorous acid solution applied to a wipe seems to be more effective than a HA-containing wipe for symptoms (OSDI) and ocular signs (tear film stability, TMH and meibomian gland expressibility) ⁴⁶¹. No difference was noted for Schirmer test, meibography, corneal staining or conjunctival redness after one month. Eyelid swabs were collected and cultured and revealed a significant reduction in bacterial load in both groups, although more pronounced with hypochlorous acid ⁴⁶¹.

Delivered by ultrasonic atomization in a two week RCT, hypochlorous acid solution outperformed 0.9% saline lid scrubs in terms of improvements in DED signs ⁵⁷³, but outcomes may be confounded by the participants concurrently being prescribed warm compresses twice daily and topical 0.5% levofloxacin three times a day. Another study demonstrated that 0.01% hypochlorous acid shortened the survival time of *Demodex*, improved ocular parameters (Schirmer, TBUT, corneal/conjunctival staining) and reduced inflammation (MMP-9 and IL-2) ⁵⁷⁴.

7.2.4 Lid hygiene products

Since the TFOS DEWS II Management & Therapy Report ², several clinical trials have been published on the use of lid hygiene products to treat anterior blepharitis. While these management options initially focused on wipes, patients now have options that include wipes, gels, foams, solutions, suspensions and sprays ⁵⁷⁵. While this review demonstrates that comparative studies are rare, studies have typically shown effectiveness in decreasing both signs and symptoms of DED and to have less adverse changes on the ocular surface than when using a commonly used method of diluted baby shampoo (Sung et al, 2018) (Table 6).

Lid hygiene products are available with and without antimicrobials. Antimicrobials can include TTO, terpinen-4-ol (T40), capryloyl glycine, okra (*Abelmoschus esculentus*), hypochlorous acid, linalool and aloe vera, which have recently been

reviewed ¹². That review also highlighted the need for more research with respect to cross product comparisons, uniform lid cleansing technique, understanding the impact of lid hygiene on patient lifestyle (compliance depending on the duration of treatment or symptomology, cost, ease of use, comfort, etc), and difficulty in product comparisons due to legislative reporting of ingredients, that may vary geographically ¹². Another consideration is the differences amongst eyecare professionals with respect to lid hygiene recommendations. Patient applied anti-*Demodex* lid cleansing wipes were recommended by more practitioners than in-office anti-*Demodex* treatment (by 1.55 times), on an international survey of 1,139 ECPs ⁵⁷⁶. A recent online survey of 261 eyecare professionals investigated the management of *Demodex* blepharitis from India and Australasia ⁵⁷⁷. Significant differences were noted amongst practitioners from the two regions with respect to the diagnostic approach (perceived prevalence, slit lamp magnification to identify mites) and in the treatment option (TTO for Australasia versus standard lid hygiene, which included warm compresses, for India), duration of treatment (longer for Australasia) and frequency of treatment (India: twice a day vs Australasia: once a day) ⁵⁷⁷. These differences in practice patterns may be influenced by legislative restrictions, accessibility of products geographically, cost and other factors, but further highlights the importance of using an evidence-based approach for the management of all forms of blepharitis. An expanded summary on the use of warm compresses to treat MGD and their efficacy can be found in a publication on a novel, water propelled heating eye mask ²⁴³.

Table 6. Studies investigating the use of various lid hygiene methods to manage anterior blepharitis

Study	Type of participants	Treatment	Product comparison	Sample size	Duration	Randomized	Outcomes showing improvement	No significant differences from comparator
Peral et al, 2016 ⁵⁷⁸	Pre-surgical candidates	Caprylol glycine lid wipe	None	45	5 days	N/A	Reduction of microbial load	N/A
Stroman et al, 2017 ⁵⁶⁸	Blepharitis	0.01% Hypochlorous acid	None	36 (71 eyes)	20 min	N/A	Decreased number of bacterial isolates, especially staphylococcal	N/A
Sung et al, 2018 ⁴⁶²	Anterior blepharitis	Eyelid cleanser (foam) bid	Diluted baby shampoo solution bid	43 Contralateral	4 weeks	Yes	Some symptoms LLT Inferior LWE Cylindrical collarettes MMP-9 expression Worsened MG capping and MUC5AC expression in baby shampoo group	Some symptoms Superior LWE Lash crusting Trichiasis
Eom et al, 2020 ⁵⁷⁹	Anterior blepharitis and obstructive MGD undergoing	Eyelid hygiene group bid	None	69	10 days (from 3 days before surgery) and	Yes	Symptoms Anterior blepharitis MG expressibility at 1 week Debris & redness/swelling	MG secretion MG area Telangiectasia Corneal and conjunctival

	cataract surgery				assessed again at 4 weeks		at 1 week TBUT at 4 weeks	fluorescein staining
Liu & Gong, 2021 ⁵⁴⁷	Demodex blepharitis	Okra-based cleanser	Tea tree oil	52	3 months	Yes	Demodex survival time OSDI Demodex count	OSDI Demodex count TBUT Meibum quality Meibomian gland expressibility
Zarei-Ghanavati et al, 2021 ⁵⁸⁰	MGD	Tea Tree Oil shampoo	Regular eyelid shampoo	40 contralateral	4 and 12 weeks	Yes	Symptoms Plugging and capping of MG orifices Foamy tears Meibomian gland expressibility TBUT Telangiectasia	Meibum quality, Conjunctival hyperemia, Corneal and conjunctival staining Schirmer Trichiasis and distichiasis
Arici et al, 2022 ⁵⁴⁹	Seborrheic blepharitis	Lid wipes (T4O+sodium hyaluronate) bid	Baby shampoo bid	48	8 weeks treatment and 4-week post follow-up	Yes	Some symptoms	Some symptoms NIBUT TBUT Schirmer

								Fluorescein corneal and conjunctival staining Demodex count MG area
Runda et al, 2022 ⁵⁸¹	MGD	Lid wipes bid + (antibiotics qid/bid and lubricants qid) + systemic antibiotic bid in severe MGD	wet towel + lid massage bid + (antibiotics qid/bid and lubricants qid) + systemic antibiotic bid in severe MGD	50	3 months	Yes		Symptoms NIBUT LLT Tear meniscus height Osmolarity Eyelash contamination Telangiectasia MG area, blockage and secretion
Aghaei et al, 2023 ⁵⁸²	Anterior blepharitis	Gel (TTO 2%) bid	Topical erythromycin ointment at night + fluorometho	61	45 days	Yes	Symptoms (day 45) Eyelash debris, Erythema Edema (day 45)	-

			lone 0.01% eyedrops tid Heated compress bid Baby shampoo bid					
--	--	--	--	--	--	--	--	--

bid: twice a day; DED: Dry Eye Disease; LLT: Lipid Layer Thickness; LW: Lid Wipes; LWE: Lid Wiper Epitheliopathy; MG: Meibomian Gland; MGD: Meibomian Gland Dysfunction; MMP-9: Matrix Metalloproteinase 9; MUC5AC: Mucin-5AC gene; NIBUT: Non-invasive breakup time; OSDI: Ocular Surface Disease Index; qid: four times a day; SANDE: Symptom Assessment in Dry Eye questionnaire; SPEED: Standard Patient Evaluation of Eye Dryness Questionnaire; TBUT: Fluorescein Breakup Time; TTO: Tea Tree Oil; T4O: Terpinen-4-ol; WC: Warm Compress.

7.2.5 Low-level light therapy (LLLT: Blue light)

While low-level light therapy with red and near-infrared light is understood to operate via photobiomodulation (see Section 6.3.1.2.3.2), the same clinical device with blue light offers different properties.

Blue light, particularly in the wavelength range of 410-430 nm, has inherent antimicrobial properties due to the generation of ROS on interaction with microbial cells, which can damage cellular components such as deoxyribonucleic acid, proteins, and lipids, leading to bacterial cell death ^{583,584}. Blue light can influence the expression of specific genes involved in bacterial metabolism and stress responses. For instance, in osteosarcoma cells, blue light application has been shown to induce apoptosis by increasing ROS levels and regulating pathways such as SOCS3 and PTEN/PI3K/AKT ⁵⁸⁵. While this study focuses on cancer cells, similar mechanisms may be at play in bacterial cells, where ROS generation leads to cellular damage and death.

Blue light application can alter the composition of the microbiome. In a study on mice with ligature-induced periodontitis, blue light irradiation significantly changed the oral microbiome composition. It decreased the α -diversity and the number of observed features and altered the relative abundances of specific bacterial phyla and genera ⁵⁸³. This suggests that blue light can selectively affect different bacterial populations, potentially reducing pathogenic bacteria while allowing beneficial bacteria to thrive. Blue light also has direct antimicrobial action. It can directly kill bacteria without the need for a photosensitizer. This has been demonstrated in various studies, including those targeting *Helicobacter pylori*, where blue light reduced bacterial load in an in vitro study ⁵⁸⁶. Finally, when combined with a photosensitizer, blue light can enhance the production of ROS, leading to more effective bacterial killing. This approach, known as antimicrobial photodynamic therapy (aPDT), has been used to target dental biofilm bacteria and other microbial infections ⁵⁸⁷.

Patients who may benefit from blue LLLT are patients with bacterial overload on their lid margins and eyelashes. By reducing this biofilm via the antimicrobial properties of blue light LLLT, the speed of resolution of blepharitis can theoretically be enhanced. Further well controlled studies are required to optimize the appropriate clinical protocols to reduce bacterial biofilm on the lid.

7.2.6 Manuka honey

Natural honey has long been renowned for its anti-inflammatory and antimicrobial qualities, which are due to its low pH, high osmolarity, as well as hydrogen peroxide content and methylglyoxal⁵⁸⁸. For ocular application, attention is focused on a specific type of honey, New Zealand native Mānuka honey (*Leptospermum scoparium*), which has a higher concentration of methylglyoxal compared to other honeys^{589,590}. When complexed with α -cyclodextrin, the antimicrobial effects of Manuka honey can be further augmented^{591,592}. The cyclical structure of α -cyclodextrin is made up of six glucopyranose units, featuring a hydrophobic cavity that accommodates lipophilic molecules. This enables the formation of water-soluble inclusion complexes, which improves the stability and solubility of hydrophobic drugs⁵⁹³. Results of one study demonstrate that the *in vitro* antiparasitic efficacy of cyclodextrin-complexed Manuka honey was comparable to 50% TTO⁵⁹⁴.

In another study, 53 participants with blepharitis applied a topical methylglyoxal Manuka honey eye cream, complexed with α -cyclodextrin in a microemulsion, to the closed eyelids of one eye overnight for three months⁵⁹⁵. Significant reductions in SANDE and SPEED symptom scores were observed in treated eyes from one month, along with clinical improvements in NIBUT, LLT and inferior lid wiper epitheliopathy at three months. After the three-month treatment period, there was also a significant decrease in ocular *Demodex*, *Corynebacterium macginleyi*, *Propionibacterium acnes*, and *Staphylococcus epidermidis* loads in treated eyes. In the first two weeks, five participants (9%)

experienced temporary ocular stinging and discomfort due to accidental application of the product too close to the eyelash margin or using an excessive amount of eye cream, likely causing the product to migrate onto the ocular surface. Otherwise, no major adverse events were reported, and visual acuity remained unchanged throughout the 90 days⁵⁹⁵. Further RCTs are needed to firmly establish the efficacy and safety of Manuka honey therapy, given the propensity for ocular surface irritation due to the low pH.

7.2.7 Topical antibiotics

An increased bacterial load on the eyelids has been found in patients presenting with both MGD and blepharitis^{167,596,597}, providing a basis for antibiotic therapy in the management of these conditions. While the use of oral antibiotics has shown promise in the management of MGD (see Sections 9.1 and 9.2), the use of topical antibiotics to manage lid conditions has been less well studied. Topical antimicrobial agents such as erythromycin, vancomycin, azithromycin, chlorhexidine, hypochlorous acid (see Section 7.2.3), melaleuca alternifolia leaf oil or TTO (see Section 7.2.1.4) can be used to reduce the bioburden along the eyelid margin, with varying degrees of antibacterial activity^{596,598}.

Antibiotic resistance is an ongoing clinical concern in eyecare, as treatment outcomes may be affected. The Antibiotic Resistance Monitoring in Ocular microOrganisms (ARMOR) surveillance study periodically reports the minimum inhibitory concentrations of numerous ocular antibiotics on conjunctival isolates⁵⁹⁹. An increase in antibiotic resistance with age was found, especially amongst staphylococci. Methicillin-resistant staphylococci showed multidrug resistance (>74%) over methicillin-susceptible isolates⁵⁹⁹.

Topical azithromycin is a macrolide antibiotic that is particularly effective against gram-negative microorganisms⁶⁰⁰ and also possesses anti-inflammatory properties^{601,602}. Azithromycin was used for 14 days to reduce the bacterial load

in patients presenting with blepharitis and MGD, with significant improvements in lid vascularity, lid plugging, and meibum grade with no adverse events even at two weeks post-treatment (on day 28) ⁶⁰³. To address the long-term effectiveness of azithromycin, a prospective observational cohort study on MGD patients revealed improved signs (TBUT, MGD grading) and symptoms (sensitivity to light, grittiness, burning sensation, blurred vision) after twice a day treatment for two weeks, followed by once a day for another two weeks ⁶⁰⁴. At a one-year follow-up, patients filled out a survey and reported a reduction in symptoms, a reduction in self-care treatments (lid hygiene, artificial tear use), and a positive impact on their quality of life (reading, night driving, computer use, etc).

Another small-scale study compared topical azithromycin (15 mg/g ophthalmic solution used twice a day for three days and then once daily for a total of one month) to oral azithromycin (500 mg on day one, followed by 250 mg for four additional days, for a total of three cycles of treatment with five day intervals) ⁶⁰⁵. Patient symptoms, eyelid margin signs, TBUT, corneal/conjunctival staining score, Schirmer test score, and conjunctival brush cytology were evaluated at baseline, one and five weeks. Both topical azithromycin and oral azithromycin were found to be effective in improving clinical signs and symptoms, however, topical treatment was superior in improving the cytology findings and TBUT. Similarly, a randomized trial compared topical azithromycin (15 mg/g applied one drop twice daily for two days and then once daily for 26 days) to doxycycline (100 mg twice daily for six weeks) ²⁶⁶. Both treatments improved signs and symptoms of ocular surface disease, with no significant difference between the groups, although, there was a higher frequency of systemic side effects with doxycycline.

8 Anti-inflammatory pharmacological therapies

8.1 Corticosteroids

Corticosteroids have long been recognized as therapeutics to treat both inflammation and pain, both relevant targets in the treatment of some forms of DED. The TFOS DEWS II Management & Therapy Report reviewed the significant body of published research on the use of several different corticosteroid preparations in improving both symptoms and signs of dry eye ². The report also noted the potential for complications from the long-term use of corticosteroids. These complications were noted even following the use of fluorometholone and loteprednol (see Section 8.1.1), which are both considered to carry a lower risk of ocular complications such as increases in intraocular pressure and cataract. The TFOS DEWS II Management & Therapy Report included topical corticosteroids in Step 2 of the staged management and treatment recommendations, with caution noted for their “limited duration” use ². Patients prescribed topical steroids require regular review by an eye care practitioner.

A number of studies on the use of corticosteroids to manage DED have been published since the TFOS DEWS II Management & Therapy Report ², including a Cochrane systematic review of 22 RCTs that included 4169 participants around the world ⁶⁰⁶⁻⁶⁰⁸. The report cited a high risk of bias associated with selective results-reporting among the included studies, but concluded that the use of topical corticosteroids likely provided a small to moderate degree of symptom relief beyond that of lubricants, a modest effect on lowering corneal staining scores, a slight increase in TBUT, but little effect on tear osmolarity ⁶⁰⁸.

Subtyping of the DED present may also be important for appropriate patient selection when considering prescribing topical steroids. This could avoid mild downstream inflammation being treated with steroids (as a ‘quick fix’) instead of

the source dysfunction being sought and addressed as a more appropriate, longer term management.

8.1.1 Loteprednol etabonate 0.25%

Loteprednol etabonate ophthalmic suspension 0.25% (Eyesuvis®; Alcon, Ft Worth, TX, USA) is an ester-based topical ophthalmic corticosteroid designed to be quickly metabolized into inactive metabolites by cellular esterase in ocular tissues, leading to an improved safety profile relative to ketone-based corticosteroids and reducing the potential side effects typically associated with topical corticosteroid use, while maintaining potent anti-inflammatory properties⁶⁰⁹⁻⁶¹³.

Eyesuvis is currently the only FDA-approved prescription corticosteroid therapy for the short-term (up to two weeks) treatment of “dry eye flares”. DED is a chronic disease, but it has also been long noted that many patients report an episodic rather than a continuous pattern of symptoms^{614,615}. The TFOS DEWS II Definition and Classification report described intermittent symptoms that occur early in the development of DED⁶¹⁶. Even later in the course of DED, episodic symptoms may be triggered by environmental stresses (e.g. dry or windy environments, contact lens wear, environmental allergens), ocular surgeries, medicamentosa including topical preservative agents and other causes⁶¹⁷. A number of reports, including a meta-analysis of 22 studies, concluded there was good evidence for the existence of episodic “flares” in DED, and identified common triggers and confirmed the presence of inflammatory cytokines in the tears of patients with DED exposed to such triggers⁶¹⁸⁻⁶²¹.

Drug delivery to the ocular surface is limited by many factors, including washout by tear flow, lymphatic and blood circulation and the challenges of drug penetration through the hydrophilic mucin layer of the tear film⁶²². For molecules to move through the mucin layer they must be small, hydrophilic and carry a

neutral charge to avoid adhesion⁶²³. Development of mucin-penetrating particle technology is ongoing^{624,625}. Such particles can offer improved physical and chemical stability over polymeric nanoparticles, and preparations can be shelf-stable in a ready-to-use form as aqueous suspensions⁶²⁶.

Delivery of 3.6x higher concentrations of mucus-penetrating loteprednol-loaded particles to the cornea compared with traditional formulations in rabbits has also been reported⁶²⁷. This body of preclinical work led to the development program for Eyesuvis for the treatment of episodic DED that involved 2800 participants⁶²⁸. Since the drug's approval, several studies have reported on both the efficacy and safety of Eyesuvis in the treatment of acute DED flares^{622,629,630}. Currently, its scope for use is unclear in the treatment of a chronic condition such as DED, particularly when precise criteria for resolution of a DED flare has not been defined, nor has a number of treatable flares per year suitable for treatment with Eyesuvis been defined. Complicating the situation further are the many more accessible topical steroid alternatives, although not specifically approved for the management of DED, and their recognized side-effects with long-term use.

8.1.2 Medicated tear supplements

Medicated tear supplements refers to when the primary component is the lubricating polymer, with the addition of an active pharmacological ingredient at a low concentration as an ancillary agent. The potential benefits of medicated tear supplements include more targeted therapy, for example, in the case of the inclusion of a corticosteroid, which can target the inflammatory pathway. A randomized study of 38 individuals with DED compared 0.2% HA with 0.001% hydrocortisone to 0.15% HA and 3% trehalose, both used four times daily for three months⁶³¹. Both groups improved, with the greater improvement noted in TBUT and LLT in the medicated tear supplements group⁶³¹. In a retrospective study of 155 participants with DED, the same formulation (0.2% HA and 0.001% hydrocortisone, Idroflog®, Alfa Intes, Italy) relative to non-steroid containing tear

supplements, resulted in improved TBUT over a 45-day period, particularly in those post-cataract surgery ⁶³².

One consideration with this management option relates to the length of use by the patients and thus the risk of side effects, including the risk of elevated intraocular pressure when using an artificial tear that includes a corticosteroid. However, in the study that compared the known-dose steroid combination with a control drop over a three-month period, no difference in intraocular pressure was noted ⁶³¹.

8.2 T-cell immunomodulatory topical drugs

8.2.1 Cyclosporine A

Cyclosporine A (CsA) is an immunomodulator ^{633,634} and since the approval of Restasis (CsA 0.05%) by the FDA in 2002 a number of products with differing formulations have been licenced in regions around the world for use in patients with DED ⁶³⁵. Cyclosporine A is a calcineurin inhibitor that exerts immunomodulatory effects by blocking T cell infiltration, activation, and the subsequent release of inflammatory cytokines ^{634,636-639}.

While over 600 peer reviewed articles have been published on the use of CsA in the management of DED since the publication of the TFOS DEWS II Management and Therapy report ², only around 60 were RCTs, with a focus on improving formulations to deliver more rapid effect and superiority relative to other DED treatments. A recent systematic review and meta-analysis identified 583 RCTs in which various formulations of CsA were used to treat DED ⁶⁴⁰. Thirty trials found significantly better efficacy with CsA, irrespective of dose or concentration, and the effect of CsA was comparable to tear supplements, to vehicle, and to fluorometholone 0.1%, tacrolimus 0.03% or diquafosol 3% in 13 trials.

The high molecular weight and hydrophobicity of CsA, combined with the continual flushing of the ocular surface through the blink action and tears, has made drug delivery of current formulations challenging⁶³⁵. Most marketed formulations are emulsions or nano-emulsions containing oils and surfactants such as cetalkonium chloride, polysorbate 80, Octoxinol-40.

Pooled data from two studies examining a 0.1% cationic CsA emulsion (Ikervis®, Santen, Japan) compared to its vehicle in participants with moderate to severe DED, suggested a reduction in corneal staining and symptoms after six months of use, but not in a population with Sjögren disease⁶⁴¹. A systematic review of current commercial formulations of CsA suggested some were better than others at improving various signs and symptoms⁶⁴².

A 0.05% CsA nano-emulsion formulation (Cycloome®, Shenyang Xingqi, China) uses Ailic-Tech® technology to create a transparent microemulsion that minimizes ocular intolerance reactions. The Phase III study showed that the treated group displayed a significant improvement in ocular surface test results from day seven⁶⁴³. In another study, it improved Schirmer scores, corneal goblet cell density, and reduced dendritic cell density more effectively than 0.1% fluorometholone after three and six months⁶⁴⁴. This formulation also showed significant improvement in OSDI, TBUT, corneal fluorescein staining and corneal sensitivity following various forms of refractive surgery⁶⁴⁵⁻⁶⁴⁷.

A water-free version was shown to significantly reduce corneal staining compared to a vehicle control, but there were no differences in symptoms compared to the semi-fluorinated alkane treatment arm⁶⁴⁸⁻⁶⁵¹. A water-free semi-fluorinated alkane-based 0.1% CsA formulation has been approved in the US (Vevye™; Harrow, Nashville, TN, USA) and in the European Union (Vevizye®; Laboratoires Thea, Clermont-Ferrand, France), comprising a solution of CsA in a

perfluorobutylpentane vehicle. The spreading and residence properties of the product are believed to lead to higher local bioavailability compared to other CsA-containing emulsions at 0.05% and 0.1%, and animal studies suggest that perfluorobutylpentane improves lipid layer grading, which may play a role in reducing tear evaporation^{136,652,653}. The product was investigated in four RCTs and an open-label, long term safety study involving more than 1500 participants with DED^{648-651,654}. The initial Phase II study showed an early onset of effect and significantly higher improvements in ocular surface staining endpoints compared to the active comparator, a 0.05% CsA emulsion⁶⁵¹. The subsequent three Phase III studies in predominantly aqueous deficient DED met the primary endpoint, reducing total corneal fluorescein staining at four weeks compared to vehicle; responder analyses showed that the magnitude of improvement was clinically meaningful in >50% of participants by week 2. Conjunctival staining improved significantly in all three studies compared to the vehicle. While symptoms improved in all trials from baseline, superiority over vehicle could not be demonstrated consistently in the studies⁶⁴⁸⁻⁶⁵⁰. The incidence of adverse events was comparable between active and vehicle groups in all studies; the most frequent ocular AEs were instillation site reactions, which occurred in <10% of participants, which is lower than has been reported with other pharmacological DED treatments^{649,650,655}.

A micellar nano-particulate CsA formulation of 0.09% CsA (OTX-101; CEQUA®; Sun Pharmaceutical Industries, Cranbury, NJ, USA) showed efficacy relative to its vehicle in participants with aqueous deficient DED⁶⁵⁶⁻⁶⁵⁹ and demonstrated safety over a 12 week study period⁶⁵⁰. A 0.05% CsA nano-emulsion (Cyporin N®; Taejoon Pharma, Seoul, Republic of Korea) improved tear stability and Schirmer test results over the course of a 12 week trial compared to HA 0.15% tear supplements, but symptoms in the mild-to-moderate DED participants were not improved in either treatment group (n=15 in each)⁶⁶⁰. The 0.05% nano-emulsion (Cyporin N) performed better than a 0.05% emulsion (Restasis) (in

conjunctival staining score) or diquafosol 3% (in tear film stability and volume) over a 12 week study in participants with DED and Sjögren disease ^{661,662}. Another study found a 0.08% nano-emulsion (TJO-087; Taejoon Pharma, Seoul, Republic of Korea) to be equivalent in efficacy to a 0.05% emulsion of CsA (Restasis) over a 32-week follow-up period ⁶⁶³. A small study (n=24) compared a CsA emulsion versus a nanoemulsion. To relieve discomfort, participants in both groups received fluorometholone concomitantly during the first four weeks. Both treatments showed improvements in signs and symptoms compared to baseline at week four to 12 ⁶⁶⁴.

A systematic review identified 11 previous RCTs on the use of CsA for the management of DED compared to tear supplements ⁶⁶⁵. Pooled results of the 1,085 participants recruited showed that CsA improved TBUT, fluorescein staining score, and patient-reported symptoms on OSDI (by approximately five points) more than tear supplements; although more adverse events, none of which were considered serious, were reported with CsA than with tear supplements ⁶⁶⁵. However, most studies were only of between two- and four months duration and the longest was only 12 months, so long-term treatment effects are not yet known. In addition, some studies observed no benefit of the CsA emulsion over tear supplements containing HA (0.1%, 0.15% and 0.3%) over a 12-week evaluation period ⁶⁶⁶. Further studies since this review found no benefit of CsA over 0.15% HA tear supplements ⁶⁶⁵, while a 0.05% CsA nano-emulsion (Cycloome®, Shenyang Xingqi, China) exhibited improved OSDI scores compared with its vehicle ⁶⁴³ and 0.05% CsA nano-emulsion (Cyporin N) was more effective than 0.15% HA and warm compress use by participants with obstructive MGD ⁶⁶⁷. In a prospective three group comparison of 0.15% HA, 0.05% CsA (Cyporin N) and 3% diquafosol sodium in the treatment of young adults with moderate-to-severe DED, corneal staining, OSDI symptoms, Schirmer test, TMH and TBUT showed similar improvements in all groups,

whereas the decrease in inflammatory markers after 12-weeks was greater with CsA than in the group prescribed HA ⁶⁶⁸.

The data on whether an artificial tear enhances the effect of CsA in reducing inflammatory markers, corneal staining and symptoms is equivocal ^{655,665,669,670}. In other combinations, CsA (0.1%) combined with loteprednol (0.2%) compared with CsA (0.05%) alone showed no benefits over a four-week follow-up, except in higher order aberrations, but how and when these were assessed is not made clear in the publication ⁶⁷¹. Topical CsA 0.1% in combination with diquafosol tetrasodium 3% improved TBUT compared to CsA alone, but did not improve symptoms or corneal and conjunctival staining scores ⁶⁷².

In an RCT, increasing the concentration of CsA (from 0.05 to 0.09%) improved symptoms, corneal staining, tear production and tear film osmolarity over three months, but had no effect on conjunctival morphology and tear film stability, and increased reported adverse events, including discomfort using the drops ⁶⁷³. Low doses of CsA (0.01 and 0.02% with 3% trehalose) have little effect in participants with severe DED compared to a placebo ⁶⁷⁴.

In a study of 62 severe DED participants in whom corneal staining had been dramatically improved after either six or 12-months of CsA 0.1% use ⁶⁷⁵, the estimated time to relapse after CsA withdrawal was 32-weeks for those who initially received 12-months of treatment, versus 25-weeks in those having received six-months of treatment ⁶⁷⁶.

Another relevant area in which CsA has been investigated is in the management of patients with MGD. In a retrospective analysis, 53 patients with MGD were enrolled in a three-month study in which treatment with topical 0.05% CsA in conjunction with a topical, preservative free HA-based lubricant (experimental group, n=74 eyes) and use of a HA lubricant only (control group, n=32 eyes)

were compared ⁶⁷⁷. The experimental group showed a statistically significant improvement in OSDI score, TBUT, Schirmer score and lid margin telangiectasia. Additionally, mean change from baseline in OSDI, TBUT, Schirmer score, corneal staining score, lid margin telangiectasia and conjunctival injection showed a greater improvement in the experimental group than in the control group after three months ⁶⁷⁷.

A prospective study included 64 patients with DED and MGD who were randomly assigned to one of three groups: Group 1 (n=24; 0.1% HA-based eye drops + conventional 0.05% CsA), Group 2 (n=21; 0.1% HA-based eye drops nano-emulsion 0.05% CsA), and Group 3 (n=19; 0.1% HA-based eye drops only; control) ⁶⁷⁸. Subjects were evaluated after four, eight and 12 weeks of treatment. In Group 3 (control), lid margin telangiectasia, corneal staining and conjunctival injection improved after eight weeks and TBUT after 12 weeks. In Group 1 (conventional CsA), lid margin telangiectasia, meibomian gland secretion and TBUT improved significantly after four weeks, whereas corneal staining, conjunctival injection Schirmer score and LLT improved significantly after eight weeks and OSDI after 12 weeks. In Group 2 (nano-CsA), lid margin telangiectasia, meibomian gland secretion, corneal staining, conjunctival injection, TBUT and OSDI significantly improved after four weeks, and Schirmer score after eight weeks. The LLT was significantly higher than in the other two groups after four weeks. These results demonstrated that both CsA formulations were superior to an ocular lubricant alone and that the nano-CsA formulation resulted in improvements in various signs and symptoms of DED in subjects with MGD faster than in the conventional CsA group ⁶⁷⁸.

In a prospective, randomized, single-blinded, three-month, controlled clinical study, 51 patients with obstructive MGD were randomly assigned to one of two groups. The CsA group received a 0.05% CsA topical nanoemulsion twice daily, 0.15% HA-based lubricants four times daily, and 10 minutes of twice daily warm

compress application⁶⁶⁷. The control group used the 0.15% HA-based lubricant six times daily and twice daily warm compresses for 10 minutes at a time. At the three-month evaluation, the CsA group showed significantly greater improvements in TBUT, eyelid debris, eyelid redness/swelling, and lower meibomian gland secretion score⁶⁶⁷.

8.2.2 Lifitegrast

Lifitegrast ophthalmic solution 5% (Xiidra®; Bausch + Lomb, Bridgewater, NJ, USA) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist which binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its ligand intercellular adhesion molecule-1. This inhibits any further downstream inflammatory cascade mediated by the migration and proliferation of lymphocytes and cytokine production⁶⁷⁹. Two large scale studies (OPUS 1 and OPUS 2) established an improvement in the signs and symptoms of DED with lifitegrast 5% solution^{680,681}. The subsequent OPUS 3, a Phase III, randomized, multicenter study, evaluated the change in eye dryness score from baseline to day 84 as the primary efficacy end point⁶⁸². A significant improvement was noted in the treated group compared with those who received placebo within 14 days of initiation of lifitegrast and persisted throughout the study period.

A post-hoc analysis reviewing the pooled data of 1429 participants from two RCTs (OPUS 2 and OPUS 3) found that concurrent improvement in both signs and symptoms was more likely to be observed in participants with moderate-to-severe DED (inferior corneal staining of >1.5 and eye dryness scores of >60)⁶⁸³. This provides added insight into the contrast between the results of OPUS 1, which reported an improvement in signs but not the symptoms, and OPUS 2, which reported an improvement in symptoms but not signs, as each study enrolled a patient population with differing severity of DED. Similarly, in a meta-analysis of 3197 participants with DED receiving lifitegrast, an improvement was

noted in the symptoms (ocular discomfort score, eye dryness score, eye discomfort score, OSDI) and signs (total corneal staining scores, nasal lissamine staining score, TBUT) ⁶⁸⁴. Pooled analysis of the safety of lifitegrast evaluated across five RCTs with 2464 participants estimated a discontinuation rate of 7% due to treatment-emergent adverse events. Overall, the drug was considered safe and well-tolerated in participants with DED ⁶⁸⁵.

A reduction in the dependency on concurrent tear supplements has also been noted with lifitegrast ⁶⁸⁶. A RCT investigating participants with MGD found that lifitegrast treatment, as compared to thermal pulsation therapy, led to a greater improvement from baseline to day 42 in eye dryness, corneal staining, and eyelid redness ⁶⁸⁷. In two prospective studies in participants with DED undergoing cataract surgery, treatment with lifitegrast improved signs and symptoms of DED and resulted in improvements in biometry accuracy and postoperative refractive outcomes ^{688,689}. Real-world data regarding lifitegrast use has reported improvement in ocular symptoms and signs, which persisted 12-months after use ⁶⁹⁰.

Reports describe patient dissatisfaction, particularly with respect to instillation site irritation (burning) and dysgeusia (metallic or salty taste post insertion that may last four to five hrs) ^{684,685,691,692}. A systematic review and meta-analysis reported that dysgeusia occurred in 16% of subjects, a rate which was 36 times higher in patients applying the drug compared with patients using a placebo ⁶⁸⁴.

8.2.3 Tacrolimus

Tacrolimus (FK-506) is a macrolide immunomodulatory agent, with a similar mechanism of action to CsA, but delivered in ointment rather than drop form, and with 10-to-100-fold greater potency ⁶⁹³. A six-month study involving the direct comparison of topical 0.03% tacrolimus and 0.05% CsA (n=30 participants per study arm) showed both significantly improved patient symptoms and ocular

surface staining, reducing the frequency of tear supplements use compared to placebo-controlled eyes ⁶⁹⁴. However, no significant difference in efficacy between the two treatments was evident in participants with severe DED due to Sjögren disease over the study period. A small RCT (n=20) demonstrated the effectiveness of one month application of 0.03% tacrolimus ointment for refractory cases of posterior blepharitis ⁶⁹⁵.

The main issue with the use of tacrolimus has been the lack of commercially available topical ophthalmic formulations in many parts of the world, although they are now becoming available in some countries. Some studies have described off-label use of a topical skin preparation of tacrolimus, demonstrating significant efficacy in resistant blepharitis and in individuals with Sjögren disease ^{694,695}.

8.3 Pharmacological compounds under development

8.3.1 Carbonized nanogels

Carbonized nanogels developed via the pyrolysis of lysine hydrochloride are topical nanogels designed to offer longer retention rates over the ocular surface. *In vivo* rabbit studies have reported similar therapeutic effectiveness of a 10-fold lower dose of carbonized nanogels as 0.05% CsA ⁶⁹⁶. This increased ocular bioavailability indicates the potential for a longer dosing interval and lower dose concentration. The nanogels exert free radical scavenging properties and improve ocular surface health via their antioxidant and anti-inflammatory properties ⁶⁹⁶.

8.3.2 Fenofibrate

Fenofibrate is a synthetic peroxisome proliferator-activated receptor α -agonist, which exerts an anti-inflammatory effect not only on the cornea and conjunctiva

but also within the lacrimal gland. Fenofibrate activates the peroxisome proliferator-activated receptor α -agonist, resulting in inhibition of Th1 and Th-17-mediated inflammation⁶⁹⁷⁻⁶⁹⁹. It also promotes T-regulatory cells and reduces IL-17 and INF- γ levels⁶⁹⁷⁻⁶⁹⁹. In other studies, fenofibrate has been reported to decrease lacrimal gland inflammation, increase aqueous tear secretion, and reduce corneal fluorescein staining in non-obese diabetic mice, as well as to partially reverse the negative lacrimal gland sequelae in a high-fat diet experimental mouse model^{697,700}.

8.3.3 Ferulic acid

Ferulic acid, an antioxidant derived from angelica root, has been studied in rabbit models and *in vitro* cell culture. The molecule reduces pro-inflammatory cytokines such as TNF- α , IL-6 and IL-8 and improves tear volume and ocular surface staining compared with a buffer saline control⁷⁰¹.

8.3.4 Lacritin

Lacritin is a glycoprotein, found naturally in tears, that is selectively reduced in DED^{702,703}. Topical lacritin can mediate a therapeutic effect in Aire mice by improving tear secretion and corneal staining scores and also reducing T cell infiltration in the lacrimal glands⁷⁰⁴. Lacripep™ (TearSolutions, Charlottesville, VA, USA) is a synthetic 19-amino acid peptide fragment of lacritin with preserved biologic activity of the full lacritin monomer. A first-in-human study carried out in 204 participants with Sjögren disease demonstrated good safety and tolerability for both the 22 μ M and 44 μ M concentrations⁷⁰⁵. However, the primary efficacy endpoints of improvement in total corneal staining score and eye dryness score were not met by the end of the study period (28 days). Participants with greater severity of disease at baseline demonstrated a better response, indicating the need for consideration of patient DED severity and subtype, and dose titration to determine the optimal dosing regimens in future studies.

8.3.5 Naringenin

Naringenin is a naturally occurring flavonoid, found in various fruits, particularly tomatoes and citrus fruits such as grapefruits and oranges. It has been widely studied for its antioxidant, anti-inflammatory, anti-neoplastic and neuroprotective properties⁷⁰⁶. In a mouse model of DED, naringenin has been shown to improve the ocular surface quality with increased tear volume and reduced corneal and conjunctival staining in animal models⁷⁰⁷.

8.3.6 Repository corticotropin injection

Acthar® Gel (repository corticotropin injection; Mallinckrodt Pharmaceuticals, Bridgewater, NJ, USA) is a naturally sourced complex mixture of adrenocorticotrophic hormone analogs and other pituitary peptides that is believed to have both steroidogenic and non-steroidogenic immunomodulatory effects via activation of melanocortin receptors in various cells throughout the body⁷⁰⁸.

In an attempt to address an unmet need for effective therapies to treat patients with refractory DED, adults with moderate or severe-acute DED received 80 units of subcutaneous repository corticotropin injection twice weekly for 12 weeks⁷⁰⁹. Fifteen subjects received at least 1 dose of repository corticotropin injection and 12 subjects completed the study. Compared to baseline (day 1), reduced corneal staining was observed at day 14 and day 84 after repository corticotropin injection treatment. Mean SANDE scores progressively declined from 62.0 at baseline to 46.9 at day 84. Schirmer test scores showed no significant changes throughout the study. These results suggest that repository corticotropin injection may be an effective treatment for moderate and severe DED, however, further, larger, masked clinical studies are required to confirm this.

8.3.7 Reproxalap

Reactive aldehyde species are involved in proinflammatory signaling and are elevated in DED. Reproxalap (Aldeyra Therapeutics; Lexington, MA, USA), a

small molecule that binds reactive aldehyde species, inhibits inflammation by competing with malondialdehyde and 4-hydroxy-2-nonenal for their biological targets. The binding of reproxalap to these reactive species, prevents reactive aldehyde species from interacting with amino and thiol groups on receptors and kinases⁷¹⁰⁻⁷¹². This disrupts upstream proinflammatory signaling cascades involving nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), inflammasomes, and other mediators, thus reducing Th1 and Th2-mediated inflammation⁷¹⁰⁻⁷¹². Additionally, reproxalap prevents reactive aldehyde species and phosphatidylethanolamine interaction in the tear lipidome, thereby preventing tear lipid modification⁷¹²⁻⁷¹⁴. In a Phase IIa trial, 51 participants were randomized to receive three formulations of reproxalap (0.1%, 0.5% ophthalmic solution, and 0.5% lipid ophthalmic solution) in a parallel-group design⁷¹². A similar response rate was noted across all three formulations with a reduction of symptom and lissamine green overall staining scores from baseline in participants with DED⁷¹². In the subsequent Phase IIb multicentre trial, 0.1% and 0.25% concentrations of reproxalap were compared to a vehicle control, and 300 participants randomized to each of these groups were assessed over a period of 12 weeks⁷¹⁵. A dose-dependent response from baseline was noted, with reproxalap performing superiorly to the vehicle with respect to improving both symptoms and signs of DED. Based on these results, the study determined that the 0.25% concentration would be used for the subsequent Phase III trials. The drug was found to be safe and tolerable.

8.3.8 Topical porphyrin

The potential benefits of porphyrin, a topical, experimental, synthetically derived antioxidant, have been explored in animal ocular surface disease models and *in vitro* cell cultures^{716,717}. An improvement in corneal fluorescein staining scores was observed with topical porphyrin in both mouse and rabbit models^{716,717}.

8.3.9 Visomitin

Oxidative stress mediated via ROS is believed to play an important role in the pathogenesis of DED ⁷¹⁸. SkQ1 is a small molecule and the active ingredient of Visomitin (Mitotech LLC, Moscow, Russian Federation) ⁷¹⁹. SkQ1 targets and neutralizes ROS within mitochondria, which are otherwise inaccessible to natural antioxidants. In a randomized, double-masked, placebo-controlled clinical study, 240 participants with DED were assigned topical Visomitin or placebo for administration three times daily for six weeks ⁷²⁰. A significant improvement was noted in TBUT at the two-, four-, and six-week time points and in central and total corneal fluorescein staining score at six weeks ⁷²⁰. In a Phase II, single-center, randomized, placebo-controlled study with 91 participants with mild-to-moderate DED, SkQ1 demonstrated efficacy in treating dry eye signs, with statistically significant improvements in corneal fluorescein staining, conjunctival lissamine green staining, lid margin redness, ocular discomfort, dryness and grittiness compared to placebo ⁷²¹. However, the primary efficacy endpoints were not met, with no difference between SkQ1 and placebo for corneal staining in the inferior region at day 29 nor in the mean score for the worst dry eye symptom over the seven days preceding the day 29 visit. The drug was shown to be safe and well-tolerated.

9 Oral antimicrobial agents

Oral tetracyclines (tetracycline, minocycline, or doxycycline) or macrolides (erythromycin and azithromycin) have been used to alleviate symptoms and improve ocular surface and tear film parameters in participants with DED. Beneficial effects include anti-inflammatory effects, reduced ocular surface bacterial load and improved meibum quality.

9.1 Tetracycline and analogues

Tetracyclines are broad-spectrum antibiotics with activity against a wide range of microorganisms, including gram-positive and gram-negative bacteria, chlamydiae, mycoplasmas, rickettsiae, and protozoan parasites. Tetracyclines penetrate bacterial cells by passive diffusion and inhibit bacterial growth by interfering with protein synthesis by inhibiting the 30S ribosomal subunit. They hinder the binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex⁷²².

A decrease in bacteria-producing lipolytic exoenzymes^{723,724} and inhibition of lipase production⁷²⁵ with resultant decrease in meibomian lipid breakdown products, may contribute to improvement in clinical parameters in evaporative DED. These agents also have anti-inflammatory properties. They impair the activity of collagenase, phospholipase A2, and several MMP types, and decrease the production of inflammatory mediators such as IL-1 and TNF-alpha in a wide range of tissues, including in the corneal epithelium^{726,727}.

Tetracycline and its analogues have been used to treat disorders that are associated with ocular surface and tear film abnormalities such as those associated with rosacea⁷²⁸, MGD^{729,730} and various forms of anterior blepharitis^{730,731}. Although there are many published papers in the field⁷³¹, thus far, only two studies have a robust study design with placebo control and double masking. A parallel group RCT compared oral doxycycline (40 mg once a day) with placebo in 70 participants with anterior blepharitis and facial rosacea over three months (NCT00560703). There was little to no effect of the doxycycline on subjective dry eye symptoms and bulbar conjunctival hyperemia at 12 weeks. Tear production measured by the Schirmer test, and tear stability measured by TBUT, showed statistically significant improvement from baseline, although the clinical relevance of these changes remain uncertain. A three-arm RCT

investigated the effect of high dose (200 mg twice a day) and low dose (20 mg twice a day) oral doxycycline versus placebo during a one month of treatment period⁷³². The study enrolled 50 participants with chronic MGD in each treatment arm (150 participants total). The results suggested that oral doxycycline could impart a modest improvement in patient reported symptoms, more so in the higher dose doxycycline group compared to placebo at one month, but the group difference was not statistically significant.

The optimal dosing of oral tetracyclines for the treatment of DED has not been well established. In general, treatment with 50 or 100 mg doxycycline once or twice a day for a period of several weeks to several months is well tolerated. Doxycycline (40 mg daily) is the only tetracycline approved by the FDA in the treatment of acne rosacea for up to 16 weeks. Of note, long term doxycycline treatment at this level does not lead to development of antibiotic resistance, likely because this antibiotic is bacteriostatic rather than bactericidal^{733,734}.

Tetracyclines are contraindicated during pregnancy and in children under 8 years old due to their potential adverse effects on dental and bone development. These antibiotics can bind to calcium ions, leading to permanent yellow-brown discoloration of teeth and enamel hypoplasia when administered during tooth development. Additionally, tetracyclines can slow down skeletal growth in young children^{735,736}. In addition to side effects such as gastrointestinal symptoms and photosensitivity, safety issues such as an increased risk of breast cancer with long-term antibiotic therapy have been raised^{737,738}. A large scale study did not substantiate these findings⁷³⁹. Nonetheless, there is currently no conclusive evidence and additional larger-scale prospective studies are needed to define any risks with longer-term tetracycline use.

9.2 Macrolide antibiotics

Macrolides are bacteriostatic antibiotics that inhibit bacterial protein biosynthesis, by binding reversibly to the P site on the 50S subunit of the bacterial ribosome⁷⁴⁰. Macrolides are actively concentrated within leukocytes and thus are transported into the site of infection. The two main macrolides used in the treatment of ocular surface diseases are azithromycin and erythromycin. Orally administered macrolides are better tolerated than tetracyclines and do not have the photosensitivity side effect. The cessation of the treatment prior to an in-office procedure to manage DED utilizing light energy, such as IPL, is not necessary.

A pre-clinical study of five days dosing on immortalized human meibomian gland cells found azithromycin, but not doxycycline, minocycline, or tetracycline significantly increased the cellular accumulation of cholesterol, cholesterol esters, phospholipids, and lysosomes⁷⁴¹.

A RCT with a crossover design enrolled 115 consecutive participants to compare oral treatment with doxycycline (4 g for 30 days; 100 mg twice a day for seven days and then 100 mg/day for a further 21 days) or azithromycin (1.25 g for five days; 500 mg on the first day and then 250 mg/day for an additional four days)⁷⁴². Therapy was switched or conservative management maintained according to signs and symptoms. Both antibiotics were effective and safe for treating participants with persistent MGD over the nine month study, although azithromycin required a reduced dose and shorter course of therapy (five days vs. four weeks)⁷⁴².

A systematic review and meta-analysis compared oral azithromycin to oral doxycycline for the management of MGD⁷⁴³. The review suggested that oral azithromycin may be more effective in reducing signs of MGD than oral doxycycline. Azithromycin also demonstrated a better safety profile, with fewer gastrointestinal adverse events. It concluded that further research is needed to

determine the optimal antibiotic treatment for MGD. The risks of azithromycin therapy should also be noted, in particular serious side effects including cardiac arrhythmias, pancreatitis, and vertigo.

Since the use of tetracycline and its analogues is contraindicated in children aged less than eight years because of dental enamel abnormalities^{735,736}, oral erythromycin may offer a reasonable alternative to tetracycline for managing childhood blepharokeratoconjunctivitis^{744,745}. Erythromycin 5 mg/Kg/day is the oral dose typically prescribed, for a period of several weeks to several months.

Two reviews suggested that participants with posterior blepharitis or MGD-related ocular surface disease may experience short-term benefits of antibiotics for the duration of the treatment^{730,731}. However, evidence for lasting improvement after cessation of treatment is lacking. In addition, there is mounting evidence regarding in-office procedures to improve MGD-related DED, without the known systemic side effects and inconvenience for the patient. Given the unclear long-term benefits, common gastrointestinal side effects, and potential serious systemic problems such as malignancies, the existing literature is insufficient to conclude that antibiotics are particularly useful in long-term MGD management, and these are rarely considered first line options.

10 Ocular surface promoters/regenerators

10.1 Biologics

10.1.1 Blood-based treatments

Blood-based eye drops represent an emerging treatment for DED and come in a wide variety of options (Figure 1). The application of blood-based eye drops increases the concentration of active growth factors and mediators that mimic the function of natural tears.




Figure 1: Processing pathways for autologous and allogeneic blood-derived eye drops. Autologous tears are derived from the patient's own blood either via the Finger-Prick Method (direct application to the eye) or through whole blood processing. Allogeneic tears are obtained from either healthy adult donors or umbilical cord serum (UCS) and are processed exclusively from whole blood. Whole blood undergoes either centrifugation without anticoagulant to produce serum tears, or centrifugation with anticoagulant to separate into platelet-poor plasma (PPP), platelet-rich plasma (PRP), white blood cells (WBC), and red blood cells (RBC). PRP-derived eye drops are further classified into PRP drops (direct extraction), PRGF (Plasma Rich in Growth Factors) drops (PPP + PRP activated with calcium chloride and incubated at 56°C for one hour), and PL (Platelet Lysate) drops (PRP chemically activated using calcium chloride, calcium gluconate, thrombin, or subjected to thermal shock). Modified from Tovar and Sabater ⁷⁴⁶.

10.1.2 Autologous serum tears

Natural tears are a complex mixture of water, electrolytes, lipids and mucins, but also vitamins, enzymes and over 1500 proteins ⁷⁴⁷, cytokines/chemokines, growth factors and neuromediators ⁷⁴⁸⁻⁷⁵⁰. Importantly, and as previously reported in TFOS DEWS II Management and Therapy report ², serum has been reported to contain growth factors such as epidermal growth factor, nerve growth factor (NGF), transforming growth factor-alpha, keratocyte growth factor, insulin growth factor-1 and others ⁷⁵¹, as well as vitamins A and E and fibronectin ⁷⁵², which are all believed to prevent apoptosis and facilitate epithelial cell growth and differentiation ^{753,754}.

The TFOS DEWS II Management and Therapy Report ² reviewed the published literature on serum tears, citing 14 clinical studies and included the use of serum tears in Step 3 of the staged treatment algorithm. The report cited the lack of a universally accepted methodology for the preparation of autologous serum, patient access issues and contamination concerns as factors that had limited more widespread adoption by clinicians.

Thus far, only a few RCTs have been performed evaluating the efficacy of serum tears for the treatment of DED. This is perhaps because of the cost of such trials and the lack of a commercial producer of serum tears. Historically, clinicians have either prepared serum tears in their offices, sometimes under non-sterile conditions, or had them prepared in compounding pharmacies or at blood donation locations, creating a lack of standardization in methodology ².

A Cochrane review identified 29 studies but found only five that satisfied the criteria for inclusion, citing high heterogeneity and a lack of quantitative reporting for many outcome metrics ⁷⁵⁵. The report concluded that there might be some short-term benefit in reducing symptoms with autologous serum tears compared with tear supplements, but additional RCTs were required to define the effects

with greater certainty. A more recent meta-analysis of seven RCTs reported better efficacy compared with tear supplements for both patient symptoms and multiple signs of ocular surface disease ⁷⁵⁶. An American Academy of Ophthalmology Preferred Practice assessment report reviewed 10 studies and found eight to be high quality, demonstrating improved symptoms and at least one objective clinical sign of dry eye with the use of serum tears ⁷⁵⁷. A task force report from the European League Against Rheumatism (EULAR) provided an algorithm for treating ocular dryness, and recommended the use of autologous serum tears in patients whose symptoms were uncontrolled after ocular lubricants and CsA ⁷⁵⁸. A report of Preferred Practice Patterns in India concluded that there was sufficient evidence to recommend the use of autologous serum tears in patients with DED, but emphasized the need for standardization of preparation methods ⁷⁵⁹.

While it is not possible to prepare and distribute serum tears in the same manner as a topical pharmacological medication, it is worth noting that providers are now preparing autologous serum tears under sterile conditions using standardized centrifugation and dilution methods, and distributing them to patients, shipped under refrigeration. Since the last TFOS Management and Therapy report ² there have been very few RCTs comparing the efficacy of autologous serum tears to current FDA-approved topical pharmacological drugs. One study reported a statistically significant reduction in OSDI scores with 20% serum tears relative to CsA 0.05% eyedrops ⁷⁶⁰.

10.1.3 Allogeneic serum tears

An alternative to autologous serum tears is the use of allogeneic serum eye drops from healthy donors. Allogeneic serum eye drops may have an advantage in patient-specific conditions such as poor venous access, fear of needles, logistical problems, cognitive decline, advanced age, limited mobility, systemic diseases and blood dyscrasias ⁷⁶¹. In a prospective, randomized crossover trial

of severe dry eye participants, a group was randomized to either receive autologous serum drops for one month, followed by a one-month washout, before receiving allogeneic serum drops for one month and the other group was treated with the serum preparations in reverse order. There was no difference in OSDI score at the end of the trial, with comparable efficacy and tolerability⁷⁶². In a randomized clinical trial of 63 severe dry eye participants comparing autologous versus allogeneic serum drops and umbilical cord serum (UCS) drops there was a significant improvement in dry eye signs, such as Schirmer, TBUT and fluorescein and lissamine green staining measurements and symptoms⁷⁶³. However, there were no noticeable differences between the treatments. Allogeneic serum eye drops seem to be a safe and efficacious alternative for certain populations of dry eye patients with limited access to autologous preparations.

In summary, there is evidence from RCTs and other high quality meta-analyses and reviews demonstrating the efficacy and rapid onset of improvement of patient symptoms and signs to treat DED for both autologous and allogeneic preparations. However, further RCTs, in addition to comprehensive guidelines for the preparation of these products, are required for more thorough assessments of their efficacy and potential adoption in treatment of patients with severe DED.

10.1.4 Platelet derived preparations

These preparations differ from autologous serum tears in that they are diluted in plasma, which contains clotting proteins and biologically active agents derived from platelets, such as epidermal growth factor, transforming growth factor-beta, platelet-derived growth factor, NGF and insulin-like growth factor. Although many platelet-rich formulations have been described, normally these involve isolating and concentrating platelets within differing volumes of plasma, and the platelets are then activated to release growth factors.

A systematic review and meta-analysis of platelet-based eye drop therapies for DED included 19 prospective studies of different formulations, such as platelet-rich plasma (PRP) and PRGF, compared outcomes with either tear supplements or autologous serum tears, observing both signs and symptoms of DED before and after treatment⁷⁶⁴. Of the ten comparative studies included, six were randomized and four were non-randomized studies. Three were prospective and six were retrospective. In terms of symptom changes after platelet-based therapies, there were significant changes in the pooled standardized mean difference and also in the overall effect size. Dry eye clinical signs, tear quality, tear quantity and corneal staining demonstrated statistically significant changes in the pooled standardized mean difference and overall effect size. However, this paper demonstrated a significant improvement in dry eye symptoms and signs with PRP only when these were compared to tear supplements. The study did not demonstrate significant differences for dry eye parameters between PRP and autologous serum.

10.1.5 Platelet Rich Plasma (PRP)

This formulation is prepared from a plasma fraction that is extracted and then centrifuged, to obtain a layer of PRP, using sodium citrate as an anticoagulant. The product is aspirated and diluted for administration from sterilized bottles with eyedrop applicators.

An interventional case series of 368 participants with moderate-to-severe DED that used PRP eye drops six times a day for six weeks reported that 87.5% of participants showed a statistically significant improvement in symptoms, as measured by OSDI, and 76.1% demonstrated a reduction in corneal staining from baseline⁷⁶⁵.

An RCT was undertaken in which monthly lacrimal gland injections of autologous PRP with topical HA drops (n=15) was compared to HA eye drops only (n=15) for

participants with Sjögren disease⁷⁶⁶. At 90 days, every patient in the treatment group demonstrated significantly improved signs, such as a reduction in corneal staining, an increase in mean Schirmer test value, and an increase in TBUT. Improved symptoms in OSDI scores were also noted, and no adverse effects were observed. Although limited by the small sample size of 30 participants, this study suggests that lacrimal gland injections of PRP may be an effective intervention for severe Sjögren disease⁷⁶⁶.

A prospective, randomized, masked intervention study on 44 participants with aqueous deficient DED treated with PRP eye drops compared results with 39 participants treated with tear supplements for 30 days⁷⁶⁷. PRP treatment resulted in a significant reduction in symptoms, hyperemia, osmolarity and corneal and conjunctival staining, as well as an increase in visual acuity, tear production and calciform cell density at 15 and 30 days of treatment, relative to control.

In a systematic review of 38 papers evaluating PRP treatments for DED⁷⁶⁸, most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products, PRP eye drops, human platelet lysate and platelet gels. Due to variations in production methods and study designs, as well as inconsistent terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.

A prospective RCT randomly assigned 38 participants with primary Sjögren disease to use either autologous serum or PRP eye drops for 12 weeks⁷⁶⁹. Corneal and conjunctival staining scores and TBUT significantly improved at 4 and 12 weeks in both groups, with no significant difference between the groups being observed. Schirmer and OSDI scores, conjunctival metaplasia grade and goblet cell density grade did not significantly change in either group. These results demonstrate that both autologous serum and PRP eye drops are equally

effective in the management of Sjögren disease. The authors concluded that as the preparation time of PRP is shorter than that of autologous serum, that PRP could be considered a useful alternative treatment for patients with Sjögren disease ⁷⁶⁹.

10.1.6 Plasma Rich in Growth Factors (PRGF)

PRGF is formulated from blood placed in tubes that contain sodium citrate anticoagulant and are spun in a centrifuge to isolate and aspirate the PRP, free of leukocytes. The platelets are then activated to release growth factors by the addition of calcium chloride. The resulting eye drops are rich in biologically active mediators such as growth factors, neurotrophic agents, vitamin A and fibronectin and do not contain high levels of pro-inflammatory molecules. Although similar in preparation to PRP, PRGF is considered a subtype of PRP that is high in growth factors, devoid of leukocytes and lacking proinflammatory activity ⁷⁷⁰.

A longitudinal, retrospective, comparative, descriptive study of 77 eyes of 42 patients with DED following laser in-situ keratomileusis (LASIK) surgery was undertaken to evaluate the efficacy of 1-4 treatment cycles (1 cycle = 6 weeks) of PRGF treatment (38 eyes) compared to a control group (39 eyes) who used ocular lubricants four times per day ⁷⁷¹. The control group only showed a significant change before and after treatment for TBUT values. There was a statistically significant improvement in visual acuity, TBUT, OSDI score, reports of frequency and severity of DED symptoms and Schirmer test scores after PRGF treatment and no adverse events were reported. These results suggest that PRGF eye drops are effective for the improvement of dry eye symptoms and signs in patients undergoing LASIK surgery in comparison to conventional dry eye therapy ⁷⁷¹.

In a retrospective, multicentre interventional case series of participants that used PRGF eyedrops for the management of different ocular surface disease for the

first time, 61 participants suffered from DED ⁷⁷². In this subgroup, corneal epitheliopathy, measured with standardized corneal fluorescein staining scales, and symptoms measured by the SANDE questionnaire, were significantly improved at three months after treatment. At the final visit, 74.3% of participants showed an improvement in corneal staining from baseline. Only one participant described an ocular surface burning sensation as a side effect.

An observational, longitudinal study compared the efficacy of PRGF in 59 participants, when added to standard treatment protocols for DED, such as tear supplements, lid hygiene, and anti-inflammatory therapies compared to standard treatment alone in 43 participants, after three months of treatment ⁷⁷³. Symptoms, as measured by the OSDI and SANDE questionnaires, and ocular redness and TBUT were significantly improved. However, no significant difference between groups was found in corneal staining.

A retrospective study involved 83 participants with DED who received PRGF eye drops in addition to standard DED treatment over a three-month period ⁷⁷⁴. Significant improvements from baseline in OSDI symptoms and Schirmer test score were noted. The group treated with PRGF demonstrated improved subbasal nerve plexus metrics as determined by *in vivo* confocal microscopy when compared to standard DED treatment alone.

10.1.7 Autologous serum versus PRP or PRGF

Few studies have directly compared outcomes in participants treated with autologous serum versus PRP. One three month, non-randomized trial compared the outcomes of 22 participants with primary Sjögren disease treated with either 100% autologous serum or 100% PRP ⁷⁷⁵. Signs and symptoms were reduced in both groups, and significantly greater improvement in visual acuity and OSDI was observed in the autologous serum group. No significant differences were observed in corneal staining, TBUT or Schirmer test. A network meta-analysis

reviewed 39 studies involving both pharmacological and blood product therapies for DED, with >50% being RCTs ⁷⁷⁶. The authors concluded that treatment with platelet lysate or PRP improved OSDI and corneal staining more than autologous serum, but described all pairwise comparisons as “low certainty of evidence” because of study limitations, inconsistency, and imprecision.

A single-centre, randomised, double-masked clinical trial was conducted on 96 subjects with moderate-to-severe DED that compared four-week treatments of PRP drops and autologous serum ⁷⁷⁷. After four weeks of treatment, there was no significant difference in OSDI scores, TBUT, ocular surface staining, Schirmer score, meibum quality or expressibility between groups ⁷⁷⁷.

The use of serum tears in 40 participants with persistent corneal epithelial defects, despite the use of amniotic membrane grafting, was reported and showed enhanced healing and better vision recovery relative to artificial tear use ⁷⁷⁸.

10.1.8 Umbilical cord serum (UCS) eye drops

Allogeneic UCS eye drops, prepared from cord samples collected from donors during the birthing process, contain higher concentrations of epidermal growth factor, transforming growth factor- β , NGF, and substance P than autologous serum drops ⁷⁷⁹. UCS can provide growth factors that facilitate proliferation, migration, and differentiation of the ocular surface epithelium ⁷⁸⁰. These components can be stable for up to one month at 4°C and three months at -20°C ⁷⁷⁹. An advantage of UCS over other hematopoietic blood products is that a considerable amount of serum can be collected from the umbilical vein at one time, instead of performing multiple phlebotomies. Another advantage is cost saving, as unlike the case of autologous serum, regulatory bodies do not require cord donors to undergo additional infection screen as this would already be completed as part of the banking requirements of a cord blood bank ⁷⁸¹.

A prospective, interventional non-controlled case series, including 20 participants, observed that UCS use was associated with increased corneal epithelial nerve density, and an improvement in nerve morphology and corneal sensitivity⁷⁸². A prospective, two-month, controlled case series compared UCS with autologous serum tears for Sjögren and non-Sjögren-associated DED⁷⁸³. Both treatments increased the TBUT similarly, but UCS resulted in a significantly larger decrease in ocular surface staining scores and symptoms than did autologous serum tears. However, a more recent RCT comparing autologous serum tears, allogeneic serum tears and UCS on a total of 63 participants over three months showed similar clinical benefits for improvements in TBUT, ocular surface staining scores and symptoms scores between the three serum types⁷⁶³.

10.1.9 Whole blood autologous tears

The use of whole blood by using a “finger-prick” protocol to deliver autologous whole blood drops as a treatment for DED has emerged as an innovative option. This technique involves collecting a small drop of the patient’s blood through a simple finger-prick method and using the autologous whole blood to treat dry eye signs and symptoms⁷⁸⁴⁻⁷⁸⁹.

A multicentre RCT compared thirty participants who were treated with the finger-prick autologous blood four times a day in addition to their conventional medical dry eye therapy, with a group of 30 participants with conventional dry eye treatment alone⁷⁸⁷. The addition of autologous blood eye drops via a finger-prick significantly decreased OSDI scores as compared to conventional therapy-alone. No adverse effects were noted. A prospective, interventional case series of sixteen participants suffering from DED were treated with a drop of their own blood via the finger-prick method and demonstrated an improvement in corneal staining, TBUT, visual acuity and ocular comfort index⁷⁸⁸. After four weeks of cessation of the therapy, corneal staining grade and symptoms worsened.

This technique appears to be patient-friendly and cost effective, does not require product refrigeration, and is readily available. However, it may be limited by the patient's willingness or ability to perform the finger-prick process multiple times a day.

10.2 Lubricin

Lubricin is a natural, mucinous surface-active, 277 kDa glycoprotein synthesized and secreted by chondrocytes and synoviocytes that plays an important role in mammalian cartilage integrity ⁷⁹⁰. Lubricin coats the cartilage surface, providing boundary lubrication and preventing cell and protein adhesion to reduce the shear stress and cartilage degradation on articular surfaces. Thus far, two forms of recombinant human lubricin with relevance to DED have been produced. Full-length recombinant human proteoglycan (rhPRG4) ⁷⁹¹ at 0.015% concentration applied twice daily over a two week period was superior to 0.18% HA-containing tear supplements, in improving signs and symptoms of DED as well as corneal staining score in a small scale RCT ⁷⁹². *In vitro*, rhPRG4 has been shown to reduce inflammation-induced cytokine production and NF- κ B activity in corneal epithelial cells, as well as to bind MMP-9 and inhibit its activity ⁷⁹³.

Another form of recombinant human lubricin (ECF843), produced from the same cell line as rhPRG4, but manufactured using a different process, was assessed in a dry eye clinical trial, but failed to improve signs or symptoms of dry eye relative to vehicle. Significant differences in the molecular structure and function of ECF843 and rhPRG4 may account for the disparate dry eye clinical trial results ⁷⁹³. Further *in vivo* studies are required to determine the effectivity of lubricin in the management of DED.

10.3 Amniotic membrane and amniotic membrane extract drops

Severe DED can lead to significant central or diffuse, coarse or confluent epithelial micro-erosions of the cornea. These erosions may then coalesce and form epithelial defects, with increased risk of infection or ulceration and subsequent loss of vision. Amniotic membrane grafts can be considered to enhance the healing of the corneal epithelium and decrease ocular surface inflammation. PROKERA® SLIM (Bio-TissueDoral, FL, USA) is a human amniotic membrane contained within a single plastic ring that permits the device to be inserted onto the ocular surface like a scleral contact lens. The membrane typically dissolves within three to five days, although the membrane does not have to be dissolved for it to be removed. Thus far, no RCTs have been published on its use. Two multicenter, retrospective chart review studies reported results in participants with severe DED, refractory to various other treatments, including autologous serum tears and CsA 0.05%, who received cryopreserved amniotic membrane^{794,795}. After a treatment period of two to seven days, two-thirds to three-quarters of the participants reported significant improvement in symptoms as well as demonstrating an improved ocular surface staining score at three months. About 10% of participants required repeat treatment to complete healing during the three-month follow-up period. Ocular discomfort was reported in both studies, albeit without the mention of severity or frequency. A cost effectiveness decision tree model found the societal (direct and indirect) cost of cryopreserved amniotic membrane was less than that of topical CsA A 0.05% over a year (cost/utility: \$18,275/0.78 vs. \$20,740/0.74). If examining direct costs only, topical CsA was the least expensive option over a one year timeframe (\$4,112 vs. \$10,300)⁷⁹⁶.

A dried, gamma ray-sterilized amniotic membrane applied using a bandage contact lens is another in-office, sutureless and painless treatment that can be used for treatment of severe DED. A retrospective review of 56 eyes in 52

participants demonstrated improvement of corneal epithelial erosions after one to two weeks of treatment ⁷⁹⁷. The amniotic membrane is semi-transparent, and many participants report blurred vision, whether it is cryopreserved or dehydrated. A large diameter (17mm) dehydrated amniotic membrane with a 6 mm central aperture, (Omnigen® VIEW, NuVision Biotherapies, Nottingham, UK) under an 18mm, 74% water content soft bandage contact lens (OmniLenz®, NuVision Biotherapies, Nottingham, UK) can be used to overcome vision-related issues. A prospective study included 35 participants diagnosed with moderate-to-severe DED treated with this membrane bilaterally for 8-10 days, who demonstrated a 31% improvement in patient symptoms and 42% decrease in ocular surface staining score ¹⁹⁰. A further RCT in participants with moderate-to-severe DED showed two applications for one week in total significantly and rapidly improved dry eye symptoms as well as ocular surface signs for at least three months as well as enhancing corneal nerve health while reducing activated/mature corneal inflammatory cell numbers ⁷⁹⁸.

A study reviewed the ability of amniotic membrane extract drops to treat ocular surface disease in 12 studies ⁷⁹⁹. In a review of 296 eyes of 205 participants, 59% of eyes were treated for DED, 23% for an epithelial defect, and the rest (18%) for other corneal wound healing disorders. Three main types of preparations were described, lyophilized, homogenized, and fresh amniotic membrane extract drops. All studies showed various grades of improvement in both signs and symptoms, the incidence of ocular side effects was 2.3% and it was concluded that overall, the available literature suggests that amniotic membrane extract drops are a valuable tool in the treatment of ocular surface disorders ⁷⁹⁹.

10.4 Cenegermin 0.002%

Nerve growth factor was first discovered in the 1950s and has since been shown to be essential to corneal and conjunctival trophism, sensitivity and healing⁸⁰⁰⁻⁸⁰². Cenegermin-bkbj ophthalmic solution 0.002% (Oxervate®; 20 µg/mL; Dompé farmaceutici, Milan, Italy) is an ophthalmic solution containing a recombinant form of human NGF⁸⁰³. Currently, it is FDA-approved for the treatment of neurotrophic keratitis⁸⁰⁴, however owing to the agent's mechanism of action, it is being investigated for its ability to treat DED⁸⁰⁵.

Cenegermin-bkbj was studied in two RCTs on participants with Stage two (moderate) or three (severe) neurotrophic keratitis^{806,807} with 65 to 72% achieving complete corneal healing after eight weeks, compared to 17 to 33% of the vehicle control groups^{806,807}. The most common adverse reaction was instillation-site pain, which was reported in approximately 16% of participants. Consistent with these findings, another study demonstrated the safety and efficacy of topically-applied human NGF (at 20 µg/mL or at 4 µg/mL concentrations) in 40 consecutive participants with moderate-to-severe DED dosed two times per day for 28 days⁸⁰⁵. However, because there was no control group, it was concluded that the improvement of symptoms and signs after topical recombinant human NGF treatment may have been due, at least in part, to a placebo effect.

10.5 RGN-259 0.1%

RGN-259 0.1% (RegeneRx Biopharmaceuticals; Glen Echo, MD, USA) contains a synthetic copy of the naturally occurring molecule thymosin beta 4 (Tβ4)⁸⁰⁸. In a dry eye mouse model, topical RGN-259 increased corneal epithelial cell migration, promoted mucin and goblet cell recovery and reduced inflammation⁸⁰⁹.

In a Phase III study, a topical ophthalmic solution was applied five times per day in participants with Stages two and three neurotrophic keratitis, resulting in an increased proportion achieving complete healing, a faster rate of healing, reduction in lesion size and severity, and improved comfort measurements, with the drug being safe and well tolerated ⁸⁰⁸.

10.6 Silk-derived protein (SDP-4)

Tear film mucins enhance ocular surface wetting properties due to their amphiphilic chemistry, while also providing natural bioactivity that works towards maintaining a healthy ocular surface ⁸¹⁰. Silk-derived protein (SDP-4) is a naturally derived protein from the *Bombyx mori* silkworm cocoon ⁸¹¹. Similar to mucin, it improves wetting of the ocular surface and acts as a replacement for demulcents and surfactants that may elicit higher toxicity profiles ⁸¹².

In vitro studies have demonstrated silk fibroin's ability to modulate pro-inflammatory signaling through inhibition of the NF- κ B pathway ⁸¹³⁻⁸¹⁵. Aqueous silk fibroin protein also was successfully used to treat ocular surface disease in a murine animal model of DED, improving clinical outcomes by increasing tear production, decreasing corneal irregularity, inhibiting epithelial cell detachment, and increasing goblet cell density through reduced inflammatory cytokine gene expression and secretion of intercellular adhesion molecule-1, MMP-2 and MMP-9 ⁸¹⁶.

In the first known in-human clinical trial using SDP-4, participants with moderate-to-severe DED were dosed twice daily for up to 84-days in a double-masked, randomized, parallel-group, and serial cohort design ⁸¹⁷. Participants who received eye drops containing 1% SDP-4 had significantly increased TBUT from baseline, which was significantly greater than that observed in the vehicle control

group. Patient symptoms were also reduced, but similarly to the control. More than 90% of participants found the formulation comfortable.

10.7 Topical insulin

Expression of insulin receptors has previously been detected on the ocular surface⁸¹⁸ as well as in the lacrimal gland^{819,820}. In addition, insulin-like growth factor has been detected in tears^{821,822}.

The potential benefits of topical insulin treatment to ocular surface issues were first reported in 2013 in a small-scale retrospective review of diabetic participants undergoing vitreoretinal surgery⁸²³. Topically applied insulin drops accelerated the healing of corneal epithelial defects created during surgery, improving visualization of the fundus intraoperatively, when compared to conventional treatment.

A single clinical trial involving 160 diabetic participants with DED compared topical insulin treatment to tear supplements, applied four times daily, over a four-week period of treatment⁸²⁴. A significant proportion of participants in both treatment arms showed improvement in their dry eye symptoms compared to baseline (66% and 63%, in the topical insulin and artificial tear groups respectively) but there was no significant difference between the two groups. This study failed to show any improvements in physician-measured tear film and ocular surface parameters.

11 Treatments for anatomical surface abnormalities

11.1 Ocular surface anatomical irregularities

Ocular surface abnormalities that impact ocular surface topography can contribute to and exacerbate DED by virtue of creating an irregular surface, over

which tear spreading and the creation and maintenance of a structured tear film may be impaired.

11.1.1 Conjunctivochalasis

Conjunctivochalasis is characterized by loose, redundant, non-edematous inferior bulbar conjunctiva located between the globe and the eyelid. This age-related ocular condition is often overlooked despite its significant impact on quality of life^{825,826}. Similarly to the milder form of conjunctival folds (described as lid parallel conjunctival folds; see Section 11.1.2), conjunctivochalasis is commonly associated with DED, with a reported prevalence as high as 54% among individuals with DED⁸²⁷.

While the exact etiology of conjunctivochalasis is not known, risk factors and associated conditions include age, female sex, contact lens wear, DED, hyperopia, the presence of pinguecula, ultraviolet exposure and eyelid disorders⁸²⁶. The underlying mechanism linking conjunctivochalasis to dry eye symptoms may involve its effect on lowering TMH^{828,829}. Additionally, epiphora is a common symptom, particularly when conjunctivochalasis is located medially, and this can often be alleviated through surgical correction^{830,831}. Participants with nasal conjunctivochalasis have worse dry eye symptoms⁸³² and signs (lower Schirmer scores, more meibomian gland dropout and eyelid vascularity) than those with conjunctivochalasis temporally or those without⁸²⁵.

Conjunctivochalasis has been closely associated with MGD and meibomian gland drop-out, suggesting that lipid deficiency may play an indirect role through a lack of lubrication, resulting in increased friction and 'dragging' of the conjunctival tissue over the ocular surface⁸³³. An alternative hypothesis is that conjunctivochalasis affects blink completeness, which drives meibomian gland drop out and subsequent lipid deficiency. In a study of 39 participants who underwent conjunctival tissue excision for conjunctivochalasis, OSDI, TBUT,

corneal staining and tear meniscus area were reported to be improved three-months post-operatively ⁸³⁴.

Management of conjunctivochalasis includes ocular lubrication through administration of topical lubricants, anti-inflammatory agents, ointment at night and various surgical techniques (see Section 14.4.1) such as cauterization, excision, scleral fixation of the conjunctiva, conjunctival ligation, laser conjunctivoplasty, radiowave electrosurgery and plasma-based conjunctivoplasty ⁸³⁵⁻⁸³⁹. Two publications have proposed the use of radiofrequency to manage conjunctivochalasis ^{839,840} and two other publications have shown that HA-based tear supplements can be helpful in the management of symptoms secondary to conjunctivochalasis ^{632,841}.

11.1.2 Lid Parallel Conjunctival Folds

Lid parallel conjunctival folds are characterized by folds in the inferonasal and inferotemporal quadrants of the bulbar conjunctiva, parallel to the lower lid margin ⁸⁴². In a systematic review of 26 studies, both lid parallel conjunctival folds and conjunctivochalasis were found to be significantly associated with dry eye symptoms in both contact lens wearers and non-lens wearers ⁸³⁸.

Treatment of DED secondary to lid parallel conjunctival folds primarily consists of regular lubrication ⁸³⁸.

11.1.3 Pingueculum

A pingueculum describes a fibrofatty, degenerative change in the bulbar conjunctiva, nasally and/or temporally, within the palpebral aperture ⁸⁴³. Its etiology is thought to be similar to that of pterygium formation, being related to UV exposure ⁸⁴³, and its physical presence similarly can alter lid/globe alignment affecting tear spreading and function. As with pterygium, surgical excision of pinguecula has been found to reduce both the signs and the symptoms of DED

⁸⁴⁴. However, the high-quality evidence for this remains to be confirmed (see Section 14.4.2).

11.1.4 Pterygium

A pterygium is a progressive, wing-shaped fibrovascular growth of the nasal and/or temporal conjunctiva that extends over time onto the cornea ⁸⁴⁵. It is one of the most commonly observed ocular conditions, with a global average prevalence of 10.2% ⁸⁴⁶. It is predominantly associated with high levels of ultraviolet light exposure ⁸⁴⁵. Pterygium presence is a recognized risk factor for developing DED ¹³, resulting in 63.6% of participants with primary or recurrent pterygia reporting dry eye symptoms ⁸⁴⁷, that include irritation, dryness, lacrimation and foreign body sensation ⁸⁴⁵. Tear breakup time is shorter in eyes with pterygium ⁸⁴⁸, and significant differences in meibomian gland scores, lid margin abnormalities and meiboscores have also been reported relative to a control group without pterygium ^{848,849}. Physical presence of a pterygium thus disrupts the normal function of the tear film and surgical excision of the pterygium (see Section 14.4.2) often offers a means of reducing dry eye symptoms ⁸⁵⁰.

12 Nutritional modifications and alternative therapies

Growing interest exists in the potential role of dietary modification and supplementation and that of alternative therapies in the management of DED. The TFOS Lifestyle Report: Impact of Nutrition on the Ocular Surface discusses nutritional impacts on DED ¹⁶ and other reviews also explore these factors in detail ^{18,851,852}.

12.1 Macronutrients

PUFA such as omega-3s can play a critical role in improving clinical symptoms associated with inflammatory disorders of the ocular surface, including DED (see

Figure 2). Derivates of omega-3 fatty acid metabolism, such as resolvins (D1 and E1) and protectins, have been shown to resolve acute inflammation of the ocular surface by inhibiting leukocyte infiltration and enhancing macrophage activity, resulting in improved corneal epithelial integrity and tear production ^{16,853-856}. The therapeutic role of neuroprotectin D1, derived from docosahexaenoic acid, in suppressing ocular surface inflammation and neuroprotection has been extensively studied ^{857,858}. The pathogenic disruption of corneal nerves due to various underlying aetiologies can result in loss of corneal epithelial integrity, delayed wound healing and ulceration ⁸⁵⁹. A study demonstrated an association between omega-3 PUFA intake and improved corneal neuronal parameters, therefore supplementing these essential fatty acids may be beneficial for ocular surface health ⁸⁶⁰.




Figure 2: Key metabolic pathways for omega-6 and omega-3 fatty acids. The conversion of short-chain to long-chain omega-3 and omega-6 fatty acids occurs through two independent metabolic pathways that share, and compete for, the same series of enzymes. Broadly speaking, the omega-6 pathway results in the production of inflammatory mediators; through a series of steps, linolenic acid is converted arachadonic acid, which is further metabolized to bioactive metabolites that include a range of prostaglandins. The omega-6 pathway also leads to generation of some anti-inflammatory mediators, in particular PGE1, although predominantly generates pro-inflammatory mediators. In the omega-3 pathway, alpha-linolenic acid is converted to long-chain fatty acids that include eicosapentaenoic (EPA) and docosahexaenoic acid (DHA), subsequently leading to the generation of various anti-inflammatory mediators, including families of resolvins and protectins; these are relevant in the context of dry eye as they can modulate physiological processes that include epithelial cell survival, recovery from oxidative stress and wound healing. Diets with a high-omega-6 to omega-3 ratio are considered pro-inflammatory, which increase the likelihood of signs and symptoms of DED, due to a bias towards the production of pro-inflammatory mediators. The red line 'inhibits' that pathway. Created in BioRender by Rohan Bir Singh MD (2025) <https://BioRender.com/n49o832>.

As highlighted in a Cochrane systematic review, the potential role of PUFAs in the treatment of DED remains uncertain ⁸⁶¹.

The DREAM study found benefits among patients with DED who were randomly assigned to receive supplements containing 3000 mg of n-3 fatty acids or 5000 mg olive oil placebo for 12 months, but did not demonstrate significantly better outcomes with the n-3 fatty acids than those receiving the placebo ^{862,863}, and thus called into question the benefits of PUFAs in the management of DED. Since the LT α genotype affects the inflammatory response to omega-3 PUFA, this should be considered as a potential confounding factor for treatment outcomes and may explain some of the differences reported between studies ⁸⁶⁴.

In a multi-center clinical trial, dietary supplementation with omega-3 PUFAs (2400 mg/day) resulted in significant improvement in DED symptoms, Schirmer score, TBUT, tear osmolarity and goblet cell density, compared to the placebo-treated control group ⁸⁶⁵. Furthermore, a meta-analysis of 19 RCTs assessing the therapeutic efficacy of omega-3 PUFA for DED indicated significant improvement in dry eye symptoms and signs with its dietary supplementation, ⁸⁶⁶. Additionally, a large cross-sectional study including women aged 45–84 years showed a reduced risk of DED in those with higher omega-3 fatty acid intake, and higher omega-6 compared to omega-3 PUFA consumption resulted in an increased risk of DED ⁸⁶⁷. The same authors showed that regular tuna consumption (a rich source of omega-3) significantly reduced the risk of DED ⁸⁶⁷. These findings point towards the importance of omega-3 PUFA in maintaining ocular health and preventing DED, although the evidence is not uncontroversial ⁸⁶².

Other vegetable oils and seeds, such as extra virgin olive oil and flaxseed oil, have been shown to play a role in maintenance of ocular surface health ^{124,126,868-871}. Oral administration of flaxseed oil (rich in α -linolenic acid) for 180 days improved the signs and symptoms of DED compared to baseline values ⁸⁷¹. In contrast, oils from palm, corn, and soybean have a high concentration of omega-

6 compared to omega-3 fatty acids, which can potentially promote chronic inflammation and adverse effects on the ocular surface⁸⁷². The ingestion of trans fatty acids from hydrogenated vegetable oils have been associated with systemic inflammation, which may further adversely impact ocular surface health⁸⁷³. A recent systematic review has discussed efficacy and the potential use of topical omega-3 PUFA, although there is still only a small number of studies and a limited availability of such products currently⁸⁷⁴.

In conclusion, the overall evidence would suggest a beneficial effect of the use of oral supplements of omega-3 PUFA, however, the optimal source, dosage and/or ratio of omega-3 to omega-6 requires further investigation.

12.2 Micronutrients

Micronutrients such as vitamins (see Section 6.1.1.10) and minerals play a critical role in maintaining ocular surface health^{15,17,851}.

Vitamin A is essential for maintaining immune function as well as integrity of the ocular surface epithelium^{875,876}. Deficiency in vitamin A can lead to severe ocular conditions such as xerophthalmia and corneal perforation, making it a significant cause of childhood blindness in developing countries⁸⁷⁷. In developed countries, gastric bypass surgery (often undertaken for weight loss) and alcoholism are common causes of vitamin A deficiency in adults⁸⁷⁷. In addition, it can occur due to restrictive diets in both adults and children⁸⁷⁸⁻⁸⁸⁰.

Oral vitamin A supplementation might help in DED if there is a deficiency, but its role in the management of patients with non-vitamin A deficient DED remains unclear¹⁵. Short-term oral vitamin A supplementation improved the quality, but not quantity, of tears in patients with DED⁸⁸¹. It was suggested that future studies should involve larger patient samples and longer periods of vitamin A supplementation. Administration of topical vitamin A drops have shown more consistent improvements in tear film stability and ocular surface health in patients

with DED^{15,164}. Combination therapy with vitamin A and CsA might be beneficial in patients with MGD-driven DED, with a study showing greater improvements in TMH, OSDI score, Schirmer test and TBUT compared to CsA in association with 0.1% HA topical drops alone when used for 12-weeks⁸⁸².

Vitamin B12 is crucial for deoxyribonucleic acid synthesis and nerve function, with deficiency linked to an increased risk of DED²⁰. In a study conducted in 30 post-menopausal women, application of eye drops containing vitamin B12, 0.3% HA, P-plus, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and stabilized complex oxychloride over a period of one-month resulted in significant improvement in ocular surface disease parameters and dry eye symptoms from baseline¹⁶⁸. In another study, participants with Sjögren disease (with severe DED) treated with a combination of vitamin B12 and topical HA-containing drops showed significant improvement in Schirmer test score, OSDI, TBUT and tear fluorescein clearance test⁸⁸³.

Vitamin D is another critical micronutrient that plays an essential role in calcium homeostasis, immune regulation, and cell proliferation and differentiation⁸⁸⁴. A meta-analysis of 14 observational studies showed that serum 25-hydroxy calcitriol was significantly lower in participants with DED¹⁷². Moreover, a randomized clinical trial including 100 Vitamin D deficient participants reported significant improvement in Schirmer test scores, TBUT and osmolarity on supplementing the diet with oral Vitamin D for eight weeks⁸⁸⁵.

Minerals like selenium, zinc, and copper also play significant roles in ocular surface health, with selenium particularly noted for its antioxidant properties⁸⁸⁶. Selenium is essential for generation of selenoprotein P in the lacrimal glands and present in tears⁸⁸⁷. Studies have shown significantly lower levels of selenoprotein P in participants with DED, which may be associated with oxidative damage at the ocular surface⁸⁸⁷.

12.3 Natural products and interventions

12.3.1 Acupuncture

The therapeutic effects of acupuncture are believed to occur via several mechanisms, including reduced expression of proinflammatory cytokines in chronic inflammatory conditions such as DED⁸⁸⁸⁻⁸⁹¹. Acupuncture is also considered to increase systemic blood flow, reduce pain sensation, and modulate the sympathetic system⁸⁹²⁻⁸⁹⁴. Several studies have shown statistically significant improvements in symptoms and the ocular surface of participants with DED who underwent acupuncture treatment⁸⁹⁵⁻⁹⁰¹. However, these findings were not replicated in all studies^{902,903}.

A prospective, randomized, double-masked clinical trial that included a sham acupuncture control group showed that two consecutive daily sessions of acupuncture improved dry eye symptoms⁸⁸⁸. The study suggested that acupuncture for DED may primarily modulate pain intensity or threshold rather than enhancing lacrimal gland function, as no improvements in tear flow, TBUT or ocular surface staining were observed. A systematic review and meta-analysis of acupuncture combined with tear supplements in managing DED was undertaken⁹⁰⁴. The review of sixteen studies including 1383 participants concluded that this integrative treatment was safe and effective when assessing objective indicators of DED.

In a randomized parallel group study, it was found that acupuncture over eight sessions improved conjunctival redness significantly compared to participants who used only an artificial lubricant⁹⁰⁵.

12.3.2 Herbs and spices

Herbs, typically referring to the leaves and stems of soft-stemmed plants grown in temperate climates, have shown potential therapeutic effects on eye health.

Cassiae semen (*Leguminosae*), which contains the vital compound emodin, plays a significant role in the linoleic acid peroxidation system due to its antioxidant properties. An RCT showed that antioxidant supplements containing anthocyanosides, astaxanthin, vitamins A, C, and E, and several herbal extracts, including Cassiae semen and *Ophiopogonis japonicus* can enhance tear production and tear film stability by reducing ROS ⁹⁰⁶.

Another herb, *Lycii Fructus*, contains the antioxidants zeaxanthin and lutein and anti-inflammatory polysaccharide ⁹⁰⁷. It also contains *lycium barbarum* (goji berry), which has anti-inflammatory, and anti-apoptotic effects. *Lycii Fructus* has been reported to improve DED in rats by increasing tear volume and TBUT and reducing corneal and conjunctival fluorescein staining ⁹⁰⁸.

Curcumin is a polyphenol that is isolated from the plant *Curcuma-Longa*, and is known for its anti-oxidative properties by scavenging reactive nitrogen and oxygen species, and has anti-inflammatory properties ^{909,910}. *In-vitro* studies have shown the therapeutic effect of curcumin against hyperosmolarity-induced IL-1 β upregulation in corneal epithelial cells through p38 mitogen-activated protein kinase (MAPK)/NF- κ B pathways ⁹¹¹.

Achyranthis radix contains several anti-inflammatory molecules such as saponins and phytoecdysones ⁹¹². In a pre-clinical study, topical treatment with *Achyranthis radix* improved corneal surface irregularities, reduced corneal epitheliopathy and increased conjunctival goblet cell density ⁷⁰¹. Herbal extracts ferulic acid (from *Angelicae sinensis Radix*) and Kaempferol (found in *Ginkgo biloba* and propolis) have been shown to downregulate pro-inflammatory cytokines (IL-1B, IL-6, IL-8, and TNF- α) in human corneal epithelial cells ⁹¹³.

Topically applied esculetin, extracted from the Chinese herb "Qinpi," has been shown to inactivate the ERK1/2 pathway, associated with chronic ocular surface

inflammation. This action was demonstrated to enhance the anti-inflammatory function of CsA in a rabbit dry eye model ⁹¹⁴.

Although preliminary evidence appears favorable, well-designed clinical trials are necessary to assess the possible benefit of dietary herbs and spices in ocular surface disease.

12.3.3 Hydration

Adequate hydration is essential for optimal bodily functions, including those of the ocular surface. While there is limited direct evidence linking hydration status to ocular surface health, studies have shown that plasma osmolality, a marker of systemic levels of hydration is directly correlated with osmolality of the tear film ^{915,916}. Patients with DED often exhibit higher plasma osmolality, suggesting that dehydration may impair lacrimal gland function and increase tear osmolality ⁹¹⁷. Interestingly, a cross-sectional study including 51,551 individuals in the Netherlands showed that higher water intake was observed in individuals with DED ⁹¹⁸. Evidence from clinical trials investigating the effect of water intake on ocular surface parameters is currently lacking.

12.3.4 Lactoferrin

Lactoferrin, an iron-binding glycoprotein, is produced by mucosal epithelial cells, and has well established anti-inflammatory, antioxidant and antimicrobial functions ⁹¹⁹. Previous studies have highlighted a significant correlation between low tear lactoferrin levels and DED ⁹²⁰⁻⁹²². Oral administration of lactoferrin maintains tear secretion in a restraint and desiccating-stress-induced mouse model of DED. This effect is postulated to be mediated through gut microbiota modulation ⁹²³.

The hyperosmolar environment in DED triggers inflammatory and oxidative cascades, resulting in impaired epithelial proliferation and differentiation ⁹²⁴. The use of lactoferrin in treating DED is based on its ability to interrupt the vicious

cycle, particularly by addressing underlying inflammation and oxidative stress. Lactoferrin, through its iron-chelating properties, provides oxygen-free radical and hydroxyl scavenging activities^{718,925,926}. These actions inhibit the pro-inflammatory and tissue-damaging effects of ROS. Additionally, lactoferrin is understood to mitigate excessive inflammation by inhibiting classical complement activation and downregulating inflammatory mediators.

12.3.5 Manuka honey

As noted in Section 7.2.6, Manuka honey has antibacterial, antifungal, antiviral, anti-inflammatory, and antioxidative properties⁹²⁷. Several clinical trials have highlighted the anti-inflammatory and therapeutic effects of topical Manuka honey in natural or compounded form for managing patients with DED^{928,929}, MGD^{930,931}, anterior and posterior blepharitis^{591,595,932}, and contact lens related dry eye⁹³³. A meta-analysis of five studies (including 323 participants) assessing the application of honey and its derivatives in the treatment of DED, showed a significant improvement in patient symptoms as measured by OSDI, along with improvements in Schirmer test and corneal fluorescein staining scores⁹²⁹.

The therapeutic effects on ocular surface disease of honey as a dietary supplement has been less thoroughly explored. A double-masked RCT assessing oral royal jelly (a gelatinous substance produced by honey bees to feed the queen bees and their young) in participants with DED found significant improvements in TBUT and Schirmer test scores, particularly in participants with lower baseline scores⁹³⁴. However, no clear improvement in dry eye symptoms was observed.

12.3.6 Nutritional supplements

Data from two prospective, randomized clinical trials evaluating a dietary supplement (blink™ NutriTears®; Bausch + Lomb, Rochester, NY) containing lutein, zeaxanthin, curcumin, and vitamin D demonstrated significant improvements in tear volume and stability, as well as a reduction in level of

MMP-9 inflammatory biomarkers within the tear film ^{175,935}. These findings suggest it may be possible to achieve clinically meaningful benefits in the management of DED through ingesting a dietary supplement.

13 Prevention and treatment of surgical iatrogenic dry eye disease

Cataract surgery and refractive surgery can cause or exacerbate existing DED ^{12,936-938}, resulting in an increase in dry eye symptoms and reduced satisfaction with surgical results ^{939,940}. Optimization of the ocular surface before and after cataract and refractive surgery has been demonstrated to reduce symptoms and improve clinical and refractive outcomes.

13.1 Dry eye disease and cataract surgery

There is consensus that the ocular surface should be optimized prior to cataract surgery ⁹³⁸ to decrease the rate of postoperative refractive errors ^{941,942}, fluctuating vision, and new or worsening ocular surface related symptomatology ⁹⁴³. Several prospective RCTs have been performed assessing preoperative treatment of MGD using different therapeutic interventions, including vectored thermal pulsation ^{940,944-946}, IPL ⁹⁴⁷, and low-level light therapy ³⁵¹. Overall, these studies demonstrated improvement in the subjective symptoms and objective signs of MGD in the treatment group as compared to controls.

A prospective, randomized, open-label, crossover, multicenter study evaluated the effect of vectored thermal pulsation in participants undergoing cataract surgery with implantation of an extended depth of focus IOL ⁹⁴⁴. Interestingly, at three months postoperatively, the group that underwent preoperative vectored thermal pulsation had a significantly lower incidence of being adversely affected by halos, but had a higher incidence of being adversely impacted by multiple or double images compared to the control group ⁹⁴⁴. Postoperative application of thermal pulsation to the control group which had not received this treatment

preoperatively resulted in significant improvement in visual acuity and total meibomian gland score ⁹⁴⁴.

Prophylactic low-level light therapy one week before and after surgery in 73 healthy participants was compared to 80 controls in a prospective, randomized, interventional, controlled, double-masked clinical trial ³⁵¹. The researchers found significantly lower OSDI scores and higher non-invasive tear film stability values in the treated group one month after surgery ³⁵¹. Future studies on prophylactic treatment would benefit from longer follow-up.

Two studies have evaluated the benefits of applying lid hygiene either preoperatively alone ⁹⁴⁸, or with application both before and after cataract surgery ⁵⁷⁹. Participants reported improved subjective and objective indicators of MGD. Another study examined participants with persistent post-cataract surgery DED lasting more than one month ⁹⁴⁹. Lid hygiene with tear supplements, topical steroid drops, and ocular shampoo with TTO, compared to a similar mixture without TTO, resulted in significantly greater patient improvements in TBUT, OSDI, tear osmolarity and number of residual Demodex. There was no significant difference between the two groups in pre- and post-Schirmer test results.

13.2 Dry eye disease and refractive surgery

Dry eye symptoms in the early period post corneal refractive surgery are common and typically improve over 6-12 months ^{938,950,951}. However, a small subset of participants fail to respond to conventional therapy and develop refractory DED.

Studies have demonstrated the benefit of treating participants with refractory DED post-laser vision correction with modalities such as IPL ^{328,952}, thermal pulsation ⁹⁵³, and warm compresses ⁹⁵⁴. IPL was used in two prospectively designed studies involving participants who had undergone refractive surgery in the previous 10 years and had been suffering from LASIK-induced refractory

DED despite conventional treatment for at least one year^{328,952}. In the first study, 42 eyes were treated with two IPL sessions, two weeks apart, resulting in statistically significant improvement at day 14 after the second treatment in the NIBUT, and at day 28 in NIBUT, OSDI, tear film lipid layer, meibomian gland quality and expressibility compared to a (non-randomized) control group (n=30 eyes)⁹⁵². The second study was a prospective, randomized study of 50 participants comparing two IPL sessions to two IPL sessions plus a once-a-day heated eye mask in participants with refractory post-LASIK DED (experiencing moderate to severe DE following LASIK for over a year), with both groups using 0.1% HA drops on a daily basis. There was an improvement in both subjective and objective dry eye parameters in both groups, with a more pronounced effect in the group combining IPL with the heated eye mask³²⁸, demonstrating the benefit of combining in-office procedures with at-home treatments. However, both studies examined only short-term effects (over 28 days).

A retrospective study examined the effect of vectored thermal pulsation in 109 eyes of 57 participants post-laser vision correction with refractory dry eye symptoms who failed conventional therapy⁹⁵³. There was a significant improvement in the SPEED II score when reassessed at one month and six to eight months after a single treatment. Along with the subjective improvement, objective findings of an increase in TBUT, improved meibomian gland patency and decreased corneal staining were also observed⁹⁵³. In a separate study, the low-cost intervention of performing lid warming with a heated eye mask for 20 minutes was employed in 37 participants with persistent DED at least two years post-laser vision correction in a prospective study⁹⁵⁴. In this open-label, non-controlled trial, a significant increase in LLT and TBUT was observed, but these parameters were assessed only five minutes following lid warming.

A masked clinical trial randomized 61 healthy participants undergoing laser vision correction to receive either IPL treatment for three sessions total: pre-surgery, postop week one and postop week three or sham treatment⁹⁵⁵. The IPL group demonstrated an improvement in OSDI score, NIBUT, TMH, and meibography at

the three-month follow-up visit, while the control group showed a worsening of TMH compared to baseline. However, at the six-month follow-up visit, the OSDI differences faded, but the objective tear parameters (NIBUT, TMH and meibography) were still significantly different between the IPL and control (sham) groups. The authors reported IPL to be safe and effective in the perioperative period, but the question of cost/benefit ratio in these asymptomatic and healthy individuals undergoing refractive surgery was raised. Another prospective interventional study of LASIK participants with pre-existing MGD compared vectored thermal pulsation therapy one week prior to LASIK (n=32) to untreated controls (n=26); OSDI and TBUT were significantly improved relative to preoperative baseline at three-months in the treatment group and the effects were confirmed when the control group was subsequently treated ⁹⁵⁶.

In summary, proactive management of patients with DED, especially those with evaporative DED, undergoing cataract and refractive surgery improves gland function before surgery, results in a better patient experience ^{944,955} and improves visual performance after surgery ⁹⁵⁷, lending support to this being recommended as standard of care in the future.

14 Surgical management

14.1 Permanent punctal occlusion

Permanent closure of the lacrimal drainage pathway can be achieved using several techniques, the most common of which is punctal cauterization. The principle is similar to punctal occlusion with punctal or intracanalicular plugs and works by conserving the volume of tears within the conjunctival cul-de-sac ⁹⁵⁸. See Section 6.2.3 for further details.

Punctal cautery is generally reserved for participants who are symptomatically improved with temporary plugs but are unable to retain or tolerate longer-term plugs ⁹⁵⁹. In a retrospective review of punctal cauterization in 80 participants, a

significant reduction in the proportion of participants with moderate-to-severe DED was noted. The overall rate of recanalization was 21% and this rate was higher with the ongoing, regular use of topical steroids ^{959,960}. Requirement for recanalization has been reported to be the lowest in patients with chronic cicatricial disorders, possibly due to contributory fibrosis associated with the underlying disease ⁹⁵⁹. In 65 participants with cicatricial disorders, the recanalization rate was only 11% after punctal cautery and participants responded well to repeat cautery where required ⁹⁶¹. The most common ocular indication for punctal cauterization in the study was graft-versus-host disease (n=36), followed by primary keratoconjunctivitis sicca (n=15) ⁹⁵⁹. The study concluded that punctal cauterization effectively treats severe ocular surface disease in participants who frequently lose punctal plugs, with 54% reporting a significant improvement in symptoms and reduced corneal staining severity ⁹⁵⁹. The procedure was able to be easily performed in a clinical setting with minimal complications.

Another study involving 23 participants with moderate-to-severe DED who received permanent inferior punctal occlusion via cautery reported improved TBUT, OSDI scores and corneal staining, along with increased corneal sub-basal nerve density, three months after treatment ⁹⁶².

Combined canalicular ablation and punctal suturing was assessed for efficacy in 11 eyes of seven participants with severe DED ⁹⁶³. This surgical punctal occlusion approach demonstrated a low recanalization rate, leading to significant objective and subjective improvements in DED signs and symptoms after one year ⁹⁶³.

A systematic review analyzed the efficacy in treating DED using permanent punctal occlusion by thermal or surgical methods ⁹⁶⁴. Among nine selected single-arm studies, five used thermal punctal cauterization, and four used surgical occlusion techniques. At the final follow-up, Schirmer I and TBUT

improvements were similar for both forms of punctal occlusion. Across the studies, punctal recanalization was reported to occur between 0 and 38.7 % of patients following thermal cauterization and between 5 and 9% who underwent surgical techniques⁹⁶⁴. Disposable thermal cautery tips inserted into the punctum resulted in lower recanalization rates than radiofrequency monopolar cautery. The authors concluded that thermal or surgical punctal occlusion can improve tear volume in DED with similar recanalization rates⁹⁶⁴. However, there is insufficient high-quality evidence, and RCTs are needed to more definitely prove the efficacy of punctal cautery in treating DED.

14.2 Tarsorrhaphy

Tarsorrhaphy is a surgical technique that involves suturing the lateral aspect of the eyelids together, to narrow the palpebral fissure height. This can help protect the cornea and improve the ocular surface environment by reducing the area of the evaporating ocular surface exposure. Based on whether the suture is directly placed on the lids, or after creating a raw area by removal or incision of the lid margin, the tarsorrhaphy can be temporary or permanent, respectively. A tarsorrhaphy is more commonly indicated for the management of neurotrophic keratopathy, lagophthalmos, and ocular surface disorders such as Stevens-Johnson syndrome⁹⁶⁵⁻⁹⁶⁷. It can be considered in severe DED when topical therapy has failed to improve corneal epithelial health or if the patient has experienced recurrent epithelial breakdown. Literature on the efficacy of a tarsorrhaphy is limited in the context of DED.

14.3 Surgical management of lid abnormalities

14.3.1 Botulinum toxin injection

Botulinum toxin, produced by *Clostridium botulinum*, functions at the neuromuscular junction by inhibiting acetylcholine release⁹⁶⁸. In ophthalmology, botulinum toxin is widely used for various indications, including first-line treatment for blepharospasm and hemifacial spasm^{969,970}. It is also employed to induce

ptosis for corneal protection in cases of persistent epithelial defects or ulcers^{971,972}, manage eyelid retraction in thyroid eye disease⁹⁷³, and treat entropion^{974,975}. Additionally, it has been used for managing refractory filamentary keratitis⁹⁷⁶ and has gained traction as a therapeutic option for DED^{40,977-979}.

Research has shown that botulinum toxin injections into the medial lower eyelid can improve DED signs and symptoms, including increased TBUT, improved Schirmer test score, MMP-9 levels, corneal fluorescein staining and enhanced OSDI scores. These benefits have been demonstrated in multiple randomized trials^{980,981} and several other studies^{843,982}. Additionally, a study reported that botulinum toxin significantly improved post-LASIK dry eye symptoms with fewer complications compared to punctal plugs and conventional topical treatments⁹⁷⁷.

Essential blepharospasm is a focal cranial dystonia affecting the eyelid and forehead muscles. Studies report that 40–60% of patients with essential blepharospasm experience dry eye symptoms and reduced Schirmer test scores^{970,983-985}. Additionally, tear fluid analysis reveals elevated pro-inflammatory cytokine levels in essential blepharospasm patients with DED, compared to those with DED alone⁹⁸⁶. Botulinum toxin injection for patients with essential blepharospasm induces temporary pharmacologic denervation of the orbicularis oculi muscle. Several case-control studies have demonstrated that botulinum toxin injections improves dry eye symptoms and enhances tear film homeostasis, evidenced by increased TMH, TBUT, tear clearance time, and LLT^{978,982,986-989}. However, these effects last for only three months⁹⁹⁰. Conversely, botulinum toxin injections administered too close to the lacrimal gland may impair tear production^{979,985,991}. A randomized trial reported that approximately 19% of patients developed dry eye symptoms following botulinum toxin injections⁹⁹².

14.3.2 Dermatochalasis

Dermatochalasis refers to the presence of loose and redundant eyelid skin, commonly associated with aging. It has been suggested that 46–51% of patients with dermatochalasis experience dry eye symptoms, while 55–86% report

subjective improvement following upper eyelid blepharoplasty ⁹⁹³⁻⁹⁹⁵. However, objective measures of tear function, such as tear osmolarity, Schirmer test score, TBUT, and conjunctival staining score, have failed to show significant improvement postoperatively. Additionally, resecting the orbicularis oculi (Müller muscle-conjunctival resection) for ptosis repair in conjunction with blepharoplasty mostly does not appear to influence outcomes ^{993,995,996}, although one study showed increased dry eye signs and symptoms after combined blepharoplasty and ptosis repair, but not after blepharoplasty surgery alone ⁹⁹⁷. The disparity between symptoms and signs improvement following surgery warrants further investigation.

14.3.3 Entropion and ectropion

Entropion and ectropion lead to ocular surface exposure, resulting in symptoms of DED, with entropion often causing concurrent trichiasis ⁹⁹⁸. Paralytic lower lid ectropion and upper eyelid retraction can occur due to facial nerve palsy, attributed to reduced orbicularis oculi function secondary to paralysis of the greater superficial petrosal nerve ⁹⁹⁹. Other contributing factors for entropion and ectropion include trauma (chemical; mechanical; surgical), tumors, facial surgery, and age-related lid laxity ¹⁰⁰⁰.

Surgical intervention is the primary management approach for both entropion and ectropion, involving techniques such as canthal tendon tightening and removal of cicatricial or mechanical causes of eyelid malposition ¹⁰⁰¹⁻¹⁰⁰⁵. Studies have demonstrated that entropion correction improved vision, punctate keratopathy and TBUT, although Schirmer test results remained unchanged ¹⁰⁰⁶. Another study found that tarsorrhaphy was effective for entropion correction and supported epithelial healing in patients with severe DED ⁹⁶⁷.

A comparative study evaluated four procedural combinations for lower lid entropion repair, pairing one method to address horizontal laxity with another for vertical laxity. Horizontal laxity procedures included lateral tarsal strip and Bick's

procedure, while vertical laxity procedures consisted of everting sutures and lower lid retractor plication. Results indicated that Bick's procedure had a lower recurrence rate and fewer complications compared to lateral tarsal strip ¹⁰⁰⁷. For moderate to severe entropion, mucous membrane grafting has been utilized in both primary and recurrent cases ¹⁰⁰⁸. A study assessing labial mucous membrane grafts for cicatricial entropion reported complete symptom resolution in 83% of patients, with an 11% recurrence rate ¹⁰⁰⁹.

14.3.4 Lagophthalmos

Lagophthalmos is the incomplete or defective closure of the eyelids, resulting in corneal exposure. Persistent or severe cases may necessitate surgical intervention, with options including upper eyelid weight implantation, lid springs, lid reconstruction, or partial/complete tarsorrhaphy ^{472,1010,1011}. Upper eyelid weights leverage gravity to facilitate passive eye closure. Traditionally, gold weights have been widely used due to their favorable safety profile and high density. However, more recent studies suggest that platinum chains may offer superior outcomes, as they require fewer revisions, have a lower risk of extrusion, and provide improved cosmesis due to their higher density, allowing for a slimmer design ^{1012,1013}.

When corneal exposure persists despite upper eyelid surgery, lower eyelid elevation can be achieved through various techniques. One study reported that auricular cartilage grafts, used in both the upper and lower eyelids, resulted in successful eyelid closure in 80% of patients with mild-to-moderate lagophthalmos ¹⁰¹⁴. Additionally, hard palate mucosa has been utilized to elevate the lower eyelid and improve ocular surface protection ¹⁰¹⁵. The lateral tarsal strip technique, which tightens and repositions the lower eyelid, has been shown to enhance eyelid-globe apposition, reducing corneal exposure and epiphora in patients with paralytic ectropion ¹⁰¹⁶.

14.4 Surgical management of anatomical surface abnormalities

14.4.1 Conjunctivochalasis

In severe cases of conjunctivochalasis that are unresponsive to ocular lubricants, topical CsA, or punctal occlusion, surgical resection of excess conjunctival tissue may be considered ¹⁰¹⁷. Various techniques have been reported to reduce excessive conjunctival folds, including electrocoagulation or thermal cauterization ^{1018,1019}, conjunctival ligation ¹⁰²⁰, simple fixation to the sclera ¹⁰²¹, argon laser conjunctivoplasty ¹⁰²², surgical excision ^{1023,1024} and more recently high-frequency radio-wave electrosurgery ^{839,1025,1026}. Studies have reported symptom improvement in over 75% of patients across all techniques. However, thermal cauterization and surgical excision have been associated with postoperative complications such as diplopia, symblepharon, and subconjunctival hemorrhage due to excessive cauterization and suturing ^{835,1027}. In contrast, high-frequency radio-wave electrosurgery has demonstrated effective resolution of redundant conjunctiva while promoting enhanced healing, likely due to its lower energy causing less thermal damage, reduced risk of scarring, and avoidance of sutures ⁸³⁵.

14.4.2 Pterygium and pinguecula

Pterygium and pinguecula are common ocular surface disorders, both characterized by abnormal overgrowth of conjunctival and limbal tissue. The key distinction is that pterygium extends over the cornea, potentially leading to visual impairment ¹⁰²⁸. These conditions can disrupt tear film stability, leading to uneven tear distribution and increased evaporation, thereby exacerbating dry eye symptoms and altering tear osmolarity ¹⁰²⁹⁻¹⁰³¹. Currently, surgery remains the most effective treatment. Some studies suggest that surgical intervention offers long term benefits by helping restore normal ocular surface anatomy and tear film function ^{843,850}.

Various surgical techniques have been explored. Recent meta-analyses of comparative studies found that limbal-conjunctival autograft yields the best long-term ocular surface outcomes by reducing inflammation and promoting healing^{1032,1033}. However, concerns exist regarding potential corneal damage from harvesting limbal and conjunctival tissue. Amniotic membrane transplantation offers an alternative that preserves the limbus and provides early post-surgical advantages¹⁰³². Both limbal-conjunctival autograft and amniotic membrane transplantation demonstrate lower recurrence rates compared to simple pterygium excision¹⁰³⁴.

Adjuvant therapies that have been used include CsA, mitomycin-C, 5-fluorouracil, beta-irradiation and large- and small-molecule antivascular endothelial growth factor (VEGF) agents, each with their own side-effect profile^{1035,1036}.

14.5 Salivary gland transplantation

Salivary gland transposition provides an option for improving ocular surface lubrication by supplementing the tear film with salivary secretions¹⁰³⁷. The lacrimal and salivary glands have similar structural composition and autonomic innervation¹⁰³⁸. The surgery may be useful in eyes with severe DED due to congenital or acquired alacrimia, facial nerve palsy, chronic cicatricial disorders such as Stevens-Johnson syndrome or chemical injuries. The transposed glands can be sourced from the major salivary glands, i.e. the parotid gland and the submandibular gland, or the minor salivary glands. A meticulous examination of these glands is crucial for optimal outcomes¹⁰³⁸. Autologous transplantation should be avoided in pathologies where both the lacrimal and the salivary glands are targeted such as in patients with Sjögren disease, graft-versus-host disease, and radiotherapy¹⁰³⁹⁻¹⁰⁴¹. In such cases, allogeneic salivary glands may be transplanted following human leukocyte antigen-typing^{1038,1039}.

Parotid gland transplantation is not routinely carried out in humans in view of its side effect profile, which include gustatory reflex secretion and the serous nature

of its secretions ¹⁰³⁸. Submandibular gland transplantation involves autologous microvascular submandibular gland transplantation into the temporal fossa, with duct placement via a subcuticular route into the conjunctival fornix ¹⁰³⁸. Several studies have reported an improvement of at least 15mm in Schirmer, improved TBUT and corneal staining scores and best corrected visual acuity ^{1038,1042,1043}. Although the tear volume increases substantially, it can lead to corneal edema due to the hypo-osmolality of the new tear film, necessitating graft explantation ^{1043,1044}. The improvement in tear production is only sustained in about half the patients with Steven-Johnson syndrome due to atrophic and degenerative changes that occur in the transplanted glands over time ¹⁰⁴⁵. Other reported adverse effects include graft necrosis, infection, fistula formation, duct obstruction, stenosis, and sialolithiasis ¹⁰³⁸.

Transplantation of the minor salivary glands is a simpler procedure that does not require an oral surgeon ¹⁰⁴⁶. The technique involves transplanting minor salivary glands into the upper or lower conjunctival fornix ¹⁰⁴⁷⁻¹⁰⁴⁹. In patients with severe DED and entropion, the minor salivary glands, together with a labial mucous membrane graft, can be transplanted in a full-thickness opening created in the upper tarsus, improving both eyelid malpositioning and ocular surface lubrication ¹⁰⁵⁰. Improvement in surface staining scores, TBUT and visual acuity has been observed in several series, along with reduced dependency on topical tear supplements ¹⁰⁵¹⁻¹⁰⁵³. Postoperative complications include graft necrosis, infection, ptosis, and donor site granuloma formation ^{1038,1051}. In a comparative series between submandibular and minor salivary gland transplantation, the former demonstrated better outcomes for severe DED, while the latter offered some improvement but was more successful in less severe DED ¹⁰⁵⁴.

14.6 Reinnervation of the lacrimal gland

A novel surgical procedure to reinnervate the denervated lacrimal gland in neurodeprivative DED due to facial nerve palsy has been recently described in a

small number of patients (n=10), reporting a high level of patient satisfaction, improved Schirmer test scores and reduced dependency on tear supplements at one year after surgery ¹⁰⁵⁵. Favourable long-term outcomes in this same patient cohort (n=9) have been reported after a mean follow-up time of 87 ± 15 (range 60 – 108) months, with improvements in subjective satisfaction, Schirmer test, TBUT and corneal fluorescein staining ¹⁰⁵⁶.

15 Prescribing algorithm

Current understanding of the pathogenesis of ocular surface disease recognizes both the heterogeneity of patients' signs and symptoms and the multiple pathogenic drivers of those signs and symptoms. Simple division of patients into "subgroups" of DED (e.g. aqueous deficient or evaporative dry eye) fails to account for the understanding that multiple drivers of signs and symptoms exist that may be present simultaneously, which may wax and wane over time and with treatment compliance. Staging or grading systems that attempt to group patients into discrete categories (e.g. mild, moderate and severe; stages 1,2,3 or 4; aqueous deficient or evaporative dry eye, etc.) are a suboptimal architecture for DED and can result in decision making that omits effective therapeutic interventions because of categorization that fails to describe the complexity and the changing nature of the multiple pathogenic drivers that result in signs and symptoms of DED.

By referring to the information in the TFOS DEWS III Diagnostic Methodology Report ¹ the most likely clinically relevant drivers of a patient's dry eye can be identified. By reviewing the information from this Management and Therapy Report, clinicians can evaluate the evidence that supports the many therapeutic options available and match these to the clinically relevant driver of symptoms and/or signs present in any given patient. Multiple treatments used together are the likely and most appropriate management strategy, considering that DED has

multiple pathogenic drivers. The mapping of the treatment to the pathogenic driver is provided in Figures 3, 4 and 5.

Treatments for which there are high quality studies performed in humans to support their use are indicated with a checkmark (✓ if compared with a placebo and ☑ if compared with another treatment). A “?” indicates only some of the studies referred to in this report confirmed this mechanism of action and resulted in a positive response to the therapy applied.

For cross-referencing purposes, the three tables are presented in composite form, as Supplementary Information.

Insert Figs 3, 4 and 5

16 Summary and conclusions

The TFOS DEWS III Management and Therapy Report provides a comprehensive, evidence-based framework for optimally managing DED. The report outlines a treatment approach based on the etiological drivers of the disease in an individual. First-line management includes ocular lifestyle modifications, tear film supplements and environmental adjustments to stabilize the tear film. Meibomian gland dysfunction, a major contributor to evaporative DED, is addressed through warm compresses, lid massage, in-office heating devices, IPL, LLLT and emerging topical drugs. For patients with primary inflammatory or immune-mediated components, anti-inflammatory therapies such as corticosteroids, CsA, and lifitegrast should be considered, along with biologic tear substitutes, including autologous serum and PRP. Lid hygiene practices, including anti-*Demodex* treatments and blepharoexfoliation, further enhance management of lid disease. Novel pharmacological and neuromodulatory therapies have shown promise for tear production enhancement.

For refractory or severe cases, advanced interventions include amniotic membrane grafts and various surgical options. Emerging approaches continue to expand therapeutic possibilities. A prescribing algorithm has been developed to aid clinicians in selecting appropriate interventions based on the patient's disease etiologies.

In conclusion, the management of DED requires a personalized, multifaceted approach that considers the underlying causes and patient-specific factors. While tear supplements remain a cornerstone of therapy, growing evidence supports the importance of optimizing meibomian gland function and implementing lifestyle modifications. As novel therapies emerge, future research should focus on refining treatment algorithms and identifying biomarkers to guide targeted therapy. The TFOS DEWS III approach of identifying the etiological drivers of an individual patient's DED and matching this with the evidence-identified mechanism of action of treatment and therapies should enhance patient outcomes and quality of life.

17 Acknowledgements

The following provided support during the preparation of this report:

- Arthur Chan (Canada)
- Matias Soifer, Luis Alberto Rodríguez-Gutiérrez, MD, Ali Khodor MD, Amr Almobayed MD: Bascom Palmer Eye Institute
- Rossen M. Hazarbassanov, MD, PhD; Chiara L. R. Silva, MD; Victoria Sakamoto, MD: Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo/Paulista School of Medicine, Sao Paulo, SP, Brazil
- Rohan Bir Singh, MD: Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School
- Kalika Bandamwar, PhD; Jordan Cooper, BOptom: Department of Ophthalmology, The University of Auckland, New Zealand

- The TFOS DEWS III effort was supported by unrestricted donations from Alcon, Bausch + Lomb, Azura, AbbVie, CooperVision, Dompé, Espansione Group, Harrow, Laboratoires Théa, SIFI, SINQI, Tarsus, Topcon and Trukera.

18 List of Tables

Table 1:	Examples of studies examining lipid containing supplements
Table 2:	Warm compress studies in the management of MGD
Table 3:	Studies examining the efficacy and safety of diquafosol
Table 4:	List of comparative trials for rebamipide
Table 5:	Comparative trials of varenicline
Table 6:	Studies investigating the use of various lid hygiene methods to manage anterior blepharitis

19 References

1. Wolffsohn JS, Benítez-Del-Castillo J, Loya-Garcia D, et al. TFOS DEWS III Diagnostic Methodology. *Am J Ophthalmol*. 2025;In press
2. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. *Ocul Surf*. Jul 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006
3. Cutrupi F, De Luca A, Di Zazzo A, Micera A, Coassin M, Bonini S. Real Life Impact of Dry Eye Disease. *Semin Ophthalmol*. Nov 2023;38(8):690-702. doi:10.1080/08820538.2023.2204931
4. Craig JP, Alves M, Wolffsohn JS, et al. TFOS Lifestyle Report Executive Summary: A Lifestyle Epidemic - Ocular Surface Disease. *Ocul Surf*. Oct 2023;30:240-253. doi:10.1016/j.jtos.2023.08.009
5. Uchino M, Uchino Y, Kawashima M, Yokoi N, Tsubota K. What Have We Learned From the Osaka Study? *Cornea*. Nov 2018;37 Suppl 1:S62-S66. doi:10.1097/ICO.0000000000001731
6. Takahashi A, Negishi K, Ayaki M, Uchino M, Tsubota K. Nocturnal Lagophthalmos and Sleep Quality in Patients with Dry Eye Disease. *Life (Basel)*. Jul 4 2020;10(7)doi:10.3390/life10070105
7. Hanyuda A, Sawada N, Uchino M, et al. Relationship between unhealthy sleep status and dry eye symptoms in a Japanese population: The JPHC-NEXT study. *Ocul Surf*. Jul 2021;21:306-312. doi:10.1016/j.jtos.2021.04.001
8. Li A, Zhang X, Guo Y, et al. The Association Between Dry Eye and Sleep Disorders: The Evidence and Possible Mechanisms. *Nat Sci Sleep*. 2022;14:2203-2212. doi:10.2147/NSS.S378751

9. Britten-Jones AC, Wang MTM, Samuels I, Jennings C, Stapleton F, Craig JP. Epidemiology and Risk Factors of Dry Eye Disease: Considerations for Clinical Management. *Medicina (Kaunas, Lithuania)*. Sep 5 2024;60(9)doi:10.3390/medicina60091458
10. Ayaki M, Tsubota K, Kawashima M, Kishimoto T, Mimura M, Negishi K. Sleep Disorders are a Prevalent and Serious Comorbidity in Dry Eye. *Invest Ophthalmol Vis Sci*. Nov 1 2018;59(14):DES143-DES150. doi:10.1167/iovs.17-23467
11. Sullivan DA, da Costa AX, Del Duca E, et al. TFOS Lifestyle: Impact of cosmetics on the ocular surface. *Ocul Surf*. Jul 2023;29:77-130. doi:10.1016/j.jtos.2023.04.005
12. Gomes JAP, Azar DT, Baudouin C, et al. TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface. *Ocul Surf*. Jul 2023;29:331-385. doi:10.1016/j.jtos.2023.04.011
13. Qian L, Wei W. Identified risk factors for dry eye syndrome: A systematic review and meta-analysis. *PLoS One*. 2022;17(8):e0271267. doi:10.1371/journal.pone.0271267
14. Wolffsohn JS, Lingham G, Downie LE, et al. TFOS Lifestyle: Impact of the digital environment on the ocular surface. *Ocul Surf*. Apr 2023;28:213-252. doi:10.1016/j.jtos.2023.04.004
15. Fogagnolo P, De Cilla S, Alkabes M, Sabella P, Rossetti L. A Review of Topical and Systemic Vitamin Supplementation in Ocular Surface Diseases. *Nutrients*. Jun 10 2021;13(6)doi:10.3390/nu13061998
16. Markoulli M, Ahmad S, Arcot J, et al. TFOS Lifestyle: Impact of nutrition on the ocular surface. *Ocul Surf*. Jul 2023;29:226-271. doi:10.1016/j.jtos.2023.04.003

17. Pilkington M, Lloyd D, Guo B, Watson SL, Ooi KG-J. Effects of dietary imbalances of micro- and macronutrients on the ocular microbiome and its implications in dry eye disease. *Exploration of Medicine*. 2024;5(1):127-147. doi:10.37349/emed.2024.00211
18. Bhandarkar NS, Shetty K, Narendra P, Kiran A, Shetty R, Shetty KB. Nutrition and diet for dry eye disease: Insights toward holistic management. *Indian J Ophthalmol*. Oct 1 2024;72(10):1412-1423. doi:10.4103/IJO.IJO_2899_22
19. Villani E, Barabino S, Giannaccare G, Di Zazzo A, Aragona P, Rolando M. From Symptoms to Satisfaction: Optimizing Patient-Centered Care in Dry Eye Disease. *J Clin Med*. Jan 1 2025;14(1)doi:10.3390/jcm14010196
20. Vehof J, Snieder H, Jansonius N, Hammond CJ. Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. *Ocul Surf*. Jan 2021;19:83-93. doi:10.1016/j.jtos.2020.04.005
21. Basiliou A, Xu CY, Malvankar-Mehta MS. Dry eye disease and psychiatric disorders: A systematic review and meta-analysis. *Eur J Ophthalmol*. Jul 2022;32(4):1872-1889. doi:10.1177/11206721211060963
22. Galor A, Britten-Jones AC, Feng Y, et al. TFOS Lifestyle: Impact of lifestyle challenges on the ocular surface. *Ocul Surf*. Apr 2023;28:262-303. doi:10.1016/j.jtos.2023.04.008
23. Yang K, Wu S, Ke L, et al. Association between potential factors and dry eye disease: A systematic review and meta-analysis. *Medicine (Baltimore)*. Dec 27 2024;103(52):e41019. doi:10.1097/MD.00000000000041019

24. Di Zazzo A, De Gregorio C, Spelta S, Demircan S. Mental burden of ocular surface discomfort. *Eur J Ophthalmol*. Dec 18 2024;11206721241305661. doi:10.1177/11206721241305661
25. Kawashima M, Uchino M, Yokoi N, et al. Associations between subjective happiness and dry eye disease: a new perspective from the Osaka study. *PLoS One*. 2015;10(4):e0123299. doi:10.1371/journal.pone.0123299
26. Alves M, Asbell P, Dogru M, et al. TFOS Lifestyle Report: Impact of environmental conditions on the ocular surface. *Ocul Surf*. Jul 2023;29:1-52. doi:10.1016/j.jtos.2023.04.007
27. Wang MTM, Chan E, Ea L, et al. Randomized Trial of Desktop Humidifier for Dry Eye Relief in Computer Users. *Optom Vis Sci*. Nov 2017;94(11):1052-1057. doi:10.1097/OPX.0000000000001136
28. Arita R, Fukuoka S. Safety and Efficacy of Photocatalytic Micro-Mist Desktop Humidifier for Dry Eye Caused by Digital Environment: A Randomized Controlled Trial. *J Clin Med*. Jun 26 2024;13(13)doi:10.3390/jcm13133720
29. Onomura S, Kawashima M, Aketa N, Kondo S, Tsubota K. Effect of Ultrasonic Moisture Glasses on Dry Eye Signs and Symptoms. *Transl Vis Sci Technol*. Sep 2018;7(5):18. doi:10.1167/tvst.7.5.18
30. Tsubota K, Yamada M, Urayama K. Spectacle side panels and moist inserts for the treatment of dry-eye patients. *Cornea*. May 1994;13(3):197-201. doi:10.1097/00003226-199405000-00001
31. Ogawa M, Dogru M, Toriyama N, Yamaguchi T, Shimazaki J, Tsubota K. Evaluation of the Effect of Moist Chamber Spectacles in Patients With Dry Eye Exposed to Adverse Environment Conditions. *Eye Contact Lens*. Nov 2018;44(6):379-383. doi:10.1097/ICL.0000000000000431

32. Waduthantri S, Tan CH, Fong YW, Tong L. Specialized moisture retention eyewear for evaporative dry eye. *Curr Eye Res.* May 2015;40(5):490-5. doi:10.3109/02713683.2014.932389
33. Shen G, Qi Q, Ma X. Effect of Moisture Chamber Spectacles on Tear Functions in Dry Eye Disease. *Optom Vis Sci.* Feb 2016;93(2):158-64. doi:10.1097/OPX.0000000000000778
34. Li J, Liao Y, Zhang SY, et al. Effect of laughter exercise versus 0.1% sodium hyaluronic acid on ocular surface discomfort in dry eye disease: non-inferiority randomised controlled trial. *BMJ.* Sep 11 2024;386:e080474. doi:10.1136/bmj-2024-080474
35. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Review. *Ocul Surf.* Jul 2017;15(3):539-574. doi:10.1016/j.jtos.2017.05.001
36. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. *Ocul Surf.* Jul 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.011
37. Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. *The British journal of ophthalmology.* Mar 2016;100(3):300-6. doi:10.1136/bjophthalmol-2015-307415
38. Stapleton F, Argüeso P, Asbell P, et al. TFOS DEWS III Digest Report. *Am J Ophthalmol.* 2025;In press
39. Dogru M, Tsubota K. Pharmacotherapy of dry eye. *Expert Opin Pharmacother.* Feb 2011;12(3):325-34. doi:10.1517/14656566.2010.518612

40. Moshirfar M, Pierson K, Hanamaikai K, Santiago-Caban L, Muthappan V, Passi SF. Artificial tears potpourri: a literature review. *Clin Ophthalmol*. 2014;8:1419-33. doi:10.2147/OPTH.S65263
41. Garrigue JS, Amrane M, Faure MO, Holopainen JM, Tong L. Relevance of Lipid-Based Products in the Management of Dry Eye Disease. *J Ocul Pharmacol Ther*. Nov 2017;33(9):647-661. doi:10.1089/jop.2017.0052
42. Daull P, Amrane M, Ismail D, et al. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. *J Ocul Pharmacol Ther*. Jul/Aug 2020;36(6):355-365. doi:10.1089/jop.2020.0011
43. Labetoulle M, Benitez-Del-Castillo JM, Barabino S, et al. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. *Int J Mol Sci*. Feb 23 2022;23(5)doi:10.3390/ijms23052434
44. Cole J. Artificial Tears: What Matters and Why. *Review of Optometry*. 2020;Nov 15(<https://www.reviewofoptometry.com/article/artificial-tears-what-matters-and-why>):54-60.
45. Guthrie SE, Jones L, Blackie CA, Korb DR. A Comparative Study Between an Oil-in-Water Emulsion and Nonlipid Eye Drops Used for Rewetting Contact Lenses. *Eye Contact Lens*. Nov 2015;41(6):373-7. doi:10.1097/ICL.0000000000000138
46. Muntz A, Marasini S, Wang MTM, Craig JP. Prophylactic action of lipid and non-lipid tear supplements in adverse environmental conditions: A randomised crossover trial. *Ocul Surf*. Oct 2020;18(4):920-925. doi:10.1016/j.jtos.2020.08.004

47. Vittitow J, Kissling R, DeCory H, Borchman D. In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease. *Curr Ther Res Clin Exp*. 2023;98:100704. doi:10.1016/j.curtheres.2023.100704
48. Zhuang-Yan A, Syed YY. Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease. *Drugs*. Apr 2024;84(4):441-448. doi:10.1007/s40265-024-02016-5
49. Bacharach J, Kannarr SR, Verachtert A, et al. Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study. *Ophthalmol Ther*. Feb 22 2025;doi:10.1007/s40123-025-01097-z
50. Taloni A, Coco G, Pellegrini M, Scordia V, Giannaccare G. Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis. *Ophthalmic research*. Dec 2 2025;68(1):41-51. doi:10.1159/000542149
51. Kojima T, Nagata T, Kudo H, et al. The Effects of High Molecular Weight Hyaluronic Acid Eye Drop Application in Environmental Dry Eye Stress Model Mice. *Int J Mol Sci*. May 15 2020;21(10)doi:10.3390/ijms21103516
52. Pauloin T, Dutot M, Joly F, Warnet JM, Rat P. High molecular weight hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial corneal cells. *Mol Vis*. 2009;15:577-83.
53. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res*. Jul 2010;29(4):312-34. doi:10.1016/j.preteyeres.2010.03.001
54. Kahook MY, Rapuano CJ, Messmer EM, Radcliffe NM, Galor A, Baudouin C. Preservatives and ocular surface disease: A review. *Ocul Surf*. Oct 2024;34:213-224. doi:10.1016/j.jtos.2024.08.001

55. Noecker R. Effects of common ophthalmic preservatives on ocular health. *Adv Ther.* Sep-Oct 2001;18(5):205-15. doi:10.1007/BF02853166
56. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. *Cutan Ocul Toxicol.* 2009;28(3):93-103. doi:10.1080/15569520902995834
57. Walsh K, Jones L. The use of preservatives in dry eye drops. *Clin Ophthalmol.* 2019;13:1409-1425. doi:10.2147/OPTH.S211611
58. Weng J, Fink MK, Sharma A. A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations. *Int J Mol Sci.* Feb 1 2023;24(3)doi:10.3390/ijms24032758
59. Benelli U. Systane lubricant eye drops in the management of ocular dryness. *Clin Ophthalmol.* 2011;5:783-90. doi:10.2147/OPTH.S13773
60. Harrell CR, Feulner L, Djonov V, Pavlovic D, Volarevic V. The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Dry Eye Disease Patients. *Cells.* Dec 1 2023;12(23)doi:10.3390/cells12232755
61. Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. *Cornea.* Jun 2008;27(5):574-9. doi:10.1097/ICO.0b013e318165b19e
62. Chen W, Zhang X, Li J, et al. Efficacy of osmoprotectants on prevention and treatment of murine dry eye. *Invest Ophthalmol Vis Sci.* Sep 19 2013;54(9):6287-97. doi:10.1167/iov.13-12081
63. Li JM, Lin N, Zhang Y, et al. Ectoine protects corneal epithelial survival and barrier from hyperosmotic stress by promoting anti-inflammatory cytokine IL-37. *Ocul Surf.* Apr 2024;32:182-191. doi:10.1016/j.jtos.2024.03.002

64. Asgharian B, Nolen L, Meadows D, Stone R. Novel Gel-Forming Ophthalmic Polymer System for Artificial Tear Solution. *Investigative Ophthalmology & Visual Science*. 2003;44(13):2472-2472.
65. Pezron E, Leibler L, Ricard A, Audebert R. Reversible gel formation induced by ion complexation. 2. Phase diagrams. *Macromolecules*. 1988/04/01 1988;21(4):1126-1131. doi:10.1021/ma00182a046
66. Srinivasan S, Williams R. Propylene Glycol and Hydroxypropyl Guar Nanoemulsion - Safe and Effective Lubricant Eye Drops in the Management of Dry Eye Disease. *Clin Ophthalmol*. 2022;16:3311-3326. doi:10.2147/OPTH.S377960
67. Pelton R, Hu Z, Ketelson H, Meadows D. Reversible flocculation with hydroxypropyl guar-borate, a labile anionic polyelectrolyte. *Langmuir*. Jan 6 2009;25(1):192-5. doi:10.1021/la803095q
68. Ng A, Keech A, Jones L. Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops. *Clin Ophthalmol*. 2018;12:695-700. doi:10.2147/OPTH.S150587
69. Srinivasan S, Manoj V. A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops. *Clin Ophthalmol*. 2021;15:2421-2435. doi:10.2147/OPTH.S294427
70. Aguilar A, Berra M, Tredicce J, Berra A. Efficacy of polyethylene glycol-propylene glycol-based lubricant eye drops in reducing squamous metaplasia in patients with dry eye disease. *Clin Ophthalmol*. 2018;12:1237-1243. doi:10.2147/OPTH.S164888

71. Aragona P, Simmons PA, Wang H, Wang T. Physicochemical Properties of Hyaluronic Acid-Based Lubricant Eye Drops. *Transl Vis Sci Technol*. Nov 2019;8(6):2. doi:10.1167/tvst.8.6.2
72. Snetkov P, Zakharova K, Morozkina S, Olekhovich R, Uspenskaya M. Hyaluronic Acid: The Influence of Molecular Weight on Structural, Physical, Physico-Chemical, and Degradable Properties of Biopolymer. *Polymers*. 2020;12(8). doi:10.3390/polym12081800
73. Muller-Lierheim WGK. Why Chain Length of Hyaluronan in Eye Drops Matters. *Diagnostics (Basel)*. Jul 23 2020;10(8)doi:10.3390/diagnostics10080511
74. Hynnekleiv L, Magno M, Vernhardsdottir RR, et al. Hyaluronic acid in the treatment of dry eye disease. *Acta Ophthalmol*. Dec 2022;100(8):844-860. doi:10.1111/aos.15159
75. Hynnekleiv L, Magno M, Moschowits E, Tonseth KA, Vehof J, Utheim TP. A comparison between hyaluronic acid and other single ingredient eye drops for dry eye, a review. *Acta Ophthalmol*. Feb 2024;102(1):25-37. doi:10.1111/aos.15675
76. Ang BCH, Sng JJ, Wang PXH, Htoon HM, Tong LHT. Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. *Sci Rep*. Aug 21 2017;7(1):9013. doi:10.1038/s41598-017-08534-5
77. Aragona P, Benitez-Del-Castillo JM, Coroneo MT, et al. Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study. *Clin Ophthalmol*. 2020;14:2951-2963. doi:10.2147/OPTH.S256480

78. Fezza JP. Cross-linked hyaluronic acid gel occlusive device for the treatment of dry eye syndrome. *Clin Ophthalmol*. 2018;12:2277-2283. doi:10.2147/OPTH.S187963
79. Postorino EI, Aragona P, Rania L, et al. Changes in conjunctival epithelial cells after treatment with 0.2% xanthan gum eye drops in mild-moderate dry eye. *Eur J Ophthalmol*. May 2020;30(3):439-445. doi:10.1177/1120672119833278
80. Pahuja P, Arora S, Pawar P. Ocular drug delivery system: a reference to natural polymers. *Expert Opin Drug Deliv*. Jul 2012;9(7):837-61. doi:10.1517/17425247.2012.690733
81. Perez-Balbuena AL, Ochoa-Tabares JC, Belalcázar-Rey S, et al. Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial. *BMC Ophthalmol*. Sep 2016;16(1):164. doi:10.1186/s12886-016-0343-9
82. Abbate I, Zappulla C, Santonocito M, et al. Preclinical study of a new matrix to help the ocular surface in dry eye disease. *Exp Eye Res*. Sep 2022;222:109168. doi:10.1016/j.exer.2022.109168
83. Aragona P, Giannaccare G, Dammino E, et al. Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment. *Ophthalmol Ther*. Oct 2024;13(10):2559-2573. doi:10.1007/s40123-024-01003-z
84. Dodi G, Sabau RE, Cretu BE, Gardikiotis I. Exploring the Antioxidant Potential of Gellan and Guar Gums in Wound Healing. *Pharmaceutics*. Aug 17 2023;15(8)doi:10.3390/pharmaceutics15082152

85. Patel J, Maji B, Moorthy N, Maiti S. Xanthan gum derivatives: review of synthesis, properties and diverse applications. *RSC Adv.* Jul 15 2020;10(45):27103-27136. doi:10.1039/d0ra04366d
86. Srinivasan S, Garofalo R, Williams R. Safe and Effective Management of Dry Eye Symptoms with Hydroxypropyl Guar and Hyaluronic Acid Dual-Polymer Lubricating Eye Drops: A Review of Preclinical and Clinical Studies. *Clin Ophthalmol.* 2023;17:3883-3898. doi:10.2147/OPTH.S428725
87. Carlson E, Kao WWY, Ogundele A. Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model. *J Ocul Pharmacol Ther.* May 2018;34(4):360-364. doi:10.1089/jop.2017.0080
88. Jia T, Stapleton F, Iqbal F, et al. Comparison of eye drop retention time using fluorophotometry in three commercially available lubricant eye drops. *Optom Vis Sci.* Sep 1 2024;101(9):603-607. doi:10.1097/OPX.0000000000002172
89. Labetoulle M, Schmickler S, Galarreta D, et al. Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study. *Clin Ophthalmol.* 2018;12:2499-2508. doi:10.2147/OPTH.S177176
90. Favuzza E, Cennamo M, Vicchio L, Giansanti F, Mencucci R. Protecting the Ocular Surface in Cataract Surgery: The Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution. *Clin Ophthalmol.* 2020;14:1769-1775. doi:10.2147/OPTH.S259704
91. Che Arif FA, Hilmi MR, Mohd Kamal K, Ithnin MH. Comparison of Immediate Effects On Usage of Dual Polymer Artificial Tears on Changes in Tear Film Characteristics. *IJUM Medical Journal Malaysia.* 01/15 2020;18(2)doi:10.31436/imjm.v18i2.613

92. Pucker AD, Lievens C, McGwin G, Jr., Franklin QX, Logan A, Wolfe GS. Quality of Life in Digital Device Users Who are Treated with Systane Hydration PF. *Clin Optom (Auckl)*. 2023;15:45-54. doi:10.2147/OPTO.S398496
93. Molina-Solana P, Dominguez-Serrano FB, Garrido-Hermosilla AM, et al. Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use. *Clin Ophthalmol*. 2020;14:1153-1159. doi:10.2147/OPHTH.S248949
94. Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS. Artificial Tears: A Systematic Review. *Clin Optom (Auckl)*. 2023;15:9-27. doi:10.2147/OPTO.S350185
95. Mikha KN, Rasmussen CEO, Ahrensberg SNG, et al. Can the choice of artificial tears harm patients? A narrative review with an overview of the Nordic market. *Acta Ophthalmol*. Feb 8 2025;doi:10.1111/aos.17455
96. Baghban R, Bamdad S, Attar A, Mortazavi M. Implications of nanotechnology for the treatment of Dry Eye Disease: Recent advances. *Int J Pharm*. Mar 15 2025;672:125355. doi:10.1016/j.ijpharm.2025.125355
97. Markoulli M, Sobbizadeh A, Tan J, Briggs N, Coroneo M. The Effect of Optive and Optive Advanced Artificial Tears on the Healthy Tear Film. *Curr Eye Res*. May 2018;43(5):588-594. doi:10.1080/02713683.2018.1433860
98. Craig JP, Muntz A, Wang MTM, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. *Ocul Surf*. Apr 2021;20:62-69. doi:10.1016/j.jtos.2020.12.006
99. Essa L, Laughton D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? *Cont Lens Anterior Eye*. Feb 2018;41(1):60-68. doi:10.1016/j.clae.2017.07.007

100. Baudouin C, Galarreta DJ, Mrukwa-Kominek E, et al. Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency. *Eur J Ophthalmol*. Mar 10 2017;27(2):122-128. doi:10.5301/ejo.5000883
101. Jerkins G, Greiner JV, Tong L, et al. A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease. *Clin Ophthalmol*. 2020;14:1665-1673. doi:10.2147/OPTH.S256351
102. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. *Clin Ophthalmol*. 2020;14:3167-3177. doi:10.2147/OPTH.S263362
103. Yeu E, Silverstein S, Guillon M, et al. Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial. *Clin Ophthalmol*. 2020;14:2561-2570. doi:10.2147/OPTH.S261318
104. Bickle K, Miller JR, Tauber J, Awisi-Gyau D. Multi-symptom Relief with Propylene Glycol-Hydroxypropyl-Guar Nanoemulsion Lubricant Eye Drops in Subjects with Dry Eye Disease: A Post-Marketing Prospective Study. *Ophthalmol Ther*. Feb 2024;13(2):481-494. doi:10.1007/s40123-023-00853-3
105. Rangarajan R, Ketelson H. Preclinical Evaluation of a New Hydroxypropyl-Guar Phospholipid Nanoemulsion-Based Artificial Tear Formulation in Models of Corneal Epithelium. *J Ocul Pharmacol Ther*. Jan/Feb 2019;35(1):32-37. doi:10.1089/jop.2018.0031
106. Kaercher T, Thelen U, Brief G, Morgan-Warren RJ, Leaback R. A prospective, multicenter, noninterventional study of Optive Plus((R)) in the treatment of patients with dry eye: the prolipid study. *Clin Ophthalmol*. 2014;8:1147-55. doi:10.2147/OPTH.S58464

107. Karcenty M, Jung C, Souied EH, et al. Evaluation of Carboxymethylcellulose Sodium plus Glycerin (Optive(R)) in Ocular Discomfort after Anti-Vascular Endothelial Growth Factor Intravitreal Injection Therapy: A Prospective Study. *Ophthalmologica Journal internationale d'ophtalmologie Internationale journal of ophthalmology Zeitschrift fur Augenheilkunde*. 2021;244(3):187-192. doi:10.1159/000512635
108. Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. *Ophthalmology*. Apr 2004;111(4):783-91. doi:10.1016/j.ophtha.2003.07.008
109. Fogagnolo P, Ottobelli L, Diguini M, Rossetti L. Short-term efficacy of two lipidic eyedrops in the treatment of evaporative dry eye. *Ital Rev Ophthalmol*. 2016;2:97-105.
110. Wang TJ, Wang IJ, Ho JD, Chou HC, Lin SY, Huang MC. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study. *Clin Ther*. Jan 2010;32(1):44-52. doi:10.1016/j.clinthera.2010.01.024
111. Chung SH, Lim SA, Tchach H. Efficacy and Safety of Carbomer-Based Lipid-Containing Artificial Tear Formulations in Patients With Dry Eye Syndrome. *Cornea*. Feb 2016;35(2):181-6. doi:10.1097/ICO.0000000000000660
112. Kim YH, Kang YS, Lee HS, Choi W, You IC, Yoon KC. Effectiveness of Combined Tear Film Therapy in Patients with Evaporative Dry Eye with Short Tear Film Breakup Time. *J Ocul Pharmacol Ther*. Oct 2017;33(8):635-643. doi:10.1089/jop.2017.0019
113. Mihaltz K, Faschinger EM, Vecsei-Marlovits PV. Effects of Lipid- Versus Sodium Hyaluronate-Containing Eye Drops on Optical Quality and Ocular

Surface Parameters as a Function of the Meibomian Gland Dropout Rate. *Cornea*. Jul 2018;37(7):886-892. doi:10.1097/ICO.0000000000001523

114. Lim P, Han TA, Tong L. Short-Term Changes in Tear Lipid Layer Thickness After Instillation of Lipid Containing Eye Drops. *Transl Vis Sci Technol*. Jul 2020;9(8):29. doi:10.1167/tvst.9.8.29

115. Robert PY, Cochener B, Amrane M, et al. Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. *Eur J Ophthalmol*. Nov 4 2016;26(6):546-555. doi:10.5301/ejo.5000830

116. Fogagnolo P, Quisisana C, Caretti A, et al. Efficacy and Safety of VisuEvo((R)) and Cationorm((R)) for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial. *Clin Ophthalmol*. 2020;14:1651-1663. doi:10.2147/OPTH.S258081

117. Makri OE, Tsekouras I, Mastronikolis S, Georgakopoulos CD. Short-term effect of non-preserved cationic oil-in-water ophthalmic emulsion on tear meniscus parameters of healthy individuals in a prospective, controlled pilot study. *Med Hypothesis Discov Innov Ophthalmol*. Spring 2021;10(1):5-10. doi:10.51329/mehdiophthal1415

118. Ousler G, 3rd, Devries DK, Karpecki PM, Ciolino JB. An evaluation of Retaine ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye. *Clin Ophthalmol*. 2015;9:235-43. doi:10.2147/OPTH.S75297

119. Korb DR, Scaffidi RC, Greiner JV, et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. *Optom Vis Sci*. Jul 2005;82(7):594-601. doi:10.1097/01.opx.0000171818.01353.8c

120. Aguilar AJ, Marquez MI, Albera PA, Tredicce JL, Berra A. Effects of Systane((R)) Balance on noninvasive tear film break-up time in patients with lipid-deficient dry eye. *Clin Ophthalmol.* 2014;8:2365-72. doi:10.2147/OPTH.S70623
121. Gokul A, Wang MTM, Craig JP. Tear lipid supplement prophylaxis against dry eye in adverse environments. *Cont Lens Anterior Eye.* Feb 2018;41(1):97-100. doi:10.1016/j.clae.2017.09.013
122. Pucker AD, McGwin G, Jr., Franklin QX, Dubey J, Nattis A, Lievens C. Application of systane complete for the treatment of contact lens discomfort. *Cont Lens Anterior Eye.* Aug 2021;44(4):101399. doi:10.1016/j.clae.2020.12.004
123. Antman G, Tessone I, Rios HA, et al. The Short-term Effects of Artificial Tears on the Tear Film Assessed by a Novel High-Resolution Tear Film Imager: A Pilot Study. *Cornea.* Oct 1 2024;43(10):1264-1271. doi:10.1097/ICO.0000000000003505
124. Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE. A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. *Ophthalmology.* Jan 2017;124(1):43-52. doi:10.1016/j.opthta.2016.09.023
125. Fogt JS, Fogt N, King-Smith PE, Liu H, Barr JT. Changes in Tear Lipid Layer Thickness and Symptoms Following the Use of Artificial Tears with and Without Omega-3 Fatty Acids: A Randomized, Double-Masked, Crossover Study. *Clin Ophthalmol.* 2019;13:2553-2561. doi:10.2147/OPTH.S228261
126. Downie LE, Hom MM, Berdy GJ, et al. An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial. *Ocul Surf.* Jan 2020;18(1):148-157. doi:10.1016/j.jtos.2019.11.004

127. Turnbull PRK, Misra SL, Craig JP. Comparison of treatment effect across varying severities of meibomian gland dropout. *Cont Lens Anterior Eye*. Feb 2018;41(1):88-92. doi:10.1016/j.clae.2017.09.004
128. McCann LC, Tomlinson A, Pearce EI, Papa V. Effectiveness of artificial tears in the management of evaporative dry eye. *Cornea*. Jan 2012;31(1):1-5. doi:10.1097/ICO.0b013e31821b71e6
129. Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the pre-ocular tear film. *Cont Lens Anterior Eye*. Apr 2010;33(2):83-7. doi:10.1016/j.clae.2009.12.007
130. Rohit A, Willcox MD, Stapleton F. Lipid Supplements and Clinical Aspects of Tear Film in Habitual Lens Wearers. *Optom Vis Sci*. Feb 2017;94(2):174-182. doi:10.1097/OPX.0000000000000996
131. Pult H, Khatum FS, Trave-Huarte S, Wolffsohn JS. Effect of Eye Spray Phospholipid Concentration on the Tear Film and Ocular Comfort. *Eye Contact Lens*. Aug 1 2021;47(8):445-448. doi:10.1097/ICL.0000000000000788
132. Jacobi C, Angstmann-Mehr S, Lange A, Kaercher T. A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study. *J Ocul Pharmacol Ther*. Jun 2022;38(5):348-353. doi:10.1089/jop.2021.0102
133. Ballesteros-Sanchez A, De-Hita-Cantalejo C, Sanchez-Gonzalez MC, et al. Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent. *Ocul Surf*. Oct 2023;30:254-262. doi:10.1016/j.jtos.2023.10.001
134. Wong JC, Barak A. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application. *Pharmacy (Basel)*. Jan 23 2024;12(1)doi:10.3390/pharmacy12010019

135. Periman LM, White DE, Katsev D. Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics. *Ophthalmol Ther.* Feb 2025;14(2):283-293. doi:10.1007/s40123-024-01076-w
136. Agarwal P, Khun D, Krosser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. *Ocul Surf.* Apr 2019;17(2):241-249. doi:10.1016/j.jtos.2019.02.010
137. Habbe KJ, Frings A, Saad A, Geerling G. The influence of a mineral oil cationic nanoemulsion or perfluorohexyloctane on the tear film lipid layer and higher order aberrations. *PLoS One.* 2023;18(1):e0279977. doi:10.1371/journal.pone.0279977
138. Schmidl D, Bata AM, Szegedi S, et al. Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial. *J Ocul Pharmacol Ther.* Apr 2020;36(3):154-161. doi:10.1089/jop.2019.0092
139. Delicado-Miralles M, Velasco E, Diaz-Tahoces A, Gallar J, Acosta MC, Aracil-Marco A. Deciphering the Action of Perfluorohexyloctane Eye Drops to Reduce Ocular Discomfort and Pain. *Front Med (Lausanne).* 2021;8:709712. doi:10.3389/fmed.2021.709712
140. Tauber J, Wirta DL, Sall K, et al. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. *Cornea.* Sep 1 2021;40(9):1132-1140. doi:10.1097/ICO.0000000000002622
141. Tauber J, Berdy GJ, Wirta DL, Krosser S, Vittitow JL, Group GS. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of

the Randomized Phase 3 GOBI Study. *Ophthalmology*. May 2023;130(5):516-524. doi:10.1016/j.ophtha.2022.12.021

142. Sheppard JD, Kurata F, Epitropoulos AT, Krosser S, Vittitow JL, Group MS. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. *Am J Ophthalmol*. Aug 2023;252:265-274. doi:10.1016/j.ajo.2023.03.008

143. Protzko EE, Segal BA, Korenfeld MS, Krosser S, Vittitow JL. Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study. *Cornea*. Sep 1 2024;43(9):1100-1107. doi:10.1097/ICO.0000000000003418

144. Tian L, Gao Z, Zhu L, et al. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. *JAMA Ophthalmol*. Apr 1 2023;141(4):385-392. doi:10.1001/jamaophthalmol.2023.0270

145. Fahmy AM, Harthan JS, Evans DG, et al. Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials. Original Research. *Front Ophthalmol (Lausanne)*. 2024-November-05 2024;4:1452422. doi:10.3389/fopht.2024.1452422

146. Jung V, Krosser S, Burian G, Grillenberger R, Korward J, Roesky C. Further contribution to the discussion on perfluorohexyloctane eye drops in dry eye disease. *Sci Total Environ*. Jan 1 2024;906:168040. doi:10.1016/j.scitotenv.2023.168040

147. Crowe JH. Trehalose as a "chemical chaperone": fact and fantasy. *Adv Exp Med Biol*. 2007;594:143-58. doi:10.1007/978-0-387-39975-1_13

148. Sharma E, Shruti PS, Singh S, et al. Trehalose and its Diverse Biological Potential. *Curr Protein Pept Sci.* 2023;24(6):503-517. doi:10.2174/1389203724666230606154719
149. Laihia J, Kaarniranta K. Trehalose for Ocular Surface Health. *Biomolecules.* May 25 2020;10(5)doi:10.3390/biom10050809
150. Hernandez E, Taisne C, Lussignol M, Esclatine A, Labetoulle M. Commercially Available Eye Drops Containing Trehalose Protect Against Dry Conditions via Autophagy Induction. *J Ocul Pharmacol Ther.* Sep 2021;37(7):386-393. doi:10.1089/jop.2020.0119
151. Astolfi G, Lorenzini L, Gobbo F, Sarli G, Versura P. Comparison of Trehalose/Hyaluronic Acid (HA) vs. 0.001% Hydrocortisone/HA Eyedrops on Signs and Inflammatory Markers in a Desiccating Model of Dry Eye Disease (DED). *J Clin Med.* Mar 10 2022;11(6)doi:10.3390/jcm11061518
152. Roszkowska AM, Inferrera L, Spinella R, et al. Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye. *J Clin Med.* Nov 26 2022;11(23)doi:10.3390/jcm11236975
153. Ballesteros-Sanchez A, Martinez-Perez C, Alvarez-Peregrina C, et al. Trehalose and Dry Eye Disease: A Comprehensive Systematic Review of Randomized Controlled Trials. *J Clin Med.* Nov 25 2023;12(23)doi:10.3390/jcm12237301
154. Sanchez-Gonzalez JM, Silva-Viguera C, Sanchez-Gonzalez MC, et al. Tear Film Stabilization and Symptom Improvement in Dry Eye Disease: The Role of Hyaluronic Acid and Trehalose Eyedrops versus Carmellose Sodium. *J Clin Med.* Oct 20 2023;12(20)doi:10.3390/jcm12206647

155. Mateo-Orobia AJ, Del Prado Sanz E, Blasco-Martinez A, Pablo-Julvez LE, Farrant S, Chiambaretta F. Efficacy of artificial tears containing trehalose and hyaluronic acid for dry eye disease in women aged 42-54 versus ≥ 55 years. *Cont Lens Anterior Eye*. Aug 2023;46(4):101845. doi:10.1016/j.clae.2023.101845
156. Mencucci R, Favuzza E, Decandia G, Cennamo M, Giansanti F. Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study. *J Clin Med*. Oct 13 2021;10(20):doi:10.3390/jcm10204699
157. Bilstein A, Heinrich A, Rybachuk A, Mosges R. Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface. *Biomed Res Int*. 2021;2021:8885032. doi:10.1155/2021/8885032
158. Nosch DS, Joos RE, Job M. Prospective randomized study to evaluate the efficacy and tolerability of Ectoin(R) containing Eye Spray (EES09) and comparison to the liposomal Eye Spray Tears Again(R) (TA) in the treatment of dry eye disease. *Cont Lens Anterior Eye*. Jun 2021;44(3):101318. doi:10.1016/j.clae.2020.04.003
159. Chen X, Lin N, Li JM, et al. Ectoine, from a Natural Bacteria Protectant to a New Treatment of Dry Eye Disease. *Pharmaceutics*. Feb 5 2024;16(2):doi:10.3390/pharmaceutics16020236
160. Lin N, Chen X, Liu H, et al. Ectoine Enhances Mucin Production Via Restoring IL-13/IFN-gamma Balance in a Murine Dry Eye Model. *Invest Ophthalmol Vis Sci*. Jun 3 2024;65(6):39. doi:10.1167/iovs.65.6.39
161. Grover AK, Samson SE. Antioxidants and vision health: facts and fiction. *Mol Cell Biochem*. Mar 2014;388(1-2):173-83. doi:10.1007/s11010-013-1908-z

162. Roszkowska AM, Spinella R, Oliverio GW, et al. Effects of the Topical Use of the Natural Antioxidant Alpha-Lipoic Acid on the Ocular Surface of Diabetic Patients with Dry Eye Symptoms. *Front Biosci (Landmark Ed)*. Jun 27 2022;27(7):202. doi:10.31083/j.fbl2707202
163. Al-Bassam L, Shearman GC, Brocchini S, Alany RG, Williams GR. The Potential of Selenium-Based Therapies for Ocular Oxidative Stress. *Pharmaceutics*. 2024;16(5). doi:10.3390/pharmaceutics16050631
164. Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. *Am J Ophthalmol*. Feb 2009;147(2):206-213 e3. doi:10.1016/j.ajo.2008.08.015
165. Szymanski L, Skopek R, Palusinska M, et al. Retinoic Acid and Its Derivatives in Skin. *Cells*. Dec 11 2020;9(12)doi:10.3390/cells9122660
166. Ding J, Kam WR, Dieckow J, Sullivan DA. The influence of 13-cis retinoic acid on human meibomian gland epithelial cells. *Invest Ophthalmol Vis Sci*. Jun 26 2013;54(6):4341-50. doi:10.1167/iovs.13-11863
167. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. *Invest Ophthalmol Vis Sci*. Mar 2011;52(4):1938-78. doi:10.1167/iovs.10-6997c
168. De-Hita-Cantalejo C, Sanchez-Gonzalez MC, Silva-Viguera C, Garcia-Romera MC, Feria-Mantero R, Sanchez-Gonzalez JM. Efficacy of hyaluronic acid 0.3%, cyanocobalamin, electrolytes, and P-Plus in menopause patients with moderate dry eye disease. *Graefes Arch Clin Exp Ophthalmol*. Feb 2022;260(2):529-535. doi:10.1007/s00417-021-05415-6
169. Labetoulle M, Mortemousque B. Performance and Safety of a Sodium Hyaluronate Tear Substitute with Polyethylene Glycol in Dry Eye Disease: A

Multicenter, Investigator-Masked, Randomized, Noninferiority Trial. *J Ocul Pharmacol Ther.* Nov 2022;38(9):607-616. doi:10.1089/jop.2022.0048

170. Gegotek A, Skrzydlewska E. Ascorbic acid as antioxidant. *Vitam Horm.* 2023;121:247-270. doi:10.1016/bs.vh.2022.10.008

171. Ma F, Feng J, Liu X, et al. A synergistic therapeutic nano-eyedrop for dry eye disease based on ascorbic acid-coupled exosomes. *Nanoscale.* Jan 27 2023;15(4):1890-1899. doi:10.1039/d2nr05178h

172. Askari G, Rafie N, Miraghajani M, Heidari Z, Arab A. Association between vitamin D and dry eye disease: A systematic review and meta-analysis of observational studies. *Cont Lens Anterior Eye.* Oct 2020;43(5):418-425. doi:10.1016/j.clae.2020.03.001

173. Arita R, Kawashima M, Ito M, Tsubota K. Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction. *BMC Ophthalmol.* Jun 7 2017;17(1):84. doi:10.1186/s12886-017-0482-7

174. Hwang JS, Lee YP, Shin YJ. Vitamin D Enhances the Efficacy of Topical Artificial Tears in Patients With Dry Eye Disease. *Cornea.* Mar 2019;38(3):304-310. doi:10.1097/ICO.0000000000001822

175. Radkar P, Lakshmanan PS, Mary JJ, Chaudhary S, Durairaj SK. A Novel Multi-Ingredient Supplement Reduces Inflammation of the Eye and Improves Production and Quality of Tears in Humans. *Ophthalmol Ther.* Sep 2021;10(3):581-599. doi:10.1007/s40123-021-00357-y

176. Chen Z, Zhang C, Jiang J, et al. The efficacy of vitamin D supplementation in dry eye disease: A systematic review and meta-analysis. *Cont Lens Anterior Eye.* Oct 2024;47(5):102169. doi:10.1016/j.clae.2024.102169

177. Bilkhu P, Sivardeen Z, Chen C, et al. Patient-reported experience of dry eye management: An international multicentre survey. *Cont Lens Anterior Eye*. Feb 2022;45(1):101450. doi:10.1016/j.clae.2021.101450
178. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. *Cochrane Database Syst Rev*. Feb 23 2016;2(2):CD009729. doi:10.1002/14651858.CD009729.pub2
179. Maity M, Allay MB, Ali MH, Basu S, Singh S. Effect of different artificial tears on tear film parameters in dry eye disease. *Optom Vis Sci*. Jan 1 2025;102(1):37-43. doi:10.1097/OPX.0000000000002206
180. Bitton E, Bouskila J. Squeezability of eye drop containers used in dry eye disease management. *Clin Exp Optom*. Jun 4 2024;1-6. doi:10.1080/08164622.2024.2361781
181. Mani S, Jin HD, Shonka B, Fortenbach CR, Russell JF. Randomized Controlled Study of Cooled vs Room-Temperature Artificial Tears for Reducing Ocular Surface Irritation After Intravitreal Injection. *J Vitreoretin Dis*. Jul-Aug 2023;7(4):310-315. doi:10.1177/24741264231175555
182. Bitton E, Crnčić V, Brunet N. Does the temperature of an artificial tear affect its comfort? *Clin Exp Optom*. Sep 2018;101(5):641-647. doi:10.1111/cxo.12664
183. Jones L, Efron N, Bandamwar K, et al. TFOS Lifestyle: Impact of contact lenses on the ocular surface. *Ocul Surf*. Jul 2023;29:175-219. doi:10.1016/j.jtos.2023.04.010
184. Papas EB, Ciolino JB, Jacobs D, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the management and therapy subcommittee. *Invest Ophthalmol Vis Sci*. Oct 18 2013;54(11):TFOS183-203. doi:10.1167/iovs.13-13166

185. Haworth K, Travis D, Leslie L, Fuller D, Pucker AD. Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety. *Cochrane Database Syst Rev*. Sep 19 2023;9(9):CD014791. doi:10.1002/14651858.CD014791.pub2
186. Chaudhary S, Ghimire D, Basu S, Agrawal V, Jacobs DS, Shanbhag SS. Contact lenses in dry eye disease and associated ocular surface disorders. *Indian J Ophthalmol*. Apr 2023;71(4):1142-1153. doi:10.4103/IJO.IJO_2778_22
187. Chen X, Yuan R, Sun M, et al. Efficacy of an ocular bandage contact lens for the treatment of dry eye after phacoemulsification. *BMC Ophthalmol*. Jan 9 2019;19(1):13. doi:10.1186/s12886-018-1023-8
188. Chen D, Xu D, Wu X, et al. The efficacy of bandage contact lens in relieving the aggravation of dry eye disease after complicated cataract or/and IOL surgery. *BMC Ophthalmol*. Mar 28 2024;24(1):141. doi:10.1186/s12886-024-03385-x
189. Li J, Zhang X, Zheng Q, et al. Comparative Evaluation of Silicone Hydrogel Contact Lenses and Autologous Serum for Management of Sjogren Syndrome-Associated Dry Eye. *Cornea*. Sep 2015;34(9):1072-8. doi:10.1097/ICO.0000000000000515
190. Trave-Huarte S, Wolffsohn JS. Bilateral Sutureless Application of Human Dehydrated Amniotic Membrane with a Specialised Bandage Contact Lens for Moderate-to-Severe Dry Eye Disease: A Prospective Study with 1-Month Follow-Up. *Clin Ophthalmol*. 2024;18:1329-1339. doi:10.2147/OPTH.S458715
191. Sharma N, Sah R, Priyadarshini K, Titiyal JS. Contact lenses for the treatment of ocular surface diseases. *Indian J Ophthalmol*. Apr 2023;71(4):1135-1141. doi:10.4103/IJO.IJO_17_23

192. Jones L, Hui A, Phan CM, et al. CLEAR - Contact lens technologies of the future. *Cont Lens Anterior Eye*. Apr 2021;44(2):398-430. doi:10.1016/j.clae.2021.02.007
193. Hoflin-Lima AL, Roizenblatt R. Therapeutic contact lens-related bilateral fungal keratitis. *The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc*. Jul 2002;28(3):149-50.
194. Bregman J, Jeng BH. Microbial Keratitis Secondary to Therapeutic Contact Lens Wear. *Current Ophthalmology Reports*. 2018/06/01 2018;6(2):126-132. doi:10.1007/s40135-018-0177-0
195. Siegel H, Bohringer D, Rhein K, Kladny AS, Reinhard T. Analysis of association of bandage contact lens with serious vision-threatening diseases and their management. *BMC Ophthalmol*. Aug 23 2024;24(1):365. doi:10.1186/s12886-024-03632-1
196. Lemp MA. Is the dry eye contact lens wearer at risk? Yes. *Cornea*. 1990;9 Suppl 1:S48-50; discussion S54. doi:10.1097/00003226-199010001-00020
197. Qiu SX, Fadel D, Hui A. Scleral Lenses for Managing Dry Eye Disease in the Absence of Corneal Irregularities: What Is the Current Evidence? *J Clin Med*. Jun 29 2024;13(13)doi:10.3390/jcm13133838
198. Asghari B, Brocks D, Carrasquillo KG, Crowley E. OSDI Outcomes Based on Patient Demographic and Wear Patterns in Prosthetic Replacement of the Ocular Surface Ecosystem. *Clin Optom (Auckl)*. 2022;14:1-12. doi:10.2147/OPTO.S337920
199. Jacobs DS, Carrasquillo KG, Cottrell PD, et al. CLEAR - Medical use of contact lenses. *Cont Lens Anterior Eye*. Apr 2021;44(2):289-329. doi:10.1016/j.clae.2021.02.002

200. Barnett M, Courey C, Fadel D, et al. CLEAR - Scleral lenses. *Cont Lens Anterior Eye*. Apr 2021;44(2):270-288. doi:10.1016/j.clae.2021.02.001
201. Bavinger JC, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. *Curr Opin Ophthalmol*. Jul 2015;26(4):319-24. doi:10.1097/ICU.0000000000000171
202. Wang M, Yennam S, McMillin J, et al. Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses. *Ocul Surf*. Jan 2022;23:162-168. doi:10.1016/j.jtos.2021.09.003
203. La Porta Weber S, Becco de Souza R, Gomes JAP, Hofling-Lima AL. The Use of the Esclera Scleral Contact Lens in the Treatment of Moderate to Severe Dry Eye Disease. *Am J Ophthalmol*. Mar 2016;163:167-173 e1. doi:10.1016/j.ajo.2015.11.034
204. Kate A, Singh S, Das AV, Basu S. Dry eye disease and risk factors for corneal complications in chronic ocular graft-versus-host disease. *Indian J Ophthalmol*. Apr 2023;71(4):1538-1544. doi:10.4103/IJO.IJO_2820_22
205. Moon J, Lee SM, Hyon JY, Kim MK, Oh JY, Choi HJ. Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial. *Sci Rep*. Jan 27 2021;11(1):2288. doi:10.1038/s41598-021-82010-z
206. Bligdon SM, Colarusso BA, Ganjei AY, Kwok A, Luo ZK, Brocks D. Scleral Lens and Prosthetic Replacement of the Ocular Surface Ecosystem Utilization in Ocular Graft-versus-Host Disease: A Survey Study. *Clin Ophthalmol*. 2021;15:4829-4838. doi:10.2147/OPTH.S337824
207. Lee SM, Kim YJ, Choi SH, Oh JY, Kim MK. Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. *Cont Lens Anterior Eye*. Aug 2019;42(4):399-405. doi:10.1016/j.clae.2018.10.011

208. Yin J, Jacobs DS. Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization. *Ocul Surf.* Jan 2019;17(1):134-141. doi:10.1016/j.jtos.2018.11.008
209. Nakhla MN, Patel R, Crowley E, Li Y, Peiris TB, Brocks D. Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study. *Clin Ophthalmol.* 2024;18:3203-3213. doi:10.2147/OPHTH.S487369
210. Kumar P, Carrasquillo KG, Chaudhary S, Basu S. A multi-parameter grading system for optimal fitting of scleral contact lenses. *F1000Res.* 2022;11:6. doi:10.12688/f1000research.74638.2
211. Fogt JS, Nau C, Harthan J, et al. Lens and solution properties in patients with and without midday fogging. *Ophthalmic Physiol Opt.* Jun 2024;44(4):769-773. doi:10.1111/opo.13293
212. Fogt JS. Midday Fogging of Scleral Contact Lenses: Current Perspectives. *Clin Optom (Auckl).* 2021;13:209-219. doi:10.2147/OPTO.S284634
213. Chaudhary S, Kate A, Chappidi K, Basu S, Shanbhag SS. Safety and Efficacy of Contact Lenses in Eyes After Simple Limbal Epithelial Transplantation. *Cornea.* Dec 1 2023;42(12):1513-1519. doi:10.1097/ICO.0000000000003228
214. Schornack MM. Limbal stem cell disease: management with scleral lenses. *Clin Exp Optom.* Nov 2011;94(6):592-4. doi:10.1111/j.1444-0938.2011.00618.x
215. Huang T, Wang Y, Zhu Z, Wu Q, Chen D, Li Y. Moisture chamber goggles for the treatment of postoperative dry eye in patients receiving SMILE and FS-

LASIK surgery. *BMC Ophthalmol.* Dec 8 2023;23(1):501. doi:10.1186/s12886-023-03241-4

216. Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. *Cochrane Database Syst Rev.* Jun 26 2017;6(6):CD006775. doi:10.1002/14651858.CD006775.pub3

217. Tong L, Zhou L, Beuerman R, Simonyi S, Hollander DA, Stern ME. Effects of punctal occlusion on global tear proteins in patients with dry eye. *Ocul Surf.* Oct 2017;15(4):736-741. doi:10.1016/j.jtos.2017.04.002

218. Lin T, Wang W, Lu Y, Gong L. Treatment of Dry Eye With Intracanalicular Injection of Hydroxybutyl Chitosan: A Prospective Randomized Clinical Trial. *Front Med (Lausanne).* 2021;8:769448. doi:10.3389/fmed.2021.769448

219. Jung I, Yoon JS, Ko BY. Microbiologic Analysis of Removed Silicone Punctal Plugs in Dry Eye Patients. *J Clin Med.* Apr 21 2022;11(9)doi:10.3390/jcm11092326

220. Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. Antimicrobial resistance in ocular infection: A review. *Clin Exp Ophthalmol.* Apr 2024;52(3):258-275. doi:10.1111/ceo.14377

221. Chandra V, Chan E, Cabrera-Aguas M, et al. Organisms causing microbial keratitis and antibiotic resistance patterns in Australia. *Clin Exp Ophthalmol.* Dec 2021;49(9):1111-1113. doi:10.1111/ceo.13988

222. Packer M, Lindstrom R, Thompson V, et al. Effectiveness and safety of a novel crosslinked hyaluronate canalicular gel occlusive device for dry eye. *J Cataract Refract Surg.* Oct 1 2024;50(10):1051-1057. doi:10.1097/j.jcrs.0000000000001505

223. Xie J, Wang C, Ning Q, et al. A new strategy to sustained release of ocular drugs by one-step drug-loaded microcapsule manufacturing in hydrogel

punctal plugs. *Graefes Arch Clin Exp Ophthalmol*. Nov 2017;255(11):2173-2184. doi:10.1007/s00417-017-3755-1

224. Cao Z, Chen Y, Bai S, et al. In situ formation of injectable organogels for punctal occlusion and sustained release of therapeutics: design, preparation, in vitro and in vivo evaluation. *Int J Pharm*. May 10 2023;638:122933. doi:10.1016/j.ijpharm.2023.122933

225. Khanna T, Akkara JD, Bawa V, Sargunam EA. Designing and making an open source, 3D-printed, punctal plug with drug delivery system. *Indian J Ophthalmol*. Jan 2023;71(1):297-299. doi:10.4103/ijo.IJO_997_22

226. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci*. Mar 2011;52(4):1930-7. doi:10.1167/iovs.10-6997b

227. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci*. Mar 30 2011;52(4):1922-9. doi:10.1167/iovs.10-6997a

228. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. *Invest Ophthalmol Vis Sci*. Mar 2011;52(4):1994-2005. doi:10.1167/iovs.10-6997e

229. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. *Invest Ophthalmol Vis Sci*. Mar 2011;52(4):2006-49. doi:10.1167/iovs.10-6997f

230. Lam PY, Shih KC, Fong PY, et al. A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction. *Eye Contact Lens*. Jan 2020;46(1):3-16. doi:10.1097/ICL.0000000000000680
231. Gostimir M, Allen LH. Is there enough evidence for the routine recommendation of eyelid wipes? A systematic review of the role of eyelid wipes in the management of blepharitis. *Can J Ophthalmol*. Oct 2020;55(5):424-436. doi:10.1016/j.jcjo.2020.05.015
232. Ngo W, Srinivasan S, Jones L. An Eyelid Warming Device for the Management of Meibomian Gland Dysfunction. *J Optom*. Apr-Jun 2019;12(2):120-130. doi:10.1016/j.optom.2018.07.002
233. Tan J, Ho L, Wong K, et al. The effects of a hydrating mask compared to traditional warm compresses on tear film properties in meibomian gland dysfunction. *Cont Lens Anterior Eye*. Feb 2018;41(1):83-87. doi:10.1016/j.clae.2017.09.006
234. Schjerven Magno M, Olafsson J, Beining M, et al. Hot towels: The bedrock of Meibomian gland dysfunction treatment - A review. *Cont Lens Anterior Eye*. Apr 2023;46(2):101775. doi:10.1016/j.clae.2022.101775
235. Garcia-Marques JV, Talens-Estarelles C, Martinez-Albert N, Garcia-Lazaro S, Cervino A. Evaluation of the MGDRx eyebag treatment in young and older subjects with dry eye symptoms. *J Fr Ophtalmol*. Jan 2022;45(1):20-27. doi:10.1016/j.jfo.2021.08.009
236. Bzovey B, Ngo W. Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy. *Clin Optom (Auckl)*. 2022;14:133-147. doi:10.2147/OPTO.S350186
237. Murphy O, V OD, Lloyd-Mckernan A. The Efficacy of Warm Compresses in the Treatment of Meibomian Gland Dysfunction and Demodex Folliculorum

Blepharitis. *Curr Eye Res.* May 2020;45(5):563-575.
doi:10.1080/02713683.2019.1686153

238. Leeungurasatien T, Paungmali A, Tantraworasin A. Efficacy of wheat hot pack (dry heat) and pottery hot pack (moist heat) on eyelid temperature and tissue blood flow in healthy eyes: a randomized control trial. *Int Ophthalmol.* Jun 2020;40(6):1347-1357. doi:10.1007/s10792-020-01300-z

239. Murakami DK, Blackie CA, Korb DR. All Warm Compresses Are Not Equally Efficacious. *Optom Vis Sci.* Sep 2015;92(9):e327-33.
doi:10.1097/OPX.0000000000000675

240. Rocha KM, Farid M, Raju L, et al. Eyelid margin disease (blepharitis and meibomian gland dysfunction): clinical review of evidence-based and emerging treatments. *J Cataract Refract Surg.* Aug 1 2024;50(8):876-882.
doi:10.1097/j.jcrs.0000000000001414

241. Lee G. Evidence-Based Strategies for Warm Compress Therapy in Meibomian Gland Dysfunction. *Ophthalmol Ther.* Sep 2024;13(9):2481-2493.
doi:10.1007/s40123-024-00988-x

242. Bitton E, Lacroix Z, Leger S. In-vivo heat retention comparison of eyelid warming masks. *Cont Lens Anterior Eye.* Aug 2016;39(4):311-5.
doi:10.1016/j.clae.2016.04.002

243. Trave-Huarte S, Wolffsohn JS. Efficacy of a novel water propelled, heating eye mask massager on tear film and ocular adnexa. *Cont Lens Anterior Eye.* Jun 2021;44(3):101344. doi:10.1016/j.clae.2020.06.002

244. Borchman D, Foulks GN, Yappert MC, et al. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. *Invest Ophthalmol Vis Sci.* Jun 1 2011;52(6):3805-17. doi:10.1167/iovs.10-6514

245. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. *Ocul Surf.* Apr 2019;17(2):360-364. doi:10.1016/j.jtos.2019.02.005
246. Arita R, Morishige N, Shirakawa R, Sato Y, Amano S. Effects of Eyelid Warming Devices on Tear Film Parameters in Normal Subjects and Patients with Meibomian Gland Dysfunction. *Ocul Surf.* Oct 2015;13(4):321-30. doi:10.1016/j.jtos.2015.04.005
247. Bilkhu PS, Naroo SA, Wolffsohn JS. Effect of a commercially available warm compress on eyelid temperature and tear film in healthy eyes. *Optom Vis Sci.* Feb 2014;91(2):163-70. doi:10.1097/OPX.0000000000000134
248. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. *Invest Ophthalmol Vis Sci.* Mar 30 2011;52(4):2050-64. doi:10.1167/iovs.10-6997g
249. Pettayil JE, Haque S, Fardin M, et al. Effect of Heating and Massaging of Meibomian Glands on Their Imaging. *Medicina.* 2024;60(10). doi:10.3390/medicina60101603
250. Wang MTM, Feng J, Wong J, Turnbull PR, Craig JP. Randomised trial of the clinical utility of an eyelid massage device for the management of meibomian gland dysfunction. *Cont Lens Anterior Eye.* Dec 2019;42(6):620-624. doi:10.1016/j.clae.2019.07.008
251. Riede-Pult BH, Evans K, Pult H. Investigating the Short-term Effect of Eyelid Massage on Corneal Topography. *Optom Vis Sci.* Jun 2017;94(6):700-706. doi:10.1097/OPX.0000000000001076

252. Wang MTM, Liu LJ, McPherson RD, Fuller JR, Craig JP. Therapeutic profile of a latent heat eyelid warming device with temperature setting variation. *Cont Lens Anterior Eye*. Apr 2020;43(2):173-177. doi:10.1016/j.clae.2019.09.004
253. Kremers I, Hohberger B, Bergua A. Infrared thermography: different options of thermal eyelid warming. *Graefes Arch Clin Exp Ophthalmol*. Jul 2020;258(7):1515-1522. doi:10.1007/s00417-020-04673-0
254. Arazi M, Lemanski M, Belkin M, Landau-Prat D. First-in-human Clinical Trial of a Novel Eyelid warming Device in Meibomian Gland Dysfunction. *Isr Med Assoc J*. Jan 2024;26(1):45-48.
255. Shen J, Huang X, Guo X, Zhou T, Li G. Safety and Efficacy of Dry Eye Intelligent Therapeutic Device in the Treatment of Meibomian Gland Dysfunction in Rabbits. *Curr Eye Res*. Oct 2024;49(10):1030-1041. doi:10.1080/02713683.2024.2357655
256. Arita R, Morishige N, Sakamoto I, et al. Effects of a warm compress containing menthol on the tear film in healthy subjects and dry eye patients. *Sci Rep*. Apr 5 2017;7(1):45848. doi:10.1038/srep45848
257. Wang DH, Guo H, Xu W, Liu XQ. Efficacy and safety of the disposable eyelid warming masks in the treatment of dry eye disease due to Meibomian gland dysfunction. *BMC Ophthalmol*. Aug 26 2024;24(1):376. doi:10.1186/s12886-024-03642-z
258. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Trans Am Ophthalmol Soc*. 2008;106:336-56.
259. Olenik A, Jimenez-Alfaro I, Alexandre-Alba N, Mahillo-Fernandez I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids

supplementation in meibomian gland dysfunction. *Clin Interv Aging*. 2013;8:1133-8. doi:10.2147/CIA.S48955

260. Olenik A, Mahillo-Fernandez I, Alexandre-Alba N, et al. Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction. *Clin Ophthalmol*. 2014;8:831-6. doi:10.2147/OPTH.S62470

261. Al-Namaeh M. A systematic review of the effect of omega-3 supplements on meibomian gland dysfunction. *Ther Adv Ophthalmol*. Jan-Dec 2020;12:2515841420952188. doi:10.1177/2515841420952188

262. Jo YJ, Lee JS. Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction. *International journal of ophthalmology*. 2021;14(11):1700-1706. doi:10.18240/ijo.2021.11.08

263. Hong S, Woo M, Eom Y, et al. A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction. *J Ocul Pharmacol Ther*. Mar 2025;41(2):65-74. doi:10.1089/jop.2024.0160

264. Yu K, Asbell PA, Shtein RM, Ying GS, for Dry Eye A, Management Study Research G. Dry Eye Subtypes in the Dry Eye Assessment and Management (DREAM) Study: A Latent Profile Analysis. *Transl Vis Sci Technol*. Nov 1 2022;11(11):13. doi:10.1167/tvst.11.11.13

265. Eom Y, Jun I, Jeon HS, et al. Re-Esterified Triglyceride omega-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial. *JAMA Ophthalmol*. Jul 1 2024;142(7):617-624. doi:10.1001/jamaophthalmol.2024.1482

266. Schlatter A, Hommer N, Kallab M, et al. Effect of Treatment with Topical Azithromycin or Oral Doxycycline on Tear Film Thickness in Patients with Meibomian Gland Dysfunction: A Randomized Controlled Trial. *J Ocul Pharmacol Ther.* Jul 2023;39(6):371-378. doi:10.1089/jop.2022.0186
267. Satitpitakul V, Ratanawongphaibul K, Kasetsuwan N, Reinprayoon U. Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial. *Graefes Arch Clin Exp Ophthalmol.* Jun 2019;257(6):1289-1294. doi:10.1007/s00417-019-04322-1
268. Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. *Eye (Lond).* Oct 2020;34(10):1797-1808. doi:10.1038/s41433-020-0876-2
269. Cohen PR, Anderson CA. Topical Selenium Sulfide for the Treatment of Hyperkeratosis. *Dermatol Ther (Heidelb).* Dec 2018;8(4):639-646. doi:10.1007/s13555-018-0259-9
270. Turcu G, Artenie C, Nowicka D, et al. Selenium Disulfide-based shampoo applied for 4 weeks significantly improves dandruff and seborrheic dermatitis. *Eur J Dermatol.* Mar 1 2023;33(S1):19-23. doi:10.1684/ejd.2023.4402
271. Watson SL, Jones LW, Stapleton F, et al. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial. *Ocul Surf.* Jul 2023;29:537-546. doi:10.1016/j.jtos.2023.07.002
272. Goldschmidt H, Kligman AM. Increased sebum secretion following selenium sulfide shampoos. *Acta Derm Venereol.* 1968;48(5):489-91.
273. Pi  rard-franchimont C AJ, Pi  rard G. Sebum flow dynamics and antidandruff shampoos. *J Soc Cosmet Chem.* 1997;48:117-121.

274. Sheppard JD, Nichols KK. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. *Ophthalmol Ther*. Jun 2023;12(3):1397-1418. doi:10.1007/s40123-023-00669-1
275. Downie LE, Craig JP, Stapleton F, et al. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial. *Ocul Surf*. Jan 2025;35:15-24. doi:10.1016/j.jtos.2024.11.008
276. Jones L, Schallhorn J, Stapleton F, Alster Y, Bosworth C. AZR-MD-001 Opens Meibomian Glands, Improves Meibum and Tear Quality Resulting in Increased Wear Time and Desired Lens Use in Patients With CLD. *Presented at ARVO*. 2024;
277. Stapleton F, Tan J, Hinds M, Alster Y, Bosworth C. AZR-MD-001 Ophthalmic Ointment Opens Meibomian Glands, Improves Meibum Quality, and Tear Film Stability Over 3 Months of Dosing in Patients with Contact Lens Discomfort. *Presented at ARVO*. 2024;
278. Blackie CA, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. *Curr Opin Ophthalmol*. Jul 2015;26(4):306-13. doi:10.1097/ICU.0000000000000165
279. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. *Clin Ophthalmol*. 2016;10:1385-96. doi:10.2147/OPTH.S109663

280. Greiner JV. Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms. *Eye Contact Lens*. Mar 2016;42(2):99-107. doi:10.1097/ICL.0000000000000166
281. Tao JP, Shen JF, Aakalu VK, et al. Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye: A Report by the American Academy of Ophthalmology. *Ophthalmology*. Dec 2023;130(12):1336-1341. doi:10.1016/j.opthta.2023.07.009
282. Pucker AD, Yim TW, Rueff E, Ngo W, Tichenor AA, Conto JE. LipiFlow for the treatment of dry eye disease. *Cochrane Database Syst Rev*. Feb 5 2024;2(2):CD015448. doi:10.1002/14651858.CD015448.pub2
283. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. *Clin Ophthalmol*. 2020;14:405-418. doi:10.2147/OPTH.S234008
284. Beining MW, Magno MS, Moschowits E, et al. In-office thermal systems for the treatment of dry eye disease. *Surv Ophthalmol*. Sep-Oct 2022;67(5):1405-1418. doi:10.1016/j.survophthal.2022.02.007
285. Wesley G, Bickle K, Downing J, et al. Systane iLux Thermal Pulsation System in the Treatment of Meibomian Gland Dysfunction: A Post-Hoc Analysis of a 12-Month, Randomized, Multicenter Study. *Clin Ophthalmol*. 2022;16:3631-3640. doi:10.2147/OPTH.S379484
286. Badawi D. A novel system, TearCare((R)), for the treatment of the signs and symptoms of dry eye disease. *Clin Ophthalmol*. 2018;12:683-694. doi:10.2147/OPTH.S160403
287. Badawi D. TearCare((R)) system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare((R))

treatment on subjects with dry eye disease. *Clin Ophthalmol*. 2019;13:189-198. doi:10.2147/OPTH.S191588

288. Karpecki P, Wirta D, Osmanovic S, Dhamdhare K. A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare((R)) System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease. *Clin Ophthalmol*. 2020;14:4551-4559. doi:10.2147/OPTH.S285953

289. Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. *Cornea*. Apr 1 2022;41(4):417-426. doi:10.1097/ICO.0000000000002837

290. Holland EJ, Loh J, Bloomenstein M, Thompson V, Wirta D, Dhamdhare K. A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease. *Clin Ophthalmol*. 2022;16:2861-2871. doi:10.2147/OPTH.S368319

291. Ayres BD, Bloomenstein MR, Loh J, et al. A Randomized, Controlled Trial Comparing Tearcare((R)) and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). *Clin Ophthalmol*. 2023;17:3925-3940. doi:10.2147/OPTH.S442971

292. Li S, Yang K, Wang J, et al. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. *Ophthalmol Ther*. Feb 2022;11(1):261-270. doi:10.1007/s40123-021-00431-5

293. Gomez ML, Afshari NA, Gonzalez DD, Cheng L. Effect of Thermoelectric Warming Therapy for the Treatment of Meibomian Gland Dysfunction. *Am J Ophthalmol*. Oct 2022;242:181-188. doi:10.1016/j.ajo.2022.06.013

294. Gomez ML, Jung J, Gonzales DD, Shacterman S, Afshari N, Cheng L. Comparison of manual versus automated thermal lid therapy with expression for meibomian gland dysfunction in patients with dry eye disease. *Sci Rep*. Sep 27 2024;14(1):22287. doi:10.1038/s41598-024-72320-3
295. Doan S, Chiambaretta F, Baudouin C, group Es. Evaluation of an eyelid warming device (Blephasteam) for the management of ocular surface diseases in France: the ESPOIR study. *J Fr Ophtalmol*. Dec 2014;37(10):763-72. doi:10.1016/j.jfo.2014.06.004
296. Purslow C. Evaluation of the ocular tolerance of a novel eyelid-warming device used for meibomian gland dysfunction. *Cont Lens Anterior Eye*. Oct 2013;36(5):226-31. doi:10.1016/j.clae.2013.02.009
297. Benitez Del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H. Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction. *Clin Ophthalmol*. 2014;8:2019-27. doi:10.2147/OPTH.S68201
298. Sim HS, Petznick A, Barbier S, et al. A Randomized, Controlled Treatment Trial of Eyelid-Warming Therapies in Meibomian Gland Dysfunction. *Ophthalmol Ther*. Dec 2014;3(1-2):37-48. doi:10.1007/s40123-014-0025-8
299. Olafsson J, Lai X, Landsend ECS, et al. TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial. *Sci Rep*. Nov 17 2021;11(1):22386. doi:10.1038/s41598-021-01899-8
300. Magno MS, Olafsson J, Beining M, et al. Chambered warm moist air eyelid warming devices - a review. *Acta Ophthalmol*. Aug 2022;100(5):499-510. doi:10.1111/aos.15052

301. Dell SJ. Intense pulsed light for evaporative dry eye disease. *Clin Ophthalmol*. 2017;11:1167-1173. doi:10.2147/OPTH.S139894
302. Yun J, Min JS. Skin temperature change in patients with meibomian gland dysfunction following intense pulsed light treatment. *Front Med (Lausanne)*. 2022;9:893940. doi:10.3389/fmed.2022.893940
303. Chen R, Lu J, Dong J, Zhu Y. Intense pulsed light therapy for ocular surface diseases. *Lasers Med Sci*. Apr 24 2024;39(1):111. doi:10.1007/s10103-024-04060-9
304. Gupta AS, Massaro M, Bunya VY. Intense pulsed light treatment for the management of meibomian gland dysfunction. *Curr Opin Ophthalmol*. Jul 1 2024;35(4):322-328. doi:10.1097/ICU.0000000000001055
305. Giannaccare G, Taroni L, Senni C, Scorgia V. Intense Pulsed Light Therapy In The Treatment Of Meibomian Gland Dysfunction: Current Perspectives. *Clin Optom (Auckl)*. 2019;11:113-126. doi:10.2147/OPTO.S217639
306. Chen C, Chen D, Chou YY, Long Q. Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction. *Medicine (Baltimore)*. Dec 10 2021;100(49):e28166. doi:10.1097/MD.00000000000028166
307. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. *PLoS One*. 2022;17(6):e0270268. doi:10.1371/journal.pone.0270268
308. Whang WJ, Yun J, Koh K. Intense pulsed-light treatment improves objective optical quality in patients with meibomian gland dysfunction. *BMC Ophthalmol*. Apr 28 2023;23(1):191. doi:10.1186/s12886-023-02939-9
309. Xue AL, Wang MTM, Ormonde SE, Craig JP. Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of

intense pulsed light therapy for meibomian gland dysfunction. *Ocul Surf.* Apr 2020;18(2):286-297. doi:10.1016/j.jtos.2020.01.003

310. Song Y, Yu S, He X, et al. Tear film interferometry assessment after intense pulsed light in dry eye disease: A randomized, single masked, sham-controlled study. *Cont Lens Anterior Eye.* Aug 2022;45(4):101499. doi:10.1016/j.clae.2021.101499

311. Yan S, Wu Y. Efficacy and safety of Intense pulsed light therapy for dry eye caused by meibomian gland dysfunction: a randomised trial. *Ann Palliat Med.* Jul 2021;10(7):7857-7865. doi:10.21037/apm-21-1303

312. Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. *Ocul Surf.* Jan 2019;17(1):104-110. doi:10.1016/j.jtos.2018.11.004

313. Rong B, Tang Y, Liu R, et al. Long-Term Effects of Intense Pulsed Light Combined with Meibomian Gland Expression in the Treatment of Meibomian Gland Dysfunction. *Photomed Laser Surg.* Oct 2018;36(10):562-567. doi:10.1089/pho.2018.4499

314. Vigo L, Taroni L, Bernabei F, et al. Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light. *Diagnostics (Basel).* Oct 13 2019;9(4)doi:10.3390/diagnostics9040147

315. Lee Y, Jang JH, Nam S, et al. Investigation of Prognostic Factors for Intense Pulsed Light Treatment with a Vascular Filter in Patients with Moderate or Severe Meibomian Gland Dysfunction. *J Clin Med.* Aug 12 2022;11(16)doi:10.3390/jcm11164724

316. Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. *Cochrane Database Syst Rev.* Mar 18 2020;3(3):CD013559. doi:10.1002/14651858.CD013559

317. Demolin L, Es-Safi M, Soyfoo MS, Motulsky E. Intense Pulsed Light Therapy in the Treatment of Dry Eye Diseases: A Systematic Review and Meta-Analysis. *J Clin Med*. Apr 21 2023;12(8)doi:10.3390/jcm12083039
318. Lei Y, Peng J, Liu J, Zhong J. Intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD)-related dry eye disease (DED): a systematic review and meta-analysis. *Lasers Med Sci*. Dec 19 2022;38(1):1. doi:10.1007/s10103-022-03690-1
319. Pratomo TG, Zaifar A, Wibowo NP, Suryono AN, Aziza Y. Current application of intense pulsed light for the management of dry eye disease: A systematic review and meta-analysis. *Indian J Ophthalmol*. Feb 1 2024;72(Suppl 2):S183-S190. doi:10.4103/IJO.IJO_671_23
320. Li D, Lin SB, Zhang MZ, Cheng B. Preliminary Assessment of Intense Pulsed Light Treatment on the Upper Eyelids for Meibomian Gland Dysfunction. *Photobiomodul Photomed Laser Surg*. Apr 2020;38(4):249-254. doi:10.1089/photob.2019.4689
321. Li D, Lin SB, Cheng B. Intense Pulsed Light Treatment for Meibomian Gland Dysfunction in Skin Types III/IV. *Photobiomodul Photomed Laser Surg*. Feb 2019;37(2):70-76. doi:10.1089/photob.2018.4509
322. Jang JH, Lee K, Nam SH, et al. Comparison of clinical outcomes between intense pulsed light therapy using two different filters in meibomian gland dysfunction: prospective randomized study. *Sci Rep*. Apr 24 2023;13(1):6700. doi:10.1038/s41598-023-33526-z
323. Wu Y, Li J, Hu M, et al. Comparison of two intense pulsed light patterns for treating patients with meibomian gland dysfunction. *Int Ophthalmol*. Jul 2020;40(7):1695-1705. doi:10.1007/s10792-020-01337-0

324. Yu H, Zeng W, Zhao G, Hong J, Feng Y. Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye. *Front Endocrinol (Lausanne)*. 2022;13:973962. doi:10.3389/fendo.2022.973962
325. Gedar Totuk OM, Kabadayi K, Ozkapi C, Aykan U. Efficacy of Intense Pulsed Light Treatment for Moderate to Severe Acute Blepharitis or Blepharoconjunctivitis: A Retrospective Case Series. *Turk J Ophthalmol*. Apr 29 2021;51(2):89-94. doi:10.4274/tjo.galenos.2020.28924
326. Di Marino M, Conigliaro P, Aiello F, et al. Combined Low-Level Light Therapy and Intense Pulsed Light Therapy for the Treatment of Dry Eye in Patients with Sjogren's Syndrome. *J Ophthalmol*. 2021;2021:2023246. doi:10.1155/2021/2023246
327. Martinez-de-la-Casa JM, Oribio-Quinto C, Milans-Del-Bosch A, et al. Intense pulsed light-based treatment for the improvement of symptoms in glaucoma patients treated with hypotensive eye drops. *Eye Vis (Lond)*. Apr 1 2022;9(1):12. doi:10.1186/s40662-022-00284-4
328. Wu Y, Xu L, Song Y, et al. Management of Post-LASIK Dry Eye with Intense Pulsed Light in Combination with 0.1% Sodium Hyaluronate and Heated Eye Mask. *Ophthalmol Ther*. Feb 2022;11(1):161-176. doi:10.1007/s40123-021-00418-2
329. Wang H, Yin X, Li Y, et al. Safety and efficacy of intense pulsed light in the treatment of severe chronic ocular graft-versus-host disease. *Ocul Surf*. Oct 2023;30:276-285. doi:10.1016/j.jtos.2023.10.002
330. Wu Y, Mou Y, Zhang Y, et al. Efficacy of Intense Pulsed Light Combined Blood Extract Eye Drops for Treatment of Nociceptive Pain in Dry Eye Patients. *J Clin Med*. Feb 27 2022;11(5)doi:10.3390/jcm11051312

331. Hoarau G, Best AL, Zina-Meziou S, et al. Effects of Intense Pulsed Light on Presumed Neuropathic Pain Associated with Meibomian Gland Dysfunction: A Before-After Study. *J Ocul Pharmacol Ther.* Jan-Feb 2025;41(1):24-32. doi:10.1089/jop.2024.0099
332. Jeon YY, Bae S, Chung HS, Kim JY, Lee H. Effects of combined intense pulsed light and cyclosporine 0.05% eyedrops in ocular surface matrix metalloproteinase-9 levels in patients with moderate-to-severe MGD. *Lasers Med Sci.* Aug 1 2024;39(1):203. doi:10.1007/s10103-024-04154-4
333. Chen J, Qin G, Li L, et al. The Combined Impact of Intense Pulsed Light Combined and 3% Diquafosol Ophthalmic Solution on Evaporative Dry Eye: A Randomized Control Study. *Ophthalmol Ther.* Dec 2023;12(6):2959-2971. doi:10.1007/s40123-023-00784-z
334. Schilling LM, Halvorson CR, Weiss RA, Weiss MA, Beasley KL. Safety of Combination Laser or Intense Pulsed Light Therapies and Doxycycline for the Treatment of Rosacea. *Dermatol Surg.* Nov 2019;45(11):1401-1405. doi:10.1097/DSS.0000000000002009
335. Li H, Huang L, Fang X, et al. The photothermal effect of intense pulsed light and LipiFlow in eyelid related ocular surface diseases: Meibomian gland dysfunction, Demodex and blepharitis. *Heliyon.* Jul 15 2024;10(13):e33852. doi:10.1016/j.heliyon.2024.e33852
336. Chung HS, Rhim JW, Park JH. Combination treatment with intense pulsed light, thermal pulsation (LipiFlow), and meibomian gland expression for refractory meibomian gland dysfunction. *Int Ophthalmol.* Nov 2022;42(11):3311-3319. doi:10.1007/s10792-022-02330-5
337. Pac CP, Ferrari F, Mercea N, Munteanu M. Efficiency of Combining Heated Eye Mask with Intense Pulsed Light Therapy as a Treatment Option for

Evaporative Dry Eye Disease. *Rom J Ophthalmol*. Apr-Jun 2024;68(2):158-165. doi:10.22336/rjo.2024.29

338. Li L, Chen J, Qin G, et al. Tear Film Lipid Layer Changes Following Combined Effect of Heated Eye Mask with Intense Pulsed Light Therapy for Evaporative Dry Eye: A Randomized Control Study. *Photobiomodul Photomed Laser Surg*. Aug 2023;41(8):435-444. doi:10.1089/photob.2023.0051

339. Ballesteros-Sanchez A, Sanchez-Gonzalez JM, Gutierrez-Ortega R, Gargallo-Martinez B. Diamond Bur Microblepharoexfoliation Combined with Intense Pulse Light and Meibomian Gland Expression for Evaporative Dry Eye: A Short-term Controlled Clinical Trial. *Ophthalmol Ther*. May 2024;13(5):1223-1237. doi:10.1007/s40123-024-00919-w

340. Gade A, Vasile G, Hohman M, Rubenstein R. Intense Pulsed Light (IPL) Therapy. *StatPearls [Internet] Treasure Island (FL): StatPearls Publishing*. 2025; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK580525/>

341. Qiao C, Li L, Wang H, et al. Adverse Events of Intense Pulsed Light Combined With Meibomian Gland Expression Versus Meibomian Gland Expression in the Treatment of Meibomian Gland Dysfunction. *Lasers Surg Med*. Jul 2021;53(5):664-670. doi:10.1002/lsm.23339

342. Martinez-Hergueta MC, Alio Del Barrio JL, Canto-Cerdan M, Amesty MA. Efficacy and safety of intense pulsed light direct eyelid application. *Sci Rep*. Sep 16 2022;12(1):15592. doi:10.1038/s41598-022-17986-3

343. de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. *IEEE J Sel Top Quantum Electron*. May-Jun 2016;22(3)doi:10.1109/JSTQE.2016.2561201

344. Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. *IUBMB Life*. Aug 2010;62(8):607-10. doi:10.1002/iub.359
345. Wu S, Zhou F, Wei Y, Chen WR, Chen Q, Xing D. Cancer phototherapy via selective photoinactivation of respiratory chain oxidase to trigger a fatal superoxide anion burst. *Antioxid Redox Signal*. Feb 10 2014;20(5):733-46. doi:10.1089/ars.2013.5229
346. Poyton RO, Ball KA. Therapeutic photobiomodulation: nitric oxide and a novel function of mitochondrial cytochrome c oxidase. *Discov Med*. Feb 2011;11(57):154-9.
347. Kashiwagi S, Morita A, Yokomizo S, et al. Photobiomodulation and nitric oxide signaling. *Nitric Oxide*. Jan 1 2023;130:58-68. doi:10.1016/j.niox.2022.11.005
348. Karu TI. Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. *Photochem Photobiol*. Sep-Oct 2008;84(5):1091-9. doi:10.1111/j.1751-1097.2008.00394.x
349. Sommer AP, Pinheiro AL, Mester AR, Franke RP, Whelan HT. Biostimulatory windows in low-intensity laser activation: lasers, scanners, and NASA's light-emitting diode array system. *J Clin Laser Med Surg*. Feb 2001;19(1):29-33. doi:10.1089/104454701750066910
350. Park Y, Kim H, Kim S, Cho KJ. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial. *Sci Rep*. Mar 4 2022;12(1):3575. doi:10.1038/s41598-022-07427-6
351. Giannaccare G, Pellegrini M, Carnovale Scalzo G, Borselli M, Ceravolo D, Scordia V. Low-Level Light Therapy Versus Intense Pulsed Light for the Treatment of Meibomian Gland Dysfunction: Preliminary Results From a

Prospective Randomized Comparative Study. *Cornea*. Feb 1 2023;42(2):141-144. doi:10.1097/ICO.0000000000002997

352. Giannaccare G, Vaccaro S, Pellegrini M, et al. Serial Sessions of a Novel Low-Level Light Therapy Device for Home Treatment of Dry Eye Disease. *Ophthalmol Ther*. Feb 2023;12(1):459-468. doi:10.1007/s40123-022-00619-3

353. Giannaccare G, Rossi C, Borselli M, et al. Outcomes of low-level light therapy before and after cataract surgery for the prophylaxis of postoperative dry eye: a prospective randomised double-masked controlled clinical trial. *The British journal of ophthalmology*. Jul 23 2024;108(8):1172-1176. doi:10.1136/bjo-2023-323920

354. Antwi A, Schill AW, Redfern R, Ritchey ER. Effect of low-level light therapy in individuals with dry eye disease. *Ophthalmic Physiol Opt*. Nov 2024;44(7):1464-1471. doi:10.1111/opo.13371

355. Markoulli M, Chandramohan N, Papas EB. Photobiomodulation (low-level light therapy) and dry eye disease. *Clin Exp Optom*. Jul 2021;104(5):561-566. doi:10.1080/08164622.2021.1878866

356. D'Souza S, James E, Koul A, Modak D, Kundu G, Shetty R. A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye. *Indian J Ophthalmol*. Apr 2023;71(4):1608-1612. doi:10.4103/IJO.IJO_2834_22

357. El Shami M, Maroun A, Hoyek S, Antoun J. Optimized combined low level light therapy and intense pulsed light therapy for the treatment of dry eye syndrome caused by Meibomian glands dysfunction. *J Fr Ophthalmol*. Dec 2022;45(10):1126-1136. doi:10.1016/j.jfo.2022.03.015

358. Marta A, Baptista PM, Heitor Marques J, et al. Intense Pulsed Plus Low-Level Light Therapy in Meibomian Gland Dysfunction. *Clin Ophthalmol*. 2021;15:2803-2811. doi:10.2147/OPTH.S318885
359. D'Souza S, Padmanabhan Nair A, Iyappan G, et al. Clinical and Molecular Outcomes After Combined Intense Pulsed Light Therapy With Low-Level Light Therapy in Recalcitrant Evaporative Dry Eye Disease With Meibomian Gland Dysfunction. *Cornea*. Sep 1 2022;41(9):1080-1087. doi:10.1097/ICO.0000000000002954
360. Stonecipher K, Abell TG, Chotiner B, Chotiner E, Potvin R. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. *Clin Ophthalmol*. 2019;13:993-999. doi:10.2147/OPTH.S213664
361. Zemanová M, Macejová I, Svobodová I, Vlková E. Treatment of mild forms of blepharitis using direct plasma discharge. *Adv Ophthalmol Vis Syst*. 2020;10(5):127-130.
362. Bernhardt T, Semmier ML, Schafer M, Bekeschus S, Emmert S, Boeckmann L. Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology. *Oxid Med Cell Longev*. 2019;2019(1):3873928. doi:10.1155/2019/3873928
363. Song B, Gu Y, Pu J, Reid B, Zhao Z, Zhao M. Application of direct current electric fields to cells and tissues in vitro and modulation of wound electric field in vivo. *Nat Protoc*. 2007;2(6):1479-89. doi:10.1038/nprot.2007.205
364. Ferrari G, Colucci A, Barbariga M, Ruggeri A, Rama P. High Frequency Electrotherapy for the Treatment of Meibomian Gland Dysfunction. *Cornea*. Nov 2019;38(11):1424-1429. doi:10.1097/ICO.0000000000002063

365. Foo VHX, Liu YC, Tho B, Tong L. Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population. *Front Med (Lausanne)*. 2023;10:1209886. doi:10.3389/fmed.2023.1209886
366. Kavroulaki D, Konstantinidou E, Tsiogka A, Rallis K, Mavrikakis E. Quantum Molecular Resonance Electrical Stimulation as a Beneficial and Safe Treatment for Multifactorial Dry Eye Disease. *Cureus*. May 2023;15(5):e39695. doi:10.7759/cureus.39695
367. Trivli A, Karmiris E, Dalianis G, Ruggeri A, Terzidou C. Evaluating the efficacy of Quantum Molecular Resonance (QMR) electrotherapy in mixed-type dry eye patients. *J Optom*. Apr-Jun 2023;16(2):128-134. doi:10.1016/j.optom.2022.06.003
368. Ballesteros-Sanchez A, Sanchez-Gonzalez JM, Tedesco GR, et al. Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye: A Randomized Interventional Study. *Ophthalmol Ther*. Feb 2024;13(2):495-507. doi:10.1007/s40123-023-00868-w
369. Shemer A, Altarescu A, Nusbaum L, et al. Quantum Molecular Resonance Effects on Patients With Dry Eye Disease: A Randomized Controlled Trial. *Cornea*. Sep 1 2024;43(9):1144-1149. doi:10.1097/ICO.0000000000003443
370. Jaccoma EH, Litherland C, Jaccoma A, Ahmed A. Pellevé™ vs Lipiflow™ MGD-related dry eye treatment study: the ThermoLid™ procedure. *Journal of Dry Eye Disease*. 2018;1(1):e11-e21.
371. Chelnis J, Garcia CN, Hamza H. Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction. *Clin Ophthalmol*. 2023;17:3089-3102. doi:10.2147/OPTH.S426564

372. Estupinan B, Souchik A, Kiszluk A, Desai S. Comprehensive Review of Thermomechanical Fractional Injury Device: Applications in Medical and Cosmetic Dermatology. *J Clin Aesthet Dermatol*. Feb 2024;17(2):32-42.
373. Safir M, Hecht I, Ahimor A, et al. The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease - A pilot prospective clinical trial. *Cont Lens Anterior Eye*. Dec 2022;45(6):101741. doi:10.1016/j.clae.2022.101741
374. Shah S, Dutta D, Barua A, Hanneken L, Naroo SA. The effect of non-ablative thermomechanical skin treatment (Tixel(R)) on dry eye disease: A prospective two centre open-label trial. *Cont Lens Anterior Eye*. Apr 2023;46(2):101811. doi:10.1016/j.clae.2022.101811
375. Sadri E, Verachtert A, Parkhurst GD, et al. Effectiveness and safety of a thermo-mechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction. *J Cataract Refract Surg*. Dec 16 2024;doi:10.1097/j.jcrs.0000000000001602
376. Blanco-Vazquez M, Gil-Cazorla R, Barua A, Taneja M, Hanneken L, Shah S. Impact of thermo-mechanical skin treatment on refraction and keratometry in patients with dry eye disease and the implications for cataract surgery. *Cont Lens Anterior Eye*. Jun 2024;47(3):102164. doi:10.1016/j.clae.2024.102164
377. Maskin SL, Alluri S. Intraductal meibomian gland probing: background, patient selection, procedure, and perspectives. *Clin Ophthalmol*. 2019;13:1203-1223. doi:10.2147/OPTH.S183174
378. Sik Sarman Z, Cucen B, Yuksel N, Cengiz A, Caglar Y. Effectiveness of Intraductal Meibomian Gland Probing for Obstructive Meibomian Gland Dysfunction. *Cornea*. Jun 2016;35(6):721-4. doi:10.1097/ICO.0000000000000820

379. Maskin SL, Alluri S. Expressible Meibomian Glands Have Occult Fixed Obstructions: Findings From Meibomian Gland Probing to Restore Intraductal Integrity. *Cornea*. Jul 2019;38(7):880-887. doi:10.1097/ICO.0000000000001954
380. Maskin SL, Alluri S. Meibography guided intraductal meibomian gland probing using real-time infrared video feed. *The British journal of ophthalmology*. Dec 2020;104(12):1676-1682. doi:10.1136/bjophthalmol-2019-315384
381. Maskin SL, Toland C. Meibomian Gland Probing Stimulates a Proliferative Epithelial Response Resulting in Duct Regeneration. *Clin Ophthalmol*. 2024;18:631-645. doi:10.2147/OPTH.S452549
382. Magno M, Moschowits E, Arita R, Vehof J, Utheim TP. Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction. *Surv Ophthalmol*. Jul-Aug 2021;66(4):612-622. doi:10.1016/j.survophthal.2020.11.005
383. Kheirkhah A, Kobashi H, Girgis J, Jamali A, Ciolino JB, Hamrah P. A randomized, sham-controlled trial of intraductal meibomian gland probing with or without topical antibiotic/steroid for obstructive meibomian gland dysfunction. *Ocul Surf*. Oct 2020;18(4):852-856. doi:10.1016/j.jtos.2020.08.008
384. Maskin SL. Comments on: Intraductal Meibomian Gland Probing and its Efficacy in the Treatment of Meibomian Gland Dysfunction. *Surv Ophthalmol*. Jul-Aug 2021;66(4):680-685. doi:10.1016/j.survophthal.2021.02.007
385. Incekalan TK, Harbiyeli, II, Yagmur M, Erdem E. Effectiveness of Intraductal Meibomian Gland Probing in Addition to the Conventional Treatment in Patients with Obstructive Meibomian Gland Dysfunction. *Ocul Immunol Inflamm*. 2019;27(8):1345-1351. doi:10.1080/09273948.2018.1522357
386. Huang X, Qin Q, Wang L, Zheng J, Lin L, Jin X. Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in

treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial. *BMC Ophthalmol.* Oct 28 2019;19(1):211. doi:10.1186/s12886-019-1219-6

387. Korb DR, Blackie CA. Debridement-scaling: a new procedure that increases Meibomian gland function and reduces dry eye symptoms. *Cornea.* Dec 2013;32(12):1554-7. doi:10.1097/ICO.0b013e3182a73843

388. Ngo W, Caffery B, Srinivasan S, Jones LW. Effect of Lid Debridement-Scaling in Sjogren Syndrome Dry Eye. *Optom Vis Sci.* Sep 2015;92(9):e316-20. doi:10.1097/OPX.0000000000000668

389. McMurren BJ, Kling MA, Fasciani A, Nymark-McMahon MH. MGrx - A Novel Multi-modal Thermal Device for Treating Moderate to Severe Meibomian Gland Dysfunction and Dry Eye. *The Open Ophthalmology Journal.* 2023;17(1)doi:10.2174/18743641-v17-231005-2023-13

390. Semp DA, Dutta D, Wolffsohn JS. Randomized clinical trial: MGrx versus standard debridement and expression for meibomian gland dysfunction. *Optom Vis Sci.* Jan 1 2025;102(1):20-27. doi:10.1097/OPX.0000000000002204

391. Moon SY, Han SA, Kwon HJ, et al. Effects of lid debris debridement combined with meibomian gland expression on the ocular surface MMP-9 levels and clinical outcomes in moderate and severe meibomian gland dysfunction. *BMC Ophthalmol.* Apr 12 2021;21(1):175. doi:10.1186/s12886-021-01926-2

392. Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. *Adv Ther.* Jul 2012;29(7):579-89. doi:10.1007/s12325-012-0033-9

393. Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. *Clin Ophthalmol.* 2015;9:865-72. doi:10.2147/OPTH.S69486

394. Liu S, Yang G, Li Q, Tang S. Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials. *Indian J Ophthalmol.* Apr 2023;71(4):1304-1315. doi:10.4103/IJO.IJO_268_23
395. Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. *Sci Rep.* Jun 24 2019;9(1):9091. doi:10.1038/s41598-019-45475-7
396. Miyake K, Yokoi N. Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study. *Clin Ophthalmol.* 2017;11:529-540. doi:10.2147/OPTH.S129178
397. Shimazaki J, Seika D, Saga M, et al. A Prospective, Randomized Trial of Two Mucin Secretagogues for the Treatment of Dry Eye Syndrome in Office Workers. *Sci Rep.* Nov 9 2017;7(1):15210. 15210. doi:10.1038/s41598-017-13121-9
398. Cui L, Li Y, Lee HS, Yang JM, Choi W, Yoon KC. Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye. *Int Ophthalmol.* Oct 2018;38(5):2021-2030. doi:10.1007/s10792-017-0693-1
399. Kaido M, Kawashima M, Shigeno Y, Yamada Y, Tsubota K. Randomized Controlled Study to Investigate the Effect of Topical Diquafosol Tetrasodium on Corneal Sensitivity in Short Tear Break-Up Time Dry Eye. *Adv Ther.* May 2018;35(5):697-706. doi:10.1007/s12325-018-0685-1
400. Jun I, Choi S, Lee GY, et al. Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial. *Sci Rep.* Sep 2 2019;9(1):12659. 12659. doi:10.1038/s41598-019-49159-0

401. Ji YW, Kim HM, Ryu SY, et al. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium. *Invest Ophthalmol Vis Sci*. Dec 2 2019;60(15):5035-5044. doi:10.1167/iovs.19-27872
402. Kim S, Shin J, Lee JE. A randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery. *Sci Rep*. Apr 27 2021;11(1):9124. doi:10.1038/s41598-021-88589-7
403. Eom Y, Kim HM. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study. *International journal of ophthalmology*. 2021;14(10):1518-1526. doi:10.18240/ijo.2021.10.07
404. Yamazaki K, Yoneyama J, Kimoto R, Shibata Y, Mimura T. Prevention of Surgery-Induced Dry Eye by Diquafosol Eyedrops after Femtosecond Laser-Assisted Cataract Surgery. *J Clin Med*. Sep 28 2022;11(19):5757. doi:10.3390/jcm11195757
405. Jung GT, Kim M, Song JS, et al. Proteomic analysis of tears in dry eye disease: A prospective, double-blind multicenter study. *Ocul Surf*. Jul 2023;29:68-76. doi:10.1016/j.jtos.2023.04.015
406. Wang T, Di Y, Li Y. Combination therapy with 3% diquafosol tetrasodium ophthalmic solution and sodium hyaluronate: an effective therapy for patients with dry eye after femtosecond laser-assisted in situ keratomileusis. *Front Med (Lausanne)*. Apr 2023;10:1160499. 1160499. doi:10.3389/fmed.2023.1160499
407. Kaido M, Arita R. Effects of a Long-Acting Diquafosol Ophthalmic Solution on the Ocular Surface, Tolerability, and Usability in Dry Eye Disease. *Adv Ther*. Jun 2024;41(6):2477-2485. doi:10.1007/s12325-024-02871-4

408. Arita R, Fukuoka S, Kaido M. Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario. *PLoS One*. 2024;19(9):e0305020. doi:10.1371/journal.pone.0305020
409. Felberg S, Dantas PEC, Sato EH. Oral pilocarpine for the treatment of dry eye in patients with Sjogren's syndrome. *Arq Bras Oftalmol*. May-Jun 2022;85(3):269-276. doi:10.5935/0004-2749.20220069
410. Wu KY, Chen WT, Chu-Bedard YK, Patel G, Tran SD. Management of Sjogren's Dry Eye Disease-Advances in Ocular Drug Delivery Offering a New Hope. *Pharmaceutics*. Dec 31 2022;15(1)147. doi:10.3390/pharmaceutics15010147
411. Kawakita T, Shimmura S, Tsubota K. Effect of Oral Pilocarpine in Treating Severe Dry Eye in Patients With Sjogren Syndrome. *Asia Pac J Ophthalmol (Phila)*. Mar-Apr 2015;4(2):101-5. doi:10.1097/APO.0000000000000040
412. Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjogren's syndrome. Article. *Clin Exp Rheumatol*. Jul-Aug 2014;32(4):575-7.
413. Nanke Y, Kobashigawa T, Yago T, Kawamoto M, Yamanaka H, Kotake S. Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts. *Biomed Res Int*. 2016;2016:6824719. 6824719. doi:10.1155/2016/6824719
414. Hori Y. Secreted Mucins on the Ocular Surface. *Invest Ophthalmol Vis Sci*. Nov 1 2018;59(14):DES151-DES156. doi:10.1167/iovs.17-23623
415. Eom Y, Chung SH, Chung TY, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. *BMC Ophthalmol*. Aug 3 2023;23(1):343. doi:10.1186/s12886-023-03004-1

416. Lee YW, Han SB. Clinical Efficacy of 2% Rebamipide in Patients With Video Display Terminal-Associated Dry Eye Disease: A Prospective, Randomized, Double-Blinded Study. *Eye Contact Lens*. Aug 1 2024;50(8):342-347. doi:10.1097/ICL.0000000000001101
417. Ballesteros-Sanchez A, Sanchez-Gonzalez MC, De-Hita-Cantalejo C, Gutierrez-Sanchez E, Rocha-de-Lossada C, Sanchez-Gonzalez JM. The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials. *J Clin Med*. Nov 17 2023;12(22)doi:10.3390/jcm12227155
418. Yan YL, Chang JY, Ling XR, Xue CY. Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis. *J Ocul Pharmacol Ther*. Dec 2024;40(10):629-637. doi:10.1089/jop.2024.0098
419. Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. *Ophthalmology*. Jun 2013;120(6):1158-65. doi:10.1016/j.opthta.2012.12.022
420. Igarashi A, Kamiya K, Kobashi H, Shimizu K. Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery. *Cornea*. Aug 2015;34(8):895-900. doi:10.1097/ICO.0000000000000456
421. Kobashi H, Kamiya K, Shimizu K. Randomized Comparison Between Rebamipide Ophthalmic Suspension and Diquafosol Ophthalmic Solution for Dry Eye After Penetrating Keratoplasty. *J Ocul Pharmacol Ther*. Jan/Feb 2017;33(1):13-18. doi:10.1089/jop.2016.0096
422. Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. *Indian J Ophthalmol*. Apr 2023;71(4):1598-1602. doi:10.4103/IJO.IJO_2586_22

423. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Review. *Ocul Surf.* Jul 2017;15(3):404-437. doi:10.1016/j.jtos.2017.05.002
424. Dieckmann G, Goyal S, Hamrah P. Neuropathic Corneal Pain: Approaches for Management. *Ophthalmology.* Nov 2017;124(11S):S34-S47. doi:10.1016/j.ophtha.2017.08.004
425. Gumus K, Pflugfelder SC. Intranasal Tear Neurostimulation: An Emerging Concept in the Treatment of Dry Eye. *Int Ophthalmol Clin.* Spring 2017;57(2):101-108. doi:10.1097/IIO.0000000000000163
426. Pflugfelder SC, Cao A, Galor A, Nichols KK, Cohen NA, Dalton M. Nicotinic acetylcholine receptor stimulation: A new approach for stimulating tear secretion in dry eye disease. *Ocul Surf.* Jul 2022;25:58-64. doi:10.1016/j.jtos.2022.05.001
427. Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease- past, present, and future. *Ocul Surf.* Jan 2019;17(1):20-27. doi:10.1016/j.jtos.2018.11.002
428. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. *Exp Eye Res.* Mar 2004;78(3):409-16. doi:10.1016/j.exer.2003.09.003
429. Pondelis N, Dieckmann GM, Jamali A, Kataguir P, Senchyna M, Hamrah P. Infrared meibography allows detection of dimensional changes in meibomian glands following intranasal neurostimulation. *Ocul Surf.* Jul 2020;18(3):511-516. doi:10.1016/j.jtos.2020.03.003
430. Swamynathan SK, Wells A. Conjunctival goblet cells: Ocular surface functions, disorders that affect them, and the potential for their regeneration. *Ocul Surf.* Jan 2020;18(1):19-26. doi:10.1016/j.jtos.2019.11.005

431. Gumus K, Schuetzle KL, Pflugfelder SC. Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation. Article. *Am J Ophthalmol*. May 2017;177:159-168. doi:10.1016/j.ajo.2017.03.002
432. Senchyna M, Ousler GW, Jerkins G, et al. Effect of TrueTear™ on Dry Eye Symptoms During Exposure to a Controlled Adverse Environment. *Investigative Ophthalmology & Visual Science*. Jul 2018;59(9)
433. Cohn GS, Corbett D, Tenen A, et al. Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease. *Invest Ophthalmol Vis Sci*. Jan 2 2019;60(1):147-153. doi:10.1167/iov.18-23984
434. Hu J, Ju M, Shi Y, Liu X, Zhu Y. Efficacy and safety of trigeminal parasympathetic pathway stimulation for dry eye: A systematic review and meta-analysis. *Indian J Ophthalmol*. May 1 2024;72(Suppl 3):S381-S392. doi:10.4103/IJO.IJO_2147_23
435. Lilley J, O'Neil EC, Bunya VY, et al. Efficacy of an Intranasal Tear Neurostimulator in Sjogren Syndrome Patients. *Clin Ophthalmol*. 2021;15:4291-4296. doi:10.2147/OPHTH.S312108
436. Ji MH, Moshfeghi DM, Periman L, et al. Novel Extranasal Tear Stimulation: Pivotal Study Results. *Transl Vis Sci Technol*. Nov 2020;9(12):23. 23. doi:10.1167/tvst.9.12.23
437. Vance CGT, Dailey DL, Chimenti RL, Van Gorp BJ, Crofford LJ, Sluka KA. Using TENS for Pain Control: Update on the State of the Evidence. *Medicina (Kaunas, Lithuania)*. Sep 22 2022;58(10)1332. doi:10.3390/medicina58101332
438. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. *Cochrane Database Syst Rev*.

Sep 14 2017;9(9):CD011976. Unsp cd011976.
doi:10.1002/14651858.CD011976.pub2

439. Zayan K, Aggarwal S, Felix E, Levitt R, Sarantopoulos K, Galor A. Transcutaneous Electrical Nerve Stimulation for the Long-Term Treatment of Ocular Pain. *Neuromodulation*. Aug 2020;23(6):871-877. doi:10.1111/ner.13146

440. Sivanesan E, Levitt RC, Sarantopoulos CD, Patin D, Galor A. Noninvasive Electrical Stimulation for the Treatment of Chronic Ocular Pain and Photophobia. *Neuromodulation*. Dec 2018;21(8):727-734. doi:10.1111/ner.12742

441. Cai MM, Zhang J. Effectiveness of transcutaneous electrical stimulation combined with artificial tears for the treatment of dry eye: A randomized controlled trial. *Exp Ther Med*. Dec 2020;20(6):175. 175. doi:10.3892/etm.2020.9305

442. Pedrotti E, Bosello F, Fasolo A, et al. Transcutaneous periorbital electrical stimulation in the treatment of dry eye. *The British journal of ophthalmology*. Jun 2017;101(6):814-819. doi:10.1136/bjophthalmol-2016-308678

443. Yang TJ, Yu Y, Yang JY, et al. Involvement of transient receptor potential channels in ocular diseases: a narrative review. *Ann Transl Med*. Aug 2022;10(15):839. doi:10.21037/atm-21-6145

444. Wei ET. Improving brain power by applying a cool TRPM8 receptor agonist to the eyelid margin. *Med Hypotheses*. Sep 2020;142:109747. doi:10.1016/j.mehy.2020.109747

445. Parra A, Madrid R, Echevarria D, et al. Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. *Nat Med*. Dec 2010;16(12):1396-9. doi:10.1038/nm.2264

446. Quallo T, Vastani N, Horridge E, et al. TRPM8 is a neuronal osmosensor that regulates eye blinking in mice. *Nat Commun.* May 22 2015;6:7150. doi:10.1038/ncomms8150
447. Wirta DL, Senchyna M, Lewis AE, et al. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). *Ocul Surf.* Oct 2022;26:166-173. doi:10.1016/j.jtos.2022.08.003
448. Yang JM, Li F, Liu Q, et al. A novel TRPM8 agonist relieves dry eye discomfort. *BMC Ophthalmol.* Jun 26 2017;17(1):101. 101. doi:10.1186/s12886-017-0495-2
449. Yoon HJ, Kim J, Yang JM, Wei ET, Kim SJ, Yoon KC. Topical TRPM8 Agonist for Relieving Neuropathic Ocular Pain in Patients with Dry Eye: A Pilot Study. *J Clin Med.* Jan 12 2021;10(2)250. doi:10.3390/jcm10020250
450. Dieckmann GM, Cox SM, Lopez MJ, et al. A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease. *Ophthalmol Ther.* Aug 2022;11(4):1551-1561. doi:10.1007/s40123-022-00530-x
451. Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease. *Cornea.* Oct 1 2022;41(10):1207-1216. doi:10.1097/ICO.0000000000002941
452. Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study. *Ocul Surf.* Apr 2022;24:15-21. doi:10.1016/j.jtos.2021.12.007

453. Katz J, Periman LM, Maiti S, et al. Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease. *Clin Ther*. Nov 2022;44(11):1463-1470. doi:10.1016/j.clinthera.2022.09.013
454. White DE, Hendrix LH, Sun L, Tam I, Macsai M, Gibson AA. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease. *J Manag Care Spec Pharm*. Jan 2023;29(1):69-79. doi:10.18553/jmcp.2022.22208
455. Hauswirth SG, Kabat AG, Hemphill M, Somaiya K, Hendrix LH, Gibson AA. Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease. *Journal of comparative effectiveness research*. Jun 2023;12(6):e220215. doi:10.57264/cer-2022-0215
456. Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. *Ophthalmology*. Apr 2022;129(4):379-387. doi:10.1016/j.opthta.2021.11.004
457. Bashrahil B, Taher N, Alzahrani Z, et al. The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis. *BMC Ophthalmol*. Jul 14 2023;23(1):319. doi:10.1186/s12886-023-03069-y
458. Ballesteros-Sanchez A, Borroni D, De-Hita-Cantalejo C, et al. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review. *Cont Lens Anterior Eye*. Feb 2024;47(1):102097. doi:10.1016/j.clae.2023.102097
459. Torkildsen GL, Pattar GR, Jerkins G, Striffler K, Nau J. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and

Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial. *Clin Ther.* Sep 2022;44(9):1178-1186. doi:10.1016/j.clinthera.2022.07.006

460. Tian L, Jin X, Wang J, et al. Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial. *Lancet Reg Health West Pac.* Apr 2024;45:101032. 101032. doi:10.1016/j.lanwpc.2024.101032

461. Mencucci R, Morelli A, Favuzza E, Galano A, Roszkowska AM, Cennamo M. Hypochlorous acid hygiene solution in patients affected by blepharitis: a prospective randomised study. *BMJ Open Ophthalmol.* Dec 7 2023;8(1)doi:10.1136/bmjophth-2022-001209

462. Sung J, Wang MTM, Lee SH, et al. Randomized double-masked trial of eyelid cleansing treatments for blepharitis. *Ocul Surf.* Jan 2018;16(1):77-83. doi:10.1016/j.jtos.2017.10.005

463. Mohammad-Rabei H, Arabi A, Shahraki T, Rezaee-Alam Z, Baradaran-Rafii A. Role of Blepharoexfoliation in Demodex Blepharitis: A Randomized Comparative Study. *Cornea.* Jan 1 2023;42(1):44-51. doi:10.1097/ICO.0000000000003046

464. Gouws P, Barabas S, Gouws A. Efficacy of Portable 445 nm Laser Versus Intense Pulsed Light Treatment for Dry Eye: A Prospective Randomized Pilot Study. *Photobiomodul Photomed Laser Surg.* Mar 2023;41(3):120-124. doi:10.1089/photob.2022.0102

465. Warren NA, Maskin SL. Review of Literature on Intraductal Meibomian Gland Probing with Insights from the Inventor and Developer: Fundamental Concepts and Misconceptions. *Clin Ophthalmol.* 2023;17:497-514. doi:10.2147/OPTH.S390085

466. Kaiserman I, Rabina G, Mimouni M, et al. The Effect of Therapeutic Meibomian Glands Expression on Evaporative Dry Eye: A Prospective

Randomized Controlled Trial. *Curr Eye Res.* Feb 2021;46(2):195-201. doi:10.1080/02713683.2020.1789663

467. Muhammad Muneeb Akhtar S, Fareed A, Sohaib Asghar M, Mumtaz M, Kaur S. Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials. *Cont Lens Anterior Eye.* Jun 2024;47(3):102148. doi:10.1016/j.clae.2024.102148

468. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). *Ophthalmology.* Oct 2023;130(10):1015-1023. doi:10.1016/j.ophtha.2023.05.030

469. Avila MY, Martinez-Pulgarin DF, Rizo Madrid C. Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial. *Cont Lens Anterior Eye.* Jun 2021;44(3):101326. doi:10.1016/j.clae.2020.04.011

470. Arita R, Fukuoka S. Efficacy of Azithromycin Eyedrops for Individuals With Meibomian Gland Dysfunction-Associated Posterior Blepharitis. *Eye Contact Lens.* Jan 1 2021;47(1):54-59. doi:10.1097/ICL.0000000000000729

471. Ashwini DL, Ve RS, Nosch D, Wilmot N. Efficacy of blink software in improving the blink rate and dry eye symptoms in visual display terminal users - A single-blinded randomized control trial. *Indian J Ophthalmol.* Oct 2021;69(10):2643-2648. doi:10.4103/ijo.IJO_3405_20

472. Pereira MV, Gloria AL. Lagophthalmos. *Semin Ophthalmol.* May 2010;25(3):72-8. doi:10.3109/08820538.2010.488578

473. Blackie CA, Korb DR. A novel lid seal evaluation: the Korb-Blackie light test. *Eye Contact Lens*. Mar 2015;41(2):98-100. doi:10.1097/ICL.0000000000000072
474. Latkany RL, Lock B, Speaker M. Nocturnal lagophthalmos: an overview and classification. *Ocul Surf*. Jan 2006;4(1):44-53. doi:10.1016/s1542-0124(12)70263-x
475. Sack RA, Beaton A, Sathe S, Morris C, Willcox M, Bogart B. Towards a closed eye model of the pre-ocular tear layer. *Prog Retin Eye Res*. Nov 2000;19(6):649-68. doi:10.1016/s1350-9462(00)00006-9
476. Melcescu E, Horton WB, Kim D, et al. Graves orbitopathy: update on diagnosis and therapy. *Southern medical journal*. Jan 2014;107(1):34-43. doi:10.1097/SMJ.0000000000000038
477. Kurihashi K. Moisture aid during sleep for the treatment of dry eye: wet gauze eye mask. *Ophthalmologica Journal internationale d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde*. 1994;208(4):216-9. doi:10.1159/000310492
478. Grey F, Carley F, Biswas S, Tromans C. Scleral contact lens management of bilateral exposure and neurotrophic keratopathy. *Cont Lens Anterior Eye*. Dec 2012;35(6):288-91. doi:10.1016/j.clae.2012.07.009
479. Gire A, Kwok A, Marx DP. PROSE treatment for lagophthalmos and exposure keratopathy. *Ophthalmic Plast Reconstr Surg*. Mar-Apr 2013;29(2):e38-40. doi:10.1097/IOP.0b013e3182674069
480. Weyns M, Koppen C, Tassignon MJ. Scleral contact lenses as an alternative to tarsorrhaphy for the long-term management of combined exposure and neurotrophic keratopathy. *Cornea*. Mar 2013;32(3):359-61. doi:10.1097/ICO.0b013e31825fed01

481. Chahal JS, Heur M, Chiu GB. Prosthetic Replacement of the Ocular Surface Ecosystem Scleral Lens Therapy for Exposure Keratopathy. *Eye Contact Lens*. Jul 2017;43(4):240-244. doi:10.1097/ICL.0000000000000265
482. Scofield-Kaplan SM, Dunbar KE, Campbell AA, Kazim M. Utility of PROSE Device in the Management of Complex Oculoplastic Pathology. *Ophthalmic Plast Reconstr Surg*. May/Jun 2018;34(3):242-245. doi:10.1097/IOP.0000000000000934
483. Chaudhary S, Chatterjee S, Jain N, Basu S. Scleral contact lenses for optimal visual recovery in a case of severe acid burn with total lagophthalmos. *BMJ Case Rep*. Jul 5 2022;15(7)doi:10.1136/bcr-2021-248384
484. Whang K, Brocks D. Case report: Utilization of a scleral lens to mitigate exposure keratopathy and associated mental health decline. *Cont Lens Anterior Eye*. Aug 2023;46(4):101871. doi:10.1016/j.clae.2023.101871
485. Young SM, Kim YD, Woo KI. Nonsurgical management of upper eyelid retraction in thyroid eye disease. *Taiwan J Ophthalmol*. Oct-Dec 2024;14(4):548-553. doi:10.4103/tjo.TJO-D-23-00043
486. Khan SH, Malik U, Ahmed F, Siddiqui ZK, Munir S, Rashid N. Conservative Management of Thyroid Eye Disease. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. May 2021;31(5):599-601. doi:10.29271/jcpsp.2021.05.599
487. Ismailova DS, Fedorov AA, Grusha YO. Ocular surface changes in thyroid eye disease. *Orbit*. Apr 2013;32(2):87-90. doi:10.3109/01676830.2013.764440
488. Takahashi Y, Vaidya A, Kakizaki H. Changes in Dry Eye Status after Steroid Pulse and Orbital Radiation Therapies in Active Thyroid Eye Disease. *J Clin Med*. Jun 22 2022;11(13)doi:10.3390/jcm11133604

489. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *N Engl J Med*. May 4 2017;376(18):1748-1761. doi:10.1056/NEJMoa1614949
490. Ugradar S, Zimmerman E, Parunakian E, Kang J, Cockerham K, Douglas RS. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. *Clin Exp Ophthalmol*. May-Jun 2023;51(4):339-348. doi:10.1111/ceo.14208
491. Mukit FA, Manley A, Patel AB, et al. Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series. *Cureus*. Apr 2024;16(4):e58585. doi:10.7759/cureus.58585
492. Hsu CK, Hsieh MW, Chang HC, Chen YH, Chien KH. Improvement of Ocular Surface Disease by Lateral Tarsoconjunctival Flap in Thyroid-Associated Orbitopathy Patients with Lid Retraction. *Journal of personalized medicine*. May 16 2022;12(5)doi:10.3390/jpm12050802
493. Sohrab M, Abugo U, Grant M, Merbs S. Management of the eye in facial paralysis. *Facial plastic surgery : FPS*. Apr 2015;31(2):140-4. doi:10.1055/s-0035-1549292
494. Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. *Am Fam Physician*. Oct 1 2007;76(7):997-1002.
495. Hohman MH, Warner MJ, Varacallo MA. Bell Palsy. *StatPearls*. 2025.
496. Biglioli F, Rabbiosi D, Bolognesi F, et al. Lipofilling of the upper eyelid to treat paralytic lagophthalmos. *Br J Oral Maxillofac Surg*. Jun 2020;58(5):558-563. doi:10.1016/j.bjoms.2020.02.017

497. Shew W, Muntz A, Dean SJ, Pult H, Wang MTM, Craig JP. Blinking and upper eyelid morphology. *Cont Lens Anterior Eye*. Dec 2022;45(6):101702. doi:10.1016/j.clae.2022.101702
498. Wang MTM, Tien L, Han A, et al. Impact of blinking on ocular surface and tear film parameters. *Ocul Surf*. Oct 2018;16(4):424-429. doi:10.1016/j.jtos.2018.06.001
499. Korb DR, Baron DF, Herman JP, et al. Tear film lipid layer thickness as a function of blinking. *Cornea*. Jul 1994;13(4):354-9. doi:10.1097/00003226-199407000-00012
500. Kim AD, Muntz A, Lee J, Wang MTM, Craig JP. Therapeutic benefits of blinking exercises in dry eye disease. *Cont Lens Anterior Eye*. Jun 2021;44(3):101329. doi:10.1016/j.clae.2020.04.014
501. McMonnies CW. Diagnosis and remediation of blink inefficiency. *Cont Lens Anterior Eye*. Jun 2021;44(3):101331. doi:10.1016/j.clae.2020.04.015
502. Nosch DS, Foppa C, Toth M, Joos RE. Blink Animation Software to Improve Blinking and Dry Eye Symptoms. *Optom Vis Sci*. Sep 2015;92(9):e310-5. doi:10.1097/OPX.0000000000000654
503. Romeo MA, Coco G, Taloni A, Carnovale-Scalzo G, Scorcio V, Giannaccare G. Digital Applications for Videoterminal-Associated Dry Eye Disease. *Vision*. 2024;8(4). doi:10.3390/vision8040067
504. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. *Ophthalmology*. Oct 1982;89(10):1173-80. doi:10.1016/s0161-6420(82)34669-2
505. Putnam CM. Diagnosis and management of blepharitis: an optometrist's perspective. *Clin Optom (Auckl)*. 2016;8:71-78. doi:10.2147/OPTO.S84795

506. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. *Cochrane Database Syst Rev*. May 16 2012;2012(5):CD005556. doi:10.1002/14651858.CD005556.pub2
507. McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. *Int Ophthalmol Clin*. Spring 1985;25(1):159-72. doi:10.1097/00004397-198502510-00010
508. Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. *Curr Opin Allergy Clin Immunol*. Oct 2010;10(5):505-10. doi:10.1097/ACI.0b013e32833df9f4
509. Nicholls SG, Oakley CL, Tan A, Vote BJ. Demodex species in human ocular disease: new clinicopathological aspects. *Int Ophthalmol*. Feb 2017;37(1):303-312. doi:10.1007/s10792-016-0249-9
510. Zhang AC, Muntz A, Wang MTM, Craig JP, Downie LE. Ocular Demodex: a systematic review of the clinical literature. *Ophthalmic Physiol Opt*. Jul 2020;40(4):389-432. doi:10.1111/opo.12691
511. Nattis A, Perry HD, Rosenberg ED, Donnenfeld ED. Influence of bacterial burden on meibomian gland dysfunction and ocular surface disease. *Clin Ophthalmol*. 2019;13:1225-1234. doi:10.2147/OPTH.S215071
512. Bhandari V, Reddy JK. Blepharitis: always remember demodex. *Middle East Afr J Ophthalmol*. Oct-Dec 2014;21(4):317-20. doi:10.4103/0974-9233.142268
513. Rhee MK, Yeu E, Barnett M, et al. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. *Eye Contact Lens*. Aug 1 2023;49(8):311-318. doi:10.1097/ICL.0000000000001003

514. Cheng AM, Hwang J, Dermer H, Galor A. Prevalence of Ocular Demodicosis in an Older Population and Its Association With Symptoms and Signs of Dry Eye. *Cornea*. Aug 1 2021;40(8):995-1001. doi:10.1097/ICO.0000000000002542
515. Trattler W, Karpecki P, Rapoport Y, et al. The Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign. *Clin Ophthalmol*. 2022;16:1153-1164. doi:10.2147/OPHTH.S354692
516. Jalbert I, Rejab S. Increased numbers of Demodex in contact lens wearers. *Optom Vis Sci*. Jun 2015;92(6):671-8. doi:10.1097/OPX.0000000000000605
517. Lee WJ, Kim M, Lee SH, Chun YS, Kim KW. The varied influence of ocular Demodex infestation on dry eye disease and meibomian gland dysfunction across different age groups. *Sci Rep*. Sep 28 2023;13(1):16324. doi:10.1038/s41598-023-43674-x
518. Farid M, Ayres BD, Donnenfeld E, et al. Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis. *Clin Ophthalmol*. 2023;17:667-679. doi:10.2147/OPHTH.S399989
519. Bitton E, Aumond S. Demodex and eye disease: a review. *Clin Exp Optom*. Apr 2021;104(3):285-294. doi:10.1111/cxo.13123
520. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. *Invest Ophthalmol Vis Sci*. Sep 2005;46(9):3089-94. doi:10.1167/iovs.05-0275
521. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. *Clin Optom (Auckl)*. 2018;10:57-63. doi:10.2147/OPTO.S142708

522. Sharma N, Martin E, Pearce EI, Hagan S. A Delphi approach to establishing consensus on best practice for the diagnosis and treatment of Demodex blepharitis. *Cont Lens Anterior Eye*. Feb 2024;47(1):102080. doi:10.1016/j.clae.2023.102080
523. Cheng S, Zhang M, Chen H, Fan W, Huang Y. The correlation between the microstructure of meibomian glands and ocular Demodex infestation: A retrospective case-control study in a Chinese population. *Medicine (Baltimore)*. May 2019;98(19):e15595. doi:10.1097/MD.00000000000015595
524. Gao H, Chen H, Xie HT, Xu KK, Shi BJ, Huang YK. Changes in Meibum Lipid Composition With Ocular Demodex Infestation. *Transl Vis Sci Technol*. Dec 1 2021;10(14):6. doi:10.1167/tvst.10.14.6
525. Lee SH, Chun YS, Kim JH, Kim ES, Kim JC. The relationship between demodex and ocular discomfort. *Invest Ophthalmol Vis Sci*. Jun 2010;51(6):2906-11. doi:10.1167/iovs.09-4850
526. Rabensteiner DF, Aminfar H, Boldin I, et al. Demodex Mite Infestation and its Associations with Tear Film and Ocular Surface Parameters in Patients with Ocular Discomfort. *Am J Ophthalmol*. Aug 2019;204:7-12. doi:10.1016/j.ajo.2019.03.007
527. Sun X, Liu Z, Sun S, Zhao S, Zhang X, Huang Y. The correlation between Demodex infestation and meibomian gland dysfunction at different ages. *BMC Ophthalmol*. Oct 1 2022;22(1):388. doi:10.1186/s12886-022-02610-9
528. Zhang XB, Ding YH, He W. The association between demodex infestation and ocular surface manifestations in meibomian gland dysfunction. *International journal of ophthalmology*. 2018;11(4):589-592. doi:10.18240/ijo.2018.04.08

529. Chen IS, Kubo Y. Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin. *J Physiol*. May 15 2018;596(10):1833-1845. doi:10.1113/JP275236
530. Navarro M, Camprubi D, Requena-Mendez A, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. *J Antimicrob Chemother*. Apr 1 2020;75(4):827-834. doi:10.1093/jac/dkz524
531. Filho PA, Hazarbassanov RM, Grisolia AB, Pazos HB, Kaiserman I, Gomes JA. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for *Demodex* spp. *The British journal of ophthalmology*. Jun 2011;95(6):893-5. doi:10.1136/bjo.2010.201194
532. Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular *Demodex folliculorum* by systemic ivermectin. *Am J Ophthalmol*. Jun 2011;151(6):1030-1034 e1. doi:10.1016/j.ajo.2010.11.024
533. Helm CJ. Treatment of ocular *Demodex* infestation with topical ivermectin cream. *Am J Ophthalmol Case Rep*. Jun 2022;26:101551. doi:10.1016/j.ajoc.2022.101551
534. Choi Y, Eom Y, Yoon EG, Song JS, Kim IH, Kim HM. Efficacy of Topical Ivermectin 1% in the Treatment of *Demodex* Blepharitis. *Cornea*. Apr 1 2022;41(4):427-434. doi:10.1097/ICO.0000000000002802
535. Valvecchia F, Greco L, Perrone F, et al. Topical ivermectin ointment treatment of *Demodex* blepharitis: a 6-year retrospective study. *Graefes Arch Clin Exp Ophthalmol*. Apr 2024;262(4):1281-1288. doi:10.1007/s00417-023-06281-0
536. Smith M, Wolffsohn JS, Chiang JCB. Topical ivermectin 1.0% cream in the treatment of ocular demodicosis. *Cont Lens Anterior Eye*. Feb 2024;47(1):102099. doi:10.1016/j.clae.2023.102099

537. Martinez-Pulgarin DF, Avila MY, Rodriguez-Morales AJ. Interventions for Demodex blepharitis and their effectiveness: A systematic review and meta-analysis. *Cont Lens Anterior Eye*. Dec 2021;44(6):101453. doi:10.1016/j.clae.2021.101453
538. Toutain CE, Seewald W, Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. *Parasit Vectors*. Nov 1 2017;10(1):522. doi:10.1186/s13071-017-2475-z
539. Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Collarette Elimination and Demodex Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25. *J Ocul Pharmacol Ther*. Oct 2021;37(8):479-484. doi:10.1089/jop.2021.0011
540. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M, Saturn ISG. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). *Cornea*. Apr 1 2023;42(4):435-443. doi:10.1097/ICO.0000000000003097
541. Sadri E, Paauw JD, Ciolino JB, et al. Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study. *Cornea*. Nov 1 2024;43(11):1368-1374. doi:10.1097/ICO.0000000000003484
542. Zhu XM, Xu R, Wang H, Chen JY, Tu ZC. Structural Properties, Bioactivities, and Applications of Polysaccharides from Okra [*Abelmoschus esculentus* (L.) Moench]: A Review. *J Agric Food Chem*. Nov 18 2020;doi:10.1021/acs.jafc.0c04475
543. Ngo W, Jones L, Bitton E. Short-Term Comfort Responses Associated With the Use of Eyelid Cleansing Products to Manage Demodex folliculorum. *Eye Contact Lens*. Nov 2018;44 Suppl 2:S87-S92. doi:10.1097/ICL.0000000000000415

544. Craig JP, Bitton E, Dantam J, Jones L, Ngo W, Wang MTM. Short-term tolerability of commercial eyelid cleansers: A randomised crossover study. *Cont Lens Anterior Eye*. Dec 2022;45(6):101733. doi:10.1016/j.clae.2022.101733
545. Chen D, Wang J, Sullivan DA, Kam WR, Liu Y. Effects of Terpinen-4-ol on Meibomian Gland Epithelial Cells In Vitro. *Cornea*. Dec 2020;39(12):1541-1546. doi:10.1097/ICO.0000000000002506
546. Park JH, Park CY. The Effect of Terpinen-4-ol on Human Corneal Epithelium. *Transl Vis Sci Technol*. Dec 2 2024;13(12):18. doi:10.1167/tvst.13.12.18
547. Liu W, Gong L. Anti-demodectic effects of okra eyelid patch in Demodex blepharitis compared with tea tree oil. *Exp Ther Med*. Apr 2021;21(4):338. doi:10.3892/etm.2021.9769
548. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. *Clin Microbiol Rev*. Jan 2006;19(1):50-62. doi:10.1128/CMR.19.1.50-62.2006
549. Arici C, Mergen B, Yildiz-Tas A, et al. Randomized double-blind trial of wipes containing terpinen-4-ol and hyaluronate versus baby shampoo in seborrheic blepharitis patients. *Eye (Lond)*. Apr 2022;36(4):869-876. doi:10.1038/s41433-021-01642-7
550. Murphy O, O'Dwyer V, Lloyd-McKernan A. The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. *Cont Lens Anterior Eye*. Feb 2018;41(1):77-82. doi:10.1016/j.clae.2017.10.012
551. Zhang X, Song N, Gong L. Therapeutic Effect of Intense Pulsed Light on Ocular Demodiosis. *Curr Eye Res*. Mar 2019;44(3):250-256. doi:10.1080/02713683.2018.1536217

552. Koo H, Kim TH, Kim KW, Wee SW, Chun YS, Kim JC. Ocular surface discomfort and Demodex: effect of tea tree oil eyelid scrub in Demodex blepharitis. *J Korean Med Sci.* Dec 2012;27(12):1574-9. doi:10.3346/jkms.2012.27.12.1574
553. Gao YY, Di Pascuale MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodectosis by lid scrub with tea tree oil. *Cornea.* Feb 2007;26(2):136-43. doi:10.1097/01.ico.0000244870.62384.79
554. Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC. Corneal manifestations of ocular demodex infestation. *Am J Ophthalmol.* May 2007;143(5):743-749. doi:10.1016/j.ajo.2007.01.054
555. Gao YY, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. *The British journal of ophthalmology.* Nov 2005;89(11):1468-73. doi:10.1136/bjo.2005.072363
556. Nicholls SG, Oakley CL, Tan A, Vote BJ. Demodex treatment in external ocular disease: the outcomes of a Tasmanian case series. *Int Ophthalmol.* Oct 2016;36(5):691-6. doi:10.1007/s10792-016-0188-5
557. Jacobi C, Doan S, Pavel V, Chiambaretta F, Karcher T. Different Approach to Manage Demodex Blepharitis - Initial and Maintenance Treatment. *Curr Eye Res.* Mar 2022;47(3):352-360. doi:10.1080/02713683.2021.1978099
558. Messaoud R, El Fekih L, Mahmoud A, et al. Improvement in ocular symptoms and signs in patients with Demodex anterior blepharitis using a novel terpinen-4-ol (2.5%) and hyaluronic acid (0.2%) cleansing wipe. *Clin Ophthalmol.* 2019;13:1043-1054. doi:10.2147/OPTH.S198585
559. Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. *Cochrane Database Syst Rev.* Jun 20 2020;6(6):CD013333. doi:10.1002/14651858.CD013333.pub2

560. Hom MM. In vitro demodocidal activity using high concentration terpinen-4-ol (T4O) encapsulated in nano-lipidic particle emulsion. *Investigative Ophthalmology & Visual Science*. 2024;65(7):3622.
561. Siddireddy JS, Tan J, Vijay AK, Willcox MDP. The Effect of Microblepharon Exfoliation on Clinical Correlates of Contact Lens Discomfort. *Optom Vis Sci*. Mar 2019;96(3):187-199. doi:10.1097/OPX.0000000000001354
562. Siddireddy JS, Vijay AK, Tan J, Willcox M. Effect of Eyelid Treatments on Bacterial Load and Lipase Activity in Relation to Contact Lens Discomfort. *Eye Contact Lens*. Jul 2020;46(4):245-253. doi:10.1097/ICL.0000000000000673
563. Tanabe H, Kawashima M, Kaido M, Ishida R, Kawakita T, Tsubota K. Safety and efficacy of wiping lid margins with lid hygiene shampoo using the "eye brush", a novel lid hygiene item, in healthy subjects: a pilot study. *BMC Ophthalmol*. Feb 4 2019;19(1):41. doi:10.1186/s12886-019-1052-y
564. Epstein IJ, Rosenberg E, Stuber R, Choi MB, Donnenfeld ED, Perry HD. Double-Masked and Unmasked Prospective Study of Terpinen-4-ol Lid Scrubs With Microblepharoexfoliation for the Treatment of Demodex Blepharitis. *Cornea*. Apr 2020;39(4):408-416. doi:10.1097/ICO.0000000000002243
565. Aldarwesh A, Almustanyir A, Fagehi R, et al. Assessment of tear film parameters post-treatment with commercial eyelid cleaning wipes: a pilot study. *International journal of ophthalmology*. 2024-04-18 2024;17(4):659-664. doi:10.18240/ijo.2024.04.08
566. Hurst JK. What really happens in the neutrophil phagosome? *Free Radic Biol Med*. Aug 1 2012;53(3):508-20. doi:10.1016/j.freeradbiomed.2012.05.008
567. Wang L, Bassiri M, Najafi R, et al. Hypochlorous acid as a potential wound care agent: part I. Stabilized hypochlorous acid: a component of the inorganic armamentarium of innate immunity. *J Burns Wounds*. Apr 11 2007;6:e5.

568. Stroman DW, Mintun K, Epstein AB, et al. Reduction in bacterial load using hypochlorous acid hygiene solution on ocular skin. *Clin Ophthalmol*. 2017;11:707-714. doi:10.2147/OPTH.S132851
569. Hejkal TW, Maloley LA, Kaddoura L. Hypochlorous Acid 0.01% vs Povidone-Iodine 5% for Ocular Antisepsis. *J Vitreoretin Dis*. Mar-Apr 2022;6(2):132-137. doi:10.1177/24741264211013622
570. Romanowski EG, Stella NA, Yates KA, Brothers KM, Kowalski RP, Shanks RMQ. In Vitro Evaluation of a Hypochlorous Acid Hygiene Solution on Established Biofilms. *Eye Contact Lens*. Nov 2018;44 Suppl 2(Suppl 2):S187-S191. doi:10.1097/ICL.0000000000000456
571. Gold MH, Andriessen A, Bhatia AC, et al. Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. *J Cosmet Dermatol*. Feb 2020;19(2):270-277. doi:10.1111/jocd.13280
572. Ishihara M, Murakami K, Fukuda K, et al. Stability of Weakly Acidic Hypochlorous Acid Solution with Microbicidal Activity. *Biocontrol Sci*. 2017;22(4):223-227. doi:10.4265/bio.22.223
573. Zhang H, Wu Y, Wan X, et al. Effect of Hypochlorous Acid on Blepharitis through Ultrasonic Atomization: A Randomized Clinical Trial. *J Clin Med*. Feb 1 2023;12(3)doi:10.3390/jcm12031164
574. Li Z, Wang H, Liang M, et al. Hypochlorous Acid Can Be the Novel Option for the Meibomian Gland Dysfunction Dry Eye through Ultrasonic Atomization. *Dis Markers*. 2022;2022:8631038. doi:10.1155/2022/8631038
575. Bitton E, Ngo W, Dupont P. Eyelid hygiene products: A scoping review. *Cont Lens Anterior Eye*. Dec 2019;42(6):591-597. doi:10.1016/j.clae.2019.09.008

576. Wolffsohn JS, Trave Huarte S, Jones L, Craig JP, Wang MTM, ambassadors T. Clinical practice patterns in the management of dry eye disease: A TFOS international survey. *Ocul Surf.* Jul 2021;21:78-86. doi:10.1016/j.jtos.2021.04.011
577. Sharma N, Martin E, Pearce EI, Hagan S, Purslow C, Craig JP. Comparison of the Diagnosis and Management of Demodex Blepharitis Between Eye Care Practitioners in India and Australasia - A Survey-Based Comparison. *Clin Optom (Auckl)*. 2024;16:255-265. doi:10.2147/OPTO.S469599
578. Peral A, Alonso J, Garcia-Garcia C, Nino-Rueda C, Calvo Del Bosque P. Importance of Lid Hygiene Before Ocular Surgery: Qualitative and Quantitative Analysis of Eyelid and Conjunctiva Microbiota. *Eye Contact Lens*. Nov 2016;42(6):366-370. doi:10.1097/ICL.0000000000000221
579. Eom Y, Na KS, Hwang HS, et al. Clinical efficacy of eyelid hygiene in blepharitis and meibomian gland dysfunction after cataract surgery: a randomized controlled pilot trial. *Sci Rep.* Jul 16 2020;10(1):11796. doi:10.1038/s41598-020-67888-5
580. Zarei-Ghanavati S, Nooghabi MJ, Zamani G. Comparison of the Effect of Tea Tree Oil Shampoo With Regular Eyelid Shampoo in Meibomian Gland Dysfunction Treatment. *Am J Ophthalmol.* Sep 2021;229:45-51. doi:10.1016/j.ajo.2021.04.009
581. Runda N, Manna S, Vanathi M, Tandon R, Gupta N. Tear film lipid layer thickness measurement from Ocular Surface Analyzer as a marker to monitor treatment of meibomian gland dysfunction in a study comparing physiological detergent-free eyelid wipes with conventional therapy: A randomized trial. *Indian J Ophthalmol.* Jun 2022;70(6):1963-1970. doi:10.4103/ijo.IJO_2885_21
582. Aghaei H, Torabi B, Abdolalizadeh P, Vaghfipناه H. Comparison of the effect of tea tree oil eye gel with standard treatment in patients with anterior

blepharitis: An open-label clinical trial. *Indian J Ophthalmol.* May 2023;71(5):2188-2192. doi:10.4103/IJO.IJO_2546_22

583. Toyoshima K, Ohsugi Y, Lin P, et al. Blue Light-Emitting Diode Irradiation Without a Photosensitizer Alters Oral Microbiome Composition of Ligature-Induced Periodontitis in Mice. *Photobiomodul Photomed Laser Surg.* Oct 2023;41(10):549-559. doi:10.1089/photob.2023.0061

584. Zhang D, Leong ASW, McMullin G. Blue light therapy in the management of chronic wounds: a narrative review of its physiological basis and clinical evidence. *Wounds.* May 2023;35(5):91-98. doi:10.25270/wnds/22097

585. Yang J, Jiang H, Fu Q, Qin H, Li Y, Liu M. Blue light photobiomodulation induced apoptosis by increasing ROS level and regulating SOCS3 and PTEN/PI3K/AKT pathway in osteosarcoma cells. *J Photochem Photobiol B.* Dec 2023;249:112814. doi:10.1016/j.jphotobiol.2023.112814

586. Darmani H, Am Smadi E, Mb Bataineh S. Blue light emitting diodes cripple *Helicobacter pylori* by targeting its virulence factors. *Minerva Gastroenterol Dietol.* Sep 2019;65(3):187-192. doi:10.23736/S1121-421X.19.02593-5

587. Goncalves MLL, Sobral APT, Gallo J, et al. Antimicrobial photodynamic therapy with erythrosine and blue light on dental biofilm bacteria: study protocol for randomised clinical trial. *BMJ Open.* Sep 19 2023;13(9):e075084. doi:10.1136/bmjopen-2023-075084

588. Albietz JM, Lenton LM. Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease. *Cornea.* Oct 2006;25(9):1012-9. doi:10.1097/01.ico.0000225716.85382.7b

589. Adams CJ, Manley-Harris M, Molan PC. The origin of methylglyoxal in New Zealand manuka (*Leptospermum scoparium*) honey. *Carbohydr Res.* May 26 2009;344(8):1050-3. doi:10.1016/j.carres.2009.03.020

590. Roberts AE, Maddocks SE, Cooper RA. Manuka honey reduces the motility of *Pseudomonas aeruginosa* by suppression of flagella-associated genes. *J Antimicrob Chemother.* Mar 2015;70(3):716-25. doi:10.1093/jac/dku448
591. Craig JP, Rupenthal ID, Seyfoddin A, et al. Preclinical development of MGO Manuka Honey microemulsion for blepharitis management. *BMJ Open Ophthalmol.* 2017;1(1):e000065. doi:10.1136/bmjophth-2016-000065
592. Swift S, Chepulis LM, Uy B, Radcliff FJ. Enhanced antibacterial activity of MGOTM manuka honey complexed with α -cyclodextrin (manuka honey with CycloPowerTM). *Functional Foods in Health and Disease.* 2014;4(5):172-181.
593. Loftsson T, Brewster ME. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. *J Pharm Sci.* Sep 2012;101(9):3019-32. doi:10.1002/jps.23077
594. Frame K, Cheung IMY, Wang MTM, Turnbull PR, Watters GA, Craig JP. Comparing the in vitro effects of MGO Manuka honey and tea tree oil on ocular *Demodex* viability. *Cont Lens Anterior Eye.* Dec 2018;41(6):527-530. doi:10.1016/j.clae.2018.06.006
595. Craig JP, Cruzat A, Cheung IMY, Watters GA, Wang MTM. Randomized masked trial of the clinical efficacy of MGO Manuka Honey microemulsion eye cream for the treatment of blepharitis. *Ocul Surf.* Jan 2020;18(1):170-177. doi:10.1016/j.jtos.2019.11.009
596. de Paula A, Oliva G, Barraquer RI, de la Paz MF. Prevalence and antibiotic susceptibility of bacteria isolated in patients affected with blepharitis in a tertiary eye centre in Spain. *Eur J Ophthalmol.* Sep 2020;30(5):991-997. doi:10.1177/1120672119854985
597. Nejima R, Eguchi H, Todokoro D, et al. Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis: second report-

bacteriological investigation. *Jpn J Ophthalmol*. Nov 2022;66(6):579-589. doi:10.1007/s10384-022-00947-8

598. Fernandez-Engroba J, Ferragut-Alegre A, Oliva-Albaladejo G, de la Paz MF. In vitro evaluation of multiple antibacterial agents for the treatment of chronic staphylococcal anterior blepharitis. *Arch Soc Esp Oftalmol (Engl Ed)*. Jun 2023;98(6):338-343. doi:10.1016/j.oftale.2023.05.003

599. Asbell PA, Sanfilippo CM, DeCory HH. Antibiotic resistance of bacterial pathogens isolated from the conjunctiva in the Antibiotic Resistance Monitoring in Ocular microorganisms (ARMOR) surveillance study (2009-2021). *Diagn Microbiol Infect Dis*. Jan 2024;108(1):116069. doi:10.1016/j.diagmicrobio.2023.116069

600. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. *Antimicrob Agents Chemother*. Dec 1987;31(12):1939-47. doi:10.1128/AAC.31.12.1939

601. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. *J Pharmacol Exp Ther*. Jan 2000;292(1):156-63.

602. Amsden GW. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? *J Antimicrob Chemother*. Jan 2005;55(1):10-21. doi:10.1093/jac/dkh519

603. Shimazaki J, Kito G, Kamoi M, Satake Y. Efficacy and safety of topical azithromycin therapy in patients with blepharitis and meibomian gland dysfunction. *Jpn J Ophthalmol*. Sep 2024;68(5):472-481. doi:10.1007/s10384-024-01079-x

604. Jarvis I, McCullough S, Jarvis J. The topical azithromycin meibomian gland dysfunction survey: The effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction. *Ophthalmic Physiol Opt.* Jul 2024;44(5):910-916. doi:10.1111/opo.13330
605. Yildiz E, Yenerel NM, Turan-Yardimci A, Erkan M, Gunes P. Comparison of the Clinical Efficacy of Topical and Systemic Azithromycin Treatment for Posterior Blepharitis. *J Ocul Pharmacol Ther.* May 2018;34(4):365-372. doi:10.1089/jop.2017.0095
606. Cutolo CA, Barabino S, Bonzano C, Traverso CE. The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. *Ocul Immunol Inflamm.* 2019;27(2):266-275. doi:10.1080/09273948.2017.1341988
607. Kallab M, Szegedi S, Hommer N, et al. Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial. *Adv Ther.* Jan 2020;37(1):329-341. doi:10.1007/s12325-019-01137-8
608. Liu SH, Saldanha IJ, Abraham AG, et al. Topical corticosteroids for dry eye. *Cochrane Database Syst Rev.* Oct 21 2022;10(10):CD015070. doi:10.1002/14651858.CD015070.pub2
609. Coffey MJ, Decory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. *Clin Ophthalmol.* 2013;7:299-312. doi:10.2147/OPTH.S40588
610. Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. *Expert Opin Pharmacother.* Mar 2018;19(4):337-353. doi:10.1080/14656566.2018.1439920

611. Druzgala P, Hochhaus G, Bodor N. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. *J Steroid Biochem Mol Biol*. Feb 1991;38(2):149-54. doi:10.1016/0960-0760(91)90120-t
612. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. *Curr Eye Res*. Oct 1991;10(10):933-7. doi:10.3109/02713689109020329
613. Samir A, Bodor N, Imai T. Identification of esterase involved in the metabolism of two corticosteroid soft drugs. *Biochem Pharmacol*. Mar 1 2017;127:82-89. doi:10.1016/j.bcp.2016.12.010
614. Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term Natural History of Dry Eye Disease from the Patient's Perspective. *Ophthalmology*. Feb 2016;123(2):425-433. doi:10.1016/j.ophtha.2015.10.011
615. Tsubota K, Pflugfelder SC, Liu Z, et al. Defining Dry Eye from a Clinical Perspective. *Int J Mol Sci*. Dec 4 2020;21(23)doi:10.3390/ijms21239271
616. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. *Ocul Surf*. Jul 2017;15(3):276-283. doi:10.1016/j.jtos.2017.05.008
617. Calonge M, Labetoulle M, Messmer EM, et al. Controlled Adverse Environment Chambers in Dry Eye Research. *Curr Eye Res*. Apr 2018;43(4):445-450. doi:10.1080/02713683.2017.1420197
618. Amparo F, Dana R. Web-based longitudinal remote assessment of dry eye symptoms. *Ocul Surf*. Apr 2018;16(2):249-253. doi:10.1016/j.jtos.2018.01.002
619. Iyer JV, Lee SY, Tong L. The dry eye disease activity log study. *ScientificWorldJournal*. 2012;2012:589875. doi:10.1100/2012/589875

620. Karakus S, Agrawal D, Hindman HB, Henrich C, Ramulu PY, Akpek EK. Effects of Prolonged Reading on Dry Eye. *Ophthalmology*. Oct 2018;125(10):1500-1505. doi:10.1016/j.opthta.2018.03.039
621. Starr CE, Dana R, Pflugfelder SC, et al. Dry eye disease flares: A rapid evidence assessment. *Ocul Surf*. Oct 2021;22:51-59. doi:10.1016/j.jtos.2021.07.001
622. Venkateswaran N, Bian Y, Gupta PK. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease. *Clin Ophthalmol*. 2022;16:349-355. doi:10.2147/OPTH.S323301
623. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. *Adv Drug Deliv Rev*. Feb 27 2009;61(2):158-71. doi:10.1016/j.addr.2008.11.002
624. Mansuri S, Kesharwani P, Jain K, Tekade RK, Jain NK. Mucoadhesion: A promising approach in drug delivery system. *Reactive and Functional Polymers*. 2016;100:151-172. doi:10.1016/j.reactfunctpolym.2016.01.011
625. Zierden HC, Josyula A, Shapiro RL, Hsueh HT, Hanes J, Ensign LM. Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery. *Trends Mol Med*. May 2021;27(5):436-450. doi:10.1016/j.molmed.2020.12.001
626. Popov A. Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions. *J Ocul Pharmacol Ther*. Jul/Aug 2020;36(6):366-375. doi:10.1089/jop.2020.0022
627. Schopf L, Enlow E, Popov A, Bourassa J, Chen H. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation. *Ophthalmol Ther*. Dec 2014;3(1-2):63-72. doi:10.1007/s40123-014-0021-z

628. Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies. *Cornea*. May 1 2021;40(5):564-570. doi:10.1097/ICO.0000000000002452
629. Barabino S, Montaldo E, Mingari MC, Mazzotta C, Giuffrida S, Rolando M. Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study. *Eur J Ophthalmol*. Jul 2022;32(4):2452-2458. doi:10.1177/11206721211048730
630. Gupta PK, Venkateswaran N. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares. *Ther Adv Ophthalmol*. Jan-Dec 2021;13:25158414211012797. doi:10.1177/25158414211012797
631. Borroni D, Mazzotta C, Rocha-de-Lossada C, et al. Dry Eye Para-Inflammation Treatment: Evaluation of a Novel Tear Substitute Containing Hyaluronic Acid and Low-Dose Hydrocortisone. *Biomedicines*. Dec 11 2023;11(12)doi:10.3390/biomedicines11123277
632. Fogagnolo P, Giannaccare G, Mencucci R, et al. Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments. *Ophthalmol Ther*. Jan 2024;13(1):251-266. doi:10.1007/s40123-023-00833-7
633. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. *Surv Ophthalmol*. May-Jun 2009;54(3):321-38. doi:10.1016/j.survophthal.2009.02.002
634. Periman LM, Mah FS, Karpecki PM. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent

Formulation Developments. *Clin Ophthalmol.* 2020;14:4187-4200. doi:10.2147/OPTH.S279051

635. Flits A, Medina R, Akpek EK. The evolution of cyclosporine treatments for treatment of ocular surface diseases. *Curr Opin Allergy Clin Immunol.* Oct 1 2024;24(5):360-367. doi:10.1097/ACI.0000000000001017

636. Gao J, Sana R, Calder V, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. *Invest Ophthalmol Vis Sci.* Jul 16 2013;54(7):4717-33. doi:10.1167/iovs.13-11681

637. Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, Skopinski P. Immunomodulation on the ocular surface: a review. *Cent Eur J Immunol.* 2016;41(2):195-208. doi:10.5114/ceji.2016.60995

638. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. *Immunopharmacology.* May 2000;47(2-3):119-25. doi:10.1016/s0162-3109(00)00192-2

639. Meyer S, Kohler NG, Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. *FEBS Lett.* Aug 18 1997;413(2):354-8. doi:10.1016/s0014-5793(97)00930-7

640. Chidi-Egboka NC, Fan L, Qureshi M, et al. Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis. *Clin Exp Ophthalmol.* Mar 8 2025;doi:10.1111/ceo.14514

641. Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. *The British journal of ophthalmology.* Jan 2019;103(1):125-131. doi:10.1136/bjophthalmol-2017-311801

642. Gao D, Da Z, Yang K, Shi Y. Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis. *Front Pharmacol.* 2022;13:882803. doi:10.3389/fphar.2022.882803
643. Chen D, Zhang S, Bian A, et al. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. *Medicine (Baltimore).* Aug 2019;98(31):e16710. doi:10.1097/MD.00000000000016710
644. Gao H, Zhao L, Du A, et al. Comparison of therapeutic effects of 0.05% Cyclosporine A versus 0.1% Fluorometholone in Chinese patients with mild dry eye unresponsive to artificial tears: a randomized control study. *BMC Ophthalmol.* Nov 27 2024;24(1):513. doi:10.1186/s12886-024-03771-5
645. Zhao L, Chen J, Duan H, et al. Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain. *BMC Ophthalmol.* Jan 22 2024;24(1):28. doi:10.1186/s12886-024-03294-z
646. Zhao L, Duan H, Ma B, et al. Impact of Topical 0.05% Cyclosporine A Eye Drops on Post-Femtosecond-Assisted Laser In Situ Keratomileusis Ocular Surface Recovery: A Randomized Clinical Trial. *Eye Contact Lens.* Aug 1 2024;50(8):348-356. doi:10.1097/ICL.0000000000001103
647. Zhu X, Li S, Wang M, Yao W, Huang X, Zhao L. Effects of Topical 0.05% Cyclosporine A on Dry Eye Symptoms and Parameters Following Small Incision Lenticule Extraction. *J Refract Surg.* Apr 2024;40(4):e229-e238. doi:10.3928/1081597X-20240311-03
648. Peng R, Jie Y, Long Q, et al. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial. *JAMA Ophthalmol.* Apr 1 2024;142(4):337-343. doi:10.1001/jamaophthalmol.2024.0101

649. Akpek EK, Wirta DL, Downing JE, et al. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial. *JAMA Ophthalmol.* May 1 2023;141(5):459-466. doi:10.1001/jamaophthalmol.2023.0709
650. Sheppard JD, Wirta DL, McLaurin E, et al. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study. *Cornea.* Oct 1 2021;40(10):1290-1297. doi:10.1097/ICO.0000000000002633
651. Wirta DL, Torkildsen GL, Moreira HR, et al. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. *Ophthalmology.* Jun 2019;126(6):792-800. doi:10.1016/j.ophtha.2019.01.024
652. Agarwal P, Scherer D, Gunther B, Rupenthal ID. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. *Int J Pharm.* Mar 1 2018;538(1-2):119-129. doi:10.1016/j.ijpharm.2018.01.019
653. Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. *Optom Vis Sci.* Jan 1997;74(1):8-13. doi:10.1097/00006324-199701000-00014
654. Wirta DL, Galor A, Aune CA, et al. Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE. *Cornea.* May 21 2024;doi:10.1097/ICO.0000000000003567
655. Lee JE, Kim S, Lee HK, et al. A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome. *Sci Rep.* Nov 4 2022;12(1):18737. doi:10.1038/s41598-022-21330-0

656. Toyos M, Gupta PK, Mitchell B, Karpecki P. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies. *Curr Eye Res*. Feb 2022;47(2):220-224. doi:10.1080/02713683.2021.1966477
657. Smyth-Medina R, Johnston J, Devries DK, et al. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials. *J Ocul Pharmacol Ther*. Sep 2019;35(7):388-394. doi:10.1089/jop.2018.0154
658. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease. *Ophthalmology*. Sep 2019;126(9):1230-1237. doi:10.1016/j.optha.2019.03.050
659. Tauber J, Schechter BA, Bacharach J, et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929. doi:10.2147/OPHTH.S175065
660. Moon SY, Chung HS, Lee JH, Lee H, Tchah H, Kim JY. Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes: objective and subjective evaluation. *BMC Ophthalmol*. Sep 9 2024;24(1):401. doi:10.1186/s12886-024-03620-5
661. Park CH, Kim MK, Kim EC, et al. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye. *Korean J Ophthalmol*. Aug 2019;33(4):343-352. doi:10.3341/kjo.2018.0116
662. Kang MJ, Kim YH, Chou M, et al. Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjogren's

Syndrome Dry Eye. *Ocul Immunol Inflamm.* Apr 2 2020;28(3):370-378. doi:10.1080/09273948.2019.1587470

663. Eom Y, Yoon KC, Kim HK, Song JS, Hyon JY, Kim HM. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye. *J Ocul Pharmacol Ther.* Jan-Feb 2023;39(1):27-35. doi:10.1089/jop.2022.0119

664. Choi YS, Paik HJ, Kim DH. Comparison of Consecutive Therapeutic Effects of Nanoemulsion and Emulsion Cyclosporin in Dry Eye Patients after Short-Term Treatment with Topical Fluorometholone. *J Ophthalmol.* 2022;2022:6037401. doi:10.1155/2022/6037401

665. Tuan HI, Chi SC, Kang YN. An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease. *Drug Des Devel Ther.* 2020;14:265-274. doi:10.2147/DDDT.S207743

666. Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. *J Ocul Pharmacol Ther.* Mar 2017;33(2):66-72. doi:10.1089/jop.2016.0086

667. Rhim JW, Eom Y, Yoon EG, et al. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. *Jpn J Ophthalmol.* May 2022;66(3):254-263. doi:10.1007/s10384-022-00906-3

668. Xu W, Zhao X, Jin H, et al. A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye. *Medicine (Baltimore).* Sep 8 2023;102(36):e34923. doi:10.1097/MD.00000000000034923

669. Priani D, Muhiddin HS, Sirajuddin J, Eka HB, Bahar B, Bukhari A. Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical

Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease. *Vision (Basel)*. Apr 3 2023;7(2)doi:10.3390/vision7020031

670. Gao M, Zhao L, Liang R, Zhu Q, Zhao Q, Kong X. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjogren's Syndrome. *Ocul Immunol Inflamm.* Oct 2023;31(8):1662-1668. doi:10.1080/09273948.2022.2094812

671. Hovanesian J, Chester T, Sorenson RC. A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye. *Clin Ophthalmol.* 2023;17:2181-2191. doi:10.2147/OPTH.S419600

672. Eom Y, Song JS, Kim HM. Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease. *J Ocul Pharmacol Ther.* Dec 2022;38(10):682-694. doi:10.1089/jop.2022.0031

673. Rajpoot M, Singh D, Pandey K, Bhargava R. Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters? *Nepal J Ophthalmol.* Jul 2022;14(28):64-77. doi:10.3126/nepjoph.v14i2.38928

674. Shin J, Rho CR, Hyon JY, Chung TY, Yoon KC, Joo CK. A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease. *J Ocul Pharmacol Ther.* Jan-Feb 2021;37(1):4-11. doi:10.1089/jop.2020.0104

675. Baudouin C, de la Maza MS, Amrane M, et al. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. *Eur J Ophthalmol.* Nov 8 2017;27(6):678-685. doi:10.5301/ejo.5001002

676. Labetoulle M, Leonardi A, Amrane M, et al. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. *Clin Ther.* Nov 2018;40(11):1894-1906. doi:10.1016/j.clinthera.2018.09.012
677. Kim HY, Lee JE, Oh HN, Song JW, Han SY, Lee JS. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. *International journal of ophthalmology.* 2018;11(4):593-600. doi:10.18240/ijo.2018.04.09
678. Jo YJ, Lee JE, Lee JS. Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction. *International journal of ophthalmology.* 2022;15(12):1924-1931. doi:10.18240/ijo.2022.12.05
679. Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. *Ther Adv Ophthalmol.* Jan-Dec 2019;11:2515841419870366. doi:10.1177/2515841419870366
680. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. *Ophthalmology.* Feb 2014;121(2):475-83. doi:10.1016/j.opthta.2013.09.015
681. Tauber J, Karpecki P, Latkany R, et al. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. *Ophthalmology.* Dec 2015;122(12):2423-31. doi:10.1016/j.opthta.2015.08.001
682. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-

Controlled Trial (OPUS-3). *Ophthalmology*. Jan 2017;124(1):53-60.
doi:10.1016/j.opthta.2016.09.025

683. Holland EJ, Jackson MA, Donnenfeld E, et al. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials. *JAMA Ophthalmol*. Nov 1 2021;139(11):1200-1208.
doi:10.1001/jamaophthalmol.2021.3943

684. Li JX, Tsai YY, Lai CT, Li YL, Wu YH, Chiang CC. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis. *J Clin Med*. Aug 26 2022;11(17):5014.
doi:10.3390/jcm11175014

685. Nichols KK, Donnenfeld ED, Karpecki PM, et al. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease. *Eur J Ophthalmol*. Jul 2019;29(4):394-401.
doi:10.1177/1120672118791936

686. Nichols KK, Donnenfeld ED, Lau C, Syntosi A, Karpecki P, Hovanesian JA. Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies. *Clin Ophthalmol*. 2022;16:909-916. doi:10.2147/OPTH.S347496

687. Tauber J. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. *Cornea*. Apr 2020;39(4):403-407. doi:10.1097/ICO.0000000000002235

688. Hovanesian J, Epitropoulos A, Donnenfeld ED, Holladay JT. The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery. *Clin Ophthalmol*. 2020;14:2709-2716.
doi:10.2147/OPTH.S264520

689. Yang Y, Gouvea L, Mimouni M, et al. Treatment of dry eyes with lifitegrast 5% before cataract surgery: A prospective trial. *The Pan-American Journal of Ophthalmology*. 2024;6(3)
690. Hovanesian JA, Nichols KK, Jackson M, et al. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra((R))) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease. *Clin Ophthalmol*. 2021 2021;15:1041-1054. doi:10.2147/OPTH.S296510
691. Donnerfeld ED, Karpecki PM, Majmudar PA, et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. *Cornea*. Jun 2016;35(6):741-8. doi:10.1097/ICO.0000000000000803
692. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease. *Clin Ophthalmol*. 2020;14:931-938. doi:10.2147/OPTH.S237832
693. Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology - is there a place for topical application? *Ophthalmologica Journal internationale d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde*. Nov-Dec 2004;218(6):359-67. doi:10.1159/000080937
694. Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. *Eur J Ophthalmol*. Jan 2022;32(1):673-679. doi:10.1177/1120672121992680
695. Sakassegawa-Naves FE, Ricci HMM, Moscovici BK, et al. Tacrolimus Ointment for Refractory Posterior Blepharitis. *Curr Eye Res*. Nov 2017;42(11):1440-1444. doi:10.1080/02713683.2017.1339805

696. Lin PH, Jian HJ, Li YJ, et al. Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels. *Acta Biomater.* Mar 15 2022;141:140-150. doi:10.1016/j.actbio.2022.01.044
697. Guo X, Dang W, Li N, et al. PPAR-alpha Agonist Fenofibrate Ameliorates Sjogren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice. *Invest Ophthalmol Vis Sci.* Jun 1 2022;63(6):12. doi:10.1167/iovs.63.6.12
698. Cheng H, Xi Y, Chi X, Wu Y, Liu G. Fenofibrate treatment of rats with experimental autoimmune myocarditis by alleviating Treg/Th17 disorder. *Cent Eur J Immunol.* 2016 2016;41(1):64-70. doi:10.5114/ceji.2016.58817
699. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. *Gastroenterology.* Jul 2007;133(1):108-23. doi:10.1053/j.gastro.2007.03.113
700. He H, Liang M, Li L, et al. PPAR-alpha Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride. *Invest Ophthalmol Vis Sci.* Mar 9 2020;61(3):54. doi:10.1167/iovs.61.3.54
701. Chen HC, Chen ZY, Wang TJ, et al. Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. *Int J Mol Sci.* Aug 3 2017;18(8):1697. doi:10.3390/ijms18081697
702. Karnati R, Laurie DE, Laurie GW. Lacritin and the tear proteome as natural replacement therapy for dry eye. *Exp Eye Res.* Dec 2013;117:39-52. doi:10.1016/j.exer.2013.05.020

703. Dias-Teixeira K, Horton X, McKown R, Romano J, Laurie GW. The Lacritin-Syndecan-1-Heparanase Axis in Dry Eye Disease. *Adv Exp Med Biol*. 2020 2020;1221:747-757. doi:10.1007/978-3-030-34521-1_31
704. Vijmasi T, Chen FY, Balasubbu S, et al. Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease. *Invest Ophthalmol Vis Sci*. Jul 17 2014;55(8):5401-9. doi:10.1167/iovs.14-13924
705. Tauber J, Laurie GW, Parsons EC, Odrich MG, Lacripeg Study G, Lacripeg Study G. Lacripeg for the Treatment of Primary Sjogren-Associated Ocular Surface Disease: Results of the First-In-Human Study. *Cornea*. Jul 1 2023;42(7):847-857. doi:10.1097/ICO.0000000000003091
706. Motallebi M, Bhia M, Rajani HF, et al. Naringenin: A potential flavonoid phytochemical for cancer therapy. *Life Sci*. Sep 15 2022;305:120752. doi:10.1016/j.lfs.2022.120752
707. Li Q, Wu X, Xin S, Wu X, Lan J. Preparation and characterization of a naringenin solubilizing glycyrrhizin nanomicelle ophthalmic solution for experimental dry eye disease. *Eur J Pharm Sci*. Dec 1 2021;167:106020. doi:10.1016/j.ejps.2021.106020
708. Kaplan J, Askanase A, Chu D, Abdellatif A, Basu D, Mirsaeidi M. Acthar((R)) Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence. *Clin Drug Investig*. Oct 2023;43(10):739-761. doi:10.1007/s40261-023-01303-5
709. Toyos M, Toyos R, Jodoin B, Bunch R. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease. *Ophthalmol Ther*. Jun 2022;11(3):1231-1240. doi:10.1007/s40123-022-00501-2

710. Higdon A, Diers AR, Oh JY, Landar A, Darley-USmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. *Biochem J*. Mar 15 2012;442(3):453-64. doi:10.1042/BJ20111752
711. Kalariya NM, Ramana KV, Srivastava SK, van Kuijk FJ. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. *Exp Eye Res*. Jan 2008;86(1):70-80. doi:10.1016/j.exer.2007.09.010
712. Clark D, Sheppard J, Brady TC. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. *J Ocul Pharmacol Ther*. May 2021;37(4):193-199. doi:10.1089/jop.2020.0087
713. Guo L, Davies SS. Bioactive aldehyde-modified phosphatidylethanolamines. *Biochimie*. Jan 2013;95(1):74-8. doi:10.1016/j.biochi.2012.07.010
714. Butovich IA. Lipidomics of human Meibomian gland secretions: Chemistry, biophysics, and physiological role of Meibomian lipids. *Prog Lipid Res*. Jul 2011;50(3):278-301. doi:10.1016/j.plipres.2011.03.003
715. Clark D, Tauber J, Sheppard J, Brady TC. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease. *Am J Ophthalmol*. Jun 2021;226:22-31. doi:10.1016/j.ajo.2021.01.011
716. Ghosh AK, Bacellar-Galdino M, Iqbal S, Pappenhagen NE, Kaja S. Topical Porphyrin Antioxidant Protects Against Ocular Surface Pathology in a Novel Rabbit Model for Particulate Matter-Induced Dry Eye Disease. *J Ocul Pharmacol Ther*. May 2022;38(4):294-304. doi:10.1089/jop.2021.0131

717. Ziniauskaite A, Ragauskas S, Ghosh AK, et al. Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease. *Ocul Surf.* Apr 2019;17(2):257-264. doi:10.1016/j.jtos.2019.02.006
718. Seen S, Tong L. Dry eye disease and oxidative stress. *Acta Ophthalmol.* Jun 2018;96(4):e412-e420. doi:10.1111/aos.13526
719. Wei Y, Troger A, Spahiu V, et al. The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface. *Ophthalmol Ther.* Mar 2019;8(1):63-73. doi:10.1007/s40123-018-0158-2
720. Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome. *Adv Ther.* Dec 2015;32(12):1263-79. doi:10.1007/s12325-015-0273-6
721. Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model. *Adv Ther.* Jan 2016;33(1):96-115. doi:10.1007/s12325-015-0274-5
722. Ory EM. The tetracyclines. *Med Clin North Am.* Sep 1970;54(5):1173-86.
723. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. *Exp Eye Res.* Apr 2003;76(4):417-20. doi:10.1016/s0014-4835(03)00005-8
724. Ta CN, Shine WE, McCulley JP, Pandya A, Trattler W, Norbury JW. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. *Cornea.* Aug 2003;22(6):545-8. doi:10.1097/00003226-200308000-00011

725. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. *Invest Ophthalmol Vis Sci*. Oct 1991;32(11):2970-5.
726. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Article. *Exp Eye Res*. Sep 2006;83(3):526-35. doi:10.1016/j.exer.2006.02.004
727. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. *Invest Ophthalmol Vis Sci*. Aug 2000;41(9):2544-57.
728. Kim YS, Kim HS. Tetracyclines Revisited: Tetracyclines in the Field of Dermatology. *Dermatology*. Oct 2024;240(5-6):844-858. doi:10.1159/000542006
729. Ben Ephraim Noyman D, Chan CC, Mimouni M, Safir M. Systemic antibiotic treatment for meibomian gland dysfunction-A systematic review and meta-analysis. *Acta Ophthalmol*. Feb 2024;102(1):e1-e10. doi:10.1111/aos.15681
730. Vernhardsdottir RR, Magno MS, Hynnekleiv L, et al. Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis - A review. *Ocul Surf*. Oct 2022;26:211-221. doi:10.1016/j.jtos.2022.08.010
731. Onghanseng N, Ng SM, Halim MS, Nguyen QD. Oral antibiotics for chronic blepharitis. *Cochrane Database Syst Rev*. Jun 9 2021;6(6):CD013697. doi:10.1002/14651858.CD013697.pub2
732. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. *Korean J Ophthalmol*. Dec 2005;19(4):258-63. doi:10.3341/kjo.2005.19.4.258

733. Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. *Cutis*. Aug 2004;74(2):118-22.
734. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. *Arch Dermatol*. Apr 2003;139(4):459-64. doi:10.1001/archderm.139.4.459
735. Peterson CK. Tetracycline's effects on teeth preclude uses in children and pregnant or lactating women. *Postgrad Med*. Nov 15 1984;76(7):24, 34.
736. Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM. Tetracyclines and bone: Unclear actions with potentially lasting effects. *Bone*. Jun 2022;159:116377. doi:10.1016/j.bone.2022.116377
737. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. *JAMA*. Feb 18 2004;291(7):827-35. doi:10.1001/jama.291.7.827
738. Velicer CM, Heckbert SR, Rutter C, Lampe JW, Malone K. Association between antibiotic use prior to breast cancer diagnosis and breast tumour characteristics (United States). *Cancer Causes Control*. Apr 2006;17(3):307-13. doi:10.1007/s10552-005-0445-9
739. Garcia Rodriguez LA, Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. *Am J Epidemiol*. Apr 1 2005;161(7):616-9. doi:10.1093/aje/kwi087
740. Ōmura S. Preface. In: Ōmura S, ed. *Macrolide Antibiotics*. Academic Press; 2003:xi.
741. Liu Y, Kam WR, Ding J, Sullivan DA. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation? *Cornea*. Mar 2015;34(3):342-6. doi:10.1097/ICO.0000000000000351

742. De Benedetti G, Vaiano AS. Oral azithromycin and oral doxycycline for the treatment of Meibomian gland dysfunction: A 9-month comparative case series. *Indian J Ophthalmol.* Apr 2019;67(4):464-471. doi:10.4103/ijo.IJO_1244_17
743. Bukhari ZM, Alsudais AS, Bshnaq AG, et al. Oral Azithromycin versus Oral Doxycycline in the Treatment of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis. *Clin Ophthalmol.* 2024;18:3353-3363. doi:10.2147/OPTH.S480719
744. Meisler DM, Raizman MB, Traboulsi EI. Oral erythromycin treatment for childhood blepharokeratitis. *J AAPOS.* Dec 2000;4(6):379-80. doi:10.1067/mpa.2000.110339
745. Hammersmith KM. Blepharokeratoconjunctivitis in children. *Curr Opin Ophthalmol.* Jul 2015;26(4):301-5. doi:10.1097/ICU.0000000000000167
746. Tovar AA, Sabater AL. Autologous Blood Products: When, Where, and How? *Current Ophthalmology Reports.* 2021/06/01 2021;9(2):48-56. doi:10.1007/s40135-021-00266-0
747. Aass C, Norheim I, Eriksen EF, Thorsby PM, Pepaj M. Single unit filter-aided method for fast proteomic analysis of tear fluid. *Anal Biochem.* Jul 1 2015;480:1-5. doi:10.1016/j.ab.2015.04.002
748. Pieragostino D, D'Alessandro M, di Ioia M, Di Ilio C, Sacchetta P, Del Boccio P. Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases. *Proteomics Clin Appl.* Feb 2015;9(1-2):169-86. doi:10.1002/prca.201400084
749. Enriquez-de-Salamanca A, Calonge M. Cytokines and chemokines in immune-based ocular surface inflammation. *Expert Rev Clin Immunol.* Jul 2008;4(4):457-67. doi:10.1586/1744666X.4.4.457

750. You J, Willcox MD, Madigan MC, et al. Tear fluid protein biomarkers. *Adv Clin Chem*. 2013;62:151-96. doi:10.1016/b978-0-12-800096-0.00004-4
751. Chan TCY, Chow SSW, Wan KHN, Yuen HKL. Update on the association between dry eye disease and meibomian gland dysfunction. *Hong Kong Med J*. Feb 2019;25(1):38-47. doi:10.12809/hkmj187331
752. Marks DC, Fisher J, Mondy P, Segatchian J, Dennington PM. Serum eye drop preparation in Australia: Current manufacturing practice. *Transfus Apher Sci*. Aug 2015;53(1):92-4. doi:10.1016/j.transci.2015.05.015
753. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. *Blood Rev*. Jul 2009;23(4):177-89. doi:10.1016/j.blre.2009.04.001
754. Tseng CL, Seghatchian J, Burnouf T. Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing. *Transfus Apher Sci*. Aug 2015;53(1):95-8. doi:10.1016/j.transci.2015.05.016
755. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. *Cochrane Database Syst Rev*. Feb 28 2017;2(2):CD009327. doi:10.1002/14651858.CD009327.pub3
756. Wang L, Cao K, Wei Z, Baudouin C, Labbe A, Liang Q. Autologous Serum Eye Drops versus Artificial Tear Drops for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ophthalmic research*. 2020;63(5):443-451. doi:10.1159/000505630
757. Shtein RM, Shen JF, Kuo AN, Hammersmith KM, Li JY, Weikert MP. Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease: A Report by the American Academy of Ophthalmology. *Ophthalmology*. Jan 2020;127(1):128-133. doi:10.1016/j.ophttha.2019.08.018

758. Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. *Ann Rheum Dis.* Jan 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114
759. Vazirani J, Sridhar U, Gokhale N, Doddigarla VR, Sharma S, Basu S. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. *Indian J Ophthalmol.* Apr 2023;71(4):1357-1363. doi:10.4103/IJO.IJO_2756_22
760. Berhuni M, Istek S, Tiskaoglu NS. 20% Autologous serum vs. 0.05% cyclosporine and preservative-free artificial tears in the treatment of Sjogren related dry eye. *Arq Bras Oftalmol.* Nov 4 2022;87(3)doi:10.5935/0004-2749.2022-0192
761. Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini M, Campos EC. Blood derived eye drops for the treatment of cornea and ocular surface diseases. *Transfus Apher Sci.* Aug 2017;56(4):595-604. doi:10.1016/j.transci.2017.07.023
762. van der Meer PF, Verbakel SK, Honohan A, et al. Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial. *Acta Ophthalmol.* Dec 2021;99(8):837-842. doi:10.1111/aos.14788
763. Rodriguez Calvo-de-Mora M, Dominguez-Ruiz C, Barrero-Sojo F, et al. Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: a double-blind randomized clinical trial. *Acta Ophthalmol.* Mar 2022;100(2):e396-e408. doi:10.1111/aos.14953
764. Kwaku Akowuah P, Junior Obinwanne C, Owusu E, et al. Platelet-rich plasma for treating dry eye disease - A systematic review and meta-analysis. *Cont Lens Anterior Eye.* Feb 2024;47(1):102091. doi:10.1016/j.clae.2023.102091

765. Alio JL, Rodriguez AE, Ferreira-Oliveira R, Wrobel-Dudzinska D, Abdelghany AA. Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study. *Ophthalmol Ther*. Dec 2017;6(2):285-293. doi:10.1007/s40123-017-0100-z
766. Avila MY, Igua AM, Mora AM. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. *The British journal of ophthalmology*. Jul 3 2018;doi:10.1136/bjophthalmol-2018-312072
767. Garcia-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efficacy and safety of treatment of hyposcretory dry eye with platelet-rich plasma. *Acta Ophthalmol*. Mar 2019;97(2):e170-e178. doi:10.1111/aos.13907
768. You J, Hodge C, Hoque M, Petsoglou C, Sutton G. Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review. *Clin Ophthalmol*. 2020;14:3195-3210. doi:10.2147/OPTH.S265701
769. Kang MJ, Lee JH, Hwang J, Chung SH. Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjogren's syndrome: a randomized trial. *Sci Rep*. Nov 7 2023;13(1):19279. doi:10.1038/s41598-023-46671-2
770. Nishiyama K, Okudera T, Watanabe T, et al. Basic characteristics of plasma rich in growth factors (PRGF): blood cell components and biological effects. *Clin Exp Dent Res*. Nov 2016;2(2):96-103. doi:10.1002/cre2.26
771. Sanchez-Avila RM, Merayo-Llodes J, Fernandez ML, et al. Plasma Rich in Growth Factors for the Treatment of Dry Eye after LASIK Surgery. *Ophthalmic research*. 2018;60(2):80-86. doi:10.1159/000487951
772. Soifer M, Tovar A, Wang M, et al. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular

surface diseases in North America. *Ocul Surf.* Jul 2022;25:40-48. doi:10.1016/j.jtos.2022.04.007

773. Lozano-Sanroma J, Barros A, Alcalde I, et al. Impact of Plasma Rich in Growth Factors (PRGF) Eye Drops on Ocular Redness and Symptomatology in Patients with Dry Eye Disease. *Medicina (Kaunas, Lithuania)*. May 11 2023;59(5)doi:10.3390/medicina59050928

774. Barros A, Lozano-Sanroma J, Queiruga-Pineiro J, et al. Recovery of Corneal Innervation after Treatment in Dry Eye Disease: A Confocal Microscopy Study. *J Clin Med.* Feb 25 2023;12(5)doi:10.3390/jcm12051841

775. Wrobel-Dudzinska D, Przekora A, Kazimierczak P, Cwiklinska-Haszcz A, Kosior-Jarecka E, Zarnowski T. The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome. *J Clin Med.* Apr 25 2023;12(9)doi:10.3390/jcm12093126

776. Jongkhajornpong P, Anothaisintawee T, Lekhanont K, et al. Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis. *Cornea.* Sep 1 2022;41(9):1137-1149. doi:10.1097/ICO.0000000000002943

777. Jongkhajornpong P, Lekhanont K, Rattanasiri S, et al. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. *BMJ Open Ophthalmol.* Oct 8 2024;9(1)doi:10.1136/bmjophth-2024-001857

778. Hristova R, Yankova P, Markov G, Oscar A, Zdravkov Y. Effect of autologous serum after amniotic membrane transplantation for persistent corneal ulcers. *International journal of ophthalmology.* 2024;17(9):1639-1644. doi:10.18240/ijo.2024.09.10

779. Yoon KC. Use of umbilical cord serum in ophthalmology. *Chonnam medical journal*. Dec 2014;50(3):82-5. doi:10.4068/cmj.2014.50.3.82
780. Anam A, Liu C, Tong L, Liu YC. Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain. *J Ocul Pharmacol Ther*. Jun 2024;40(5):281-292. doi:10.1089/jop.2023.0155
781. Wong J, Govindasamy G, Prasath A, et al. Allogeneic Umbilical Cord Plasma Eyedrops for the Treatment of Recalcitrant Dry Eye Disease Patients. *J Clin Med*. Oct 25 2023;12(21)doi:10.3390/jcm12216750
782. Giannaccare G, Buzzi M, Fresina M, Velati C, Versura P. Efficacy of 2-Month Treatment With Cord Blood Serum Eye Drops in Ocular Surface Disease: An In Vivo Confocal Microscopy Study. *Cornea*. Aug 2017;36(8):915-921. doi:10.1097/ICO.0000000000001257
783. Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. *Am J Ophthalmol*. Jul 2007;144(1):86-92. doi:10.1016/j.ajo.2007.03.016
784. Sharma A, Sharma BA, Moore J, Nolan M. Simple finger prick fresh blood technique for use on the ocular surface. *Cont Lens Anterior Eye*. Feb 2011;34(1):49. doi:10.1016/j.clae.2010.08.004
785. Balal S, Udoh A, Pappas Y, et al. The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. *BMJ Open*. Oct 31 2018;8(10):e026770. doi:10.1136/bmjopen-2018-026770
786. Balal S, Nitiahpapand R, Hassan A, et al. Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects. *Cornea*. May 2020;39(5):594-597. doi:10.1097/ICO.0000000000002230

787. Hassan A, Balal S, Cook E, et al. Finger-Prick Autologous Blood (FAB) Eye Drops for Dry Eye Disease: Single Masked Multi-Centre Randomised Controlled Trial. *Clin Ophthalmol.* 2022;16:3973-3979. doi:10.2147/OPTH.S384586
788. Than J, Balal S, Wawrzynski J, et al. Fingerprick autologous blood: a novel treatment for dry eye syndrome. *Eye (Lond)*. Dec 2017;31(12):1655-1663. doi:10.1038/eye.2017.118
789. Eriktila OO, Williams O, Fern A, Lyall D. Fingerprick Autologous Blood in the Treatment of Severe Dry Eyes and Ocular Surface Disease. *Cornea*. Sep 1 2021;40(9):1104-1109. doi:10.1097/ICO.0000000000002624
790. Watkins AR, Reesink HL. Lubricin in experimental and naturally occurring osteoarthritis: a systematic review. *Osteoarthritis Cartilage*. Oct 2020;28(10):1303-1315. doi:10.1016/j.joca.2020.05.009
791. Samsom ML, Morrison S, Masala N, et al. Characterization of full-length recombinant human Proteoglycan 4 as an ocular surface boundary lubricant. *Exp Eye Res*. Oct 2014;127:14-9. doi:10.1016/j.exer.2014.06.015
792. Lambiase A, Sullivan BD, Schmidt TA, et al. A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 mug/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed(R)) in Patients with Moderate Dry Eye Disease. *Ocul Surf*. Jan 2017;15(1):77-87. doi:10.1016/j.jtos.2016.08.004
793. Menon NG, Tanguay AP, Zhou L, et al. A structural and functional comparison between two recombinant human lubricin proteins: Recombinant human proteoglycan-4 (rhPRG4) vs ECF843. *Exp Eye Res*. Oct 2023;235:109643. doi:10.1016/j.exer.2023.109643

794. McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. *Clin Ophthalmol*. 2018;12:677-681. doi:10.2147/OPTH.S162203
795. McDonald M, Janik SB, Bowden FW, et al. Association of Treatment Duration and Clinical Outcomes in Dry Eye Treatment with Sutureless Cryopreserved Amniotic Membrane. *Clin Ophthalmol*. 2023;17:2697-2703. doi:10.2147/OPTH.S423040
796. Voigt J. Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome. *Cost Eff Resour Alloc*. Dec 1 2020;18(1):56. doi:10.1186/s12962-020-00252-6
797. Jo KS, Kim KY, Lee YW, Han SB, Choi CY. Clinical Outcomes and Indications of In-Office Sutureless Dried Gamma Ray-Sterilized Human Amniotic Membrane Transplantation With Bandage Contact Lenses in Various Ocular Surface Disorders. *Cornea*. Nov 1 2024;43(11):1383-1391. doi:10.1097/ICO.0000000000003491
798. Trave-Huarte S, Wolffsohn JS. Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial. *Medicina (Kaunas, Lithuania)*. Jun 15 2024;60(6)doi:10.3390/medicina60060985
799. Kilian R, Bonacci E, Donner R, et al. Spotlight on Amniotic Membrane Extract Eye Drops: A Review of the Literature. *Eye Contact Lens*. Nov 5 2024;In pressdoi:10.1097/ICL.0000000000001136
800. Bonini S, Aloe L, Bonini S, Rama P, Lamagna A, Lambiase A. Nerve growth factor (NGF): an important molecule for trophism and healing of the ocular surface. *Adv Exp Med Biol*. 2002;506(Pt A):531-7. doi:10.1007/978-1-4615-0717-8_75

801. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. *Invest Ophthalmol Vis Sci*. Apr 2000;41(5):1063-9.
802. Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. *Curr Opin Ophthalmol*. Jul 2012;23(4):296-302. doi:10.1097/ICU.0b013e3283543b61
803. Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. *Prog Retin Eye Res*. Sep 2018;66:107-131. doi:10.1016/j.preteyeres.2018.04.003
804. Deeks ED, Lamb YN. Cenergermin: A Review in Neurotrophic Keratitis. *Drugs*. Apr 2020;80(5):489-494. doi:10.1007/s40265-020-01289-w
805. Sacchetti M, Lambiase A, Schmidl D, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. *The British journal of ophthalmology*. Jan 2020;104(1):127-135. doi:10.1136/bjophthalmol-2018-312470
806. Bonini S, Lambiase A, Rama P, et al. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. *Ophthalmology*. Sep 2018;125(9):1332-1343. doi:10.1016/j.ophtha.2018.02.022
807. Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical Recombinant Human Nerve Growth Factor (Cenergermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. *Ophthalmology*. Jan 2020;127(1):14-26. doi:10.1016/j.ophtha.2019.08.020
808. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin ss4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-

Controlled, Double-Masked Phase III Clinical Trial. *Int J Mol Sci.* Dec 29 2022;24(1)doi:10.3390/ijms24010554

809. Kim CE, Kleinman HK, Sosne G, et al. RGN-259 (thymosin beta4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. *Sci Rep.* Jul 12 2018;8(1):10500. doi:10.1038/s41598-018-28861-5

810. Pflugfelder SC, Stern ME. Biological functions of tear film. *Exp Eye Res.* Aug 2020;197:108115. doi:10.1016/j.exer.2020.108115

811. Babu PJ, Suamte L. Applications of silk-based biomaterials in biomedicine and biotechnology. *Engineered Regeneration.* 2024;5(1):56-69.

812. Lawrence BD, Infanger DW. Effect of silk fibroin protein hydrolysis on biochemistry, gelation kinetics, and NF- κ B bioactivity in vitro. *Int J Biol Macromol.* Jun 2024;272(Pt 1):132702. doi:10.1016/j.ijbiomac.2024.132702

813. Chon JW, Kim H, Jeon HN, et al. Silk fibroin hydrolysate inhibits osteoclastogenesis and induces apoptosis of osteoclasts derived from RAW 264.7 cells. *Int J Mol Med.* Nov 2012;30(5):1203-10. doi:10.3892/ijmm.2012.1120

814. Infanger DW, Abdel-Naby W, Kalal JJ, Paulson NB, Bai Y, Lawrence BD. Silk-derived protein-4 (SDP-4) inhibits nuclear factor Kappa B (NF- κ B) inflammatory signaling that underlies dry eye disease (DED). *Investigative Ophthalmology & Visual Science.* 2019;60(9):2820-2820.

815. Yao S, Xu Z, Chen S, et al. Silk fibroin hydrolysate improves memory impairment via multi-target function. *Journal of Functional Foods.* 2022;89:104942.

816. Kim CE, Lee JH, Yeon YK, Park CH, Yang J. Effects of silk fibroin in murine dry eye. *Sci Rep.* Mar 10 2017;7:44364. doi:10.1038/srep44364

817. Lawrence BD, Karpecki PM, Infanger DW, Levy B. Silk-Derived Protein-4 Versus Vehicle Control in Treating Patients With Moderate to Severe Dry Eye Disease: A Randomized Clinical Trial. *Am J Ophthalmol*. Jan 2025;269:315-326. doi:10.1016/j.ajo.2024.08.034
818. Rocha EM, Cunha DA, Carneiro EM, Boschero AC, Saad MJ, Velloso LA. Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface. *Invest Ophthalmol Vis Sci*. Apr 2002;43(4):963-7.
819. Rocha EM, Hirata AE, Carneiro EM, Saad MJ, Velloso LA. Impact of gender on insulin signaling pathway in lacrimal and salivary glands of rats. *Endocrine*. Jul 2002;18(2):191-9. doi:10.1385/ENDO:18:2:191
820. Cunha DA, de Alves MC, Stoppiglia LF, et al. Extra-pancreatic insulin production in RAT lachrymal gland after streptozotocin-induced islet beta-cells destruction. *Biochim Biophys Acta*. Aug 2007;1770(8):1128-35. doi:10.1016/j.bbagen.2007.05.002
821. Stuard WL, Titone R, Robertson DM. Tear Levels of Insulin-Like Growth Factor Binding Protein 3 Correlate With Subbasal Nerve Plexus Changes in Patients With Type 2 Diabetes Mellitus. *Invest Ophthalmol Vis Sci*. Dec 1 2017;58(14):6105-6112. doi:10.1167/iovs.17-22425
822. Wu YC, Buckner BR, Zhu M, Cavanagh HD, Robertson DM. Elevated IGFBP3 levels in diabetic tears: a negative regulator of IGF-1 signaling in the corneal epithelium. *Ocul Surf*. Apr 2012;10(2):100-7. doi:10.1016/j.jtos.2012.01.004
823. Bastion ML, Ling KP. Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients. *Med J Malaysia*. Jun 2013;68(3):208-16.

824. Aniah Azmi N, Bastion MC. Short-Term Results of Trial of Topical Insulin for Treatment of Dry Eyes in Diabetics. *Eye Contact Lens*. Jan 2020;46 Suppl 1:S25-S32. doi:10.1097/ICL.0000000000000623
825. Chhadva P, Alexander A, McClellan AL, McManus KT, Seiden B, Galor A. The impact of conjunctivochalasis on dry eye symptoms and signs. *Invest Ophthalmol Vis Sci*. May 2015;56(5):2867-71. doi:10.1167/iovs.14-16337
826. Marmalidou A, Kheirkhah A, Dana R. Conjunctivochalasis: a systematic review. *Surv Ophthalmol*. Jul-Aug 2018;63(4):554-564. doi:10.1016/j.survophthal.2017.10.010
827. Uchino M, Dogru M, Yagi Y, et al. The features of dry eye disease in a Japanese elderly population. *Optom Vis Sci*. Nov 2006;83(11):797-802. doi:10.1097/01.opx.0000232814.39651.fa
828. Huang Y, Sheha H, Tseng SC. Conjunctivochalasis interferes with tear flow from fornix to tear meniscus. *Ophthalmology*. Aug 2013;120(8):1681-7. doi:10.1016/j.optha.2013.01.007
829. Pult H, Riede-Pult BH. Impact of conjunctival folds on central tear meniscus height. *Invest Ophthalmol Vis Sci*. Feb 3 2015;56(3):1459-66. doi:10.1167/iovs.14-15908
830. Liu D. Conjunctivochalasis. A cause of tearing and its management. *Ophthalmic Plast Reconstr Surg*. 1986;2(1):25-8.
831. Petris CK, Holds JB. Medial conjunctival resection for tearing associated with conjunctivochalasis. *Ophthalmic Plast Reconstr Surg*. Jul-Aug 2013;29(4):304-7. doi:10.1097/IOP.0b013e3182831dd3
832. Dalianis G, Trivli A, Terzidou C. The Location of Conjunctivochalasis and Its Clinical Correlation with the Severity of Dry Eye Symptoms. *Medicines (Basel)*. Jan 22 2018;5(1)doi:10.3390/medicines5010012

833. Ahn H, Ji YW, Jun I, Kim TI, Lee HK, Seo KY. Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease. *Ocul Surf*. Oct 2022;26:295-299. doi:10.1016/j.jtos.2022.02.002
834. Qiu W, Zhang M, Xu T, et al. Evaluation of the Effects of Conjunctivochalasis Excision on Tear Stability and Contrast Sensitivity. *Sci Rep*. Nov 28 2016;6:37570. doi:10.1038/srep37570
835. Marmalidou A, Palioura S, Dana R, Kheirkhah A. Medical and surgical management of conjunctivochalasis. *Ocul Surf*. Jul 2019;17(3):393-399. doi:10.1016/j.jtos.2019.04.008
836. Ucar F, Unluzeybek M. Comparison of 2 Different Treatments for Conjunctivochalasis: Plasma-Based Conjunctivoplasty Versus Argon Laser Photocoagulation. *Cornea*. Oct 1 2024;43(10):1257-1263. doi:10.1097/ICO.0000000000003464
837. Ucar F. Alternative Approach for the Treatment of Conjunctivochalasis: Plasma-Based Conjunctivoplasty. *Cornea*. Feb 1 2024;43(2):201-206. doi:10.1097/ICO.0000000000003276
838. Ballesteros-Sanchez A, Sanchez-Gonzalez JM, Borrone MA, Borroni D, Rocha-de-Lossada C. The Influence of Lid-Parallel Conjunctival Folds and Conjunctivochalasis on Dry Eye Symptoms with and Without Contact Lens Wear: A Review of the Literature. *Ophthalmol Ther*. Mar 2024;13(3):651-670. doi:10.1007/s40123-023-00877-9
839. Ji YW, Seong H, Lee S, et al. The correction of conjunctivochalasis using high-frequency radiowave electrosurgery improves dry eye disease. *Sci Rep*. Jan 28 2021;11(1):2551. doi:10.1038/s41598-021-82088-5

840. Trivli A, Dalianis G, Terzidou C. A Quick Surgical Treatment of Conjunctivochalasis Using Radiofrequencies. *Healthcare (Basel)*. Feb 12 2018;6(1)doi:10.3390/healthcare6010014
841. Kiss HJ, Nemeth J. Isotonic Glycerol and Sodium Hyaluronate Containing Artificial Tear Decreases Conjunctivochalasis after One and Three Months: A Self-Controlled, Unmasked Study. *PLoS One*. 2015;10(7):e0132656. doi:10.1371/journal.pone.0132656
842. Schirra F, Hoh H, Kienecker C, Ruprecht KW. Using LIPCOF (lid-parallel conjunctival fold) for assessing the degree of dry eye, it is essential to observe the exact position of that specific fold. *Adv Exp Med Biol*. 1998;438:853-8. doi:10.1007/978-1-4615-5359-5_120
843. Linaburg T, Choi D, Bunya VY, Massaro-Giordano M, Briceno CA. Systematic Review: Effects of Pterygium and Pingueculum on the Ocular Surface and Efficacy of Surgical Excision. *Cornea*. Feb 1 2021;40(2):258-267. doi:10.1097/ICO.0000000000002575
844. Jeong J, Rand GM, Kwon T, Kwon JW. The Improvement of Dry Eye Symptoms after Pinguecula Excision and Conjunctival Autograft with Fibrin Glue. *J Ophthalmol*. 2019;2019:6438157. doi:10.1155/2019/6438157
845. Ding P, Wang R, He Y. Risk factors for pterygium: Latest research progress on major pathogenesis. *Exp Eye Res*. Jun 2024;243:109900. doi:10.1016/j.exer.2024.109900
846. Liu L, Wu J, Geng J, Yuan Z, Huang D. Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. *BMJ Open*. Nov 19 2013;3(11):e003787. doi:10.1136/bmjopen-2013-003787
847. Tan J, Vollmer-Conna U, Tat L, Coroneo M. Dry-Eye Disease in Recurrent Pterygium. *Ophthalmic research*. 2019;61(4):199-203. doi:10.1159/000493544

848. Chang J, Lin X, Kang Z, Xu R, Xue C. The unique properties of tear film breakup process in patients with nasal unilateral pterygium. *Optom Vis Sci.* Jan 1 2024;101(1):62-70. doi:10.1097/OPX.0000000000002084
849. Devebacak A, Teker ME, Palamar M. The Influence of Pterygium on Meibomian Glands and Dry Eye Parameters. *Optom Vis Sci.* Mar 1 2023;100(3):207-210. doi:10.1097/OPX.0000000000001996
850. Turkyilmaz K, Oner V, Sevim MS, Kurt A, Sekeryapan B, Durmus M. Effect of pterygium surgery on tear osmolarity. *J Ophthalmol.* 2013/01/01 2013;2013(1):863498. doi:10.1155/2013/863498
851. Serhan HA, Alma'aitah HW, Irshaidat S, Ameer MA, Asghar MS, Tahir MJ. Ophthalmic manifestations of nutritional deficiencies: A mini review. *J Family Med Prim Care.* Oct 2022;11(10):5899-5901. doi:10.4103/jfmprc.jfmprc_790_22
852. Cong Y, Zhang Y, Han Y, Wu Y, Wang D, Zhang B. Recommendations for nutritional supplements for dry eye disease: current advances. *Front Pharmacol.* 2024;15:1388787. doi:10.3389/fphar.2024.1388787
853. Dartt DA, Hodges RR, Serhan CN. Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. *Adv Exp Med Biol.* 2019;1161:13-25. doi:10.1007/978-3-030-21735-8_3
854. Erdinest N, Ovadia H, Kormas R, Solomon A. Anti-inflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro study. *J Inflamm (Lond).* Mar 2 2014;11(1):6. doi:10.1186/1476-9255-11-6
855. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? *Am J Pathol.* Oct 2010;177(4):1576-91. doi:10.2353/ajpath.2010.100322

856. Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. *J Ocul Pharmacol Ther.* Oct 2010;26(5):431-9. doi:10.1089/jop.2010.0019
857. Pham TL, Bazan HEP. Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain. *J Lipid Res.* 2021;62:100033. doi:10.1194/jlr.TR120000954
858. Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. *Curr Opin Clin Nutr Metab Care.* Mar 2007;10(2):136-41. doi:10.1097/MCO.0b013e32802b7030
859. Labetoulle M, Baudouin C, Calonge M, et al. Role of corneal nerves in ocular surface homeostasis and disease. *Acta Ophthalmol.* Mar 2019;97(2):137-145. doi:10.1111/aos.13844
860. Britten-Jones AC, Craig JP, Anderson AJ, Downie LE. Association between systemic omega-3 polyunsaturated fatty acid levels, and corneal nerve structure and function. *Eye (Lond).* Jun 2023;37(9):1866-1873. doi:10.1038/s41433-022-02259-0
861. Downie LE, Ng SM, Lindsley KB, Akpek EK. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. *Cochrane Database Syst Rev.* Dec 18 2019;12(12):CD011016. doi:10.1002/14651858.CD011016.pub2
862. Asbell PA, Maguire MG, Pistilli M, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. *N Engl J Med.* May 3 2018;378(18):1681-1690. doi:10.1056/NEJMoa1709691
863. Asbell PA, Maguire MG, Group DSR. Why DREAM should make you think twice about recommending Omega-3 supplements. *Ocul Surf.* Oct 2019;17(4):617-618. doi:10.1016/j.jtos.2019.08.003

864. Paik B, Tong L. Polymorphisms in Lymphotoxin-Alpha as the "Missing Link" in Prognosticating Favourable Response to Omega-3 Supplementation for Dry Eye Disease: A Narrative Review. *Int J Mol Sci.* Feb 20 2023;24(4)doi:10.3390/ijms24044236
865. Bhargava R, Pandey K, Ranjan S, Mehta B, Malik A. Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective? *Indian J Ophthalmol.* Apr 2023;71(4):1619-1625. doi:10.4103/IJO.IJO_2789_22
866. Wang WX, Ko ML. Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med.* Nov 10 2023;12(22)doi:10.3390/jcm12227026
867. Miljanovic B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. *Am J Clin Nutr.* Oct 2005;82(4):887-93. doi:10.1093/ajcn/82.4.887
868. Valero-Vello M, Peris-Martinez C, Garcia-Medina JJ, et al. Searching for the Antioxidant, Anti-Inflammatory, and Neuroprotective Potential of Natural Food and Nutritional Supplements for Ocular Health in the Mediterranean Population. *Foods.* May 28 2021;10(6)doi:10.3390/foods10061231
869. Molina-Leyva I, Molina-Leyva A, Riquelme-Gallego B, Cano-Ibanez N, Garcia-Molina L, Bueno-Cavanillas A. Effectiveness of Mediterranean Diet Implementation in Dry Eye Parameters: A Study of PREDIMED-PLUS Trial. *Nutrients.* May 1 2020;12(5)doi:10.3390/nu12051289
870. Chinnery HR, Naranjo Golborne C, Downie LE. Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. *Ophthalmic Physiol Opt.* Jul 2017;37(4):473-481. doi:10.1111/opo.12365

871. Pinheiro MN, Jr., dos Santos PM, dos Santos RC, Barros Jde N, Passos LF, Cardoso Neto J. [Oral flaxseed oil (*Linum usitatissimum*) in the treatment for dry-eye Sjogren's syndrome patients]. *Arq Bras Oftalmol.* Jul-Aug 2007;70(4):649-55. Uso oral do óleo de linhaça (*Linum usitatissimum*) no tratamento do olho seco de pacientes portadores da síndrome de Sjogren. doi:10.1590/s0004-27492007000400016
872. Willett WC. The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. *J Cardiovasc Med (Hagerstown)*. Sep 2007;8 Suppl 1:S42-5. doi:10.2459/01.JCM.0000289275.72556.13
873. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. *Am J Clin Nutr.* Apr 2004;79(4):606-12. doi:10.1093/ajcn/79.4.606
874. Paik B, Tong L. Topical Omega-3 Fatty Acids Eyedrops in the Treatment of Dry Eye and Ocular Surface Disease: A Systematic Review. *Int J Mol Sci.* Oct 29 2022;23(21)doi:10.3390/ijms232113156
875. Yu C, Chen P, Xu J, et al. Corneal Epithelium-Derived Netrin-1 Alleviates Dry Eye Disease via Regulating Dendritic Cell Activation. *Invest Ophthalmol Vis Sci.* Jun 1 2022;63(6):1. doi:10.1167/iovs.63.6.1
876. Blaner WS. Vitamin A and provitamin A carotenoids. In: Marriott BP, Birt DF, Stallings VA, Yates AA, eds. *Present Knowledge in Nutrition*. Academic Press; 2020:73-91.
877. Wiseman EM, Bar-El Dadon S, Reifen R. The vicious cycle of vitamin a deficiency: A review. *Critical Reviews in Food Science and Nutrition*. 2017/11/22 2017;57(17):3703-3714. doi:10.1080/10408398.2016.1160362

878. Chiu M, Dillon A, Watson S. Vitamin A deficiency and xerophthalmia in children of a developed country. *J Paediatr Child Health*. Jul 2016;52(7):699-703. doi:10.1111/jpc.13243
879. Chiu M, Watson S. Xerophthalmia and vitamin A deficiency in an autistic child with a restricted diet. *BMJ Case Rep*. Oct 5 2015;2015doi:10.1136/bcr-2015-209413
880. Sanli E, Figueira EC, Bhardwaj G, Watson SL, Francis IC. Tunnel vision and night blindness in a 52-year-old man. *Med J Aust*. Sep 5 2011;195(5):287-8. doi:10.5694/mja11.10292
881. Alanazi SA, El-Hiti GA, Al-Baloud AA, et al. Effects of short-term oral vitamin A supplementation on the ocular tear film in patients with dry eye. *Clin Ophthalmol*. 2019;13:599-604. doi:10.2147/OPTH.S198349
882. Hao YR, Li SY, Bao JY, et al. [Efficacy of 0.05% cyclosporine A combined with vitamin A palmitate in the treatment of meibomian gland dysfunction-related dry eye]. *Zhonghua Yan Ke Za Zhi*. Feb 11 2024;60(2):127-136. doi:10.3760/cma.j.cn112142-20231109-00221
883. Macri A, Scanarotti C, Bassi AM, et al. Evaluation of oxidative stress levels in the conjunctival epithelium of patients with or without dry eye, and dry eye patients treated with preservative-free hyaluronic acid 0.15 % and vitamin B12 eye drops. *Graefes Arch Clin Exp Ophthalmol*. Mar 2015;253(3):425-30. doi:10.1007/s00417-014-2853-6
884. Gorimanipalli B, Shetty R, Sethu S, Khamar P. Vitamin D and eye: Current evidence and practice guidelines. *Indian J Ophthalmol*. Apr 2023;71(4):1127-1134. doi:10.4103/IJO.IJO_3174_22
885. Najjaran M, Zarei-Ghanavati S, Arjmand Askari E, Eslampoor A, Ziaei M. Effect of oral vitamin D supplementation on dry eye disease patients with vitamin

D deficiency. *Clin Exp Optom.* Apr 2023;106(3):257-262.
doi:10.1080/08164622.2022.2033601

886. Rayman MP. The importance of selenium to human health. *Lancet.* Jul 15 2000;356(9225):233-41. doi:10.1016/S0140-6736(00)02490-9

887. Higuchi A, Takahashi K, Hirashima M, Kawakita T, Tsubota K. Selenoprotein P controls oxidative stress in cornea. *PLoS One.* Mar 29 2010;5(3):e9911. doi:10.1371/journal.pone.0009911

888. Dhaliwal DK, Zhou S, Samudre SS, Lo NJ, Rhee MK. Acupuncture and dry eye: current perspectives. A double-blinded randomized controlled trial and review of the literature. *Clin Ophthalmol.* 2019;13:731-740. doi:10.2147/OPTH.S175321

889. Prinz J, Maffulli N, Fuest M, Walter P, Hildebrand F, Migliorini F. Acupuncture for the management of dry eye disease. *Front Med.* Dec 2022;16(6):975-983. doi:10.1007/s11684-022-0923-4

890. Lee JH, Han K, Kim TH, et al. Acupuncture for dry eye syndrome after refractive surgery: A randomized controlled pilot trial. *Integr Med Res.* Mar 2021;10(1):100456. doi:10.1016/j.imr.2020.100456

891. Hu WL, Wu PC, Pan LY, Yu HJ, Pan CC, Hung YC. Effect of laser acupuncture on dry eye: A study protocol for a 2-center randomized controlled trial. *Medicine (Baltimore).* Jun 2018;97(22):e10875. doi:10.1097/MD.00000000000010875

892. Andersson S, Lundberg T. Acupuncture--from empiricism to science: functional background to acupuncture effects in pain and disease. *Med Hypotheses.* Sep 1995;45(3):271-81. doi:10.1016/0306-9877(95)90117-5

893. Nepp J, Jandrasits K, Schauersberger J, et al. Is acupuncture an useful tool for pain-treatment in ophthalmology? *Acupunct Electrother Res.* 2002;27(3-4):171-82. doi:10.3727/036012902816025988
894. Uchida S, Hotta H. Acupuncture affects regional blood flow in various organs. *Evidence-based Complementary and Alternative Medicine*2008.
895. Zhang Y, Yang W. Effects of acupuncture and moxibustion on tear-film of the patients with xerophthalmia. *J Tradit Chin Med.* Dec 2007;27(4):258-60.
896. Gronlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. *Acta Ophthalmol Scand.* Jun 2004;82(3 Pt 1):283-90. doi:10.1111/j.1600-0420.2004.00254.x
897. Yang L, Yang Z, Yu H, Song H. Acupuncture therapy is more effective than artificial tears for dry eye syndrome: Evidence based on a meta-analysis. *Evidence-based Complementary and Alternative Medicine*2015.
898. Nepp J, Wedrich A, Akramian J, et al. Dry eye treatment with acupuncture - A prospective, randomized, double-masked study. *Advances in Experimental Medicine and Biology.* 1998;438doi:10.1007/978-1-4615-5359-5_146
899. Lin T, Gong L, Liu X, Ma X. Fourier-domain optical coherence tomography for monitoring the lower tear meniscus in dry eye after acupuncture treatment. *Evid Based Complement Alternat Med.* 2015;2015:492150. doi:10.1155/2015/492150
900. Kim TH, Kang JW, Kim KH, et al. Acupuncture for the treatment of dry eye: a multicenter randomised controlled trial with active comparison intervention (artificial teardrops). *PLoS One.* 2012;7(5):e36638. doi:10.1371/journal.pone.0036638

901. Gong L, Sun X, Chapin WJ. Clinical curative effect of acupuncture therapy on xerophthalmia. *Am J Chin Med.* 2010;38(4):651-9. doi:10.1142/S0192415X10008123
902. Lee MS, Shin BC, Choi TY, Ernst E. Acupuncture for treating dry eye: a systematic review. *Acta Ophthalmol.* Mar 2011;89(2):101-6. doi:10.1111/j.1755-3768.2009.01855.x
903. Shin MS, Kim JI, Lee MS, et al. Acupuncture for treating dry eye: a randomized placebo-controlled trial. *Acta Ophthalmol.* Dec 2010;88(8):e328-33. doi:10.1111/j.1755-3768.2010.02027.x
904. Wang Y, Peng J, Xiao L, et al. Effectiveness of acupuncture combined with artificial tears in managing dry eye syndrome: A systematic review and meta-analysis. *Medicine (Baltimore).* Jan 5 2024;103(1):e36374. doi:10.1097/MD.00000000000036374
905. Tong L, Htoon HM, Hou A, et al. Acupuncture and herbal formulation compared with artificial tears alone: evaluation of dry eye symptoms and associated tests in randomised clinical trial. *BMJ Open Ophthalmol.* 2018;3(1):e000150. doi:10.1136/bmjophth-2018-000150
906. Huang JY, Yeh PT, Hou YC. A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. *Clin Ophthalmol.* 2016;10:813-20. doi:10.2147/OPTH.S106455
907. Xu X, Hang L, Huang B, Wei Y, Zheng S, Li W. Efficacy of Ethanol Extract of Fructus lycii and Its Constituents Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against Oxidative Stress: In Vivo and In Vitro Models of Age-Related Macular Degeneration. *J Ophthalmol.* 2013;2013:862806. doi:10.1155/2013/862806

908. Chien KJ, Horng CT, Huang YS, et al. Effects of *Lycium barbarum* (goji berry) on dry eye disease in rats. *Mol Med Rep*. Jan 2018;17(1):809-818. doi:10.3892/mmr.2017.7947
909. Radomska-Lesniewska DM, Osiecka-Iwan A, Hyc A, Gozdz A, Dabrowska AM, Skopinski P. Therapeutic potential of curcumin in eye diseases. *Cent Eur J Immunol*. 2019;44(2):181-189. doi:10.5114/ceji.2019.87070
910. Liu XF, Hao JL, Xie T, et al. Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review. *Front Pharmacol*. 2017;8(FEB):66. doi:10.3389/fphar.2017.00066
911. Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1 β elevation in human corneal epithelial cell via MAPK pathways. *Exp Eye Res*. Mar 2010;90(3):437-43. doi:10.1016/j.exer.2009.12.004
912. Lee TG, Hyun SW, Jo K, et al. *Achyranthis radix* Extract Improves Urban Particulate Matter-Induced Dry Eye Disease. *Int J Environ Res Public Health*. Sep 4 2019;16(18)doi:10.3390/ijerph16183229
913. Wang LY, Tang YP, Liu X, et al. Effects of ferulic acid on antioxidant activity in *Angelicae Sinensis Radix*, *Chuanxiong Rhizoma*, and their combination. *Chin J Nat Med*. Jun 2015;13(6):401-8. doi:10.1016/S1875-5364(15)30032-7
914. Jiang D, Liu X, Hu J. Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome. *Eye (Lond)*. Dec 2017;31(12):1724-1732. doi:10.1038/eye.2017.117
915. Walsh NP, Fortes MB, Esmaeelpour M. Influence of modest changes in whole-body hydration on tear fluid osmolarity: Important considerations for dry eye disease detection. *Cornea*2011.

916. Walsh NP, Fortes MB, Raymond-Barker P, et al. Is whole-body hydration an important consideration in dry eye? *Invest Ophthalmol Vis Sci*. Sep 25 2012;53(10):6622-7. doi:10.1167/iov.12-10175
917. Fortes MB, Diment BC, Di Felice U, et al. Tear fluid osmolarity as a potential marker of hydration status. *Med Sci Sports Exerc*. Aug 2011;43(8):1590-7. doi:10.1249/MSS.0b013e31820e7cb6
918. Nguyen L, Magno MS, Utheim TP, Jansonius NM, Hammond CJ, Vehof J. The relationship between habitual water intake and dry eye disease. *Acta Ophthalmol*. Feb 2023;101(1):65-73. doi:10.1111/aos.15227
919. Gruden Š, Ulrih NP. Diverse mechanisms of antimicrobial activities of lactoferrins, lactoferricins, and other lactoferrin-derived peptides. *International Journal of Molecular Sciences* 2021.
920. Mackie IA, Seal DV. Diagnostic implications of tear protein profiles. *The British journal of ophthalmology*. May 1984;68(5):321-4. doi:10.1136/bjo.68.5.321
921. Boukes RJ, Boonstra A, Breebaart AC, et al. Analysis of human tear protein profiles using high performance liquid chromatography (HPLC). *Doc Ophthalmol*. Sep-Oct 1987;67(1-2):105-13. doi:10.1007/BF00142704
922. Sonobe H, Ogawa Y, Yamada K, et al. A novel and innovative paper-based analytical device for assessing tear lactoferrin of dry eye patients. *Ocular Surface* 2019.
923. Connell S, Kawashima M, Nakamura S, et al. Lactoferrin Ameliorates Dry Eye Disease Potentially through Enhancement of Short-Chain Fatty Acid Production by Gut Microbiota in Mice. *Int J Mol Sci*. Nov 17 2021;22(22):doi:10.3390/ijms222212384
924. Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immune-mediated ocular surface disorder. *Archives of Ophthalmology* 2012.

925. Vagge A, Senni C, Bernabei F, et al. Therapeutic effects of lactoferrin in ocular diseases: From dry eye disease to infections. *International Journal of Molecular Sciences* 2020.
926. Dogru M, Matsumoto Y, Yamamoto Y, et al. Lactoferrin in Sjögren's Syndrome. *Ophthalmology* 2007.
927. Ahmed S, Sulaiman SA, Baig AA, et al. Honey as a Potential Natural Antioxidant Medicine: An Insight into Its Molecular Mechanisms of Action. *Oxid Med Cell Longev*. 2018;2018:8367846. doi:10.1155/2018/8367846
928. Hu J, Kong L, Zhu S, Ju M, Zhang Q. Efficacy and safety of manuka honey for dry eye. *Clin Exp Optom*. Jul 2023;106(5):455-465. doi:10.1080/08164622.2022.2106779
929. Prinz J, Maffulli N, Fuest M, Walter P, Hildebrand F, Migliorini F. Honey-Related Treatment Strategies in Dry Eye Disease. *Pharmaceuticals (Basel)*. May 18 2023;16(5)doi:10.3390/ph16050762
930. Albiets JM, Schmid KL. Randomised controlled trial of topical antibacterial Manuka (*Leptospermum* species) honey for evaporative dry eye due to meibomian gland dysfunction. *Clin Exp Optom*. Nov 2017;100(6):603-615. doi:10.1111/cxo.12524
931. Li AL, Li SL, Kam KW, Young AL. Randomised assessor-masked trial evaluating topical manuka honey (Optimel) in treatment of meibomian gland dysfunction. *The British journal of ophthalmology*. Jun 2022;106(6):777-780. doi:10.1136/bjophthalmol-2020-317506
932. Craig JP, Wang MTM, Ganesalingam K, et al. Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis. *BMJ Open Ophthalmol*. 2017;1(1):e000066. doi:10.1136/bmjophth-2016-000066

933. Wong D, Albietsz JM, Tran H, et al. Treatment of contact lens related dry eye with antibacterial honey. *Cont Lens Anterior Eye*. Dec 2017;40(6):389-393. doi:10.1016/j.clae.2017.10.001
934. Inoue S, Kawashima M, Hisamura R, et al. Clinical Evaluation of a Royal Jelly Supplementation for the Restoration of Dry Eye: A Prospective Randomized Double Blind Placebo Controlled Study and an Experimental Mouse Model. *PLoS One*. 2017;12(1):e0169069. doi:10.1371/journal.pone.0169069
935. Gioia N, Gerson J, Ryan R, et al. A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial. Original Research. *Front Ophthalmol (Lausanne)*. 2024-April-24 2024;4:1362113. doi:10.3389/fopht.2024.1362113
936. Giannaccare G, Barabino S, Di Zazzo A, Villani E. Preventing and Managing Iatrogenic Dry Eye Disease during the Entire Surgical Pathway: A Study Focusing on Patients Undergoing Cataract Surgery. *J Clin Med*. Jan 27 2024;13(3)doi:10.3390/jcm13030748
937. Sambhi RS, Sambhi GDS, Mather R, Malvankar-Mehta MS. Dry eye after refractive surgery: a meta-analysis. *Can J Ophthalmol*. Apr 2020;55(2):99-106. doi:10.1016/j.jcjo.2019.07.005
938. Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. *Ocul Surf*. Jul 2017;15(3):511-538. doi:10.1016/j.jtos.2017.05.004
939. Han KE, Yoon SC, Ahn JM, et al. Evaluation of dry eye and meibomian gland dysfunction after cataract surgery. *Am J Ophthalmol*. Jun 2014;157(6):1144-1150 e1. doi:10.1016/j.ajo.2014.02.036

940. Park J, Yoo YS, Shin K, et al. Effects of Lipiflow Treatment Prior to Cataract Surgery: A Prospective, Randomized, Controlled Study. *Am J Ophthalmol*. Oct 2021;230:264-275. doi:10.1016/j.ajo.2021.04.031
941. Biela K, Winiarczyk M, Borowicz D, Mackiewicz J. Dry Eye Disease as a Cause of Refractive Errors After Cataract Surgery - A Systematic Review. *Clin Ophthalmol*. 2023;17:1629-1638. doi:10.2147/OPTH.S406530
942. Ahn S, Eom Y, Song JS, Kim DH. Short-term variability in ocular biometry and the impact of preoperative dry eye. *Sci Rep*. Nov 5 2024;14(1):26762. doi:10.1038/s41598-024-77572-7
943. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg*. May 2019;45(5):669-684. doi:10.1016/j.jcrs.2019.03.023
944. Matossian C, Chang DH, Whitman J, et al. Preoperative Treatment of Meibomian Gland Dysfunction with a Vectored Thermal Pulsation System Prior to Extended Depth of Focus IOL Implantation. *Ophthalmol Ther*. Oct 2023;12(5):2427-2439. doi:10.1007/s40123-023-00740-x
945. Zhao Y, Li J, Xue K, et al. Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: A Prospective, Controlled Clinical Trial. *Semin Ophthalmol*. Feb 17 2021;36(1-2):2-8. doi:10.1080/08820538.2021.1881567
946. Mencucci R, Mercuri S, Cennamo M, Morelli A, Favuzza E. Efficacy of vector thermal pulsation treatment in reducing postcataract surgery dry eye disease in patients affected by meibomian gland dysfunction. *J Cataract Refract Surg*. Apr 1 2023;49(4):423-429. doi:10.1097/j.jcrs.0000000000001124
947. Ge J, Liu N, Wang X, et al. Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction

in the perioperative period. *BMC Ophthalmol.* Mar 18 2020;20(1):111. doi:10.1186/s12886-020-01357-5

948. Song P, Sun Z, Ren S, et al. Preoperative Management of MGD Alleviates the Aggravation of MGD and Dry Eye Induced by Cataract Surgery: A Prospective, Randomized Clinical Trial. *Biomed Res Int.* 2019;2019:2737968. doi:10.1155/2019/2737968

949. Mohammadpour M, Maleki S, Khorrami-Nejad M. The effect of tea tree oil on dry eye treatment after phacoemulsification cataract surgery: A randomized clinical trial. *Eur J Ophthalmol.* Nov 2020;30(6):1314-1319. doi:10.1177/1120672119867642

950. De Paiva CS, Chen Z, Koch DD, et al. The incidence and risk factors for developing dry eye after myopic LASIK. *Am J Ophthalmol.* Mar 2006;141(3):438-45. doi:10.1016/j.ajo.2005.10.006

951. Nitzan I, Heller D, Chan CC, Mimouni M, Safir M. Dry eye disease treatment following refractive surgery among young patients: a population-based study. *Eye (Lond).* Apr 3 2025;doi:10.1038/s41433-025-03783-5

952. Pazo EE, Huang H, Fan Q, et al. Intense Pulse Light for Treating Post-LASIK Refractory Dry Eye. *Photobiomodul Photomed Laser Surg.* Mar 2021;39(3):155-163. doi:10.1089/photob.2020.4931

953. Schallhorn CS, Schallhorn JM, Hannan S, Schallhorn SC. Effectiveness of an Eyelid Thermal Pulsation Procedure to Treat Recalcitrant Dry Eye Symptoms After Laser Vision Correction. *J Refract Surg.* Jan 1 2017;33(1):30-36. doi:10.3928/1081597X-20161006-05

954. Zhou X, Shen Y, Shang J, Zhou X. Effects of warm compress on tear film, blink pattern and Meibomian gland function in dry eyes after corneal refractive

surgery. *BMC Ophthalmol.* Sep 10 2021;21(1):330. doi:10.1186/s12886-021-02091-2

955. Martinez-Hergueta MC, Canto-Cerdan M, Amesty MA, et al. Perioperative intense pulsed light to prevent and improve symptoms of post-laser corneal refractive surgery dry eye. A randomized clinical trial. *Asia Pac J Ophthalmol (Phila)*. Jan-Feb 2024;13(1):100029. doi:10.1016/j.apjo.2023.100029

956. Shetty R, Khamar P, Nair AP, et al. Assessing clinical and molecular outcomes of prophylactic thermal pulsation therapy on ocular surface health following refractive surgery. *Indian J Ophthalmol.* Apr 2023;71(4):1508-1516. doi:10.4103/IJO.IJO_3361_22

957. Cochener B, Cassan A, Omiel L. Prevalence of meibomian gland dysfunction at the time of cataract surgery. *J Cataract Refract Surg.* Feb 2018;44(2):144-148. doi:10.1016/j.jcrs.2017.10.050

958. Donthineni PR, Doctor MB, Shanbhag S, et al. Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management. *Indian J Ophthalmol.* Apr 2023;71(4):1332-1347. doi:10.4103/IJO.IJO_2808_22

959. Wang Y, Carreno-Galeano JT, Singh RB, Dana R, Yin J. Long-term Outcomes of Punctal Cauterization in the Management of Ocular Surface Diseases. *Cornea.* Feb 1 2021;40(2):168-171. doi:10.1097/ICO.0000000000002384

960. Dohlman CH. Punctal occlusion in keratoconjunctivitis sicca. *Ophthalmology.* Dec 1978;85(12):1277-81. doi:10.1016/s0161-6420(78)35555-x

961. Agarwal M, Srinivasan B, Agarwal S, et al. Aqueous deficiency dry eye in post conjunctivitis cicatrization - Effect of deep thermal punctal cautery. *Indian J Ophthalmol.* Apr 2023;71(4):1630-1637. doi:10.4103/IJO.IJO_2572_22

962. Latifi G, Banafshe Afshan A, Houshang Beheshtnejad A, et al. Changes in Corneal Subbasal Nerves after Punctal Occlusion in Dry Eye Disease. *Curr Eye Res.* Jun 2021;46(6):777-783. doi:10.1080/02713683.2020.1833349
963. Kuroda K, Toshida H, Sorita Y, Ichikawa K, Matsuzaki Y, Ohta T. Surgical Punctal Occlusion; Combined Lacrimal Canaliculi Cauterization and Punctal Suturing for Severe Dry Eye. *J Ophthalmic Vis Res.* Apr-Jun 2023;18(2):143-149. doi:10.18502/jovr.v18i2.13179
964. Ranjan A, Basu S, Singh S. Punctal cautery in dry eye disease: A systematic review. *Ocul Surf.* Oct 2024;34:235-240. doi:10.1016/j.jtos.2024.08.006
965. Moller-Hansen M, Utheim TP, Heegaard S. Surgical Procedures in the Treatment of Dry Eye Disease. *J Ocul Pharmacol Ther.* Dec 2023;39(10):692-698. doi:10.1089/jop.2023.0063
966. Kate A, Deshmukh R, Donthineni PR, Sharma N, Vajpayee RB, Basu S. Management of corneal perforations in dry eye disease: Preferred practice pattern guidelines. *Indian J Ophthalmol.* Apr 2023;71(4):1373-1381. doi:10.4103/IJO.IJO_2826_22
967. Cosar CB, Cohen EJ, Rapuano CJ, et al. Tarsorrhaphy: clinical experience from a cornea practice. *Cornea.* Nov 2001;20(8):787-91. doi:10.1097/00003226-200111000-00002
968. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. *Trends Biochem Sci.* Nov 2002;27(11):552-8. doi:10.1016/s0968-0004(02)02177-1
969. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. *Surv Ophthalmol.* Jan-Feb 2007;52(1):13-31. doi:10.1016/j.survophthal.2006.10.003

970. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. *J Neurol Neurosurg Psychiatry*. Jun 1988;51(6):767-72. doi:10.1136/jnnp.51.6.767
971. Adams GG, Kirkness CM, Lee JP. Botulinum toxin A induced protective ptosis. *Eye (Lond)*. 1987;1 (Pt 5):603-8. doi:10.1038/eye.1987.93
972. Naik MN, Gangopadhyay N, Fernandes M, Murthy R, Honavar SG. Anterior chemodeneervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection. *Eye (Lond)*. Sep 2008;22(9):1132-6. doi:10.1038/sj.eye.6702866
973. Salour H, Bagheri B, Aletaha M, et al. Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. *Orbit*. Apr 2010;29(2):114-8. doi:10.3109/01676830903324268
974. Neetens A, Rubbens MC, Smet H. Botulinum A-toxin treatment of spasmodic entropion of the lower eyelid. *Bull Soc Belge Ophtalmol*. 1987;224:105-9.
975. Deka A, Saikia SP. Botulinum toxin for lower lid entropion correction. *Orbit*. Jan 2011;30(1):40-2. doi:10.3109/01676830.2010.544443
976. Gumus K, Lee S, Yen MT, Pflugfelder SC. Botulinum toxin injection for the management of refractory filamentary keratitis. *Arch Ophthalmol*. Apr 2012;130(4):446-50. doi:10.1001/archophthalmol.2011.2713
977. Fouda SM, Mattout HK. Comparison Between Botulinum Toxin A Injection and Lacrimal Punctal Plugs for the Control of Post-LASIK Dry Eye Manifestations: A Prospective Study. *Ophthalmol Ther*. Jun 2017;6(1):167-174. doi:10.1007/s40123-017-0079-5

978. Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. *Am J Ophthalmol*. Apr 2000;129(4):481-6. doi:10.1016/s0002-9394(99)00408-0
979. Sahlin S, Linderöth R. Eyelid botulinum toxin injections for the dry eye. *Dev Ophthalmol*. 2008;41:187-192. doi:10.1159/000131089
980. Serna-Ojeda JC, Nava-Castaneda A. Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye. *Acta Ophthalmol*. Mar 2017;95(2):e132-e137. doi:10.1111/aos.13140
981. Choi MG, Yeo JH, Kang JW, Chun YS, Lee JK, Kim JC. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines. *Graefes Arch Clin Exp Ophthalmol*. Feb 2019;257(2):331-338. doi:10.1007/s00417-018-4194-3
982. Ho RW, Fang PC, Chang CH, Liu YP, Kuo MT. A Review of Periocular Botulinum Neurotoxin on the Tear Film Homeostasis and the Ocular Surface Change. *Toxins (Basel)*. Jan 24 2019;11(2)doi:10.3390/toxins11020066
983. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. *Ann Neurol*. Apr 1983;13(4):402-11. doi:10.1002/ana.410130406
984. Elston JS, Marsden CD, Grandas F, Quinn NP. The significance of ophthalmological symptoms in idiopathic blepharospasm. *Eye (Lond)*. 1988;2 (Pt 4):435-9. doi:10.1038/eye.1988.79
985. Price J, O'Day J. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. *J Clin Neuroophthalmol*. Mar 1993;13(1):67-71.

986. Lu R, Huang R, Li K, et al. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. *Am J Ophthalmol.* Mar 2014;157(3):591-7 e1-2. doi:10.1016/j.ajo.2013.11.014
987. Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. *Acta Ophthalmol.* Mar 2013;91(2):e108-12. doi:10.1111/aos.12002
988. Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. *Sci Rep.* May 30 2018;8(1):8367. doi:10.1038/s41598-018-26750-5
989. Bayraktar Bilen N, Bilen S, Topcu Yilmaz P, Evren Kemer O. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm. *Int Ophthalmol.* Aug 2022;42(8):2625-2632. doi:10.1007/s10792-022-02253-1
990. Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. *Eur J Ophthalmol.* Nov-Dec 2014;24(6):830-4. doi:10.5301/ejo.5000482
991. Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. *The British journal of ophthalmology.* Jan 2003;87(1):54-6. doi:10.1136/bjo.87.1.54
992. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. *Mov Disord.* Jul 2011;26(8):1521-8. doi:10.1002/mds.23658

993. Hollander MHJ, Pott JWR, Delli K, Vissink A, Schepers RH, Jansma J. Impact of upper blepharoplasty, with or without orbicularis oculi muscle removal, on tear film dynamics and dry eye symptoms: A randomized controlled trial. *Acta Ophthalmol.* Aug 2022;100(5):564-571. doi:10.1111/aos.15036
994. Vold SD, Carroll RP, Nelson JD. Dermatochalasis and dry eye. *Am J Ophthalmol.* Feb 15 1993;115(2):216-20. doi:10.1016/s0002-9394(14)73926-1
995. Floegel I, Horwath-Winter J, Muellner K, Haller-Schober EM. A conservative blepharoplasty may be a means of alleviating dry eye symptoms. *Acta Ophthalmol Scand.* Jun 2003;81(3):230-2. doi:10.1034/j.1600-0420.2003.00064.x
996. Rymer BL, Marinho DR, Cagliari C, Marafon SB, Procianoy F. Effects of Muller's muscle-conjunctival resection for ptosis on ocular surface scores and dry eye symptoms. *Orbit.* Feb 2017;36(1):1-5. doi:10.1080/01676830.2016.1243134
997. Zloto O, Matani A, Prat D, Leshno A, Ben Simon G. The Effect of a Ptosis Procedure Compared to an Upper Blepharoplasty on Dry Eye Syndrome. *Am J Ophthalmol.* Apr 2020;212:1-6. doi:10.1016/j.ajo.2019.11.021
998. Lucena A, Akaishi PM, Rodrigues Mde L, Cruz AA. Upper eyelid entropion and dry eye in cicatricial trachoma without trichiasis. *Arq Bras Oftalmol.* Nov-Dec 2012;75(6):420-2. doi:10.1590/s0004-27492012000600010
999. De Seta D, Mancini P, Minni A, et al. Bell's palsy: symptoms preceding and accompanying the facial paresis. *ScientificWorldJournal.* 2014;2014:801971. doi:10.1155/2014/801971
1000. Khan AZ, Ueland HO, Bohman E, Tonseth KA, Utheim TP. Entropion. *Tidsskr Nor Laegeforen.* Dec 17 2024;144(15)Entropion. doi:10.4045/tidsskr.24.0191

1001. Geerling G, Borrelli M. Adnexal surgery for severe ocular surface disease. *Semin Ophthalmol.* Apr-Jun 2005;20(2):101-12. doi:10.1080/08820530590931377
1002. Hintschich C. Correction of entropion and ectropion. *Dev Ophthalmol.* 2008;41:85-102. doi:10.1159/000131075
1003. Ross AH, Cannon PS, Selva D, Malhotra R. Management of upper eyelid cicatricial entropion. *Clin Exp Ophthalmol.* Aug 2011;39(6):526-36. doi:10.1111/j.1442-9071.2011.02503.x
1004. Al-Amry MA. Ocular manifestation of Ichthyosis. *Saudi J Ophthalmol.* Jan-Mar 2016;30(1):39-43. doi:10.1016/j.sjopt.2015.12.004
1005. Damasceno RW, Avgitidou G, Belfort R, Jr., Dantas PE, Holbach LM, Heindl LM. Eyelid aging: pathophysiology and clinical management. *Arq Bras Oftalmol.* Sep-Oct 2015;78(5):328-31. doi:10.5935/0004-2749.20150087
1006. Monga P, Gupta VP, Dhaliwal U. Clinical evaluation of changes in cornea and tear film after surgery for trichomatous upper lid entropion. *Eye (Lond).* Jul 2008;22(7):912-7. doi:10.1038/sj.eye.6702768
1007. Poon JS, Vandani K, Thaller VT. Comparison of four Combined Procedures for Correction of Involutional Lower Eyelid Entropion. *J Craniofac Surg.* Jun 2019;30(4):1239-1244. doi:10.1097/SCS.00000000000005466
1008. Singh S, Malhotra R, Watson SL. Mucous membrane grafting for cicatricial entropion repair: review of surgical techniques and outcomes. *Orbit.* Aug 2024;43(4):539-548. doi:10.1080/01676830.2023.2204498
1009. Osaki TH, Sant'Anna AE, Osaki MH, et al. Management of Severe Cicatricial Entropion With Labial Mucous Membrane Graft in Cicatricial Ocular Surface Disorders. *J Craniofac Surg.* Sep 2018;29(6):1531-1534. doi:10.1097/SCS.00000000000004584

1010. Linder T, Linstrom C, Robert Y. [Rehabilitation of the eye in patients with facial paralyses: indications and results of gold weight implantation]. *Klin Monbl Augenheilkd*. May 1997;210(5):293-5. Rehabilitation des Auges bei Patienten mit Fazialisparalysen: Indikationen und Resultate von Gold-Gewicht-Implantaten. doi:10.1055/s-2008-1035055
1011. Kartush JM, Linstrom CJ, McCann PM, Graham MD. Early gold weight eyelid implantation for facial paralysis. *Otolaryngol Head Neck Surg*. Dec 1990;103(6):1016-23. doi:10.1177/019459989010300622
1012. Siah WF, Nagendran S, Tan P, Ali Ahmad SM, Litwin AS, Malhotra R. Late outcomes of gold weights and platinum chains for upper eyelid loading. *The British journal of ophthalmology*. Feb 2018;102(2):164-168. doi:10.1136/bjophthalmol-2016-310089
1013. Silver AL, Lindsay RW, Cheney ML, Hadlock TA. Thin-profile platinum eyelid weighting: a superior option in the paralyzed eye. *Plast Reconstr Surg*. Jun 2009;123(6):1697-1703. doi:10.1097/PRS.0b013e3181a65a56
1014. Friedhofer H, Coltro PS, Vassiliadis AH, et al. Alternative surgical treatment of paralytic lagophthalmos using autogenic cartilage grafts and canthopexy. *Ann Plast Surg*. Aug 2013;71(2):135-9. doi:10.1097/SAP.0b013e318248b87c
1015. Cohen MS, Shorr N. Eyelid reconstruction with hard palate mucosa grafts. *Ophthalmic Plast Reconstr Surg*. 1992;8(3):183-95. doi:10.1097/00002341-199209000-00005
1016. Kwon KY, Jang SY, Yoon JS. Long-Term Outcome of Combined Lateral Tarsal Strip With Temporal Permanent Tarsorrhaphy for Correction of Paralytic Ectropion Caused By Facial Nerve Palsy. *J Craniofac Surg*. Jul 2015;26(5):e409-12. doi:10.1097/SCS.0000000000001875

1017. Yokoi N, Komuro A, Nishii M, et al. Clinical impact of conjunctivochalasis on the ocular surface. *Cornea*. Nov 2005;24(8 Suppl):S24-S31. doi:10.1097/01.ico.0000178740.14212.1a
1018. Zhang XR, Zhang ZY, Hoffman MR. Electrocoagulative surgical procedure for treatment of conjunctivochalasis. *Int Surg*. Jan-Mar 2012;97(1):90-3. doi:10.9738/CC59.1
1019. Chan TC, Ye C, Ng PK, Li EY, Yuen HK, Jhanji V. Change in Tear Film Lipid Layer Thickness, Corneal Thickness, Volume and Topography after Superficial Cauterization for Conjunctivochalasis. *Sci Rep*. Jul 17 2015;5:12239. doi:10.1038/srep12239
1020. Nakasato S, Uemoto R, Mizuki N. Thermocautery for inferior conjunctivochalasis. *Cornea*. May 2012;31(5):514-9. doi:10.1097/ICO.0b013e3181dc81d2
1021. Otaka I, Kyu N. A new surgical technique for management of conjunctivochalasis. *Am J Ophthalmol*. Mar 2000;129(3):385-7. doi:10.1016/s0002-9394(99)00384-0
1022. Yang HS, Choi S. New approach for conjunctivochalasis using an argon green laser. *Cornea*. May 2013;32(5):574-8. doi:10.1097/ICO.0b013e318255eaaa
1023. Doss LR, Doss EL, Doss RP. Paste-pinch-cut conjunctivoplasty: subconjunctival fibrin sealant injection in the repair of conjunctivochalasis. *Cornea*. Aug 2012;31(8):959-62. doi:10.1097/ICO.0b013e3182400100
1024. Santiago E, Yang Y, Conlon R, Compan J, Baig K, Ziai S. Surgical techniques for the treatment of conjunctivochalasis: paste-pinch-cut conjunctivoplasty versus thermal cautery conjunctivoplasty. *Can J Ophthalmol*. Jun 2017;52(3):308-312. doi:10.1016/j.jcjo.2016.11.003

1025. Trivli A, Dalianis G, Terzidou C. A Quick Surgical Treatment of Conjunctivochalasis Using Radiofrequencies. *Healthcare (Basel)*. Feb 12 2018;6(1):14. doi:10.3390/healthcare6010014
1026. Youm DJ, Kim JM, Choi CY. Simple surgical approach with high-frequency radio-wave electrosurgery for conjunctivochalasis. *Ophthalmology*. Nov 2010;117(11):2129-33. doi:10.1016/j.opthta.2010.02.023
1027. Haefliger IO, Vysniauskiene I, Figueiredo AR, Piffaretti JM. Superficial conjunctiva cauterization to reduce moderate conjunctivochalasis. *Klin Monbl Augenheilkd*. Apr 2007;224(4):237-9. doi:10.1055/s-2007-962928
1028. Chui J, Di Girolamo N, Wakefield D, Coroneo MT. The pathogenesis of pterygium: current concepts and their therapeutic implications. *Ocul Surf*. Jan 2008;6(1):24-43. doi:10.1016/s1542-0124(12)70103-9
1029. Ishioka M, Shimmura S, Yagi Y, Tsubota K. Pterygium and dry eye. *Ophthalmologica Journal internationale d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde*. May-Jun 2001;215(3):209-11. doi:10.1159/000050860
1030. Ozsutcu M, Arslan B, Erdur SK, Gulkilik G, Kocabora SM, Muftuoglu O. Tear osmolarity and tear film parameters in patients with unilateral pterygium. *Cornea*. Nov 2014;33(11):1174-8. doi:10.1097/ICO.0000000000000221
1031. Julio G, Lluch S, Pujol P, Alonso S, Merindano D. Tear osmolarity and ocular changes in pterygium. *Cornea*. Dec 2012;31(12):1417-21. doi:10.1097/ICO.0b013e318259c934
1032. Chang J, Cao Q, Yong J, et al. The effect of different pterygium surgery techniques on the ocular surface parameters in different durations: a systematic review and meta-analysis. *Graefes Arch Clin Exp Ophthalmol*. May 2024;262(5):1383-1396. doi:10.1007/s00417-023-06191-1

1033. Yin CJ, Bao YL, Zhang QC, Kang SF, Chen GL. Comparison of postoperative recovery of primary pterygium excision combined with either limbal stem cell transplantation or amniotic membrane transplantation: a randomized controlled trial-based meta-analysis. *Am J Transl Res*. 2023;15(2):641-652.
1034. Zheng K, Cai J, Jhanji V, Chen H. Comparison of pterygium recurrence rates after limbal conjunctival autograft transplantation and other techniques: meta-analysis. *Cornea*. Dec 2012;31(12):1422-7. doi:10.1097/ICO.0b013e31823cbeeb
1035. Baheran SS, Alany RG, Schwikkard S, et al. Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products. *Drug Discov Today*. Jan 2023;28(1):103416. doi:10.1016/j.drudis.2022.103416
1036. Chu WK, Choi HL, Bhat AK, Jhanji V. Pterygium: new insights. *Eye (Lond)*. Jun 2020;34(6):1047-1050. doi:10.1038/s41433-020-0786-3
1037. Chen J, Bai T, Su J, et al. Salivary Gland Transplantation as a Promising Approach for Tear Film Restoration in Severe Dry Eye Disease. *J Clin Med*. Jan 17 2024;13(2)doi:10.3390/jcm13020521
1038. Singh S, Basu S, Geerling G. Salivary gland transplantation for dry eye disease: Indications, techniques, and outcomes. *Ocul Surf*. Oct 2022;26:53-62. doi:10.1016/j.jtos.2022.07.013
1039. Jacobsen HC, Hakim SG, Trenkle T, Nitschke M, Steven P, Sieg P. Allogenic submandibular gland transplantation following hematopoietic stem cell transplantation. *J Craniomaxillofac Surg*. Dec 2013;41(8):764-9. doi:10.1016/j.jcms.2013.01.015
1040. Wang Z, Li W, Hong X, et al. Minor salivary glands function is decreased in hyposalivation-related diseases. *Arch Oral Biol*. Sep 2016;69:63-70. doi:10.1016/j.archoralbio.2016.05.012

1041. Singh S, Basu S. A novel diagnostic technique of measuring labial minor salivary gland secretions using sodium fluorescein dye: Implications for patients with dry eyes. *Semin Ophthalmol.* Jan 2 2022;37(1):111-116. doi:10.1080/08820538.2021.1926518
1042. Zhang L, Su JZ, Cai ZG, et al. Factors influencing the long-term results of autologous microvascular submandibular gland transplantation for severe dry eye disease. *Int J Oral Maxillofac Surg.* Jan 2019;48(1):40-47. doi:10.1016/j.ijom.2018.07.006
1043. Wang DK, Zhang SE, Su YX, Zheng GS, Yang WF, Liao GQ. Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 61 Grafts. *J Oral Maxillofac Surg.* Nov 2018;76(11):2443-2452. doi:10.1016/j.joms.2018.05.008
1044. Borrelli M, Schroder C, Dart JK, et al. Long-term follow-up after submandibular gland transplantation in severe dry eyes secondary to cicatrizing conjunctivitis. *Am J Ophthalmol.* Dec 2010;150(6):894-904. doi:10.1016/j.ajo.2010.05.010
1045. Wang YP, Su JZ, Sun ZP, et al. Clinical and histopathologic characteristics of submandibular gland in Stevens-Johnson syndrome: A comparative study. *Oral Surg Oral Med Oral Pathol Oral Radiol.* Mar 2022;133(3):326-332. doi:10.1016/j.oooo.2021.09.005
1046. Geerling G, Raus P, Murube J. Minor salivary gland transplantation. *Dev Ophthalmol.* 2008;41:243-254. doi:10.1159/000131093
1047. Sant' Anna AE, Hazarbassanov RM, de Freitas D, Gomes JA. Minor salivary glands and labial mucous membrane graft in the treatment of severe symblepharon and dry eye in patients with Stevens-Johnson syndrome. *The British journal of ophthalmology.* Feb 2012;96(2):234-9. doi:10.1136/bjo.2010.199901

1048. Wakamatsu TH, Dos Santos MS, Barreiro TP, et al. Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in Brazil. *Front Med (Lausanne)*. 2021;8:649369. doi:10.3389/fmed.2021.649369
1049. Wakamatsu TH, Sant'Anna A, Cristovam PC, Alves VAF, Wakamatsu A, Gomes JAP. Minor Salivary Gland Transplantation for Severe Dry Eyes. *Cornea*. Nov 2017;36 Suppl 1:S26-S33. doi:10.1097/ICO.0000000000001358
1050. Sant'Anna A, Sant'Anna E, Osaki TH, Pereira Gomes JA. A new option for treatment of severe cicatricial entropion in patients with Stevens-Johnson syndrome. *Ocul Surf*. Oct 2021;22:80-82. doi:10.1016/j.jtos.2021.07.005
1051. Vazirani J, Bhalekar S, Amescua G, Singh S, Basu S. Minor salivary gland transplantation for severe dry eye disease due to cicatrising conjunctivitis: multicentre long-term outcomes of a modified technique. *The British journal of ophthalmology*. Nov 2021;105(11):1485-1490. doi:10.1136/bjophthalmol-2020-316611
1052. Marinho DR, Burmann TG, Kwitko S. Labial salivary gland transplantation for severe dry eye due to chemical burns and Stevens-Johnson syndrome. *Ophthalmic Plast Reconstr Surg*. May-Jun 2010;26(3):182-4. doi:10.1097/IOP.0b013e3181b8c3ad
1053. Sharma N, Kumar V, Bari A, et al. The clinical outcomes of minor salivary gland transplantation for severe dry eye disease secondary to chronic Stevens-Johnson syndrome. *Ocul Surf*. Oct 2024;34:277-282. doi:10.1016/j.jtos.2024.08.010
1054. Su JZ, Zheng B, Wang Z, et al. Submandibular Gland Transplantation vs Minor Salivary Glands Transplantation for Treatment of Dry Eye: A Retrospective Cohort Study. *Am J Ophthalmol*. Sep 2022;241:238-247. doi:10.1016/j.ajo.2022.05.019

1055. Giannaccare G, Bolognesi F, Fogagnolo P, et al. Sural Nerve Vertical Cross-Face Graft for Lacrimal Gland Neurotization to Improve Tear Secretion in Neurodeprivative Dry Eye. *Cornea*. Jan 1 2023;42(1):121-126. doi:10.1097/ICO.0000000000003126

1056. Strianese A, Bolognesi F, Giannaccare G, et al. Long-term outcomes of sural nerve vertical cross-face graft for lacrimal gland neurotization in neurodeprivative dry eye. *Graefes Arch Clin Exp Ophthalmol*. Nov 25 2024;doi:10.1007/s00417-024-06697-2

Declaration of Interest / Disclosure forms

According to Dr Sullivan, we are awaiting confirmation from the journal as to the required format that these should take. Please advise and these will be uploaded as requested.




Figure 3. Guide to dry eye subclassification following diagnosis of dry eye disease according to the TFOS DEWS III diagnostic criteria (symptoms plus clinical signs of tear film instability, hyperosmolarity and/or ocular surface staining). The figure highlights tear film deficiency-related subtypes of dry eye disease. The top section provides a checklist of identification tests relevant to the individual etiological drivers (left), a schematic representation of the tear film structure (centre) and a checklist of evidence-based interventions aligned to the etiological drivers (right). The lower section offers more detail in the form of an evidence-based treatment algorithm aligned to identified tear film-related drivers of dry eye disease. Dry eye subtypes are not mutually exclusive and concurrent management targeting identified deficiencies is appropriate to restore tear film and ocular surface homeostasis.

Fura, A. 2006. 'Role of pharmacologically active metabolites in drug discovery and development', *Drug Discov Today*, 11: 133-42.





Figure 4. Guide to dry eye subclassification following diagnosis of dry eye disease according to the TFOS DEWS III diagnostic criteria (symptoms plus clinical signs of tear film instability, hyperosmolarity and/or ocular surface staining). The figure highlights eyelid-related subtypes of dry eye disease. The top section provides a checklist of identification tests relevant to the individual etiologic drivers (left), a schematic representation of eyelid-related dry eye disease drivers (centre) and a checklist of evidence-based interventions aligned to the etiologic drivers (right). The lower section offers more detail in the form of an evidence-based treatment algorithm aligned to identified eyelid-related drivers of dry eye disease. Dry eye subtypes are not mutually exclusive and concurrent management targeting identified deficiencies is appropriate to restore tear film and ocular surface homeostasis.

Fura, A. 2006. 'Role of pharmacologically active metabolites in drug discovery and development', *Drug Discov Today*, 11: 133-42.



IPL = Intense pulsed light therapy; LLLT = low level light therapy; QMR = quantum molecular resonance electrotherapy

Note: Treatments are listed in no particular order and selection for an individual patient from the options identified should be based on shared decision-making with the patient. Refer to the associated text for more details.

Blank cells indicate where sufficient evidence is not currently available.

Treatments are named when differences exist within a treatment category.

Pharmacological is defined as having a direct biological effect (Fura 2006).

Primary inflammation is considered to be that linked to underlying systemic disease, whereas secondary inflammation, a sequela of dry eye disease.

✓	RCT effective vs placebo
☐	RCT effective vs comparator
?	Conflicting evidence

Figure 5. Guide to dry eye subclassification following diagnosis of dry eye disease according to the TFOS DEWS III diagnostic criteria (symptoms plus clinical signs of tear film instability, hyperosmolarity and/or ocular surface staining). The figure highlights ocular surface-related subtypes of dry eye disease. The top section shows a checklist of identification tests relevant to the individual etiological drivers (left), a schematic representation of ocular surface disease drivers (centre) and a checklist of evidence-based interventions aligned to the etiological drivers (right). The lower section offers more detail in the form of an evidence-based treatment algorithm aligned to identified ocular surface-related drivers of dry eye disease. Dry eye subtypes are not mutually exclusive and concurrent management targeting identified deficiencies is appropriate to restore tear film and ocular surface homeostasis.

Fura, A. 2006. 'Role of pharmacologically active metabolites in drug discovery and development', *Drug Discov Today*, 11: 133-42.